SMILES,Label,DrugBank ID,Name,Patent_id,Status,NCT_Number,Conditions,Gender,Age_y,Funder_Type,Study Designs,Locations,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,PCT_code_2,CPC_code_0,CPC_code_1,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Completed,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Not Yet Recruiting,,ADVANCED PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Not Yet Recruiting,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Recruiting,,PROSTATIC NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O,1,DB00035,__DESMOPRESSIN,5500413,Completed,,HEMOPHILIA A,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.65775477935889,17.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1069.22,435.41,15.0,14.0,4.0,104.78,279.78,19.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,1,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,DB00080,__DAPTOMYCIN,6468967,Recruiting,NCT04141787,STAPHYLOCOCCAL INFECTIONS|OSTEOMYELITIS|CNS INFECTION|SEPTIC ARTHRITIS|DIABETIC FOOT INFECTION|VERTEBRAL OSTEOMYELITIS|ABSCESS|COAGULASE NEGATIVE STAPHYLOCOCCAL INFECTION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada",A61K38/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,DB00080,__DAPTOMYCIN,6468967,Terminated,NCT01734694,HEALTH CARE ASSOCIATED PNEUMONIA|OSTEOMYELITIS/SEPTIC ARTHRITIS|ENDOCARDITIS|BACTEREMIA|ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Henry Ford Hospital, Detroit, Michigan, United States",A61K38/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,36.9288897102609,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.47,1620.693,702.02,27.0,22.0,4.0,158.96,393.57,35.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00209859,RHEUMATOID ARTHRITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hvidovre University Hospital, Hvidovre, Denmark",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,NCT00595140,ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Klinik - Innenstadt of the University of Munich, Munich, Germany",A61K38/31,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,NCT01371643,PITUITARY ADENOMA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"New York University School of Medicine, New York, New York, United States",A61K38/31,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,,HYPOTHALAMIC OBESITY,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/31,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00106,__ABARELIX,5843901,Suspended,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.8242674387564,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,1416.09,424.98,16.0,13.0,6.0,149.31,373.91,38.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,HYPEREMESIS GRAVIDARUM,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,1,DB00121,__BIOTIN,3946115,Unknown Status,,HYPERURICEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/158,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,20.4357379001622,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.17,244.31099999999998,78.43,3.0,3.0,2.0,24.92,60.05,5.0,0.0,1.0,0.0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
N=C(N)NCCC[C@H](N)C(=O)O,1,DB00125,__ARGININE,4271152,Completed,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07K14/672,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Unknown status,NCT01765010,OSTEOPOROSIS,Male,20 Years to 40 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Medical School, Seoul, Korea, Republic of",A61K9/0019,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Terminated,NCT01725113,KIDNEY FAILURE|SECONDARY HYPERPARATHYROIDISM|HYPERPHOSPHATEMIA|HYPERCALCEMIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Winthrop University Hospital, Mineola, New York, United States",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Recruiting,NCT03820518,X-LINKED HYPOPHOSPHATEMIA,All,1 Year to 12 Years Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Peking Union Medical College Hospital, Beijing, Beijing, China",A61K9/0019,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Completed,NCT01350934,"OSTEOPOROSIS, POSTMENOPAUSAL",Female,"56 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0019,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C,1,DB00140,__RIBOFLAVIN,3936272,Recruiting,NCT03012529,OSTEOMYELITIS|DIABETES|AMPUTATION,All,"18 Years to 89 Years Â  (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Northern California Health Care System, Mather, CA, Sacramento, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia, United States|Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Dayton VA Medical Center, Dayton, OH, Dayton, Ohio, United States|Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",G01N15/042,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,11.8606131542742,4111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,376.3639,155.05,9.0,5.0,3.0,37.5,96.27,5.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0
NCC(=O)O,1,DB00145,__GLYCINE,,Completed,NCT01913808,"POSTOPERATIVE ANEMIA|OSTEOARTHRITIS, KNEE",All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hospital de la Esperanza (Parc de Salut MAR), Barcelona, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.3,75.0666,63.32,3.0,2.0,0.0,6.65,16.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,1,DB00153,__ERGOCALCIFEROL,4572915,Unknown status,NCT01153243,VITAMIN D DEFICIENCY|DIABETES,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61K9/1075,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,21.8484979157682,655.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.59,396.6484,20.23,1.0,1.0,3.0,50.73,128.89,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,1,DB00153,__ERGOCALCIFEROL,4572915,Completed,NCT04472481,ACTIVE RHEUMATOID ARTHRITIS,All,33 Years to 60 Years Â  (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Souzan Ezzat Gado, Tanta, EL-gharbia, Egypt",A61K9/1075,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,21.8484979157682,655.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.59,396.6484,20.23,1.0,1.0,3.0,50.73,128.89,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,1,DB00153,__ERGOCALCIFEROL,4572915,Unknown status,NCT03228862,VITAMIN D2 SUPPLEMENTATION IN VITAMIN D INSUFFICIENCY,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Chulalongkorn Univerity and King Chulalongkorn Memorial Hospital, Bangkok, Thailand",A61K9/1075,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,21.8484979157682,655.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.59,396.6484,20.23,1.0,1.0,3.0,50.73,128.89,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,1,DB00158,__FOLIC_ACID,3960757,Completed,NCT01308255,RHEUMATOID ARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom",A61K9/1694,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,1,DB00163,__VITAMIN_E,3932634,Enrolling by invitation,NCT03176966,MUSCLE CRAMP|CIRRHOSIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,1,DB00163,__VITAMIN_E,3932634,Completed,NCT00754247,"KELOID|HYPERTROPHIC SCAR|CICATRIX, HYPERTROPHIC",All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University of Miami Skin Research Group Office, Miami, Florida, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT00785473,"MULTIPLE SCLEROSIS, OSTEOPOROSIS",All,18 Years to 50 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University Hospital of North Norway, TromsÃ¸, Norway",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT00592917,FRACTURES|OSTEOPOROSIS,Female,65 Years and older Â  (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Bone and Cartilage Research Unit, Clinical Research Centre, University of Kuopio, Kuopio, Finland",6,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT02214563,"KIDNEY FAILURE, CHRONIC|ANEMIA|VITAMIN D DEFICIENCY|BONE DISEASES, METABOLIC",All,"20 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan|Higashikouri hospital, Hirakata, Osaka, Japan|Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine, Suita, Osaka, Japan|Akebono clinic, Kumamoto, Japan|Obi clinic, Osaka, Japan|Nishi clinic, Osaka, Japan|Futaba clinic, Osaka, Japan",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Terminated,NCT01817699,"KIDNEY TRANSPLANTATION|ANEMIA|VITAMIN D DEFICIENCY|RENAL INSUFFICIENCY, CHRONIC",All,"20 Years to 79 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CANDLE Trial Study Group, Suita, Osaka, Japan",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT00491920,OSTEOPOROSIS|OSTEOPENIA,Female,"50 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical Dpt. B, University Hospital of Northern Norway, TromsÃ¸, Norway",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Unknown status,NCT01765010,OSTEOPOROSIS,Male,20 Years to 40 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Medical School, Seoul, Korea, Republic of",6,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT00729651,OSTEOPOROSIS POSTMENOPAUSAL,Female,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT02572960,OSTEOPOROSIS|VITAMIN D DEFICIENCY|CARDIOVASCULAR DISEASE,Female,"60 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Endocrinology and Internal Medicine, Aarhus, Denmark",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT01263288,VITAMIN DEFICIENCY,All,18 Years to 50 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of Oslo, Institute of Health and Society, Oslo, Norway",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT02890823,EPILEPSY,All,"15 Years and older Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT01419119,VITAMIN D DEFICIENCY,All,"25 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ãlidhems hÃ¤lsocentral, UmeÃ¥, UmeÃ¥, Sweden",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,1,DB00175,__PRAVASTATIN,5622985,Completed,NCT00738296,CARDIOVASCULAR DISEASE,All,"30 Years to 75 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT02572960,OSTEOPOROSIS|VITAMIN D DEFICIENCY|CARDIOVASCULAR DISEASE,Female,"60 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Endocrinology and Internal Medicine, Aarhus, Denmark",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Unknown status,NCT00819845,DUCHENNE MUSCULAR DYSTROPHY|BECKER MUSCULAR DYSTROPHY,Male,"2 Years to 45 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Unione Italiana lotta Distrofia Muscolare, Rome, Italy",A61K38/556,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Recruiting,NCT02842424,PERIPHERAL ARTERIAL DISEASE,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VA Medical Center, Omaha, Nebraska, United States",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/556,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/556,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Completed,NCT04523935,CEREBRAL PALSY|CRYING,All,up to 15 Years Â  (Child),Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Completed,NCT00179114,SPASTICITY,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Completed,NCT01955655,RECURRENT CRYING SPELLS,All,up to 12 Years Â  (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sathbhavana Brain Clinic, Secunderabad, Andhra Pradesh, India",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Completed,NCT01032239,SEVERE SPASTICITY,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California Irvine, Irvine, California, United States|MedStar National Rehabilitation Network, Washington, District of Columbia, United States|Design Neuroscience Center, Doral, Florida, United States|Rehabilitation Medical Group - Florida Hospital, Orlando, Florida, United States|Tallahassee Neurological Clinic Department of Neurosurgery, Tallahassee, Florida, United States|Saint Alphonsus Regional Med Center, Boise, Idaho, United States|Research Medical Center, Kansas City, Missouri, United States|Einstein Hospital/Moss Rehabilitation, Elkins Park, Pennsylvania, United States|TIRR Memorial Herman Hospital, Houston, Texas, United States|Sozialmedizinisches Zentrum Baumgartner HÃ¶he Otto-Wagner-Spital, Vienna, Austria|Landeskrankenhaus Hochzirl, Zirl, Austria|Clin. Univ. UCL Saint Luc, Bruxelles, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Universitaire Ziekenhuizen Leuven, campus Pellenberg, Leuven, Belgium|Kliniken Beelitz GmbH Neurologische Rehabilitationsklinik, Beelitz-HeilstÃ¤tten, Germany|Ambulantes Neurologisches Rehabilitationszentrum, Bonn, Germany|Therapiezentrum Burgau, Burgau, Germany|Rhein-Sieg-Klinik Dr. Becker Klinikgesellschaft, Numbrecht, Germany|Centro di Riabilitazione ""Villa Beretta"", Costa Masnaga, Italy|Fondazione Salvatore Maugeri Clinica del lavoro e della riabilitazione IRCSS, Pavia, Italy|Afdeling Revalidatie Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Univerzitetni rehabilitacijski inÅ¡titut Republike Slovenije SoÄa, Ljubljana, Slovenia|FundaciÃ³ Privada Institut de NeurorehabilitaciÃ³ Guttmann, Badalona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|St George's Hospital, London, United Kingdom",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Recruiting,NCT02462317,MUSCLE SPASTICITY,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","University Hospital, Toulouse, Toulouse, Haute-Garonne, France|CHU Jean Minjoz, BesanÃ§on, France|Groupe Pellegrin, University Hospital Bordeaux, Bordeaux, France|Centre de rÃ©Ã©ducation MARIENIA, Cambo Les Bains, France|Centre Bouffard- Vercelli, Cerbere, France|University Hospital Dijon, Dijon, France|University Hospital Grenoble, Echirolles, France|HÃ´pital R. PoincarrÃ©, Garches, France|HÃ´pital Swynghedauw, Lille, France|HÃ´pital J Rebeyrol, Limoges, France|CHU Gui de Chauliac, Montpellier, France|University Hospital CarÃ©meau, Nimes, France|Hopital Rothschild, Paris, France|GH LariboisiÃ¨re F.Widal, Paris, France|Groupe Hospitalier PitiÃ©-SalpÃªtriÃ¨re, Paris, France|UniversitÃ© Reims Champagne Ardenne, Reims, France|PÃ´le MPR St HÃ©lier, Rennes, France",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Not yet recruiting,NCT03860662,STROKE SEQUELAE|SPASTIC HEMIPLEGIA,All,18 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hatay Mustafa Kemal University, Hatay, Turkey",A61K9/0056,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Terminated,NCT00752934,CEREBRAL PALSY,All,"1 Year to 18 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Saare Zedek Medical Center, Jerusalem, Israel",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Active Not Recruiting,,"SPASTICITY, MUSCLE",,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00187,__ESMOLOL,6310094,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,9.56077126840386,564.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.02,295.374,67.79,4.0,2.0,1.0,33.68,81.05,10.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT00246168,RHEUMATOID ARTHRITIS,All,"18 Years to 79 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT01063842,OSTEOARTHRITIS,All,"35 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT00766675,PAIN|FIBROMYALGIA,All,"20 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, HajdÃº-Bihar, Hungary",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT00733421,POSTOPERATIVE PAIN,Female,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Foot & Ancle Surgical Center, Stockholm, Sweden",A61K9/2081,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Terminated,NCT00766402,"SPONDYLITIS, ANKYLOSING|PAIN",All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Recruiting,NCT03781544,OSTEOARTHRITIS OF MULTIPLE JOINTS OF ANKLE OR FOOT|HEALTHY,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Heart Center Zurich, Zurich, Switzerland",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Recruiting,NCT04391855,"ANALGESIA|PAIN, POSTOPERATIVE|SPINAL STENOSIS|SPINAL DISEASE",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AHEPA University Hospital, Thessaloniki, Greece",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT02416804,"SPINAL STENOSIS|PAIN, POSTOPERATIVE",All,"20 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT00426647,OSTEOARTHRITIS|PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Dr. Olavi Airaksinen, Oma LÃ¤Ã¤kÃ¤ri Oy, Vuorikatu 20, Kuopio, Finland",A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT01843660,LOW BACK PAIN|SHOULDER PAIN|NECK PAIN,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,,ANKYLOSING SPONDYLITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2081,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,1,DB00198,__OSELTAMIVIR,5866601,Completed,,METABOLIC DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",C07D309/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,43.92698002012361,466.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.3,312.4045,90.65,4.0,2.0,1.0,34.65,84.2,8.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1694,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Completed,,PANCREATITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1694,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC1=C2[N+]3=C(C=C4[N+]5=C(C(C)=C6N7[C@@H]8[C@H](CC(N)=O)[C@@]6(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)n6c[n+](c9cc(C)c(C)cc96)[Co-3]753(O)[N+]3=C1[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]83C)[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O,1,DB00200,__HYDROXOCOBALAMIN,5834448,Completed,,VITAMIN B12 DEFICIENCY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/19,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,23.8526458448838,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-14.0,1346.3551,437.23,14.0,10.0,12.0,135.56,340.03,16.0,1.0,0.0,0.0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,DB00202,__SUCCINYLCHOLINE,4474752,Terminated,NCT01579864,ANESTHESIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Hopital Foch, Suresnes, Ile de France, France",A61K47/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,290.399,52.6,2.0,0.0,0.0,33.15,100.94,11.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,DB00202,__SUCCINYLCHOLINE,4474752,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,290.399,52.6,2.0,0.0,0.0,33.15,100.94,11.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Not yet recruiting,NCT03633565,MYOPATHY,Male,5 Years to 15 Years Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/04,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00644956,ERECTILE DYSFUNCTION,Male,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Leeds, United Kingdom",C07D487/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,NCT00598585,CHRONIC FATIGUE SYNDROME,All,18 Years to 49 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Charles Drew University of Medicine and Science, Los Angeles, California, United States",C07D487/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT01888536,NEUROLOGIC CLAUDICATION IN PATIENTS WITH LUMBAR SPINAL STENOSIS,All,"20 Years to 75 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of|KyungHee University Medical Center, Seoul, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT04532684,KNEE OSTEOARTHRITIS,All,"40 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT02612233,HAND OSTEOARTHRITIS,All,"40 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hotung Centre for Musculoskeletal Diseases, London, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Recruiting,NCT02464813,SCOLIOSIS|SPONDYLOLISTHESIS,All,"10 Years to 21 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Turku University Hospital, Turku, Finland",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT00791739,FIBROMYALGIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto de Neurociencias, Granada, Spain",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT03241875,"PAIN, POSTOPERATIVE|CHOLECYSTECTOMY, LAPAROSCOPIC",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Sahloul Teaching Hospital, Sousse, Tunisia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Unknown status,NCT02747940,CHRONIC PAIN|CHRONIC MIGRAINE|FIBROMYALGIA,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Headache Center, Teipei Veterans General Hospital, Taipei, Taiwan",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT01061697,CERVICAL SPONDYLOSIS|CERVICAL SPONDYLOTIC MYELOPATHY|CERVICAL SPONDYLOTIC RADICULOPATHY,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Singapore General Hospital, Singapore, Outram Road, Singapore",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Terminated,NCT00381095,"BONE NEOPLASMS|PAIN, INTRACTABLE|CANCER",All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Celebration, Florida, United States|Pfizer Investigational Site, Kissimmee, Florida, United States|Pfizer Investigational Site, Pensacola, Florida, United States|Pfizer Investigational Site, Pensacola, Florida, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Edina, Minnesota, United States|Pfizer Investigational Site, Canton, Ohio, United States|Pfizer Investigational Site, Dover, Ohio, United States|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Benesov U Prahy, Czechia|Pfizer Investigational Site, Horovice, Czechia|Pfizer Investigational Site, Jablonec nad Nisou, Czechia|Pfizer Investigational Site, Plzen, Czechia|Pfizer Investigational Site, Praha 1 - Nove Mesto, Czechia|Pfizer Investigational Site, Praha 6 - Hradcany, Czechia|Pfizer Investigational Site, Cairo, Egypt|Pfizer Investigational Site, Helsinki, Finland|Pfizer Investigational Site, Joensuu, Finland|Pfizer Investigational Site, Bordeaux Cedex, France|Pfizer Investigational Site, Villejuif, France|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Nyiregyhaza, Hungary|Pfizer Investigational Site, Szentes, Hungary|Pfizer Investigational Site, Tata, Hungary|Pfizer Investigational Site, Aviano (PN), Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Monterrey, Nuevo Leon, Mexico|Pfizer Investigational Site, MÃ©xico D.F, Mexico|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Manila, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Bialystok, Poland|Pfizer Investigational Site, Gdansk, Poland|Pfizer Investigational Site, Kielce, Poland|Pfizer Investigational Site, Lodz, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Vsevolozhsk, Vsevolozhsk District, Leningrad Region, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Alcorcon, Madrid, Spain|Pfizer Investigational Site, Lleida, Spain|Pfizer Investigational Site, Orebro, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taichung City, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Rachathewi, Bangkok, Thailand|Pfizer Investigational Site, Ratchathewi, Bangkok, Thailand|Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT00638443,LUMBAR SPINAL STENOSIS,All,"50 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2180 South Clinton Avenue, Rochester, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Unknown status,NCT03584074,SPINAL STENOSIS LUMBAR,All,"40 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT00353704,INTERVERTEBRAL DISK DISPLACEMENT|DISK PROLAPSE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asker and Baerum Hospital, Rud, Norway",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Not yet recruiting,NCT04471233,"KNEE OSTEOARTHRITIS|PAIN, POSTOPERATIVE",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Northwell Health Orthopedic Institute at Great Neck, Great Neck, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT03712475,DIABETIC PERIPHERAL NEUROPATHY|FIBROMYALGIA|PARTIAL SEIZURE DISORDER,Male,20 Years to 45 Years Â  (Adult),Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Taichung Veterans General Hospital, Taichung, Taiwan",1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT03604354,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","All India Institute of Medical Sciences, Bhubaneswar, Odisha, India",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT00908375,"NEUROPATHY; RADICULAR, LUMBAR, LUMBOSACRAL|FAILED BACK SURGERY SYNDROME|SPINAL STENOSIS|HERNIATED DISC",All,18 Years to 64 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pain Medicine Center, Chicago, Illinois, United States",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,1,DB00248,__CABERGOLINE,5705510,Completed,NCT00595140,ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Klinik - Innenstadt of the University of Munich, Munich, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,26.415326803425106,154.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.97,451.6043,71.68,4.0,2.0,4.0,52.5,133.5,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,1,DB00248,__CABERGOLINE,5705510,"Active, not recruiting",NCT01794793,CUSHING'S DISEASE|ACROMEGALY|NEUROENDOCRINE TUMORS|PITUITARY TUMORS|ECTOPIC ACTH SECRETING (EAS) TUMORS|DUMPING SYNDROME|PROSTATE CANCER|MELANOMA NEGATIVE FOR BRAF|MELANOMA NEGATIVE FOR NRAS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ximed Research SC - SOM230B2412, La Jolla, California, United States|Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States|Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford, California, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center SC, New York, New York, United States|Virginia Endocrinology Research SC, Chesapeake, Virginia, United States|Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, Botucatu, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Toulouse, Cedex 9, France|Novartis Investigative Site, Angers cedex 09, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, TÃ¼bingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Nankoku city, Kochi, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, MÃ©xico, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,26.415326803425106,154.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.97,451.6043,71.68,4.0,2.0,4.0,52.5,133.5,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,1,DB00252,__PHENYTOIN,3962430,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61L2/0023,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,252.268,58.2,2.0,2.0,3.0,25.48,70.18,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,1,DB00252,__PHENYTOIN,3962430,Completed,,SUBARACHNOID HEMORRHAGE,,,,,"FISABIO, Elche, Alicante, Spain",A61L2/0023,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,252.268,58.2,2.0,2.0,3.0,25.48,70.18,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT01318356,"Q FEVER|FATIGUE SYNDROME, CHRONIC|COXIELLA INFECTION",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Radboud university medical center, Nijmegen, Gelderland, Netherlands",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Recruiting,NCT03479502,ADHESIVE CAPSULITIS|ADHESIVE CAPSULITIS OF UNSPECIFIED SHOULDER|FROZEN SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt Medical Center, Nashville, Tennessee, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
N[C@@H]1CONC1=O,1,DB00260,__CYCLOSERINE,,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,102.0919,64.35,3.0,2.0,1.0,8.87,21.85,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Terminated,NCT01837069,OSTEOARTHRITIS|CARDIOVASCULAR DISEASE,All,"21 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NYU Hospital for Joint Diseases, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCCN(CCC)CCc1cccc2c1CC(=O)N2,1,DB00268,__ROPINIROLE,5422123,Enrolling by invitation,NCT03176966,MUSCLE CRAMP|CIRRHOSIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",A61K9/2086,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,20.468592784246,396.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.16,260.3746,32.34,2.0,1.0,2.0,31.19,81.43,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CCCN(CCC)CCc1cccc2c1CC(=O)N2,1,DB00268,__ROPINIROLE,5422123,Enrolling by Invitation,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2086,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.468592784246,396.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.16,260.3746,32.34,2.0,1.0,2.0,31.19,81.43,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Completed,NCT04523935,CEREBRAL PALSY|CRYING,All,up to 15 Years Â  (Child),Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",,3,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O,1,DB00277,__THEOPHYLLINE,3935196,Not yet recruiting,NCT03718403,PHP IA|PHP IB|PHP1C,All,"5 Years to 21 Years Â  (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.26,180.16400000000002,69.3,3.0,1.0,2.0,16.86,44.93,0.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT02372786,TATTOO|ACNE KELOIDALIS NUCHAE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Erasmus MC, Rotterdam, Zuid-Holland, Netherlands",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03625076,SHOULDER DISLOCATION,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kendall Regional Medical Center, Miami, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT03540030,OPIOID USE|SHOULDER OSTEOARTHRITIS|AVASCULAR NECROSIS|ROTATOR CUFF TEAR|ARTHRITIS;INFLAMMATORY,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OrthoCarolina Research Institute, Charlotte, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Terminated,NCT02592629,SHOULDER PAIN,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT02832115,RADIAL ARTERY SPASM|ANGINA|CORONARY ARTERY DISEASE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Aultman Hospital, Canton, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Terminated,NCT02120261,MYOFASCIAL PAIN SYNDROME,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Lyndon Baines Johnson General Hospital, Houston, Texas, United States|Memorial Hermann Hospital Texas Medical Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT04123652,CHRONIC NEUROPATHIC PAIN AND FIBROMYALGIA,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Allevio Pain Management Clinic, Toronto, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Terminated,NCT01045694,ARTHRITIS MULTIPLE JOINT,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Missouri, Columbia, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT03120923,IMPINGEMENT SHOULDER,All,"20 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT00826462,"TENNIS ELBOW|EPICONDYLITIS, LATERAL HUMERAL",All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GrÃ¥lum legesenter, Sarpsborg, Norway",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03982862,SCAR KELOID|HYPERTROPHIC SCAR,All,18 Years to 60 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Kaohsiung Medical University Hospital, Kaohsiung, Taiwan",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT04023695,TRIGGER FINGER DISORDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT02121119,HALLUX VALGUS,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DivisiÃ³n de Anestesia - Facultad de Medicina Pontificia Universidad CatÃ³lica, Santiago, RegiÃ³n Metropolitana, Chile",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT01751347,CARPAL TUNNEL SYNDROME|TRIGGER FINGER,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Vancouver General Hospital, Vancouver, British Columbia, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Unknown status,NCT02535273,SPINAL DISEASES|LOCAL ANESTHESIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT01250184,MYOFASCIAL PAIN SYNDROME|PAIN|MYOFASCIAL TRIGGER POINT PAIN|MUSCULOSKELETAL PAIN,All,18 Years to 60 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Clinica de Las AmÃ©ricas, Medellin, Antioquia, Colombia|Ips Universitaria, Medellin, Antioquia, Colombia",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03630198,KELOID|ALOPECIA AREATA|ACNE|HYPERTROPHIC SCAR|EPIDERMAL INCLUSION CYST|FRONTAL FIBROSING ALOPECIA|LICHEN PLANO-PILARIS|KERATOACANTHOMA|PLAQUE PSORIASIS|LICHEN SIMPLEX CHRONICUS|PRURIGO NODULARIS|NUMMULAR ECZEMA|GRANULOMA ANNULARE|MORPHEA|LICHEN PLANUS,All,"12 Years and older Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Withdrawn,NCT02809755,OBESITY,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","New York University School of Medicine, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT02001740,ADHESIVE CAPSULITIS,All,"19 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kingston General and Hotel Dieu Hospitals, Kingston, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Terminated,NCT01833221,FACIAL PARESIS,All,"6 Years to 70 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Centre Hospitalier Universitaire, Caen, Basse-normandie, France",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Suspended,NCT03704584,TENOSYNOVITIS,All,"18 Years to 95 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory Clinic A, Clifton Road Clinic, Atlanta, Georgia, United States|12 Executive Park Drive, Atlanta, Georgia, United States|Emory Healthcare Orthopaedics and Spine Center, Atlanta, Georgia, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Unknown status,NCT02762656,SPINAL DISEASES,All,18 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Sheba Medical Center, Ramat Gan, Israel",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Withdrawn,NCT00863889,BURSITIS,All,"17 Years and older Â  (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Dr. Tom Bradbury, Atlanta, Georgia, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT02176304,KNEE OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Puerto Rico School Of Medicine Outpatient Clinics, San Juan, Puerto Rico",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT02102620,HANDS OSTEOARTHRITIS,All,"40 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Federal University of SÃ£o Paulo, SÃ£o Paulo, SP, Brazil",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Terminated,NCT00628355,PELVIC PAIN,Female,18 Years to 45 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Center of Chronic Pelvic Pain and Gynecologic Endoscopy of Ribeirao Preto Medical School, University of Sao Paulo, RibeirÃ£o Preto, Sao Paulo, Brazil",1,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT02632565,CHRONIC PAIN,All,"50 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Completed,NCT04143165,EPIDURAL BLOCK IN AXIAL SPONDYLOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Sohag university, Sohag, Egypt",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Unknown status,NCT02613455,LATERAL EPICONDYLITIS|TENNIS ELBOW,All,"18 Years and older Â  (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Walter Reed National Military Medical Ceneter, Bethesda, Maryland, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03893318,SYSTEMIC LIDOCAINE IMPROVES PAIN CONTROL AFTER SURGERY BY ATTENUATING THE SYSTEMIC INFLAMMATORY RESPONSE TO SURGERY,All,"12 Years to 18 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Barnes Jewish Hospital and St. Louis Children Hospital / Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,1,DB00285,__VENLAFAXINE,5916923,Completed,NCT00592384,MAJOR DEPRESSIVE DISORDER|DYSTHYMIA|SPINAL CORD INJURIES,All,18 Years to 64 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama, Birmingham, Alabama, United States|University of Miami, Miami, Florida, United States|Rehabilitation Institute of Chicago, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Baylor Institute for Rehabilitation, Dallas, Texas, United States|University of Washington/Harborview Medical Center, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,26.678165876096,374.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.69,277.4018,32.7,3.0,1.0,2.0,32.33,83.02,5.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,1,DB00285,__VENLAFAXINE,5916923,Completed,NCT00611676,OSTEOARTHRITIS|PAIN,All,"50 Years to 80 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,26.678165876096,374.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.69,277.4018,32.7,3.0,1.0,2.0,32.33,83.02,5.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
CCOC(=O)c1cncn1[C@H](C)c1ccccc1,1,DB00292,__ETOMIDATE,4289783,Recruiting,NCT03625076,SHOULDER DISLOCATION,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kendall Regional Medical Center, Miami, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,19.975769522988106,145.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.66,244.28900000000002,44.12,2.0,0.0,2.0,26.43,69.59,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Terminated,NCT02056301,PECTUS EXCAVATUM,All,"8 Years to 18 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Texas Children't Hospital, Houston, Texas, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT02292082,OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT01953978,PAIN,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Glostrup University Hospital, Glostrup, Denmark",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT01502644,CHRONIC LOW BACK PAIN|DEGENERATIVE DISC DISEASE|DEPRESSION|ANXIETY,All,"21 Years to 75 Years Â  (Adult, Older Adult)",Other|NIH,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Withdrawn,NCT02426164,"PAIN, POSTOPERATIVE|ARTHROPLASTY, REPLACEMENT, KNEE|OSTEOARTHRITIS",All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Miller Orthopedic Specialists, Council Bluffs, Iowa, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT02530151,"FEMORACETABULAR IMPINGEMENT|PAIN, POSTOPERATIVE",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Joshua Barett, Chicago, Illinois, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT02658149,OSTEOARTHRITIS|ARTHROPLASTY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Beaumont Hospital, Royal Oak, Michigan, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT00901628,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 81 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Joint Reconstruction Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT00353704,INTERVERTEBRAL DISK DISPLACEMENT|DISK PROLAPSE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asker and Baerum Hospital, Rud, Norway",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Withdrawn,NCT02765815,"OSTEOARTHRITIS, KNEE|ARTHROPLASTY, REPLACEMENT, KNEE",All,"18 Years to 88 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Holy Cross Hospital Orthopedic Research Institute, Fort Lauderdale, Florida, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Terminated,NCT00270322,"PAIN, POSTOPERATIVE|OSTEOARTHRITIS",All,"55 Years to 85 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Rambam Health Care Campus, Haifa, Israel",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Unknown status,NCT02282956,HALLUX VALGUS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Spital Grabs, Grabs, Switzerland",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Completed,NCT00880607,PAIN MANAGEMENT|SPINAL FUSION|SCOLIOSIS,All,8 Years to 17 Years Â  (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The Children's Hospital- Denver, Aurora, Colorado, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Unknown status,NCT01281891,PRIMARY OSTEOARTHRITIS REQUIRING TOTAL HIP REPLACEMENT,All,"50 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ãrebro University Hospital, Ãrebro, Sweden",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Recruiting,NCT04388111,"KNEE DISEASE|ARTHRITIS KNEE|PAIN, ACUTE",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Houston Methodist Hospital, Houston, Texas, United States",A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT02576249,OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT01450007,SHOULDER INJURY,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Mayo Clinic in Arizona, Phoenix, Arizona, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Withdrawn,NCT02365727,KNEE OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Steadman Hawkins Clinic of the Carolinas - Greenville Health System, Greenville, South Carolina, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Terminated,NCT03119038,OSTEOARTHRITIS|DEGENERATIVE JOINT DISEASE,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Enrolling by invitation,NCT02570503,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Virginia Commonwealth University, Richmond, Virginia, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT02658149,OSTEOARTHRITIS|ARTHROPLASTY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Beaumont Hospital, Royal Oak, Michigan, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Not yet recruiting,NCT04257682,KNEE OSTEOARTHRITIS|HIP OSTEOARTHRITIS,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,C07D211/60,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Recruiting,NCT04391855,"ANALGESIA|PAIN, POSTOPERATIVE|SPINAL STENOSIS|SPINAL DISEASE",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AHEPA University Hospital, Thessaloniki, Greece",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Terminated,NCT03219983,GLENOHUMERAL ARTHRITIS|TOTAL SHOULDER ARTHROPLASTY,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Christ Hospital, Cincinnati, Ohio, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Not yet recruiting,NCT04209504,SHOULDER SURGERY|SHOULDER PAIN|SHOULDER INJURIES|SHOULDER ARTHRITIS|SHOULDER DISEASE|ROTATOR CUFF TEARS|ROTATOR CUFF INJURIES|ROTATOR CUFF ARTHROPATHY OF LEFT SHOULDER|ROTATOR CUFF ARTHROPATHY OF RIGHT SHOULDER|ROTATOR CUFF REPAIR,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Duke University Hospital, Durham, North Carolina, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Recruiting,NCT03474510,"PAIN, POSTOPERATIVE|SHOULDER OSTEOARTHRITIS",All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Good Samarian Hospital, Cincinnati, Ohio, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT01987128,HALLUX VALGUS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Istituto Ortopedico G. Pini, Milan, Milano, Italy",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Not yet recruiting,NCT04481451,"PAIN, POSTOPERATIVE|REGIONAL ANESTHESIA|HIP DYSPLASIA",All,"15 Years to 30 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Boston Children""S Hospital, Boston, Massachusetts, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Recruiting,NCT04074265,"CEREBRAL PALSY|HIP DYSPLASIA|PAIN, POSTOPERATIVE",All,"up to 18 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Orthopaedic Institute for Children, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UCLA Medical Center, Santa Monica, Santa Monica, California, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT03921034,ARTHROPATHY OF KNEE|ANESTHESIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Recruiting,NCT02944526,ADHESIVE CAPSULITIS|FROZEN SHOULDER|NERVE BLOCK,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinique Saint-Jean, Brussels, Belgium",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Withdrawn,NCT03506620,FEMOROACETABULAR IMPINGEMENT,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Suspended,NCT03353233,KNEE OSTEOARTHRITIS|PRIMARY TOTAL KNEE ARTHROPLASTY|PHYSICAL THERAPY|PAIN|KNEE EXTENSION,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Duke University Hospital, Durham, North Carolina, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT01537146,OSTEOARTHRITIS|MALALIGNMENT,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Northern Orthopaedic Division, Clinik Farsoe, Aalborg University Hospital, Farsoe, Northern Jutland, Denmark",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Unknown status,NCT02903719,SHOULDER PAIN|SURGERY|NERVE BLOCK,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rigshospitalet, Copenhagen, Denmark",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT03513276,HIP OSTEOARTHRITIS,All,"20 Years to 100 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Suspended,NCT02933671,HIP OSTEOARTHRITIS|PRIMARY TOTAL HIP ARTHROPLASTY|PAIN,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Duke University Hospital, Durham, North Carolina, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Unknown status,NCT01703130,SHOULDER PAIN,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sunnybrook Health Sciences Centre - Holland Orthopaedic and Arthritic Centre, Toronto, Ontario, Canada",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Terminated,NCT02299271,OSTEOARTHRITIS OF THE HIP,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Christ Hospital, Cincinnati, Ohio, United States",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT02173418,POSTOPERATIVE PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Departement of Anaesthesia and intensive care, Odense University Hospital, Odense, Region of Southern Denmark, Denmark",C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Unknown status,NCT02808728,OSTEOARTHRITIS|TOTAL KNEE ARTHROPLASTY|PAIN MANAGEMENT,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D211/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB00296,__ROPIVACAINE,4870086,Completed,NCT03265223,ROPIVACAINE|LAPAROSCOPIC CHOLECYSTECTOMY|PAIN,All,"15 Years to 80 Years Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07D211/60,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,34.0705147949649,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.91,274.4011,32.34,2.0,1.0,2.0,32.67,85.59,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02292082,OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Withdrawn,NCT02426164,"PAIN, POSTOPERATIVE|ARTHROPLASTY, REPLACEMENT, KNEE|OSTEOARTHRITIS",All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Miller Orthopedic Specialists, Council Bluffs, Iowa, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02346110,"ARTHROSIS, UNSPECIFIED, ANKLE AND FOOT",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Department of Anesthesiology, Aarhus University Hospital, Aarhus, Midtjylland, Denmark",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02464176,"OSTEOARTHRITIS, HIP",All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02462148,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT01586806,"ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION|REGIONAL ANESTHESIA, SAPHENOUS NERVE BLOCK",All,"16 Years to 65 Years Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Withdrawn,NCT02624856,"OSTEOARTHRITIS|PAIN, POSTOPERATIVE",All,"40 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Albany Medical Center, Albany, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Withdrawn,NCT02365727,KNEE OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Steadman Hawkins Clinic of the Carolinas - Greenville Health System, Greenville, South Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Terminated,NCT03119038,OSTEOARTHRITIS|DEGENERATIVE JOINT DISEASE,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Not yet recruiting,NCT04257682,KNEE OSTEOARTHRITIS|HIP OSTEOARTHRITIS,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Unknown status,NCT02022722,DYSPAREUNIA,Female,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Division of Urogynecology, University of Cincinnati Medical Center, Cincinnati, Ohio, United States",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT04361513,PAIN|JOINT FUNCTION DISORDER|INFLAMMATION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Minia university, Minya, Egypt",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT03586154,BREAST NEOPLASM,Female,18 Years to 64 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MansouraU, Mansourah, Mansoura, Egypt",1,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Not yet recruiting,NCT03909594,"PAIN, MUSCULOSKELETAL",All,"18 Years to 120 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Maimonides Medical Center, Brooklyn, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Withdrawn,NCT02765815,"OSTEOARTHRITIS, KNEE|ARTHROPLASTY, REPLACEMENT, KNEE",All,"18 Years to 88 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Holy Cross Hospital Orthopedic Research Institute, Fort Lauderdale, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02121119,HALLUX VALGUS,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DivisiÃ³n de Anestesia - Facultad de Medicina Pontificia Universidad CatÃ³lica, Santiago, RegiÃ³n Metropolitana, Chile",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Recruiting,NCT03514277,LOW BACK PAIN|LUMBOSACRAL RADICULOPATHY|LUMBAR DISC DEGENERATION|LUMBAR DISC HERNIATION|STENOSIS|SPONDYLOLISTHESIS|SPONDYLOLYSIS|DEFORMITY OF SPINE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Basic Science","Virtua Memorial Hospital, Mount Holly, New Jersey, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Recruiting,NCT04082676,MATERNAL HYPOTENSION AFTER SPINAL ANESTHESIA,Female,18 Years to 40 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BP Koirala Institute of Health Sciences (BPKIHS), DharÄn BÄzÄr, Koshi, Nepal",1,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT01751347,CARPAL TUNNEL SYNDROME|TRIGGER FINGER,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Vancouver General Hospital, Vancouver, British Columbia, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,"Active, not recruiting",NCT03663283,ARTHROPATHY SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mayo Clinic in Arizona, Phoenix, Arizona, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Unknown status,NCT03375112,ARTHRITIS OF HIP,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Henry Ford Hospital, Detroit, Michigan, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Terminated,NCT03219983,GLENOHUMERAL ARTHRITIS|TOTAL SHOULDER ARTHROPLASTY,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Christ Hospital, Cincinnati, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT03272139,"JOINT DISEASE|PAIN|PAIN, ACUTE|PAIN, CHRONIC",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Terminated,NCT01874236,SI JOINT PAIN,All,"21 Years to 75 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic","Orthopedic Center of Southern Illinois, Mount Vernon, Illinois, United States|Bluegrass Orthopaedics and Hand Care Research, LLC, Lexington, Kentucky, United States|Cleveland Clinic, Cleveland, Ohio, United States|Penn State College Of Medicine, Hershey, Pennsylvania, United States|Precision Spine Care, Tyler, Texas, United States|Physicians' Research Options, LLC, Sandy, Utah, United States|Virginia iSpine Research Institute, Inc, Richmond, Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02086474,HIP OSTEOARTHRITIS,All,"45 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pavillon de l'Ãducation Physique et des Sports - UniversitÃ© Laval, Quebec, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT00508066,SCOLIOSIS,All,"8 Years to 18 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Shriners Hospitals for Children - Los Angeles, Los Angeles, California, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02697955,ARTHROSIS|ARTHRITIS,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Department of Anesthesiology, Aarhus University Hospital, Aarhus, Denmark",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT02630160,MUSCULOSKELETAL PAIN|HIP INJURIES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital del Mar, Barcelona, Spain",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Recruiting,NCT03913091,SHOULDER PAIN,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"NYU Langone Health, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT03862404,POST THORACIC SURGERY,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Montreal General Hospital, Montreal, Quebec, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Recruiting,NCT03745040,LUMBAR SPINAL STENOSIS|LUMBAR DISC HERNIATION|LUMBAR DISC DISEASE|LUMBAR SPONDYLOLISTHESIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Abbott Northwestern Hospital, Allina Health System, Minneapolis, Minnesota, United States|United Hospital, Allina Health System, Saint Paul, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Unknown status,NCT03638960,SHOULDER PAIN|POSTOPERATIVE PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Southern California, Los Angeles, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT01364194,"PAIN, POSTOPERATIVE|ARTHROPATHY OF KNEE JOINT",All,"50 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT03079076,"PAIN, POSTOPERATIVE|SPINE DISEASE",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Ataturk University, Erzurum, Turkey",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Not yet recruiting,NCT04209504,SHOULDER SURGERY|SHOULDER PAIN|SHOULDER INJURIES|SHOULDER ARTHRITIS|SHOULDER DISEASE|ROTATOR CUFF TEARS|ROTATOR CUFF INJURIES|ROTATOR CUFF ARTHROPATHY OF LEFT SHOULDER|ROTATOR CUFF ARTHROPATHY OF RIGHT SHOULDER|ROTATOR CUFF REPAIR,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Duke University Hospital, Durham, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Recruiting,NCT04134442,"OSTEOARTHRITIS OF THE SHOULDER|SHOULDER PAIN|PAIN, POSTOPERATIVE",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","UMASS Memorial, Worcester, Massachusetts, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Not yet recruiting,NCT04382144,TENNIS ELBOW|LATERAL EPICONDYLITIS,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT01977352,SHOULDER PAIN|ROTATOR CUFF TEAR,All,"17 Years and older Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","St. Luke's Roosevelt Hospital Center, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Terminated,NCT02909257,"OSTEOARTHRITIS, KNEE|KNEE INJURIES",All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Hospital Clinico Universidad de Chile, Santiago, Metropolitan, Chile",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Terminated,NCT00314457,ACL REPAIR|MENISCECTOMY|BANKART REPAIR,All,"11 Years to 19 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Terminated,NCT02787226,POSTOPERATIVE PAIN|SHOULDER ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Rehabilitation and Orthopaedic Institute, Baltimore, Maryland, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Recruiting,NCT03474510,"PAIN, POSTOPERATIVE|SHOULDER OSTEOARTHRITIS",All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Good Samarian Hospital, Cincinnati, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Recruiting,NCT03887650,POST-OPERATIVE PAIN|TOTAL SHOULDER ARTHROPLASTY|OSTEOARTHRITIS OF THE SHOULDER|PAIN MANAGEMENT,All,"18 Years to 100 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","The Bone and Joint Institute at Hartford Hospital, Hartford, Connecticut, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Enrolling by invitation,NCT03845894,SHOULDER ARTHROPLASTY,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1,DB00300,__TENOFOVIR_DISOPROXIL,5814639,Recruiting,NCT02322099,BONE DEMINERALIZATION,All,"30 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Mater Misericordiae University Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Unknown status,NCT02453802,OSTEO ARTHRITIS OF THE KNEES,All,"50 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Kaohsiung Chang Gung Memorial Hospital, Koahsiung, Taiwan",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT00958581,SCOLIOSIS,All,"10 Years to 80 Years Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","New York University School of Medicine - Department of Orthopaedic Surgery - Spine, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT02422056,CLEFT PALATE|HEMORRHAGE,All,"6 Months and older Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT03653429,FOOT AND ANKLE SURGERIES|BUNION,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Icahn School of Medicine at Mount Sinai, New York, New York, United States|Ichan School of Medicine, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Terminated,NCT00722436,CRANIOSYNOSTOSIS|BLEEDING,All,"6 Months to 18 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT02584725,ARTHROPATHY OF HIP|ARTHROPATHY OF KNEE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT01937559,OSTEOARTHRITIS|HIP ARTHROPATHY|SHOULDER ARTHROPATHY,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Steadman Hawkins Clinic of the Carolinas - Greenville Health System, Greenville, South Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT01873768,OSTEOARTHRITIS,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Miller Orthopedic Specialists, Council Bluffs, Iowa, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT03631355,ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION,All,18 Years to 60 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New York University School of Medicine, New York, New York, United States",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Recruiting,NCT03606109,TIBIAL TUBERCLE OSTEOTOMY,All,18 Years to 60 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New York University School of Medicine, New York, New York, United States",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Recruiting,NCT03109652,KNEE OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Seoul National University Boramae Medical Center, Seoul, Dongjak Gu, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Completed,NCT02063035,LUMBAR SPINAL STENOSIS|THORACIC SPINAL STENOSIS,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Massachusetts General Hospital Orthopedic Spine, Boston, Massachusetts, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,"Active, not recruiting",NCT04042688,ANTERIOR CRUCIATE LIGAMENT RUPTURE,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Korea University Guro Hospital, Seoul, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00246168,RHEUMATOID ARTHRITIS,All,"18 Years to 79 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT01063842,OSTEOARTHRITIS,All,"35 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00766675,PAIN|FIBROMYALGIA,All,"20 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT03540030,OPIOID USE|SHOULDER OSTEOARTHRITIS|AVASCULAR NECROSIS|ROTATOR CUFF TEAR|ARTHRITIS;INFLAMMATORY,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OrthoCarolina Research Institute, Charlotte, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Terminated,NCT01264965,ARTHRITIS|PAIN|COGNITIVE IMPAIRMENT,All,65 Years and older Â  (Older Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Chicago Medical Center Outpatient Senior Health Center South Shore, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Recruiting,NCT04122443,MUSCULOSKELETAL PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Montefiore Medical Center, Bronx, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Terminated,NCT02029235,CARPAL TUNNEL|GANGLION CYST|TRIGGER FINGER|DE QUERVAIN DISEASE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00377364,ASTHMA|RHEUMATIC DISEASE,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UT Southwestern Medical Center at Dallas, Dallas, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT02839876,"OSTEOARTHRITIS|ACETAMINOPHEN|ARTHROPLASTY, HIP REPLACEMENT",All,"56 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Duke University Hospital, Durham, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00489424,OSTEOPOROSIS,Female,"45 Years to 79 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Refer to the E-portal link for ZOL446HUS136, Http://www.osteoporosisclinicalresearch.com, New Jersey, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Recruiting,NCT03651804,VERTEBRAL COMPRESSION FRACTURE|FACET JOINT PAIN,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"UC Davis Medical Center, Davis, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00510536,ARTHRITIS|ARTHRALGIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"K. Papp Clinical Research Inc., Waterloo, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT02113566,DELAYED ONSET MUSCLE SORENESS,All,18 Years to 55 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Jean Brown Research, Salt Lake City, Utah, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00240838,PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT03448536,DYSMENORRHEA,Female,"15 Years to 35 Years Â  (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Radiant Research, Inc., Chandler, Arizona, United States|Radiant Research, Inc., Scottsdale, Arizona, United States|Radiant Research, Inc., Pinellas Park, Florida, United States|Radiant Research, Inc., Chicago, Illinois, United States|Radiant Research, Inc., Akron, Ohio, United States|Radiant Research, Inc., Cincinnati, Ohio, United States|Radiant Research, Inc., Dallas, Texas, United States|Synexus US, LP- Plano, Plano, Texas, United States",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00318,__CODEINE,6383471,Completed,NCT03784105,ESOPHAGEAL MOTILITY DISORDERS,All,18 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","Jan Tack, Leuven, Belgium|UZ Leuven, Leuven, Belgium",A61K47/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00318,__CODEINE,6383471,Completed,NCT00386269,CLEFT PALATE REPAIR,All,4 Months to 8 Months Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Great Ormond Street Hospital, Anaesthetics, London, United Kingdom",A61K47/02,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00318,__CODEINE,6383471,Withdrawn,NCT02032927,CHRONIC PAIN,All,"60 Years to 100 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Azienda Ospedaliera della Provincia di Pavia - Ospedale ""Carlo Mira"" - U.O. Medicina Interna - Servizio di Anestesia e Rianimazione - Ambulatorio di Terapia del dolore, Casorate Primo, Italy|Azienda Istituti Ospitalieri di Cremona, Presidio Ospedaliero di Cremona - U.O. di Anestesia, Analgesia e Medicina Perioperatoria, Cremona, Italy|Azienda Ospedaliera della provincia di Lodi Dipartimento emergenza urgenza, Lodi, Italy|Azienda Ospedaliera Istituto Ortopedico Gaetano Pini - U.O.C. Anestesia e Rianimazione, Milano, Italy|Azienda Ospedaliera della Provincia di Pavia - Ospedale Asilo Vittoria di Mortara - U.O. di Pneumotisiologia, Mortara, Italy|Clinica San Carlo - Casa di Cura Polispecialistica S.p.A. - UnitÃ  di Terapia del Dolore, Paderno Dugnano, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Servizi alla Persona, ASP, ""II.AA.RR."" - Istituto di Riabilitazione ""Santa Margherita"" - Struttura Complessa di Riabilitazione, Pavia, Italy|Fondazione Salvatore Maugeri - sede di Via Boezio - UO Cure Palliative e Terapia del Dolore, Pavia, Italy|IRCCS Istituto Clinico ""Humanitas"" - Anestesia, Day Hospital chirurgico - Chronic Pain Service, Rozzano, Italy|Dipartimento Integrato di Lungassistenza Anziani - ASL TO1, Torino, Italy|Ospedale di circolo Fondazione Macchi - SSD Anestesia Day Surgery, Varese, Italy|Azienda Ospedaliera della Provincia di Pavia - Ospedale Civile di Vigevano - Servizio di Anestesia e Rianimazione, Vigevano, Italy|Azienda Ospedaliera della Provincia di Pavia - Ospedale Civile di Voghera- U.O. di Medicina Interna - U.O. di Riabilitazione specialistica, Voghera, Italy",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00318,__CODEINE,6383471,Completed,NCT00784810,OSTEOARTHRITIS|BACK PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Coventry, United Kingdom",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,1,DB00318,__CODEINE,6383471,Completed,NCT02501564,OSTEOARTHRITIS,All,"40 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CN(C)CCC=C1c2ccccc2CCc2ccccc21,1,DB00321,__AMITRIPTYLINE,3965255,Completed,NCT04523935,CEREBRAL PALSY|CRYING,All,up to 15 Years Â  (Child),Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",,A61K9/282,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,25.725374237664,663.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.1,277.4033,3.24,1.0,0.0,3.0,33.74,101.51,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CN(C)CCC=C1c2ccccc2CCc2ccccc21,1,DB00321,__AMITRIPTYLINE,3965255,Completed,NCT00766350,FIBROMYALGIA,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clinico Universitario San Cecilio, Granada, Spain",A61K9/282,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,25.725374237664,663.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.1,277.4033,3.24,1.0,0.0,3.0,33.74,101.51,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CN(C)CCC=C1c2ccccc2CCc2ccccc21,1,DB00321,__AMITRIPTYLINE,3965255,Unknown status,NCT02339662,MYOFACIAL PAIN,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hadassah MO, Jerusalem, Israel",A61K9/282,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,25.725374237664,663.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.1,277.4033,3.24,1.0,0.0,3.0,33.74,101.51,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Recruiting,NCT04111328,"ANALGESIA, PATIENT-CONTROLLED",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"The First Affiliated Hosipital of China Medical University, Shenyang, Liaoning, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Terminated,NCT02056301,PECTUS EXCAVATUM,All,"8 Years to 18 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Texas Children't Hospital, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Active Not Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Completed,,ABDOMINAL PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Completed,NCT00142558,ACUTE GOUT,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Completed,NCT03582332,AXIAL SPONDYLOARTHRITIS,All,18 Years to 45 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Terminated,NCT03473665,ANKYLOSING SPONDYLITIS|AXIAL SPONDYLOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Columbia University Irving Medical Center, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Terminated,NCT00554476,LATERAL EPICONDYLITIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Azad University of Medical Sciences, Boo-Ali Hospital, Tehran, Iran, Islamic Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Completed,,ACUTE GOUTY ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Completed,,ANKLE SPRAINS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
CC[C@@H](CO)NCCN[C@@H](CC)CO,1,DB00330,__ETHAMBUTOL,5322689,Unknown status,NCT02477852,"TUBERCULOSIS, SPINAL",All,"15 Years to 75 Years Â  (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing chest hospital, Beijing, Beijing, China",A61K9/0014,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,286.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.12,204.3098,64.52,4.0,4.0,0.0,24.47,57.89,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02060383,CUSHING'S DISEASE|ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States|LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States|Coastal Metabolic Research Centre SC, Ventura, California, United States|East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States|Washington University SC - SOM230B2411, Saint Louis, Missouri, United States|Great Falls Clinic, Great Falls, Montana, United States|Robert Wood Johnson Medical School - Rutgers SC, New Brunswick, New Jersey, United States|The Mount Sinai Hospital SC, New York, New York, United States|Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC, New York, New York, United States|Allegheny Endocrinology Associates SC, Pittsburgh, Pennsylvania, United States|Vanderbilt Clinical Trials Center SOM230B2219, Nashville, Tennessee, United States|Baylor College of Medicine Ben Taub General Hosp., Houston, Texas, United States|Virginia Endocrinology Research SC-2, Chesapeake, Virginia, United States|Swedish Medical Center Dept.ofSeattle Neuroscience(2), Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, SÃ£o Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,NCT01691079,"BRONCHOSPASM, EXERCISE-INDUCED",All,"13 Years and older Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Francisco, San Francisco, California, United States",F04B53/125,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,EXERCISE-INDUCED BRONCHOSPASM,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Completed,NCT02206685,THORACOLUMBAR SCOLIOSIS,All,10 Years to 17 Years Â  (Child),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Texas Children't Hospital, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Completed,,"PAIN, CHRONIC",,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D495/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D495/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,NCT01295047,MARFAN SYNDROME,All,"16 Years to 60 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wales Heart Research Institute, Cardiff University, Cardiff, United Kingdom",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",A61F9/0017,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT02500641,GOUT,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Klinik und Poliklinik III/Rheumatologie UniversitÃ¤tsklinikum ""Carl Gustav Carus"" Der Technischen UniversitÃ¤t, Dresden, Germany|Presidio Ospedaliero San Filippo e Nicola UniversitÃ  degli Studi dell'Aquila U.O.C Geriatria e Lungodegenza Geriatrica, Avezzano, L'Aquila, Italy|Ospedale San Salvatore U.O.C. Medicina Interna e Nefrologia Dipartimento MeSVA UniversitÃ  degli Studi dell'Aquila, Coppito, L'Aquila, Italy|Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Policlinico SS. Annunziata UniversitÃ  degli Studi ""G. d'Annunzio"". Dipartimento di Medicina e Scienze dell'Invecchiamento., Chieti, Italy|Reade Clinic, Amsterdam, Netherlands|GdaÅskie Centrum Zdrowia Sp.z o.o., GdaÅsk, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, GrudziÄdz, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Centrum Medyczne Plejady, KrakÃ³w, Poland|Krakowski Szpital Specjalistyczny im. Jana PawÅa II w Krakowie, KrakÃ³w, Poland|Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, KrakÃ³w, Poland|Pratia S,A, Warsaw, Poland|Reumatika- Centrum Reumatologii, Warsaw, Poland|OddziaÅ Kardiologiczny, WSS im. W. BiegaÅskiego w Åodzi, ÅÃ³dÅº, Poland|Polimedica, ÅÃ³dÅº, Poland|Clinica MedicalÄ Data Plus SRL, Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|S.C. Centrul Medical Sana S.R.L., Bucharest, Romania|S.C. Cardiomed S.R.L., Craiova, Romania|Institutul de Boli Cardiovasculare Clinica de Cardiologie si Recuperare Cardiovasculara, Timisoara, Romania|Cabinet Medical Medicina Interna, TimiÅoara, Romania|Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia|Institut za reumatologiju, Belgrade, Serbia|KliniÄko-bolniÄki centar ""BeÅ¾anijska kosa"" Klinika za imunologiju i alergologiju, Belgrade, Serbia|Vojnomedicinska akademija Klinika za reumatologiju, Belgrade, Serbia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT00141102,"OSTEOARTHRITIS|ARTHRITIS, RHEUMATOID",All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, LiÃ¨ge, Belgium|Pfizer Investigational Site, GoiÃ¢nia, GO, Brazil|Pfizer Investigational Site, GoiÃ¢nia, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, SÃ£o Paulo, SP, Brazil|Pfizer Investigational Site, SÃ£o Paulo, SP, Brazil|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste Foy, Quebec, Canada|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Chengdu, Sichuan, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Floridablanca, Santander, Colombia|Pfizer Investigational Site, Cartago, Costa Rica|Pfizer Investigational Site, Heredia, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Opatija, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Plzen, Bory, Czech Republic|Pfizer Investigational Site, Ostrava, Trebovice, Czech Republic|Pfizer Investigational Site, Ceske Budejovice, Czech Republic|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Prague 1, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 4, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Cuenca, Azuay, Ecuador|Pfizer Investigational Site, Guayaquil, Guayas, Ecuador|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Amiens, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Deggingen, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hoyerswerda, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Ciudad de Guatemala, Guatemala|Pfizer Investigational Site, Guatemala 01010, Guatemala|Pfizer Investigational Site, Lai Chi Kok, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Alytus, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Klaipeda, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vlaardingen, ZH, Netherlands|Pfizer Investigational Site, Alkmaar, Netherlands|Pfizer Investigational Site, Leidschendam, Netherlands|Pfizer Investigational Site, Ciudad de Panama, Panama|Pfizer Investigational Site, Surco, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisbon, Portugal|Pfizer Investigational Site, Ponta Delgada, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ekaterinburg, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Petrozavodsk, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Niska Banja, Serbia|Pfizer Investigational Site, Novi Sad, Serbia|Pfizer Investigational Site, Sinapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bloemfontein, Free State, South Africa|Pfizer Investigational Site, Johannesburg, Gauteng Province, South Africa|Pfizer Investigational Site, Durban, KZN, South Africa|Pfizer Investigational Site, Parow, Western Cape, South Africa|Pfizer Investigational Site, Bellville, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Kempton Park, South Africa|Pfizer Investigational Site, Observatory Cape Town, South Africa|Pfizer Investigational Site, Partida de Bacarot, Alicante, Spain|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Barakaldo, Vizcaya, Spain|Pfizer Investigational Site, Avila, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Lulea, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Tao-Yuan, Taiwan|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Ivano-Frankivsk, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kiev, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lutsk, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Simferopol, Ukraine|Pfizer Investigational Site, Zaporizhzhia, Ukraine|Pfizer Investigational Site, Helensburgh, Argyle & Clyde, United Kingdom|Pfizer Investigational Site, Maidenhead, Berks, United Kingdom|Pfizer Investigational Site, Aston Clinton, Buckinghamshire, United Kingdom|Pfizer Investigational Site, St Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Aldershot, Hampshire, United Kingdom|Pfizer Investigational Site, Basingstoke, Hampshire, United Kingdom|Pfizer Investigational Site, Odiham, Hampshire, United Kingdom|Pfizer Investigational Site, Ashford, Middlesex, United Kingdom|Pfizer Investigational Site, Harrow, Middlesex, United Kingdom|Pfizer Investigational Site, Camberley, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Leatherhead, Surrey, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Bradford-on-Avon, Wiltshire, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, United Kingdom|Pfizer Investigational Site, Upton, Wirral, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, United Kingdom|Pfizer Investigational Site, Canterbury, United Kingdom|Pfizer Investigational Site, Chesterfield, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, St Leonards on Sea, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom|Pfizer Investigational Site, Vale of Glamorgan, United Kingdom|Pfizer Investigational Site, Wansford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT02394340,TINEA PEDIS|TINEA CRURIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"TKL Research, Fair Lawn, New Jersey, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT00582972,OSTEOPOROSIS|ACHLORHYDRIA|GERD|HIP FRACTURE,Female,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,,FOOD ALLERGY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,Unknown status,NCT02477852,"TUBERCULOSIS, SPINAL",All,"15 Years to 75 Years Â  (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing chest hospital, Beijing, Beijing, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,1,DB00343,__DILTIAZEM,5286497,Recruiting,NCT04310995,CORONARY ARTERY BYPASS GRAFT|RADIAL ARTERY GRAFTS|ANTISPASTIC THERAPY|PILOT STUDY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,9.363641963900688,2015.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.09,414.51800000000003,59.08,4.0,0.0,3.0,43.65,114.37,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,1,DB00343,__DILTIAZEM,5286497,Completed,NCT03930433,CORONARY VASOSPASM,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Korea University Anam Hospital, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,9.363641963900688,2015.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.09,414.51800000000003,59.08,4.0,0.0,3.0,43.65,114.37,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,1,DB00343,__DILTIAZEM,5286497,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,9.363641963900688,2015.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.09,414.51800000000003,59.08,4.0,0.0,3.0,43.65,114.37,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
Nc1ccc(C(=O)NCC(=O)O)cc1,1,DB00345,__AMINOHIPPURIC_ACID,4292154,Not Yet Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",G01N27/44747,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,17.708782521201602,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,194.1873,92.42,4.0,3.0,1.0,19.13,50.82,3.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
O=c1[nH]c2cc(Cl)ccc2o1,1,DB00356,__CHLORZOXAZONE,4551473,Completed,NCT02405104,"OSTEOARTHRITIS OF HIP|OSTEOARTHRITIS, KNEE",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Northern Orthopaedic Division, Clinic FarsÃ¸, Aalborg University Hospital, FarsÃ¸, Northern Jutland, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,18.333025318795,443.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.09,169.565,38.33,2.0,1.0,2.0,14.94,41.07,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1,1,DB00376,__TRIHEXYPHENIDYL,4175119,Completed,NCT04523935,CEREBRAL PALSY|CRYING,All,up to 15 Years Â  (Child),Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",,A61K9/209,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,360.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.93,301.4662,23.47,2.0,1.0,3.0,36.73,93.21,5.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1
Cc1cccc(C)c1OCC(C)N,1,DB00379,__MEXILETINE,3954872,Completed,NCT01811355,MUSCLE CRAMPS IN AMYOTROPHIC LATERAL SCLEROSIS,All,"21 Years to 89 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCD Telehealth Network - Lake Almanor Clinic, Chester, California, United States|UCSD Department of Neurosciences ALS Clinical Trials (ACT) Program, La Jolla, California, United States|UCLA Neuromuscular Research Program, Los Angeles, California, United States|UCD Telehealth Network, Multiple Locations, California, United States|UC Irvine Health ALS & Neuromuscular Center, Orange, California, United States|UC, Davis Medical Center ALS Clinic, Sacramento, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.088687652723802,501.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.17,179.2588,35.25,2.0,1.0,1.0,21.17,54.97,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB00396,__PROGESTERONE,5543150,Completed,NCT00294463,POSTMENOPAUSE|OSTEOPOROSIS,Female,"Child, Adult, Older Adult",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus MC, Rotterdam, Netherlands",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,34.694757592558304,3548.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.58,314.4617,34.14,2.0,0.0,4.0,37.26,92.71,1.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB00396,__PROGESTERONE,5543150,Unknown status,NCT01698164,MENOPAUSAL SYNDROME|CARDIOVASCULAR DISEASE|OSTEOPOROSIS|BREAST CANCER,Female,40 Years to 60 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PUMCH, Peking, Beijing, China",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,34.694757592558304,3548.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.58,314.4617,34.14,2.0,0.0,4.0,37.26,92.71,1.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00795483,HIV INFECTION,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00334139,PROSTATE CANCER|BREAST CANCER|BONE METASTASIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Ulm, Germany",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Not yet recruiting,NCT02480634,NON-SMALL CELL LUNG CANCER|BONE METASTASIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Recruiting,NCT02286830,MULTIPLE MYELOMA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Odense University Hospital, Odense C, Denmark",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT01129336,FIRST OR SECOND LINE HER2-NEGATIVE BREAST CANCER|METASTATIC DISEASE WITHOUT BONE METASTASIS,Female,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, Fayetteville, Arkansas, United States|Clopton Clinic, Jonesboro, Arkansas, United States|Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States|Kaiser Permanente Medical Group Kaiser Permanente - Hawaii, Anaheim, California, United States|Wilshire Oncology Medical Group, La Verne, California, United States|Loma Linda University Loma Linda Cancer Center, Loma Linda, California, United States|Hematology and Medical Oncology, Waterbury, Connecticut, United States|Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States|Lakeland Regional Cancer Center Dept. of Lakeland Regional, Lakeland, Florida, United States|Space Coast Medical Associates, Titusville, Florida, United States|Kootenai Medical Center Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Oncology Specialists, SC Lutheran General Cancer Instit, Park Ridge, Illinois, United States|Cancer Center of Kansas, Witchita, Kansas, United States|Park Nicollet Institute Dept. of Park Nicollet, St. Louis Park, Minnesota, United States|St. John's Mercy Medical Center St. John's Mercy Med Ctr, St. Louis, Missouri, United States|Hematology Oncology Centers of the Northern Rockies Hema Onc Ctr N. Rockies (4, Billings, Montana, United States|Southeast Nebraska Oncology Cancer Center, Lincoln, Nebraska, United States|Reno Oncology Consultants, Reno, Nevada, United States|Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2), Somerset, New Jersey, United States|Cooper Cancer Center, Voorhees, New Jersey, United States|NYU Langone Arena Oncology, Lake Success, New York, United States|Marion L. Shepard Cancer Center, Washington, North Carolina, United States|Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2), Winston-Salem, North Carolina, United States|Hematology Oncology Center, Inc., Elyria, Ohio, United States|Milton S Hershey Medical Center Hershey Medical Center (4), Hershey, Pennsylvania, United States|Berks Hematology Oncology, West Reading, Pennsylvania, United States|Abington Hematology Oncology Associates, Inc, Willow Grove, Pennsylvania, United States|The West Clinic, Memphis, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|South Texas Oncology and Hematology, PA South Texas Oncology (2), San Antonio, Texas, United States|East Texas Medical Center Cancer Institute Tyler Hem/Onc (3), Tyler, Texas, United States|Medical Oncology & Hematology Associates of Northern VA Med. Onc&Hem Assoc. of No.VA, Reston, Virginia, United States|Northwest Medical Specialties, Tacoma, Washington, United States",C07F9/65031,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00434447,BONE NEOPLASMS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Novartis Investigative Site, Canberra, Australian Capital Territory, Australia|Novartis Investigative Site, Concord, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, Wagga Wagga, New South Wales, Australia|Novartis Investigative Site, Redcliffe, Queensland, Australia|Novartis Investigative Site, Townsville, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Ballarat, Victoria, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Frankston, Victoria, Australia",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00241111,PROSTATE CANCER WITH BONE METASTASIS,Male,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65031,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00237159,PROSTATE CANCER PATIENTS WITH BONE METASTASIS,Male,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65031,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00172029,BREAST CANCER WITH METASTATIC BONE DISEASE,Female,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Bursa, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kayseri, Turkey|Novartis Investigative Site, Trabzon, Turkey",C07F9/65031,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Recruiting,NCT03924414,PARKINSON DISEASE|OSTEOPOROSIS|PARKINSONISM,All,65 Years and older Â  (Older Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mayo Clinic, Scottsdale, Arizona, United States|Loma Linda University, Loma Linda, California, United States|Valley Parkinson Clinic, Los Gatos, California, United States|UC Davis Medical Center, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Mayo Clinic, Jacksonville, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Cook County Health & Hospitals System, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|Mayo Clinic, Rochester, Minnesota, United States|Northwell Health, Glen Cove, New York, United States|Northwell Health, Great Neck, New York, United States|Northwell Health, Manhasset, New York, United States|Duke University, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Veracity Neuroscience LLC, Memphis, Tennessee, United States|University of Wisconsin, Madison, Wisconsin, United States",C07F9/65031,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00063609,PROSTATE CANCER,Male,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,"Millennium Therapeutics & Research, Birmingham, Alabama, United States|Medical Affiliated Research Center, Huntsville, Alabama, United States|Alaska Clinical Research Center, Anchorage, Alaska, United States|Advanced Clinical Therapeutics, Tucson, Arizona, United States|Donald Gleason, MD, Tucson, Arizona, United States|Arkansas Urology, Little Rock, Arkansas, United States|Advanced Urology Med. Center, Anaheim, California, United States|Atlantic Urological Medical Group, Long Beach, California, United States|San Diego Uro. Research, San Diego, California, United States|Western Clinical Research, Torrance, California, United States|Connecticut Surgical Group, Hartford, Connecticut, United States|Grove Hill Urology, New Britain, Connecticut, United States|Atlantic Urological Associates, Daytona Beach, Florida, United States|University of Miami School of Medicine, Dept. of Urology, Miami, Florida, United States|Advanced Research Institute, Inc., New Port Richey, Florida, United States|Urosearch, Ocala, Florida, United States|Southeastern Urological Center, PA, Tallahassee, Florida, United States|Medisphere Medical Research Center, LLC, Evansville, Indiana, United States|The Iowa Clinic, PC, Iowa Urology Research, Des Moines, Iowa, United States|Summitt Clinical Research, Owings Mills, Maryland, United States|Millennium Medical Center, Southfield, Michigan, United States|Quality Clinical Research LLC, Springfield, Nebraska, United States|Associated Urologic Specialist, PA, Marlton, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Associates In Urology, LLC, West Orange, New Jersey, United States|AccuMed Research Associates, Garden City, New York, United States|Urological Surgeons of L.I., Garden City, New York, United States|Staten Island Urological Research, PC, Staten Island, New York, United States|The Urology Group, Cincinnati, Ohio, United States|Urological Associates, Inc., Columbus, Ohio, United States|Mount Vernon Urological Associates, Mount Vernon, Ohio, United States|Oregon Urology Specialists, Eugene, Oregon, United States|The Urology Clinic, Portland, Oregon, United States|Urologic Associates of Allentown, Allentown, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Triangle Urological Group, Pittsburgh, Pennsylvania, United States|Urologic Surgeons of New England, P.C., Providence, Rhode Island, United States|University Urological Research Institute, Providence, Rhode Island, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Integrity Clinical Research, LLC, Germantown, Tennessee, United States|Urology San Antonio Research, San Antonio, Texas, United States|Salt Lake Research, Salt Lake City, Utah, United States|Seattle Urological Associates, Seattle, Washington, United States|Rockwood Clinic, Spokane, Washington, United States",C07F9/65031,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT01675089,RENAL OSTEODYSTROPHY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital das Clinicas - Faculdade de Medicina da Universidade de SÃ£o Paulo, Sao Paulo, Brazil",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Recruiting,NCT03735537,OSTEOGENESIS IMPERFECTA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"St Vincent's Hospital, Dublin, Ireland|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Royal Victoria Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal Liverpool Hospital, Liverpool, United Kingdom|Llandough University Hospital, Llandough, United Kingdom|Guy's and St Thomas' Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom|Queen Alexandria Hospital, Portsmouth, United Kingdom|Northern General Hospital, Sheffield, United Kingdom|University Hospital Southampton, Southampton, United Kingdom|Royal National Orthopaedic Hospital, Stanmore, United Kingdom|Haywood Community Hospital, Stoke-on-Trent, United Kingdom|Wishaw General Hospital, Wishaw, United Kingdom",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Recruiting,NCT04085419,PRIMARY HYPERPARATHYROIDISM|OSTEOPOROSIS,Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Endocrinology Department, Ljubljana, Slovenia",C07F9/65031,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Not yet recruiting,NCT04115397,SEROPOSITIVE MUSKULOSKELETAL COMPLAINTS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT02808988,CHRONIC PERIODONTITIS,Female,"50 Years to 66 Years Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Screening,,C07F9/65031,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00774020,PAGET'S DISEASE OF THE BONE,All,"30 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Beijing, China|Novartis Investigative site, Guangzhou, China|Novartis Investigative site, Nanjing, China|Novartis Investigative site, Shanghai, China",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Recruiting,NCT04087096,BARIATRIC SURGERY CANDIDATE|BONE LOSS,All,"25 Years and older Â  (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of California, San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT01153425,"OSTEOPOROSIS, OSTEOPENIA",Female,"60 Years and older Â  (Adult, Older Adult)",Other|Industry|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",C07F9/65031,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00164008,OSTEOPENIA|COMPLICATIONS OF HEART-LUNG TRANSPLANT|OTHER COMPLICATIONS OF LUNG TRANSPLANT,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Recruiting,NCT03868033,OSTEOPOROSIS,All,"55 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Department of Orthopedics, National Taiwan University Hospital, Taipei, N/A = Not Applicable, Taiwan",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Unknown status,NCT03158246,"OSTEOPOROSIS, POSTMENOPAUSAL",Female,"46 Years to 80 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07F9/65031,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT02499237,POSTMENOPAUSAL OSTEOPOROSIS,Female,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"251 Airforce & VA General Hospital, Athens, Greece|424 General Military Hospital, Thessaloniki, Greece",C07F9/65031,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT01732770,POST MENOPAUSAL OSTEOPOROSIS,Female,"55 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Santa Monica, California, United States|Research Site, Lakewood, Colorado, United States|Research Site, Longmont, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Bethesda, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, West Haverstraw, New York, United States|Research Site, Houston, Texas, United States|Research Site, Maroubra, New South Wales, Australia|Research Site, Penrith, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Brussels, Belgium|Research Site, Brussel, Belgium|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Genk, Belgium|Research Site, Leuven, Belgium|Research Site, LiÃ¨ge, Belgium|Research Site, Merksem, Belgium|Research Site, Tessenderlo, Belgium|Research Site, Wilrijk, Belgium|Research Site, Yvoir, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Aalborg, Denmark|Research Site, Ballerup, Denmark|Research Site, Vejle, Denmark|Research Site, Bialystok, Poland|Research Site, KrakÃ³w, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Granada, AndalucÃ­a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain",C07F9/65031,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT01218035,HIP OSTEOARTHRITIS,Female,"20 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Turku University Hospital, Turku, Finland",C07F9/65031,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00927186,"OSTEOPOROSIS, POST-MENOPAUSAL",Female,"55 Years to 89 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lakewood, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Haverstraw, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada",C07F9/65031,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00114556,OSTEOPOROSIS|LIVER TRANSPLANTATION|FRACTURES,All,"17 Years to 70 Years Â  (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention,"Royal Prince Alfred Hospital, Sydney, New South Wales, Australia",C07F9/65031,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00668200,PAGET'S DISEASE OF THE BONE|HYPOCALCEMIA,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Gainesville, Georgia, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Syracuse, New York, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Waco, Texas, United States|Novartis Investigative Site, Madison, Wisconsin, United States",C07F9/65031,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,"Active, not recruiting",NCT02589600,"OSTEOPOROTIC FRACTURES|OSTEOPOROSIS, POSTMENOPAUSAL",Female,65 Years and older Â  (Older Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Pittsburgh Osteoporosis Prevention & Treatment Center, Pittsburgh, Pennsylvania, United States",C07F9/65031,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,"Active, not recruiting",NCT02753283,"OSTEOPOROSIS, POSTMENOPAUSAL|OSTEOPOROSIS|OSTEOPOROTIC FRACTURES",All,65 Years and older Â  (Older Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UPMC Senior Communities, Pittsburgh, Pennsylvania, United States",C07F9/65031,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT02042872,DISUSE OSTEOPOROSIS,All,18 Years to 49 Years Â  (Adult),U.S. Fed|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kessler Institute for Rehabilitation, West Orange, New Jersey, United States",C07F9/65031,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-],1,DB00401,__NISOLDIPINE,5422123,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2086,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.468592784246,168.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.63,388.4144,110.45,5.0,1.0,2.0,39.72,105.91,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,NCT00392041,FIBROMYALGIA|INSOMNIA,All,18 Years to 64 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey, United States",C07D487/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,FIBROMYALGIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,1,DB00410,__MUPIROCIN,6013657,Completed,,CHRONIC RHINOSINUSITIS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.135896014291802,384.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CCCN[C@H]1CCc2nc(N)sc2C1,1,DB00413,__PRAMIPEXOLE,4886812,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/82,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,13.996180619725196,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.18,211.327,50.94,3.0,2.0,2.0,24.47,59.77,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00415,__AMPICILLIN,3931150,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,17.2488141440275,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.88,349.405,112.73,5.0,3.0,3.0,34.54,87.52,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00417,__PHENOXYMETHYLPENICILLIN,4046759,Recruiting,,INFECTIOUS DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,24.411178874309503,110.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,350.39,95.94,5.0,2.0,3.0,34.37,85.77,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,NCT02046668,OSTEO ARTHRITIS OF THE KNEES,All,70 Years and older Â  (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NHS Fife, Kirkcaldy, Fife, United Kingdom|NHS Tayside, Dundee, Tayside, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
COC(=O)C(c1ccccc1)C1CCCCN1,1,DB00422,__METHYLPHENIDATE,5958446,Recruiting,NCT00768820,VELOCARDIOFACIAL SYNDROME|WILLIAMS SYNDROME|FRAGILE X SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Schneider Children's Mediac Center of Israel, Petach-Tikva, Israel",A61L15/585,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,75.0,52.83065360685021,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.21,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
COC(=O)C(c1ccccc1)C1CCCCN1,1,DB00422,__METHYLPHENIDATE,5958446,Completed,,NEUROFIBROMATOSIS TYPE 1,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/585,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,75.0,52.83065360685021,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.21,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,NCT00530556,SLEEP DISORDERS,All,"45 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Enrolling by invitation,NCT03336203,GOUT|CKD STAGE 1-4|SUA LEVEL (>8 MG/DL; 480 ÎMOL/L),All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical Practice Prof D.Ivanov, Kiev, Ukraine",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,"Active, not recruiting",NCT02579096,GOUT|CHRONIC KIDNEY DISEASES,All,"18 Years and older Â  (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States|Iowa City VA Health Care System, Iowa City, IA, Iowa City, Iowa, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri, United States|Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|Asheville VA Medical Center, Asheville, NC, Asheville, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Completed,NCT02500641,GOUT,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Klinik und Poliklinik III/Rheumatologie UniversitÃ¤tsklinikum ""Carl Gustav Carus"" Der Technischen UniversitÃ¤t, Dresden, Germany|Presidio Ospedaliero San Filippo e Nicola UniversitÃ  degli Studi dell'Aquila U.O.C Geriatria e Lungodegenza Geriatrica, Avezzano, L'Aquila, Italy|Ospedale San Salvatore U.O.C. Medicina Interna e Nefrologia Dipartimento MeSVA UniversitÃ  degli Studi dell'Aquila, Coppito, L'Aquila, Italy|Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Policlinico SS. Annunziata UniversitÃ  degli Studi ""G. d'Annunzio"". Dipartimento di Medicina e Scienze dell'Invecchiamento., Chieti, Italy|Reade Clinic, Amsterdam, Netherlands|GdaÅskie Centrum Zdrowia Sp.z o.o., GdaÅsk, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, GrudziÄdz, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Centrum Medyczne Plejady, KrakÃ³w, Poland|Krakowski Szpital Specjalistyczny im. Jana PawÅa II w Krakowie, KrakÃ³w, Poland|Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, KrakÃ³w, Poland|Pratia S,A, Warsaw, Poland|Reumatika- Centrum Reumatologii, Warsaw, Poland|OddziaÅ Kardiologiczny, WSS im. W. BiegaÅskiego w Åodzi, ÅÃ³dÅº, Poland|Polimedica, ÅÃ³dÅº, Poland|Clinica MedicalÄ Data Plus SRL, Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|S.C. Centrul Medical Sana S.R.L., Bucharest, Romania|S.C. Cardiomed S.R.L., Craiova, Romania|Institutul de Boli Cardiovasculare Clinica de Cardiologie si Recuperare Cardiovasculara, Timisoara, Romania|Cabinet Medical Medicina Interna, TimiÅoara, Romania|Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia|Institut za reumatologiju, Belgrade, Serbia|KliniÄko-bolniÄki centar ""BeÅ¾anijska kosa"" Klinika za imunologiju i alergologiju, Belgrade, Serbia|Vojnomedicinska akademija Klinika za reumatologiju, Belgrade, Serbia",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Completed,NCT02600780,HYPERURICEMIA,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dow University of Health Sciences, Karachi, Sindh, Pakistan",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Completed,NCT01451645,INTERCRITICAL GOUT,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Alabaster, Alabama, United States|Mesa, Arizona, United States|Upland, California, United States|Trumbull, Connecticut, United States|Debary, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Canton, Georgia, United States|Boise, Idaho, United States|Lexington, Kentucky, United States|Bethesda, Maryland, United States|Reisterstown, Maryland, United States|Bingham Farms, Michigan, United States|Brooklyn Center, Minnesota, United States|Kansas City, Missouri, United States|Billings, Montana, United States|Elizabeth, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Morganton, North Carolina, United States|Winston-Salem, North Carolina, United States|Duncansville, Pennsylvania, United States|Reading, Pennsylvania, United States|West Reading, Pennsylvania, United States|Greer, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Johnson City, Tennessee, United States|Dallas, Texas, United States|Katy, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Wauwatosa, Wisconsin, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Completed,NCT01310673,GOUT|GOUT ACUTE,Male,"18 Years and older Â  (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","White River Junction VA Medical Center, White River Junction, Vermont, United States",7,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Completed,NCT02477488,GOUT|RENAL INSUFFICIENCY,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Completed,NCT02956278,CHRONIC GOUT|HYPERURICEMIA,All,18 Years to 40 Years Â  (Adult),Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Open Medicine Institute, Mountain View, California, United States",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
C=C1[C@@H](n2cnc3c(=O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO,1,DB00442,__ENTECAVIR,5206244,"Active, not recruiting",NCT01907230,RHEUMATOID ARTHRITIS|HEPATITIS B REACTIVATION|EXPOSURE TO HEPATITIS B VIRUS,All,"20 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Division of Gastroenterology & Division of Allergy Immunology and Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan",C07D239/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.220107189059306,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,277.2792,125.76,7.0,4.0,3.0,27.31,71.0,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Not yet recruiting,NCT04278833,OSTEOARTHRITIS|TENDINOPATHY|IMPINGEMENT SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Stanford University, Redwood City, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Completed,NCT00209859,RHEUMATOID ARTHRITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hvidovre University Hospital, Hvidovre, Denmark",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Unknown status,NCT03215407,RHEUMATOID ARTHRITIS OF KNEE,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Recruiting,NCT02038634,DEQUERVAIN'S TENOSYNOVITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Froedtert Hospital, Wauwatosa, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Unknown status,NCT02612272,KNEE OSTEOARTHRITIS,Male,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","St Luke's Health and University Network, Bethlehem, Pennsylvania, United States",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Recruiting,NCT03156829,TRIGGER FINGER DISORDER,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lawson Health Research Institute, London, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Completed,NCT00542139,OSTEOARTHRITIS,All,"50 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hadassah Medical Organization, Jerusalem, Israel",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1,1,DB00450,__DROPERIDOL,4246894,Unknown status,NCT02282956,HALLUX VALGUS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Spital Grabs, Grabs, Switzerland",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,20.1728988274913,364.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.93,379.4274,52.65,3.0,1.0,4.0,40.31,109.52,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Completed,NCT02491008,"THYROID DYSFUNCTION|BONE MINERAL DENSITY|OSTEOPOROSIS|FRACTURES, BONE",All,65 Years and older Â  (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of General Internal Medicine, Lausanne, Vaud, Switzerland|Clinic for General Internal Medicine, Bern University Hospital Bern, Bern, Switzerland",A61K9/2009,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Terminated,NCT03694821,OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UConn Health, Farmington, Connecticut, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Terminated,NCT03119038,OSTEOARTHRITIS|DEGENERATIVE JOINT DISEASE,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Enrolling by invitation,NCT02570503,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Virginia Commonwealth University, Richmond, Virginia, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT02658149,OSTEOARTHRITIS|ARTHROPLASTY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Beaumont Hospital, Royal Oak, Michigan, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT02638831,GONARTHROSIS|LOW BACK PAIN,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Withdrawn,NCT03319784,ROTATOR CUFF TEAR|ROTATOR CUFF INJURY|ROTATOR CUFF TENDINITIS|DIABETES MELLITUS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Penn State College of Medicine, Hershey, Pennsylvania, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Unknown status,NCT02612272,KNEE OSTEOARTHRITIS,Male,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","St Luke's Health and University Network, Bethlehem, Pennsylvania, United States",A61K9/0048,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Withdrawn,NCT02765815,"OSTEOARTHRITIS, KNEE|ARTHROPLASTY, REPLACEMENT, KNEE",All,"18 Years to 88 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Holy Cross Hospital Orthopedic Research Institute, Fort Lauderdale, Florida, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Unknown status,NCT02604537,DEQUERVAIN TENDINOPATHY,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","OrthoCarolina, Charlotte, North Carolina, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Recruiting,NCT04115644,FULL THICKNESS ROTATOR CUFF TEAR|ROTATOR CUFF TENDINITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","John Hopkins Shoulder & Sports Medicine, Baltimore, Maryland, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,1,DB00469,__TENOXICAM,4636498,Unknown Status,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,16.953120187272805,1159.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.42,337.37,99.6,5.0,2.0,3.0,31.96,83.93,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,1,DB00470,__DRONABINOL,6703418,Not Yet Recruiting,,POST OPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00273689,EXERCISE INDUCED BRONCHOSPASM,All,7 Years to 17 Years Â  (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of New Mexico, Albuquerque, New Mexico, United States",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Active Not Recruiting,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1623,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O,1,DB00474,__METHOHEXITAL,4126684,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,23.425532351793603,204.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.43,262.3043,66.48,3.0,1.0,1.0,27.4,71.51,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,NCT00609557,OSTEOARTHRITIS|PAIN,All,"50 Years to 80 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,NCT00965081,"FIBROMYALGIA, PRIMARY|FIBROMYALGIA, SECONDARY",All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Merida, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morelia, Mexico",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Unknown status,NCT02535000,INTERVERTEBRAL DISC DEGENERATION,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care",,C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,NCT04532684,KNEE OSTEOARTHRITIS,All,"40 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,NCT02612233,HAND OSTEOARTHRITIS,All,"40 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hotung Centre for Musculoskeletal Diseases, London, United Kingdom",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,NCT01558700,OSTEOARTHRITIS,All,"40 Years to 80 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Withdrawn,NCT01619566,FIBROMYALGIA,Female,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Diego Medical Centers, San Diego, California, United States",C07D333/20,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Not yet recruiting,NCT04117893,"OSTEOARTHRITIS, KNEE|CHRONIC PAIN",All,"50 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Beijing Tiantan Hospital, Beijing, Beijing, China",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,NCT02208778,OSTEOARTHRITIS|CHRONIC PAIN,All,"35 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Nottingham - School of Medicine - Radiological Sciences, Nottingham, Nottinghamshire, United Kingdom",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Not yet recruiting,NCT04395001,CHRONIC PAIN,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Wake Forest Baptist Health Department of Rheumatology, Winston-Salem, North Carolina, United States",C07D333/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,1,DB00477,__CHLORPROMAZINE,3976763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/539,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,15.8360541284215,1011.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,318.8640000000001,6.48,2.0,0.0,3.0,35.1,93.76,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,NCT01544894,POSTMENOPAUSAL OSTEOPOROSIS|COMPLIANCE,Female,"50 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Dr Peset, Valencia, Spain",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,NCT00431444,OSTEOPOROSIS,Female,"45 Years to 80 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Women's Health Research, Phoenix, Arizona, United States|Associated Pharma Research Center, Buena Park, California, United States|Washington, District of Columbia, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Women's Physicians of Jacksonville, Jacksonville, Florida, United States|Tampa Clinical Research, Tampa, Florida, United States|Springfield Clinic, Springfield, Illinois, United States|Consultants in Women's Health Care, St Louis, Missouri, United States|Alegent Health, Omaha, Nebraska, United States|Specialty Medical and Research Center, Pahrump, Nevada, United States|UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States|Columbia University, New York, New York, United States|Kernodle Clinic, Inc., Burlington, North Carolina, United States|The Portland Clinic, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Texas Institute for Clinical Research, Fort Worth, Texas, United States|Valley Women's Health Clinic, Renton, Washington, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Recruiting,NCT03006003,DEPRESSIVE SYNDROME,Female,"20 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"outpatient clinic of the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Recruiting,NCT03623633,"OSTEOPOROSIS, POSTMENOPAUSAL|OSTEOPOROSIS",Female,"45 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Terminated,NCT00790101,"OSTEOPOROSIS, POSTMENOPAUSAL",Female,"up to 65 Years Â  (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Sanofi-Aventis, Bridgewater, New Jersey, United States",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,NCT00532428,"OSTEOPOROSIS, POST-MENOPAUSAL",Female,"55 Years to 85 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Granada, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,NCT00079924,POSTMENOPAUSAL OSTEOPOROSIS,Female,"50 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huntsville, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Des Moines, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Haverstraw, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Unknown status,NCT02638896,ANKYLOSING SPONDYLITIS,All,18 Years to 45 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT03540030,OPIOID USE|SHOULDER OSTEOARTHRITIS|AVASCULAR NECROSIS|ROTATOR CUFF TEAR|ARTHRITIS;INFLAMMATORY,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OrthoCarolina Research Institute, Charlotte, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00565500,ISCHEMIC HEART DISEASE|OSTEOARTHRITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Ce.S.I., Center of Excellence on Aging, G. d'Annunzio University, Chieti, CH, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00346216,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Carol M. Johnson MD, LLC, Alabaster, Alabama, United States|Orthopaedics West, Bessemer, Alabama, United States|Central Alabama Research, Birmingham, Alabama, United States|Simon Williamson Clinic/Clinical Research Advantage, Inc., Birmingham, Alabama, United States|Achieve Clinical Research, LLC, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Cahaba Research Inc., Birmingham, Alabama, United States|Winston Technology Inc., Haleyville, Alabama, United States|Clinical Research Consultants, Inc, Hoover, Alabama, United States|Medical Affiliated Research Center, Incorporated, Huntsville, Alabama, United States|Rheumatology Associates of North Alabama, PC, Huntsville, Alabama, United States|Montgomery Rheumatology Associates, Montgomery, Alabama, United States|James P. Beretta, PC, Pelham, Alabama, United States|Alabama Clinical Research Associates, Pell City, Alabama, United States|Pell City Internal and Family Medicine, Pell City, Alabama, United States|Scottsboro Quick Care Clinic, Scottsboro, Alabama, United States|Clinic for Rheumatic Diseases, Tuscaloosa, Alabama, United States|Terence T. Hart , MD, Tuscumbia, Alabama, United States|Clinical Research Advantage Inc./ Warner Family Practice, PC, Chandler, Arizona, United States|ArthroCare, Arthritis Care & Research P.C., Gilbert, Arizona, United States|Clinical Research Advantage Inc., /Thunderbird Internal Medicine, Glendale, Arizona, United States|Arizona Center for Clinical Research, Glendale, Arizona, United States|Clinical Research Advantage, Inc./ Lenzmeier Family Medicine, Glendale, Arizona, United States|Clinical Research Advantage, Inc./Central Arizona Medical Associates, PC, Mesa, Arizona, United States|Novara Clinical Research, Mesa, Arizona, United States|Clinical Research Advantage, Inc., Mesa, Arizona, United States|Sun Valley Arthritis Center, Limited, Peoria, Arizona, United States|Lovelace Scientific Resources, Inc., Phoenix, Arizona, United States|Clinical Research Advantage, Inc./ Family Practice Specialists, LTD, Phoenix, Arizona, United States|NPHC Research, Phoenix, Arizona, United States|Phoenix Clinical, Phoenix, Arizona, United States|Arizona Research Center, Inc., Phoenix, Arizona, United States|Precision Trials AZ. LLC; AZ, Phoenix, Arizona, United States|43rd Medical Associates, P.C., Phoenix, Arizona, United States|Southwest Health Ltd., Scottsdale, Arizona, United States|Advanced Arthritis Care and Research, Scottsdale, Arizona, United States|Arizona Pain Specialist, PLLC, Scottsdale, Arizona, United States|Sonora Quest Laboratories, Scottsdale, Arizona, United States|Cochise Clinical Research, Sierra Vista, Arizona, United States|Clinical Research Advantage, Inc./Skyline Medical Center PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Urban Family Practice Associates, PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Warner Family Practice, PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc/Manning Family Care, Tempe, Arizona, United States|Clinical Research Advantage, Incl Colorado Springs Health Partners, East, Tempe, Arizona, United States|Family Medicine Associates/Clinical Research Advantage, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Fiel Family and Sports Medicine, PC, Tempe, Arizona, United States|ARA-Arizona Research Associates, Tucson, Arizona, United States|Canyon Clinical Research LLC, Tucson, Arizona, United States|Tucson Clinical Researh, Tucson, Arizona, United States|ACRC/Arizona Clinical Research Center, Incorporated, Tucson, Arizona, United States|Clinical Research Advantage, Inc./ Orange Grove Family Practice, Tucson, Arizona, United States|Genova Clinical Research, Tucson, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Fayetteville Diagnostic Clinic Limited, Fayetteville, Arkansas, United States|Hearne Family Practice Clinic, Little Rock, Arkansas, United States|Larry S. Watkins, M.D., Little Rock, Arkansas, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Rx Medical Research of AR, Little Rock, Arkansas, United States|Anaheim Family Medical Center, Anaheim, California, United States|Advanced Research Center, Anaheim, California, United States|Advanced Arthritis & Rheumatology Center, Artesia, California, United States|Bina Akamdar MD, Azusa, California, United States|Rx for Life, Inc, Bell, California, United States|Clinical Research Advantage Inc., /Cassidy Medical Group-Carlsbad, Carlsbad, California, United States|Capitol Interventional Cardiology, Carmichael, California, United States|Northern California Research, Carmichael, California, United States|CORE Orthopaedic Medical Center, Encinitas, California, United States|Arthritis Medical Clinic of North County, Inc., Escondido, California, United States|Med Investigations, Inc., Fair Oaks, California, United States|Valley Research, Fresno, California, United States|Creekside Clinical Research, Greenbrae, California, United States|C. V. Mehta, MD Medical Corporation, Hemet, California, United States|Talbert Medical Group, Huntington Beach, California, United States|Alia Clinical Research, Inc, Huntington Park, California, United States|Time Clinical Research Inc., Huntington Park, California, United States|Lindora Research Center, Irvine, California, United States|Office of Dr. Robert L. Freed, MD, Irvine, California, United States|Office of Dr. Alan Schenk, Laguna Hills, California, United States|Prime Care Clinical Research, Laguna Hills, California, United States|Jeremy Anuntiyo, Lakewood, California, United States|Premiere Clinical Research, LLC, Lakewood, California, United States|Stuart J. Finkelstein, Lakewood, California, United States|Clinical Trials Research, Lincoln, California, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|Narbonne Multi-Specialty Medical Group Inc., Lomita, California, United States|Office of Dr. Arvind J. Mehta, Long Beach, California, United States|Pacific Internal Medicine Group, Inc, Long Beach, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|National Institute of Clinical Research, Long Beach, California, United States|Alliance Research, LLC, Long Beach, California, United States|Valerius Medical Group and Research Center, Los Alamitos, California, United States|IMD Medical Group, Los Angeles, California, United States|Pacific Arthritis Care Center, Los Angeles, California, United States|Wagdy W. Kades, MD, Inc., Los Angeles, California, United States|Samaritan Center for Medical Research Medical Group, Los Gatos, California, United States|Office of Lewis Gamarra, MD M.P.H., Los Osos, California, United States|Adegbenga A. Adetola, M.D., Lynwood, California, United States|Facey Medical Group, Mission Hills, California, United States|Providence Clinical Research, North Hollywood, California, United States|Desert Medical Group, Palm Springs, California, United States|The Office of Dr. Marcos Yang, Palos Verdes Estates, California, United States|Bayview Research Group, LLC, Paramount, California, United States|Sierra Rheumatology, Roseville, California, United States|Center for Clinical Trials of Sacramento, Inc., Sacramento, California, United States|Sacramento Heart and Vascular Research Center, Sacramento, California, United States|California Research Foundation, San Diego, California, United States|San Diego Arthritis Medical Clinic, San Diego, California, United States|Wetlin Research Associates, Inc, San Diego, California, United States|Medical Associates Research Group, San Diego, California, United States|San Jose Valley Research, Inc., San Jose, California, United States|Comprehensive Adult Risk Evaluation, San Leandro, California, United States|East Bay Rheumatology Medical Group Inc, San Leandro, California, United States|Central Coast Pathology Consultants, San Luis Obispo, California, United States|Coastal Medical Research Group, Inc., San Luis Obispo, California, United States|Family Medical Center, San Luis Obispo, California, United States|Office of Ajay G. Meka, MD, Santa Ana, California, United States|Pacific Arthritis Center Medical Group, Santa Maria, California, United States|Orrin M. Troum & Medical Associates, Santa Monica, California, United States|Northern California Medical Associates, Santa Rosa, California, United States|Robert Simon, MD, Sherman Oaks, California, United States|St. Joseph Medical Associates, Stockton, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Paradigm Clinical Research Institute, Inc., Torrance, California, United States|Orange County Research Center, Tustin, California, United States|Inland Rheumatology and Osteoporosis Medical Group, Upland, California, United States|Inland Rheumatology Clinical Trials, Inc., Upland, California, United States|Bayview Research Group, Valley Village, California, United States|Medvin Clinical Research, Van Nuys, California, United States|Center for Clinical Trials of San Gabriel, West Covina, California, United States|Agilence Arthritis and Osteoporosis Medical Center, Inc., Whittier, California, United States|Avalon Family Medical Group, Wilmington, California, United States|Darrell E. Gorman, MD, Arvada, Colorado, United States|Aurora Denver Cardiology Associates, Aurora, Colorado, United States|Azmi Emil Farag, MD, Colorado Springs, Colorado, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Colorado Springs Health Partners- East/Clinical Research Advantage, Colorado Springs, Colorado, United States|Mountain View Clinical Research, Inc., Denver, Colorado, United States|Saint Luke's Medical Clinic, Fort Collins, Colorado, United States|New West Physicians, Golden, Colorado, United States|Ranch View Family Medicine, Highlands Ranch, Colorado, United States|Colorado Center for Bone Research PC, Lakewood, Colorado, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Lynn Institute of Pueblo, Pueblo, Colorado, United States|Connecticut Clinical Research, LLC, Bridgeport, Connecticut, United States|Connecticut Gastroenterology Institute, Bristol, Connecticut, United States|Arthritis and Osteoporosis Center, PC, Hamden, Connecticut, United States|Robert Lang, MD, P.C., Hamden, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Office of Edward J. McDermott, Jr., MD, New London, Connecticut, United States|Orthopaedics Foundation for Active Lifestyles, Stamford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|New England Research Associates, LLC, Trumbull, Connecticut, United States|Arthritis Center of Connecticut, Waterbury, Connecticut, United States|Rheumatology Consultants of Delaware, Lewes, Delaware, United States|Office of Cynthia Morgan, MD, Washington, D.C., District of Columbia, United States|The Center for Rheumatology and Bone Research, Washington, D.C., District of Columbia, United States|Medical Specialist of the Palm Beaches, Atlantis, Florida, United States|South Florida Medical Research, Aventura, Florida, United States|RASF - Clinical Research Center, Boca Raton, Florida, United States|Orthopedic Research Institute, Boynton Beach, Florida, United States|Clinical Research of Brandon, LLC, Brandon, Florida, United States|Family Healthcare of Chipley, Chipley, Florida, United States|Health First Clinical Research Group, Inc., Chipley, Florida, United States|Southern Family Healthcare and Health First Research Group Inc., Chipley, Florida, United States|Florida Research & Testing, LLC, Clearwater, Florida, United States|Alba Clinical Research, Clearwater, Florida, United States|Appletree Medical, Clearwater, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Rameshwar N. Mathur, MD, PA, Cocoa, Florida, United States|Nature Coast Clinical Research, LLC, Crystal River, Florida, United States|Atlantic Institute of Clinical Research, Daytona Beach, Florida, United States|International Medical Research, Daytona Beach, Florida, United States|Omega Research Consultants, LLC, DeBary, Florida, United States|Physicians Research Alliance, LLC, DeBary, Florida, United States|Deerfield Beach Cardiology Associates, Deerfield Beach, Florida, United States|Doctors Medical Center of Walton County, DeFuniak Springs, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Florida Research Associates, LLC/Florida Orthopaedic Associates, P.A., DeLand, Florida, United States|Cohen Medical Associates, PA, Delray Beach, Florida, United States|Clark Family Medicine & Emerald Coast Research Group, Destin, Florida, United States|SJS Clinical Research, Inc, Destin, Florida, United States|Robert W. Levin MD, Dunedin, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Invesclinic, Fort Lauderdale, Florida, United States|M&O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Maxine Hamilton, MD PA, Fort Lauderdale, Florida, United States|Holy Cross Medical Group Northridge Internal Medicine, Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|Emerald Coast Mood & Memory, Fort Walton Beach, Florida, United States|White-Wilson Medical Center, PA, Fort Walton Beach, Florida, United States|Cardiology West, Gainesville, Florida, United States|Florida Research Network, LLC, Gainesville, Florida, United States|Southeastern Integrated Medical, PL, Gainesville, Florida, United States|Shands at the University of Florida, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Genetic Medical Research Corporation, Hialeah, Florida, United States|Direct Helpers Medical Center, Inc., Hialeah, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Reliable Clinical Research, LLC, Hialeah, Florida, United States|Orthopaedic Associates of South Broward, P.A., Hollywood, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Pasco Cardiology Center, Hudson, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Jacksonville Center for Clincal Research, Jacksonville, Florida, United States|St. Vincent's Cardiology, Jacksonville, Florida, United States|Dr. Ricardo A. Bedoya, M.D., Jupiter, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Christopher Chappel, Kissimmee, Florida, United States|Florida Arthritis Center, LLC, Lake Mary, Florida, United States|Pedro Ylisastigui, MD, Lehigh Acres, Florida, United States|Adult Medicine Specialists, Longwood, Florida, United States|Genesis Research International, Longwood, Florida, United States|Doctors Inn, Madeira Beach, Florida, United States|Everest Medical Care and Palm Court Research Group, Marianna, Florida, United States|Panhandle Family Care Associates & Emerald Coast Research Group, Marianna, Florida, United States|The Doctor's Office, Marianna, Florida, United States|Health First Medical Group, Melbourne, Florida, United States|Holmes Regional Medical Center, Melbourne, Florida, United States|Pharmaceutical Research Associates, Merritt Island, Florida, United States|Orthopaedic Specialist of Miami Beach, Miami Beach, Florida, United States|AMPM Research Clinic, Miami Gardens, Florida, United States|Crystal Biomedical Research, LLC, Miami Lakes, Florida, United States|Pembroke Clinical Trials, Miami Lakes, Florida, United States|Homestead Associates in Research, Inc, Miami, Florida, United States|Pharmax Research Clinic, Miami, Florida, United States|Life Spring Research Foundation, Miami, Florida, United States|Miami International Cardiology Consultants, Miami, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|The Center for Arthritis and Rheumatic Diseases, Miami, Florida, United States|Well Pharma Medical Research Corporation, Miami, Florida, United States|DC Health Clinical Trials, Miami, Florida, United States|School of Clinical Research USA, LLC, Miami, Florida, United States|Advance Medical Research Services, Corp, Miami, Florida, United States|Future Care Solution, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Miami Cardiology Group, Miami, Florida, United States|M & M Medical Center, Miami, Florida, United States|Office of Dr. Juvenal E. Martinez, MD, PA, Miami, Florida, United States|Anchor Research Center, Naples, Florida, United States|Jeffrey Alper M.D. Research, Naples, Florida, United States|Anchor Health Centers, Naples, Florida, United States|Medical Surgical Specialists, Physicians Regional Medical Center, Naples, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Magnolia Research Group, Inc., Ocala, Florida, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|Paddock Park Clinical Research, Ocala, Florida, United States|Southeastern Rehabilitation Medicine, Ocala, Florida, United States|Tequesta Research Group, Ocala, Florida, United States|CEC Research, INC., Ocoee, Florida, United States|Florida Heart Group, PA, Orlando, Florida, United States|Florida Hospital, Orlando, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|DCT FMC, LLC dba Discovery Clinical Trials, Orlando, Florida, United States|DCT-FMC, LLC dba Discovery Clinical Trials, Orlando, Florida, United States|Arthur L. Hall MD PA, Orlando, Florida, United States|Block and Nation, PA, Oviedo, Florida, United States|Arthritis Research of Florida, Inc., Palm Harbor, Florida, United States|Florida Med Center of Countryside, Palm Harbor, Florida, United States|Rene CaSanova Medical Office Inc, Pembroke Pines, Florida, United States|Boulevard Professional Centre, Pembroke Pines, Florida, United States|Research Physician Network Alliance, Pembroke Pines, Florida, United States|South Broward Research LLC, Pembroke Pines, Florida, United States|South Florida Research Solutions, LLC, Pembroke Pines, Florida, United States|DMI Research, Inc., Pinellas Park, Florida, United States|Sunbelt Research, LLC, Plantation, Florida, United States|Boca Raton Clinical Research, Plantation, Florida, United States|St. Johns Center for Clinical Research, Ponte Vedra, Florida, United States|Accord Clinical Research, LLC, Port Orange, Florida, United States|Administrative Address: Florida Arthritis & Osteoporosis Center, Port Richey, Florida, United States|Heart & Vascular Center Research, Sarasota, Florida, United States|Edgar R. Blecker, MD, Sebastian, Florida, United States|Phoenix Clinical Research, LLC., Tamarac, Florida, United States|Clinical Research of West Florida, Tampa, Florida, United States|Soutwest Florida Clinical Research Center, Tampa, Florida, United States|Clinyx/Floria Cardiovascular, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|West Wind'r Research, Tampa, Florida, United States|Health Point Medical Group, Inc, Tampa, Florida, United States|Causeway Medical Clinic, Tampa, Florida, United States|Office of Alastair C. Kennedy, MD, Vero Beach, Florida, United States|Metabolic Research Institute, Incorporated, West Palm Beach, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Central Florida Primary Care, Winter Park, Florida, United States|Florida Medical Clinic, PA, Zephyrhills, Florida, United States|The Kaufmann Clinic, Atlanta, Georgia, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States|Atlanta Center for Clinical Research, Corp., Atlanta, Georgia, United States|Atlanta Vascular Research Foundation, Atlanta, Georgia, United States|Executive Health and Research Associates, Atlanta, Georgia, United States|Southern Clinical Research and Management, Inc. (SCRAM), Augusta, Georgia, United States|Masters of Clinical Research, Inc., Augusta, Georgia, United States|Amelia Medical Plaza, Bainbridge, Georgia, United States|Bainbridge Medical Associates, Bainbridge, Georgia, United States|Abdul Bari MD Inc, Cairo, Georgia, United States|Southern Clinical Research Management and Consulting, Cairo, Georgia, United States|North Georgia Rheumatology Group, PC, Duluth, Georgia, United States|United Osteoporosis Centers, Gainesville, Georgia, United States|North Georgia Rheumatology Group, PC, Lawrenceville, Georgia, United States|GCH Research Dr. G Craig Heigerick DO, Lilburn, Georgia, United States|Mercer University Mercer Medicine, Macon, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Clinical Research Advantage, Inc./Urban Family Practice Associates, PC, Marietta, Georgia, United States|In-Quest Medical Research, LLC, Norcross, Georgia, United States|Harbin Clinic, Rome, Georgia, United States|Atlanta Center for Clinical Research, Roswell, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Archibold Primary Care, Thomasville, Georgia, United States|Clinical Trial Providers, Inc., Tucker, Georgia, United States|VSC, Valdosta, Georgia, United States|Kaufmann Clinic, INC, Woodstock, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|North Georgia Internal Medicine, Woodstock, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Orthopedic Health Care Clinic, Boise, Idaho, United States|Sonora Clinical Research, LLC, Boise, Idaho, United States|Eagle's View Family Medicine, Boise, Idaho, United States|Coeur D'Alene Arthritis Clinic, Coeur d'Alene, Idaho, United States|CTL Research, Eagle, Idaho, United States|Women's Healthcare Associates P.A. dba Rosemark WomenCare Specialists, Idaho Falls, Idaho, United States|Idaho Arthritis and Osteoporosis Center, Meridian, Idaho, United States|Advanced Clinical Research, Meridian, Idaho, United States|AMR Sakeena Research, Aurora, Illinois, United States|Arthur I Davida, MD PC, Bloomingdale, Illinois, United States|Cardiac Wellness Consultants, Chicago, Illinois, United States|Chicago Peripheral Nerve Center, Chicago, Illinois, United States|ICCT Research International Incorporated, Chicago, Illinois, United States|Claude Mandel Medical Center, Chicago, Illinois, United States|Windy City Orthopedics and Sports Medicine, Evanston, Illinois, United States|South Suburban Health Professional Group, Hazel Crest, Illinois, United States|Prairie Rheumatology Associates, SC, Joliet, Illinois, United States|Lake Zurich Family Treatment Center, Lake Zurich, Illinois, United States|Southern Illiniois Clinical Research Centre, O'Fallon, Illinois, United States|Speciality phhysicians of Illinois, LLC, Olympia Fields, Illinois, United States|Redhead Research Inc., DBA Research Associates of Central Illinois, Peoria, Illinois, United States|Trinity Medical Center, Rock Island, Illinois, United States|Rockford Health Physicians, Rockford, Illinois, United States|Prairie Cardiovascular Consultants, Springfield, Illinois, United States|Prairie Education & Research, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Deerbrook Medical Associates, Vernon Hills, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|American Health Network of Indiana, LLC, Avon, Indiana, United States|Robert D. Barnes, MD, LLC, Evansville, Indiana, United States|Clinical Research Advantage, Inc., Evansville, Indiana, United States|Destiny Clinical Research, LLC, Evansville, Indiana, United States|Clinical Research Advantage/Family Medicine Associates, Evansville, Indiana, United States|American Health Network of Indiana, LLC, Franklin, Indiana, United States|Internal Medicine Center of Northwest Indiana, P.C., Gary, Indiana, United States|Beacon Medical Group Rheumatology, Granger, Indiana, United States|American Health Network of IN, LLC, Greenfield, Indiana, United States|Diagnostic Rheumatology And Research, PC, Indianapolis, Indiana, United States|Investigators research Group, Indianapolis, Indiana, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|Dawes Fretzin Dermatology Group, LLC, Indianapolis, Indiana, United States|Arthritis Associates of Southern Indiana, Jeffersonville, Indiana, United States|Research Institute of Middle America/River Cities Cardiology, Jeffersonville, Indiana, United States|Beacon Medical Group LaPorte, LaPorte, Indiana, United States|Cardiovascular Clinics, PC, Merrillville, Indiana, United States|Community Clinical Research Center, Muncie, Indiana, United States|Medical Specialists Clinical Research Center, Munster, Indiana, United States|Medical Specialists, Munster, Indiana, United States|Arthritis Associates of Southern Indiana, New Albany, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Physician's Clinic of Iowa, PC, Cedar Rapids, Iowa, United States|Ridge Family Practice, PC/Clinical Research Advantage, Inc., Council Bluffs, Iowa, United States|Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States|Office of Jerrold V Flatt, Des Moines, Iowa, United States|Medical Associates Clinic, PC, Dubuque, Iowa, United States|Family Health Center of Waterloo, PC, Waterloo, Iowa, United States|Northeast IA Medical Education Foundation/Family Practice Center, Waterloo, Iowa, United States|Heartland Research Associates LLC, Arkansas City, Kansas, United States|Community House of Wellness, Kansas City, Kansas, United States|Associates Reseach Inc., Lansing, Kansas, United States|Radiant Research, Inc., Overland Park, Kansas, United States|International Clinical Research Institute, Inc, Overland Park, Kansas, United States|Arthritis Specialists of Greater KC, Overland Park, Kansas, United States|Pinnacle Medical Research, Overland Park, Kansas, United States|Quivira Internal Medicine, Overland Park, Kansas, United States|Health Science Research Center, Pratt, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Via Christi Clinic, Wichita, Kansas, United States|Howard L. Feinberg, D.O., Ashland, Kentucky, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Internal Medicine Research Association, Campbellsville, Kentucky, United States|Center for Arthritis and Osteoporosis, Elizabethtown, Kentucky, United States|Arthritis Center of Lexington, Lexington, Kentucky, United States|Kentuckiana Center for Better Bone and Joint Health, Louisville, Kentucky, United States|KY Research PLLC., Louisville, Kentucky, United States|University Medical Associates, Louisville, Kentucky, United States|Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, United States|Office of Gaurang B. Shah,MD, PSC, Richmond, Kentucky, United States|Richmond Regional Research, Richmond, Kentucky, United States|Chandler Family Practice, Bossier City, Louisiana, United States|McFarland Family Clinic, Shreveport, Louisiana, United States|TFD Research, LLC, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Southern Maine Health Care, Biddeford, Maine, United States|Central Maine Heart & Vascular Institute, Lewiston, Maine, United States|Chesapeake CardioVascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, PA, Baltimore, Maryland, United States|Health Trends Research, LLC, Baltimore, Maryland, United States|One Heart, LLC, Baltimore, Maryland, United States|Chesapeake CardioVascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, Pa, Baltimore, Maryland, United States|Saint Agnes HealthCare Incorporated, Baltimore, Maryland, United States|Stephen R Smith, MD FACP, Baltimore, Maryland, United States|MidAtlantic Cardiovascular Associates, PA, Baltimore, Maryland, United States|Peter A. Holt, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates PA, Bel Air, Maryland, United States|Shah Associates MD, LLC, Charlotte Hall, Maryland, United States|Cardiovascular Specialists, LLC, Columbia, Maryland, United States|Johns Hopkins University, Columbia, Maryland, United States|The Osteoporosis & Clinical Trials Center, Cumberland, Maryland, United States|Arthritis Treatment Center, Frederick, Maryland, United States|The Spine & Joint Center, Greenbelt, Maryland, United States|Klein & Associates, MD, PA, Hagerstown, Maryland, United States|Community Health Research, North East, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Shah Associates, Prince Frederick, Maryland, United States|Cardiac Associates, Shady Grove Adventist Hospital, Rockville, Maryland, United States|The Center for Rheumatology and Bone Research, Rockville, Maryland, United States|Rockville Internal Medicine Group, Rockville, Maryland, United States|IRC Clinics, Towson, Maryland, United States|Midatlantic Cardiovascular Associates, P.A., Westminster, Maryland, United States|The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States|Primary Care Cardiology Research, Ayer, Massachusetts, United States|Genesis Clinical Research & Consulting, Fall River, Massachusetts, United States|NECCR Internal Medicine and Cardiology Associates, LLC, Fall River, Massachusetts, United States|Phase III Clinical Research, Fall River, Massachusetts, United States|Pentucket Medical Associates, Incorporated, Haverhill, Massachusetts, United States|Clinical Research Center of Cape Cod, Inc., Hyannis, Massachusetts, United States|Charles River Medical Associates, Pchi, Natick, Massachusetts, United States|Novex Clinical Research, LLC, New Bedford, Massachusetts, United States|Northampton Internal Medicine Associates, PC, Northampton, Massachusetts, United States|FutureCare Studies, Springfield, Massachusetts, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Great Lakes Research Group, Incorporated, Bay City, Michigan, United States|Professional Clinical Research-Benzonia, Benzonia, Michigan, United States|Cadillac Clinical Research, Cadillac, Michigan, United States|Livernois Family Medical Services, Detroit, Michigan, United States|Office of Dr. Susan Courtnage, Eaton Rapids, Michigan, United States|McLaren Regional Medical Center-Research Dept., Flint, Michigan, United States|Grand Valley Medical Specialist, PLC, Grand Rapids, Michigan, United States|Spectrum Health Medical Group-Rheumatology, Grand Rapids, Michigan, United States|Michigan Medical Cardiovascular PC, Grand Rapids, Michigan, United States|Professional Clinical Research, Interlochen, Michigan, United States|Justus J Fiechtner, MD, Lansing, Michigan, United States|Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Synergy Medical Education Alliance, Saginaw, Michigan, United States|Shores Rheumatology, Saint Clair Shores, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|Troy Internal Medicine Research, Troy, Michigan, United States|St. Luke's Hospital Association of Duluth, DBA St Luke's Rheumatology Assoc., Duluth, Minnesota, United States|St. Luke's Hospital Association of Duluth, Inc., Duluth, Minnesota, United States|St. Luke's Hospital Association of Duluth, Duluth, Minnesota, United States|Central Minnesota Heart Center at St. Cloud Hospital, Saint Cloud, Minnesota, United States|St. Paul Heart Clinic, Saint Paul, Minnesota, United States|The Center for Clinical Trials, Biloxi, Mississippi, United States|Planters Clinic, Port Gibson, Mississippi, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|Cape Girardeau Physicians Associates, Cape Girardeau, Missouri, United States|Patterson Medical Clinic / d.b.a. Prime Care Research Associates, Florissant, Missouri, United States|Allergy Asthma Immunology Services, LLC, Jefferson City, Missouri, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|University of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States|Truman Medical Center, Inc., Kansas City, Missouri, United States|Clinical Research Advantage, Inc./Manning Family Care, LLC, Kansas City, Missouri, United States|St. Louis Center for Clinical Research, Saint Louis, Missouri, United States|Physician Groups, LC, DBA Rheumatology and Internal Medicine Associates, Saint Louis, Missouri, United States|Southampton Healthcare, Inc., Saint Louis, Missouri, United States|Barbara A. Caciolo, MD, Saint Louis, Missouri, United States|A & A Pain Institute, Saint Louis, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Patients First Health Care, LLC, Washington, Missouri, United States|Glacier View Research Institute, Cardiology, Kalispell, Montana, United States|Alliance Medical Center, Alliance, Nebraska, United States|Cody Medical Associates, Alliance, Nebraska, United States|Bellevue Family Practice/Clinical Research Advantage, Inc., Bellevue, Nebraska, United States|Clinical Research Advantage, Inc./ Skyline Medical Center, PC, Elkhorn, Nebraska, United States|Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC, Fremont, Nebraska, United States|Internal Medicine Associates, PC, Grand Island, Nebraska, United States|Physician, Research Collaboration, Southwest Family Health, Lincoln, Nebraska, United States|Lincoln Internal Medicine Associates, Lincoln, Nebraska, United States|Platte River Nephrology, North Platte, Nebraska, United States|Quality Clinical Research LLC, Omaha, Nebraska, United States|Westroads Medical Group, Omaha, Nebraska, United States|Heartland Clinical Research, Inc., Omaha, Nebraska, United States|Clinical Research Advantage, Inc./Primary Care Physicians, LLP, Omaha, Nebraska, United States|Clinical Research Advantage, Inc., Henderson, Nevada, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Henderson, Nevada, United States|Sierra Internal Medicine Associates, Incline Village, Nevada, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Clinical Research Advantage/Peter Philander, MD, Las Vegas, Nevada, United States|Rancho Internal Medicine, Las Vegas, Nevada, United States|Steven D. Folkerth, MD, Las Vegas, Nevada, United States|Ladner Family Practice, Las Vegas, Nevada, United States|VA Southern Nevada Healthcare System, North Las Vegas, Nevada, United States|Arthritis Center of Reno, Reno, Nevada, United States|New Jersey Physicians, LLC, Clifton, New Jersey, United States|Clifton-Wallington Medical Group, Clifton, New Jersey, United States|Anderson and Collins, Clinical Research Inc., Edison, New Jersey, United States|Drs. Collins and Uthappa, Edison, New Jersey, United States|Central Jersey Health Care, Elizabeth, New Jersey, United States|Andron Medical Associates, Englewood, New Jersey, United States|Advocare Heights Primary Care, Haddon Heights, New Jersey, United States|Hazlet Health Care, Hazlet, New Jersey, United States|Family Care Physicians, Lawrenceville, New Jersey, United States|Penn Cardiac Care at Mercer Bucks, Lawrenceville, New Jersey, United States|Family Medicine of Lindenwold, Lindenwold, New Jersey, United States|Rheumatology and Arthritis Associates PC, Medford, New Jersey, United States|Adult & Pediatric Rheumatology, Midland Park, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Maynard Holgado LLC, Sicklerville, New Jersey, United States|Shore Health Group, Toms River, New Jersey, United States|Hopewell Valley Medical Group, P.A., Trenton, New Jersey, United States|Arthritis, Rheumatic and Back Disease Associates, PA, Voorhees, New Jersey, United States|Lourdes Medical Associates, Willingboro, New Jersey, United States|Kenneth F. Solinsky, MD, Babylon, New York, United States|LifeLine Research Institute, Brooklyn, New York, United States|Lee Medical Associates, Dunkirk, New York, United States|AMS Research, Elmira, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Drug Trials America, Inc., Hartsdale, New York, United States|United Health Service Hospitals, Office of Clinical Trials, Johnson City, New York, United States|IMA Medical Research PC, Kew Gardens, New York, United States|NYU Langone Medical Center, Laura and Issac Perlmutter Cancer Center, Infusion Center, Lake Success, New York, United States|NYU Langone Medical Center, Laura and Issac Perlmutter Cancer Center, Investigational Pharmacy, Lake Success, New York, United States|NYU Langone Rheumatology Associates Long Island, Lake Success, New York, United States|Office of Dr. Allen Chodock, Mamaroneck, New York, United States|Winthrop University Hospital / Clinical Trials Center, Mineola, New York, United States|New York University Pain Management Center, New York, New York, United States|NYU Pain Research, New York, New York, United States|Office of Dr. Richard Stern, New York, New York, United States|DiGiovanna Family Care Center, North Massapequa, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|AAIR Research Center, Rochester, New York, United States|Institute for Clinical Studies, Rosedale, New York, United States|Rheumatology Associates of Long Island, Smithtown, New York, United States|Office of Dr. Chadia Morcos, Syosset, New York, United States|Arthritis Health Associates, Syracuse, New York, United States|Crouse Medical Practice, PLLC d/b/a Internist Associates of Central New York, Syracuse, New York, United States|East Meadow Family Practice Associates, PC, Wantagh, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|Buffalo Cardiology and Pulmonary Associates, PC, Williamsville, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Asheville Arthritis & Osteoporosis, PA, Asheville, North Carolina, United States|Kernodle Clinic Inc., Burlington, North Carolina, United States|Calabash Medical Center, Calabash, North Carolina, United States|PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States|Chapel Hill Family Medicine, Chapel Hill, North Carolina, United States|Thurston Arthritis Reaserch Ctr, Chapel Hill, North Carolina, United States|Mid Carolina Cardiology Research, Charlotte, North Carolina, United States|Presbyterian Novant Heart and Wellness, Charlotte, North Carolina, United States|Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, United States|PMG Research of Charlotte, Charlotte, North Carolina, United States|Barat Research Group, Inc., Charlotte, North Carolina, United States|Sensenbrenner Primary Care, Charlotte, North Carolina, United States|Duke Health Center at Pickett Road, Durham, North Carolina, United States|Bland Clinic, PA, Greensboro, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Physicians East P. A., Greenville, North Carolina, United States|Physicians East, PA, Greenville, North Carolina, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|PMG Research Of Hickory, LLC, Hickory, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Research Institute of the Carolinas, PLLC, Mooresville, North Carolina, United States|Crystal Coast Family Practice, Morehead City, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|Pinehurst Medical Clinic. Inc., Pinehurst, North Carolina, United States|Blue Ridge Family Physicians, PPLC, Raleigh, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|Wake Internal Medicine Consultants, Inc., Raleigh, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Boice-Willis Clinic, Rocky Mount, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Tabor City Family Medicine, Tabor City, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|PMG Research Wilmington Research Associates, Wilmington, North Carolina, United States|Natalie A. Doyle, MD PA, Wilson, North Carolina, United States|Ardmore Family Practice, Winston-Salem, North Carolina, United States|Clinical Trials of America, Inc., Winston-Salem, North Carolina, United States|Clinical Trials of America, inc, Winston-Salem, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Winston-Salem Health Care, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, Fargo, North Dakota, United States|Daystar Clinical Research, Akron, Ohio, United States|CFP Research, Inc., Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Feldman Family Practice, Columbus, Ohio, United States|MidWest Cardiology Research Foundation, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Remington-Davis Incorporated, Columbus, Ohio, United States|Midtowne Family Practice Centre, Columbus, Ohio, United States|PriMed Clinical Research, Dayton, Ohio, United States|HWC Women's Research Center, Englewood, Ohio, United States|Cleveland Clinic Fairview Cardiovascular Medicine, Fairview Park, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|TriPhase Research, Ltd., Franklin, Ohio, United States|Holzer Clinic, Inc, Gallipolis, Ohio, United States|Office of Dr. Saleem Khan, MD, Inc, London, Ohio, United States|North Central Research, Mansfield, Ohio, United States|OhioHealth Research Institute, Mansfield, Ohio, United States|R&R Research-Smith Clinic, Marion, Ohio, United States|David R. Mandel, MD, Inc, Mayfield, Ohio, United States|Paramount Medical Research and Consulting, LLC, Middleburg Heights, Ohio, United States|Newark Physician Associates, Newark, Ohio, United States|Family Medicine and Occupational Health Center, Inc., Shaker Heights, Ohio, United States|Abner Cordero, M.D., Tiffin, Ohio, United States|Arthritis Associates of Northwest Ohio, Inc., Toledo, Ohio, United States|Mercy St Vincent Medical Center, Toledo, Ohio, United States|Toledo Cardiology Consultants c/o Cardiac Research, Toledo, Ohio, United States|South Toledo Internists, Toledo, Ohio, United States|University of Toledo Health Science Campus, Toledo, Ohio, United States|UT Medical Center Medicine Clinic, Toledo, Ohio, United States|Trenton Family Medicine, Trenton, Ohio, United States|Lake Medical Research, LLC, Willoughby Hills, Ohio, United States|Pharmacotherapy Research Associates Incorporated, Zanesville, Ohio, United States|LION Research, Norman, Oklahoma, United States|Integris Physicians Services, Oklahoma City, Oklahoma, United States|Integris Cardiovascular Physicians LLC, Oklahoma City, Oklahoma, United States|Integris Family Care Central, Oklahoma City, Oklahoma, United States|Integris Physician Services, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Healthcare Research Consultants, Tulsa, Oklahoma, United States|Integrated Medical Research, PC, Ashland, Oregon, United States|Lane Medical Research Group, Eugene, Oregon, United States|Oregon Medical Group Adult Medicine Clinic, Eugene, Oregon, United States|Oregon Medical Group Clinical Research, Eugene, Oregon, United States|Institute of Diabetes and Endocrinology, Medford, Oregon, United States|Rogue Valley Physicians-Clinical Research Group, Medford, Oregon, United States|Fanno Creek Clinic, Portland, Oregon, United States|Affinity Research, Portland, Oregon, United States|Portland Rheumatology Clinic, LLC, Portland, Oregon, United States|Internal Medicine Research, Portland, Oregon, United States|University Orthopedics Center, Altoona, Pennsylvania, United States|Tri-State Medical Group, Beaver, Pennsylvania, United States|East Penn Rheumatology Associates, PC, Bethlehem, Pennsylvania, United States|Buckingham Family Medicine, Buckingham, Pennsylvania, United States|Camp Hill Clinical Research Center, Camp Hill, Pennsylvania, United States|Butler Medical Associates, Chicora, Pennsylvania, United States|Perkiomen Valley Family Practice, PC, Collegeville, Pennsylvania, United States|Rheumatology Associates, Ltd, Colmar, Pennsylvania, United States|Office of J. Miller Oppy, MD, Youghiogheny Primary Care Practice, Connellsville, Pennsylvania, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Saint Vincent Consultant in Cardiovascular Diseases, LLC, Erie, Pennsylvania, United States|Arthritis Associates, Erie, Pennsylvania, United States|Center for Assessment and Research of Erie, Erie, Pennsylvania, United States|Stan F. Slabic, M.D., Erie, Pennsylvania, United States|AMH Feasterville Family HealthCare Center, Feasterville, Pennsylvania, United States|Westmoreland Neurology Associates, Incorporated, Greensburg, Pennsylvania, United States|Harleysville Medical Assoc, Harleysville, Pennsylvania, United States|Lederach Family Medicine, Harleysville, Pennsylvania, United States|Dr. Bruce Morrison, Family Practice, Huntingdon Valley, Pennsylvania, United States|Detweiler Family Medicine and Associates, PC, Lansdale, Pennsylvania, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Lansdale Medical Group Family Practice, Lansdale, Pennsylvania, United States|Bucks County Clinical Research, Morrisville, Pennsylvania, United States|Pearl Clinical Research, Inc., Norristown, Pennsylvania, United States|Lehigh Wellness Center Outpatient Services, Philadelphia, Pennsylvania, United States|Founders Research Corporation, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Dairyland Medical Center, Red Lion, Pennsylvania, United States|Sfm Clinical Trials, PC, Scotland, Pennsylvania, United States|Elite Medical Research, Inc., Sellersville, Pennsylvania, United States|Prime Health Network, Springfield, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|The Office of Dr. Joseph T. Morelli, DO, Stoneboro, Pennsylvania, United States|Tipton Medical and Diagnostic Center, Tipton, Pennsylvania, United States|Pish Medical Associates, Uniontown, Pennsylvania, United States|PEAK Research, LLC, Upper Saint Clair, Pennsylvania, United States|Allegheny Rheumatology - WPAHS - ASRI, Wexford, Pennsylvania, United States|Clinical Research Center of Reading, LLC, Wyomissing, Pennsylvania, United States|Cardiology Consultants of Philadelphia, Yardley, Pennsylvania, United States|Jeffry A. Lindenbaum DO, PC, Yardley, Pennsylvania, United States|New England Center for Clinical Research, Cranston, Rhode Island, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Hugo M. Yamada, MD, Lincoln, Rhode Island, United States|Rheumatology Associates, Pawtucket, Rhode Island, United States|Medical Office Center, Providence, Rhode Island, United States|Anderson Heart, Anderson, South Carolina, United States|AnMed Health, Anderson, South Carolina, United States|Low Country Rheumatology, PA/Low Country Research Center, Charleston, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|St. Andrews Medical, Charleston, South Carolina, United States|Neem Research Group Inc., Columbia, South Carolina, United States|Columbia Arthritis Center Pa, Columbia, South Carolina, United States|MedTrial, Columbia, South Carolina, United States|Clinical Research Associates, LLC, Florence, South Carolina, United States|Palmetto Clinical Trial Services, LLC, Greenville, South Carolina, United States|Paris View Family Practice, Greenville, South Carolina, United States|John Milas, Greer, South Carolina, United States|Radiant Research, Inc, Greer, South Carolina, United States|DeGarmo Institute of Medical Research, Greer, South Carolina, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Palmetto Clinical Trial Services, LLC at the Family Healthcare Center, Laurens, South Carolina, United States|Berkeley Medical Center, Moncks Corner, South Carolina, United States|PMG Research of Charleston, Mount Pleasant, South Carolina, United States|North Myrtle Beach Family Practice, North Myrtle Beach, South Carolina, United States|Coulter Clinic, Orangeburg, South Carolina, United States|Orangeburg Medical Associates, PA, Orangeburg, South Carolina, United States|The Carolina Center for Rheumatology & Arthritis Care, PA, Rock Hill, South Carolina, United States|Hillcrest Clinical Research, LLC, Simpsonville, South Carolina, United States|Hillcrest Family Practice, Simpsonville, South Carolina, United States|Palmetto Research, Spartanburg, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Southeastern Research Associates, Inc., Taylors, South Carolina, United States|Odyssey Research/Sanford Clinic - Aberdeen, Aberdeen, South Dakota, United States|Sanford Clinic - Aberdeen, Aberdeen, South Dakota, United States|Regional Health Clinic Research, Rapid City, South Dakota, United States|Regional Medical Clinic-Rheumatology, Rapid City, South Dakota, United States|Health Concepts, Rapid City, South Dakota, United States|Brown Clinic PLLP, Watertown, South Dakota, United States|Odyssey Research, Watertown, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|Internal Medicine & Pediatric Associates of Bristol, Bristol, Tennessee, United States|PMG Research of Bristol, Bristol, Tennessee, United States|Parkway Medical Group, Fayetteville, Tennessee, United States|Stern Cardiovascular Foundation, inc., Germantown, Tennessee, United States|Arthritis Clinic, Jackson, Tennessee, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|State of Franklin Healthcare Associates Clinical Research, Johnson City, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Holston Valley Surgery Center, Kingsport, Tennessee, United States|Gupta, Ramesh C MD, Memphis, Tennessee, United States|Access Clinical Trials, Inc., Nashville, Tennessee, United States|Premier Orthopaedics, Nashville, Tennessee, United States|The Cholesterol Center of Nashville, Nashville, Tennessee, United States|Nashville Medical Research Institute, Nashville, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Amarillo Medical Specialists, LLP, Amarillo, Texas, United States|Pharma Tex Research, LLC, Amarillo, Texas, United States|Family Health Care Association, Arlington, Texas, United States|South Arlington Primary Care Associates PA, Arlington, Texas, United States|DCT - Anchor, LLC dba Discovery Clinical Trials, Arlington, Texas, United States|DCT-AACT, LLC dba Discovery Clinical Trials, Austin, Texas, United States|Southeast Texas Cardiology Associates, Beaumont, Texas, United States|Southeast Texas Clinical Research Center, Beaumont, Texas, United States|Kaner Medical Group PA, Bedford, Texas, United States|Nexxus Research Group, LLC, Bedford, Texas, United States|Texas Orthopedic Specialists, PLLC, Bedford, Texas, United States|MedicalEdge Healthcare Group, PA, dba Leading Edge Research, PA, Carrollton, Texas, United States|Prentiss Family Medicine, Colleyville, Texas, United States|Carlos B. Everett, MD, Corpus Christi, Texas, United States|Discovery Clinical Research, Corpus Christi, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Soltero Cardiovascular Research Center/Baylor University Medical Center, Dallas, Texas, United States|Arthritis Care and Diagnostic Center, P.A., Dallas, Texas, United States|Medical Specialists Associated, Dallas, Texas, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|SouthWest Rheumatology, P.A., Dallas, Texas, United States|DCT - Genesis Neighborhood Research, LLC dba Discovery Clinical Trials, Dallas, Texas, United States|Rajendra K. Marwah, MD, El Paso, Texas, United States|Kaner Medical Group, PA, Euless, Texas, United States|The Medical Group of Texas, Fort Worth, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|T & R Clinic, P. A., Fort Worth, Texas, United States|Rheumatology-UTMB, Galveston, Texas, United States|Towngate Plaza Medical Center, Garland, Texas, United States|ProCare Clinical Trials, Grand Prairie, Texas, United States|The Office of Amer Zaheer MD, PA, Houston, Texas, United States|Salim Gopalani, MD, PA, Houston, Texas, United States|Office of Cyril Wolf, MD, Houston, Texas, United States|Village Family Practice, Houston, Texas, United States|Kelsey Seybold Clinic, Houston, Texas, United States|Oxford Clinical Research, LLC, Houston, Texas, United States|MCA Research, Houston, Texas, United States|Texas Health Physicians Group, Irving, Texas, United States|One World Medical Associates, P.A., Lewisville, Texas, United States|Pri-Med Care, Lewisville, Texas, United States|South Texas Institute of Health, McAllen, Texas, United States|DCT - Genesis Seidmeyer Research, LLC dba Discovery Clinical Trials, McKinney, Texas, United States|Southwest Rheumatology, PA, Mesquite, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Basin Orthopedics Surgical Specialists, Odessa, Texas, United States|Center for Hypertension and Internal Medicine, Odessa, Texas, United States|Odessa Heart Institute, Odessa, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Office of David K. McDonald, M.D.. P.A., Pasadena, Texas, United States|Centex Studies, Inc., Pharr, Texas, United States|Clinical Investigations of Texas, LLC, Plano, Texas, United States|DCT-Genesis naini, LLC dba Discovery Clinical Trials, Plano, Texas, United States|North Texas Medical Research, Plano, Texas, United States|MedicalEdge Healthcare Group, PA, Richardson, Texas, United States|Texas Health Physicians Group, Richardson, Texas, United States|Ivan N. Mefford, MD, PhD, PA, Richmond, Texas, United States|Paragon Research Center, LLC, San Antonio, Texas, United States|Quality Assurance Research Center, San Antonio, Texas, United States|Quality Research Inc., San Antonio, Texas, United States|Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute, San Antonio, Texas, United States|GSA Research, San Antonio, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Radiant Research San Antonio Northeast, San Antonio, Texas, United States|Briggs Clinical Research, LLC, San Antonio, Texas, United States|DCT - Barlite, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|S.A.M. Clinical Research Center, San Antonio, Texas, United States|WellMed Clinical Research, San Antonio, Texas, United States|DCT-Westover Hills, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|DCT - Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|The Office of Shahbaz Yazdani, MD, PA, San Antonio, Texas, United States|Southlake Clinical Trials, Southlake, Texas, United States|Sugar Land Med-Ped Clinic, PA, Sugar Land, Texas, United States|Crossroads Clinical Research, LLC, Victoria, Texas, United States|Crossroads Clinical Research, Victoria, Texas, United States|Office of Pamela Dugano-Daphnis, Webster, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Burke Internal Medicine, Burke, Virginia, United States|Center for Arthritis and Rheumatic Diseases, Chesapeake, Virginia, United States|Bayview Physicians oa Cardiovascular Associates, Ltd, Chesapeake, Virginia, United States|David Ramstad, MD, MPH and Associates, Chesapeake, Virginia, United States|Danville Internal Medicine, Inc., Danville, Virginia, United States|Danville Orthopedic Clinic, Danville, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|Hampton Family Practice, Hampton, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Bruton Avenue Family Practice, Newport News, Virginia, United States|Internal Medicine Kidney and Hypertension Center, Norfolk, Virginia, United States|National Clinical Research - Norfolk Inc., Norfolk, Virginia, United States|Sentara Medical Group, Norfolk, Virginia, United States|Ettrick Health Center, Petersburg, Virginia, United States|Arthritis and Rheumatic Research, Portsmouth, Virginia, United States|Roanoke Heart Institute, Roanoke, Virginia, United States|Harbourview Professional Center, Suffolk, Virginia, United States|Chase Research Group, LLC, Virginia Beach, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Highline Medical Center Laboratory, Burien, Washington, United States|Puget Sound Osteoporosis Center, Seattle, Washington, United States|Arthritis Northwest, Seattle, Washington, United States|Arthritis Northwest Rheumatology, Spokane, Washington, United States|Lawrence S. Eastburn, MD, PS, Spokane, Washington, United States|Pulmonary and Research Associates, Spokane, Washington, United States|The Office of William Gray, Md, Family Practice, Spokane, Washington, United States|John F. Long, D.O., Spokane, Washington, United States|George H. Krick, MD, Tacoma, Washington, United States|Northwest Family and Spinal Clinic, Tacoma, Washington, United States|Rheumatology Infusion Services, Tacoma, Washington, United States|Tacoma Center for Arthritis Research, PS, Tacoma, Washington, United States|Wenatchee Valley Medical Center, Research Department, Wenatchee, Washington, United States|Clinical Trials Northwest, Yakima, Washington, United States|Rheumatology and Pulmonary Clinic, Beckley, West Virginia, United States|Mountain State Clinical Research, Clarksburg, West Virginia, United States|University Cardiovascular Services. Robert C. Byrd Clinical Center, Huntington, West Virginia, United States|WVVA Healthcare Alliance, Lewisburg, West Virginia, United States|Parkersburg Cardiology Associates, Parkersburg, West Virginia, United States|Meriter Medical Group, Madison, Wisconsin, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|UW Health Physicians, Madison, Wisconsin, United States|St. Lukes Pain Management Center, Milwaukee, Wisconsin, United States|Zablocki VA Medical Center, Milwaukee, Wisconsin, United States|Aspirus Cardiovascular Associates - Rhinelander, Rhinelander, Wisconsin, United States|Aspirus Cardiovascular Associates, Wausau, Wisconsin, United States|Aspirus Heart & Vascular lnstitute--Research & Education), Wausau, Wisconsin, United States|Aspirus Wausau Hospital, Wausau, Wisconsin, United States|Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States|Hunter Clinical Research, Broadmeadow, New South Wales, Australia|Wesley Medical Centre, Auchenflower, Queensland, Australia|Australian Clinical Research Organisation, Caboolture, Queensland, Australia|Rheumatology Department, Cairns, Queensland, Australia|AusTrials Pty Ltd, Kippa Ring, Queensland, Australia|Core Research Group, Milton, Queensland, Australia|AusTrials Pty Ltd, Sherwood, Queensland, Australia|Monash Medical Centre, Department of Rheumatology, Clayton, Victoria, Australia|Rheumatology Department, Heidelberg West, Victoria, Australia|Emeritus Research, Malvern East, Victoria, Australia|The Goatcher Clinical Research Unit, Shenton Park, Western Australia, Australia|The Colin Bayliss Research and Teaching Unit, Victoria Park, Western Australia, Australia|CLINCOR - Clinica de Exames Cardiologicos e Ecografia S/C Ltda, Maceio, AL, Brazil|Hospital do Coracao de Alagoas, Maceio, AL, Brazil|CIP - Centro Internacional de Pesquisas, Goiania, GO, Brazil|Via Medica - Centro Clinico, Goiania, GO, Brazil|CMIP - Centro Mineiro de Pesquisa, Juiz de Fora, MG, Brazil|Hopsital das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Hospital e Maternidade Angelina Caron, Sala Pesquisa Clinica, Campina Grande do Sul, PR, Brazil|CEPEME-CERHFAC Centro de Estudos e Pesquisas Medicas, Curitiba, PR, Brazil|Centro de Estudos do Hospital de ClÃ­nicas da UFPR, Curitiba, PR, Brazil|Hospital UniversitÃ¡rio Clementino Fraga Filho - UFRJ, Rio de Janeiro, RJ, Brazil|CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda, Rio de Janeiro, RJ, Brazil|Hospital Ipanema Plus, Rio de Janeiro, RJ, Brazil|Clinica de Reumatologia do Centro MÃ©dico BarraShopping, Rio de Janeiro, RJ, Brazil|Centro de Pesquisa Clinica, Porto Alegre, RS, Brazil|AssociaÃ§Ã£o Hospitalar Moinhos de Vento (AHMV) / CMIC, Porto Alegre, RS, Brazil|Hospital SÃ£o Lucas - Pontificia, Porto Alegre, RS, Brazil|Hospital e Maternidade Celso Pierro - Puc Campinas, Campinas, Sao Paulo, Brazil|Centro de Ensino e Pesquisa Hospital Sao Lucas, Aracaju, SE, Brazil|PUC Campinas, Campinas, SP, Brazil|Hospital das Clinicas da UNICAMP, Campinas, SP, Brazil|Hospital das Clinicas da Faculdade de Medicina de Marilia, Marilia, SP, Brazil|Hospital de Base - Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Setor de Lip., Arterosc. e BioVasc. - Disc. de Cardiologia, Sao Paulo, SP, Brazil|CEPIC - Centro Paulista de Investigacao ClÃ­nica, Sao Paulo, SP, Brazil|IMA Brasil - Instituto de Medicina Avancada, Sao Paulo, SP, Brazil|CPCLIN - Centro de Pesquisas ClÃ­nicas, SÃ£o Paulo, SP, Brazil|Hospital Sao Salvador - Medicos Reunidos Ltda., Goiania-GO, Brazil|Ambulatorio de Especialidades Mario Covas, Marilia/SP, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital das Clinicas da UFPE, Recife - Pernambuco, Brazil|Hospital Dos Servidores Do Estado do Rio de Janeiro, Rio de Janeiro, Brazil|Faculdade de Medicina DO ABC, Santo Andre, Brazil|South Calgary Medical Clinic - Sunpark Professional Center, Calgary, Alberta, Canada|Allin Clinic, Edmonton, Alberta, Canada|Dr. MPJ Senaratne Professional Corporation, Edmonton, Alberta, Canada|Medical Arts Health Research Group, Kelowna, British Columbia, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|Ocean West Research Clinic Inc., Surrey, British Columbia, Canada|Prohealth Clinical Research Inc., Vancouver, British Columbia, Canada|Office of Dr. Milton F. Baker, Victoria, British Columbia, Canada|The Medical Arts Health Research Group, West Vancouver, British Columbia, Canada|Rivergrove Medical Clinic, Winnipeg, Manitoba, Canada|Manitoba Clinic, Winnipeg, Manitoba, Canada|G.A. Research Associates Ltd/Ltee, Moncton, New Brunswick, Canada|Eric N. Grant Professional Corporation, Quispamis, New Brunswick, Canada|Office of Dr. Brian N. Craig, Saint John, New Brunswick, Canada|Commonwealth Medical Clinic, Mount Pearl, Newfoundland and Labrador, Canada|Paradise Medical Clinic, Paradise, Newfoundland and Labrador, Canada|White Hills Medical Clinic, St. John's, Newfoundland and Labrador, Canada|Nexus Clinic Research, St. John's, Newfoundland and Labrador, Canada|The Clinical Trials Centre, St. John's, Newfoundland and Labrador, Canada|Topsail Road Medical Clinic, St. John's, Newfoundland and Labrador, Canada|MSHJ Research Associates, Inc., Halifax, Nova Scotia, Canada|Colchester Research Group, Truro, Nova Scotia, Canada|Office of Dr. Rohit Nagpal, Brampton, Ontario, Canada|Aggarwal and Associates Ltd., Brampton, Ontario, Canada|Aviva Clinical Trial Group Inc., Burlington, Ontario, Canada|Corunna Medical Research Center, Corunna, Ontario, Canada|C & L Research, Fort Erie, Ontario, Canada|Office of Dr. Jonathan D. Adachi, Hamilton, Ontario, Canada|Office of Dr. John Mutrie, Kitchener, Ontario, Canada|KW Musculoskeletal Research Inc., Kitchener, Ontario, Canada|East London Medical Centre, London, Ontario, Canada|London East Medical Centre, London, Ontario, Canada|Office of Dr. Gordon Schacter, London, Ontario, Canada|Office of Dr. William Blake Bowler, London, Ontario, Canada|Office of Dr. Robert G. Luton, London, Ontario, Canada|Malton Medical Centre, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|SKDS Research Inc., Newmarket, Ontario, Canada|Office of Dr. Azim M. Velji, Niagara Falls, Ontario, Canada|AIM Health Group Trainyards Health and Wellness Centre, Ottawa, Ontario, Canada|London Road Diagnostic Clinic & Medical Center, Sarnia, Ontario, Canada|London Road Diagnostic Clinic & Medical Centre, Sarnia, Ontario, Canada|Office of Dr. Swaran K. Syan, Sudbury, Ontario, Canada|Keele Medical Place, Toronto, Ontario, Canada|Prime Health Clinical Research, Toronto, Ontario, Canada|Office of Dr. Ira Bernstein, Toronto, Ontario, Canada|Office of Dr. Subodh Kanani, Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|North Walkerville Orthopaedic Associates, Windsor, Ontario, Canada|Research Office, Windsor, Ontario, Canada|Clinical Research and Arthritis Centre, Windsor, Ontario, Canada|Centre de sante et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada|ECOGENE-21 / Centre de sante et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada|Clinique de Medicine Familiale de Cowansville, Cowansville, Quebec, Canada|Centre de recherche clinique Adapra Inc., L'Ancienne-Lorette, Quebec, Canada|Centre de Recherche Hochelaga/ Clinique Medicale Hochelaga, Montreal, Quebec, Canada|Recherche Medicale Appliquee Informatics (AMIR) Inc., Montreal, Quebec, Canada|Kells Medical Research Group, Inc., Pointe-Claire, Quebec, Canada|Le Manoir de l'Atrium, Quebec City, Quebec, Canada|Clinique Services Sante Rosemere, Rosemere, Quebec, Canada|Centre Medical des Carrieres, Saint-Marc-des-Carrieres, Quebec, Canada|St-Jerome Medical Research Inc., St-Jerome, Quebec, Canada|Centre de Recherche Musculo-Squelettique, Trois-Rivieres, Quebec, Canada|Cardiology and Research, Westmount, Quebec, Canada|Downtown Medical Specialists, Saskatoon, Saskatchewan, Canada|Recherche Clinique Sigma, Inc., Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de QuÃ©bec, Quebec, Canada|Hospital Pablo Tobon Uribe - Unidad de Investigaciones, Medellin, Antioquia, Colombia|Reumalab S.A.S., Medellin, Antioquia, Colombia|IPS Rodrigo Botero S.A.S., Medellin, Antioquia, Colombia|Fundacion Cardioinfantil, Bogota, Cundinamarca, Colombia|Clinica Colsanitas Sa, Bogota, Cundinamarca, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Santander, Colombia|Fundacion Valle del Lili, Cali, Colombia|ClÃ­nica VÃ­a San Juan, La union de Tres Rios, Cartago, Costa Rica|Clinica San Agustin, Desamparados Centro, San Jose, Costa Rica|Hospital CIMA San Jose, Escazu, San Jose, Costa Rica|Hospital Hotel La Catolica, Goicoechea, San Jose, Costa Rica|Consultorio Privado Dr. Alberto Lainez Ventosilla, Moravia, San JosÃ©, Costa Rica|Centro Medico San Rafael, Alajuela, Costa Rica|Centro de Reumatologia y Osteoporosis, Cartago, Costa Rica|ClÃ­nica Garzona, Cartago, Costa Rica|Clinica de Especialidades Medicas Drs. Saenz Castro, Heredia, Costa Rica|ClÃ­nica Monte SiÃ³n, Heredia, Costa Rica|ClÃ­nica San Antonio, Heredia, Costa Rica|Centro Medico San Jose, San Jose, Costa Rica|Edificio Panda, San Jose, Costa Rica|Hospital Clinica Biblica, San Jose, Costa Rica|Hospital ClÃ­nica Biblica, San Jose, Costa Rica|Oficina Privada, San Jose, Costa Rica|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Centre for Assessment and Treatment of Rheumatic Diseases, Department of Medicine and Geriatrics, New Territories, NT, Hong Kong|Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong|Department of Medicine, North District Hospital, Sheung Shui, NT, Hong Kong|Centro de Investigacion del Noroeste SC, Tijuana, Baja California, Mexico|Comite Mexicano para la Prevencion de la Osteoporosis, A.C., Mexico, D.f., Mexico|Instituto Mexicano de InvestigaciÃ³n ClÃ­nica, S.A. de C.V, Mexico, D.f., Mexico|CIF-BIOTEC, Medica Sur, Mexico, DF, Mexico|Centro Medico Toluca, Metepec, Estado de Mexico, Mexico|Hospital Regional ISSSTE, Leon, Guanajuato, Mexico|Instituto Jalisciense de InvestigaciÃ³n ClÃ­nica SA de CV, Guadalajara, Jalisco, Mexico|Centro de Estudios de Investigacion Basica y Clinica SC., Guadalajara, Jalisco, Mexico|Unidad de Investigacion Dr. Mario Alvizouri MuÃ±oz Ac Del Hospital General Dr. Miguel Silva, Morelia, Michoacan, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"" Unidad Regional de Reumatologia y Osteoporosis, San Luis Potosi, SLP, Mexico|Clinicos Asociados BOCM, S.C., Mexico City, Mexico|Centro de InvestigaciÃ³n Marbella, Panama City, Panama|IPC - Centro de Salud Integral S.A., San Isidro, Lima, Peru|Centro Empresarial - Altavista Polo 4, Santiago de Surco, Lima, Peru|Instituto de Ginecologia y ReproducciÃ³n & Cirugia Minimamente Invasiva, Santiago de Surco, Lima, Peru|Clinica San Felipe, Lima, Peru|Centro de Investigaciones Medical, Lima, Peru|Clinica San Juan Bautista, Lima, Peru|Mary Mediatrix Medical Center, Lipa City, Batangas, Philippines|De La Salle Health Sciences Institute, Dasmarinas, Cavite, Philippines|Chong Hua Hospital, Cebu City, Philippines|Southern Philippines Medical Center, Davao City, Philippines|Jose R. Reyes Memorial Medical Center, Manila, Philippines|Chinese General Hospital and Medical Center, Manila, Philippines|Hospital Research Unit, University of Santo Tomas Hospital, Manila, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Chang Gung Memorial Hospital-Kaohsiung branch, Section of Allergy, Immunology, Nio Sung Township, Kaohsiung County, Taiwan|Tri-Service General Hospital, Neihu District, Taipei City, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Gueishan Township, Taoyuan County, Taiwan|Chi-Mei Medical Center, Tainan, Yung Kang, Taiwan|Buddhist Tzu Chi Dailin General Hospital, Chia-Yi County, Taiwan|Chung-Ho Memorial Hospital, Kaoshiung Medical University Hospital, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tri-service General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|CRI ""Clinical Territorial Medical Association ""University Clinic"",, Simferopol, Crimea, Ukraine|Municipal Medical Institution ""City Clinical Hospital #3"", Department of Rheumatology, Chernivtsi, Ukraine|MI Dnipropetrovsk Regional Clinical Hospital named after I.I Mechnikov, Dnipropetrovsk, Ukraine|State Institution ""Dnipropetrovsk Medical Academy of MOH, Ukraine, Dnipropetrovsk, Ukraine|Rheumatology Department, MMI ""City Clinical Hospital #5"", DNMU n.a. M.Gorkyy,, Donetsk, Ukraine|Donetsk National Med University, Chair of Propaedeutics and Internal Medicine, Donetsk, Ukraine|Municipal Establishment of Health Care, Kharkiv, Ukraine|City Clinical Hospital # 8, Dept of Cardiology and Functional Diagnostics, Kharkiv, Ukraine|City Clinical Hospital #1, Kyiv, Ukraine|National Scientific Center ""The Strazhesko Institute of Cardiology"", Kyiv, Ukraine|State Institution ""Republican clinical hospital of MOH of Ukraine"", Kyiv, Ukraine|Family Medicine Department of NMAPE named after PL Shupyk,, Kyiv, Ukraine|Lutsk City Clinical Hospital, Lutsk, Ukraine|Municipal City Clinical Hospital #5, Lviv, Ukraine|Center of Reconstructive and Regenerative Medicine (University clinic) of, Odesa, Ukraine|Treatment-and-Diagnostic Center LLC ""Desna"" Ltd, Ternopil, Ukraine|Municipal enterprise "" City Hospital # 7"",, Zaporizhzhia, Ukraine|Municipal Institution ""Zaporizhzhya City Multiple Discipline Clinical Hospital #9"", Zaporizhzhya, Ukraine|Zhytomyr Regional Clinical Hospital n.a. O.F. Gerbachevs'kyy/ Rheumatology Center, Zhytomyr, Ukraine",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT01860833,KNEE OSTEOARTHRITIS,All,"50 Years to 85 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Orthopedic and Trauma Surgery, Catanzaro, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00630929,OSTEO ARTHRITIS OF THE KNEES,All,"40 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Bad Muender, Germany|Pfizer Investigational Site, Beckum, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Ostseebad Damp, Germany|Pfizer Investigational Site, Schwerin, Germany|Pfizer Investigational Site, Stade, Germany|Pfizer Investigational Site, Tostedt, Germany|Pfizer Investigational Site, Weener, Germany|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Cadiz, Spain|Pfizer Investigational Site, Guadalajara, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Oviedo, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Chelmsly Wood, Birmingham, United Kingdom|Pfizer Investigational Site, Truro, Cornwall, United Kingdom|Pfizer Investigational Site, Chorley, Lancs, United Kingdom|Pfizer Investigational Site, Liverpool, Lancs, United Kingdom|Pfizer Investigational Site, Cannock, Mid Staffordshire, United Kingdom|Pfizer Investigational Site, Addlestone, Surrey, United Kingdom|Pfizer Investigational Site, Huddersfield, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Newcastle Upon Tyne, United Kingdom|Pfizer Investigational Site, Wigan, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Terminated,NCT03473665,ANKYLOSING SPONDYLITIS|AXIAL SPONDYLOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Columbia University Irving Medical Center, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00447759,OSTEOARTHRITIS|RHEUMATOID ARTHRITIS,All,"60 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Southern Denmark, Odense, Denmark|Julius Clinical Research, Zeist, Netherlands|University of Aberdeen, Aberdeen, United Kingdom|University of Birmingham, Birmingham, United Kingdom|University of Dundee, Dundee, United Kingdom|University of Edinburgh, Edinburgh, United Kingdom|University of Glasgow, Glasgow, United Kingdom|NHS Highlands, Inverness, United Kingdom|University of Nottingham, Nottingham, United Kingdom|University of Oxford, Oxford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00141102,"OSTEOARTHRITIS|ARTHRITIS, RHEUMATOID",All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, LiÃ¨ge, Belgium|Pfizer Investigational Site, GoiÃ¢nia, GO, Brazil|Pfizer Investigational Site, GoiÃ¢nia, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, SÃ£o Paulo, SP, Brazil|Pfizer Investigational Site, SÃ£o Paulo, SP, Brazil|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste Foy, Quebec, Canada|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Chengdu, Sichuan, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Floridablanca, Santander, Colombia|Pfizer Investigational Site, Cartago, Costa Rica|Pfizer Investigational Site, Heredia, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Opatija, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Plzen, Bory, Czech Republic|Pfizer Investigational Site, Ostrava, Trebovice, Czech Republic|Pfizer Investigational Site, Ceske Budejovice, Czech Republic|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Prague 1, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 4, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Cuenca, Azuay, Ecuador|Pfizer Investigational Site, Guayaquil, Guayas, Ecuador|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Amiens, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Deggingen, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hoyerswerda, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Ciudad de Guatemala, Guatemala|Pfizer Investigational Site, Guatemala 01010, Guatemala|Pfizer Investigational Site, Lai Chi Kok, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Alytus, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Klaipeda, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vlaardingen, ZH, Netherlands|Pfizer Investigational Site, Alkmaar, Netherlands|Pfizer Investigational Site, Leidschendam, Netherlands|Pfizer Investigational Site, Ciudad de Panama, Panama|Pfizer Investigational Site, Surco, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisbon, Portugal|Pfizer Investigational Site, Ponta Delgada, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ekaterinburg, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Petrozavodsk, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Niska Banja, Serbia|Pfizer Investigational Site, Novi Sad, Serbia|Pfizer Investigational Site, Sinapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bloemfontein, Free State, South Africa|Pfizer Investigational Site, Johannesburg, Gauteng Province, South Africa|Pfizer Investigational Site, Durban, KZN, South Africa|Pfizer Investigational Site, Parow, Western Cape, South Africa|Pfizer Investigational Site, Bellville, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Kempton Park, South Africa|Pfizer Investigational Site, Observatory Cape Town, South Africa|Pfizer Investigational Site, Partida de Bacarot, Alicante, Spain|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Barakaldo, Vizcaya, Spain|Pfizer Investigational Site, Avila, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Lulea, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Tao-Yuan, Taiwan|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Ivano-Frankivsk, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kiev, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lutsk, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Simferopol, Ukraine|Pfizer Investigational Site, Zaporizhzhia, Ukraine|Pfizer Investigational Site, Helensburgh, Argyle & Clyde, United Kingdom|Pfizer Investigational Site, Maidenhead, Berks, United Kingdom|Pfizer Investigational Site, Aston Clinton, Buckinghamshire, United Kingdom|Pfizer Investigational Site, St Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Aldershot, Hampshire, United Kingdom|Pfizer Investigational Site, Basingstoke, Hampshire, United Kingdom|Pfizer Investigational Site, Odiham, Hampshire, United Kingdom|Pfizer Investigational Site, Ashford, Middlesex, United Kingdom|Pfizer Investigational Site, Harrow, Middlesex, United Kingdom|Pfizer Investigational Site, Camberley, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Leatherhead, Surrey, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Bradford-on-Avon, Wiltshire, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, United Kingdom|Pfizer Investigational Site, Upton, Wirral, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, United Kingdom|Pfizer Investigational Site, Canterbury, United Kingdom|Pfizer Investigational Site, Chesterfield, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, St Leonards on Sea, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom|Pfizer Investigational Site, Vale of Glamorgan, United Kingdom|Pfizer Investigational Site, Wansford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00174317,"OSTEOARTHRITIS, HIP",All,"45 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Pfizer Investigational Site, Aston Clinton, Bucks, United Kingdom|Pfizer Investigational Site, Ely, Cambs, United Kingdom|Pfizer Investigational Site, St. Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Lancaster, England, United Kingdom|Pfizer Investigational Site, Sheffield, England, United Kingdom|Pfizer Investigational Site, Newport, Gwent, United Kingdom|Pfizer Investigational Site, Chingford, London, United Kingdom|Pfizer Investigational Site, Harrow, Middlesex, United Kingdom|Pfizer Investigational Site, Greenisland, Carrickfergus, Northern Ireland, United Kingdom|Pfizer Investigational Site, Oxford, Oxon, United Kingdom|Pfizer Investigational Site, Greenock, Renfrewshire, United Kingdom|Pfizer Investigational Site, Barry, South Glamorgan, United Kingdom|Pfizer Investigational Site, Barnsley, South Yorkshire, United Kingdom|Pfizer Investigational Site, Ashford, Surrey, United Kingdom|Pfizer Investigational Site, Newcastle-Upon-Tyne, Tyne & Wear, United Kingdom|Pfizer Investigational Site, Trowbridge, Wiltshire, United Kingdom|Pfizer Investigational Site, Aberdeen, United Kingdom|Pfizer Investigational Site, Amersham, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Bradford, United Kingdom|Pfizer Investigational Site, Cardiff, United Kingdom|Pfizer Investigational Site, Carshalton, United Kingdom|Pfizer Investigational Site, Chertsey, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Lancaster, United Kingdom|Pfizer Investigational Site, Leystonstone, London, United Kingdom|Pfizer Investigational Site, Liverpool, United Kingdom|Pfizer Investigational Site, Liverpool, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Northampton, United Kingdom|Pfizer Investigational Site, Norwich, United Kingdom|Pfizer Investigational Site, Nuneaton, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, Sheffield, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom|Pfizer Investigational Site, Truro, United Kingdom|Pfizer Investigational Site, Wansford, United Kingdom|Pfizer Investigational Site, Watford, United Kingdom|Pfizer Investigational Site, Westbury, United Kingdom|Pfizer Investigational Site, Wigan, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Unknown status,NCT03699293,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Inova Heart and Vascular Institute, Falls Church, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT02198924,PAIN|INFLAMMATION,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking Union Medical College Hospital, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00807846,"ARTHRITIS, JUVENILE RHEUMATOID",All,2 Years to 17 Years Â  (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Catalina Pointe Clinical Research, Inc., Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Children's Hospital-San Diego, San Diego, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Children's National Medical Center / Division of Rheumatology, Washington, District of Columbia, United States|Arthritis Associates of South Florida, Delray Beach, Florida, United States|Delray Research Associates, Delray Beach, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Administrative Site-Hawaii Pacific Health Research Institute, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Kosair Charities Pediatric Clinical Research Unit - University of Louisville, Louisville, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|University Pediatric Rheumatology of Kentucky, Louisville, Kentucky, United States|Children's Hospital and Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center Pediatric Research Office, Omaha, Nebraska, United States|Akron Children's Hospital, Akron, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital Roberto del Rio, Santiago, RM, Chile|Hospital Regional de Concepcion Guillermo Grant Benavente, Concepcion, VIII Region, Chile|Instituto de Atencion Pediatrica, San Jose, Costa Rica|Clinica San Borja/Centro de Investigacion de Reumatologia, San Borja, Lima, Peru|Clinica Ricardo Palma/Sitio de Investigacion de Reumatologia, San Isidro, Lima, Peru|Philippine General Hospital, Manila, Philippines|University of Santo Tomas Hospital, Manila, Philippines|State Healthcare Institution of Moscow ""Izmailovskaya City Children's Hospital"", Moscow, Russian Federation|First Moscow State Medical University I.M. Sechenov of the Minzdravsocrazvitiya of Russia, Moscow, Russian Federation|Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|SEIHPE ""Smolensk State Medical Academy""of the Minzdravsocrazvitiya of Russia, Smolensk, Russian Federation|Institute of Rheumatology, Belgrade, Serbia|Children's Clinic of Internal Medicine, Nis, Serbia|Clinical Research Unit, Pretoria, Gauteng Province, South Africa|CHUV - Unit of Immuno-Allergology and Rhumatology, CH-1011 Lausanne, Switzerland|Universitaets-Kinderspital, CH-8032 Zuerich, Switzerland|Department of Cardioreumatology, Kharkiv, Ukraine|Institute of Pediatrics, Obstetrics and Gynecology, Kiev, Ukraine|Kyiv City Children Clinical Hospital #1, Kyiv, Ukraine|Crimean State Medical University, Chair of Pediatrics with a course of Children Infectious Diseases, Simferopol, Ukraine|Zaporizhzhya Regional Clinical Pediatric Hospital, Zaporizhzhya, Ukraine",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Unknown status,NCT02355236,OSTEOARTHRITIS,All,"50 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hallym University Medical Center, Anyang-si, Korea, Republic of|Inje University Ilsan Paik Hospital, Goyang-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ewha Womans University Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT03067194,OSTEOARTHRITIS HAND,All,"19 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Soon Chun Hyang University Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Terminated,NCT00359151,OSTEOARTHRITIS|PAIN,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Englewood, Colorado, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Bellaire, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00139776,"OSTEOARTHRITIS, KNEE|OSTEOARTHRITIS, HIP",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Peoria, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Anaheim, California, United States|Pfizer Investigational Site, Huntington Beach, California, United States|Pfizer Investigational Site, Long Beach, California, United States|Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Paramount, California, United States|Pfizer Investigational Site, Stockton, California, United States|Pfizer Investigational Site, Tustin, California, United States|Pfizer Investigational Site, Walnut Creek, California, United States|Pfizer Investigational Site, Whittier, California, United States|Pfizer Investigational Site, Wheatridge, Colorado, United States|Pfizer Investigational Site, Danbury, Connecticut, United States|Pfizer Investigational Site, New Milford, Connecticut, United States|Pfizer Investigational Site, Waterbury, Connecticut, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Palm Harbor, Florida, United States|Pfizer Investigational Site, South Miami, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Zephyrhills, Florida, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Dubuque, Iowa, United States|Pfizer Investigational Site, Dubuque, Iowa, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Madisonville, Kentucky, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Clinton, Maryland, United States|Pfizer Investigational Site, Frederick, Maryland, United States|Pfizer Investigational Site, Greenbelt, Maryland, United States|Pfizer Investigational Site, Wheaton, Maryland, United States|Pfizer Investigational Site, Brockton, Massachusetts, United States|Pfizer Investigational Site, Jefferson City, Missouri, United States|Pfizer Investigational Site, Jefferson City, Missouri, United States|Pfizer Investigational Site, Springfield, Missouri, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Great Neck, New York, United States|Pfizer Investigational Site, Manlius, New York, United States|Pfizer Investigational Site, Mineola, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Rochester, New York, United States|Pfizer Investigational Site, Winston Salem, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Zanesville, Ohio, United States|Pfizer Investigational Site, Eugene, Oregon, United States|Pfizer Investigational Site, Beaver, Pennsylvania, United States|Pfizer Investigational Site, Camp Hill, Pennsylvania, United States|Pfizer Investigational Site, Duncansville, Pennsylvania, United States|Pfizer Investigational Site, Johnstown, Pennsylvania, United States|Pfizer Investigational Site, Philadephia, Pennsylvania, United States|Pfizer Investigational Site, Johnson City, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, New Tazewell, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Arlington, Virginia, United States|Pfizer Investigational Site, Renton, Washington, United States|Pfizer Investigational Site, Tacoma, Washington, United States|Pfizer Investigational Site, Yakima, Washington, United States|Pfizer Investigational Site, Yakima, Washington, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, Ham, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Campinas, SP, Brazil|Pfizer Investigational Site, SÃ£o Paulo, SP, Brazil|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Corunna, Ontario, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, North York, Ontario, Canada|Pfizer Investigational Site, Sarnia, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Charlottetown, Prince Edward Island, Canada|Pfizer Investigational Site, Montague, Prince Edward Island, Canada|Pfizer Investigational Site, Mirabel, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Rimouski, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste-Foy, Quebec, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, ViÃ±a Del Mar, V Region, Chile|Pfizer Investigational Site, Rancagua, VI RegiÃ³n, Chile|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Barranquila, Colombia|Pfizer Investigational Site, Bogota, Colombia|Pfizer Investigational Site, Bucaramanga, Colombia|Pfizer Investigational Site, Joue Les Tours, France|Pfizer Investigational Site, L'Union, France|Pfizer Investigational Site, Poitiers, France|Pfizer Investigational Site, Tours, France|Pfizer Investigational Site, Randalstown, Co Antrim, United Kingdom|Pfizer Investigational Site, Newtownabbey, Co.Antrim, United Kingdom|Pfizer Investigational Site, Leslie, Fife, United Kingdom|Pfizer Investigational Site, Watford, Herts, United Kingdom|Pfizer Investigational Site, Canterbury, Kent, United Kingdom|Pfizer Investigational Site, Wigan, Lancs, United Kingdom|Pfizer Investigational Site, Bradwell Common, Milton Keynes, United Kingdom|Pfizer Investigational Site, Greenisland, Carrickfergus, Northern Ireland, United Kingdom|Pfizer Investigational Site, Barry, Vale of Glamorgan, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Bradford on Avon, Wiltshire, United Kingdom|Pfizer Investigational Site, Midsomer Norton, Wiltshire, United Kingdom|Pfizer Investigational Site, Bangor, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Blackpool, United Kingdom|Pfizer Investigational Site, Cardiff, United Kingdom|Pfizer Investigational Site, Cookstown, United Kingdom|Pfizer Investigational Site, Trowbridge, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT03190603,SPONDYLARTHROPATHIES|MAGNETIC RESONANCE IMAGING,All,18 Years to 30 Years Â  (Adult),Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Armed Forces Capital Hospital, Seongnam-si, Korea, Republic of",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,ARTHROSCOPY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,PEPTIC ULCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,ANKLE SPRAINS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Active Not Recruiting,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,1,DB00485,__DICLOXACILLIN,4199566,Not yet recruiting,NCT04563325,OSTEOMYELITIS|SEPTIC ARTHRITIS|BONE INFECTION|JOINT INFECTION|BONE AND JOINT INFECTION,All,3 Months to 17 Years Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,22.538450481529303,914.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,470.32599999999996,112.74,5.0,2.0,4.0,42.86,111.44,3.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1
Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,1,DB00485,__DICLOXACILLIN,4199566,Recruiting,,BONE AND JOINT INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,22.538450481529303,914.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,470.32599999999996,112.74,5.0,2.0,4.0,42.86,111.44,3.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1
CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C,1,DB00492,__FOSINOPRIL,5006344,Completed,NCT01014338,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Royal Brompton Hospital, London, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,9.42935173206841,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.71,563.672,110.21,5.0,1.0,3.0,61.83,149.12,15.0,1.0,0.0,0.0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Terminated,NCT01264965,ARTHRITIS|PAIN|COGNITIVE IMPAIRMENT,All,65 Years and older Â  (Older Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Chicago Medical Center Outpatient Senior Health Center South Shore, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Completed,NCT01502644,CHRONIC LOW BACK PAIN|DEGENERATIVE DISC DISEASE|DEPRESSION|ANXIETY,All,"21 Years to 75 Years Â  (Adult, Older Adult)",Other|NIH,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Completed,NCT01811238,SPINAL DISORDERS,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Recruiting,NCT04122443,MUSCULOSKELETAL PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Montefiore Medical Center, Bronx, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Withdrawn,NCT02032927,CHRONIC PAIN,All,"60 Years to 100 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Azienda Ospedaliera della Provincia di Pavia - Ospedale ""Carlo Mira"" - U.O. Medicina Interna - Servizio di Anestesia e Rianimazione - Ambulatorio di Terapia del dolore, Casorate Primo, Italy|Azienda Istituti Ospitalieri di Cremona, Presidio Ospedaliero di Cremona - U.O. di Anestesia, Analgesia e Medicina Perioperatoria, Cremona, Italy|Azienda Ospedaliera della provincia di Lodi Dipartimento emergenza urgenza, Lodi, Italy|Azienda Ospedaliera Istituto Ortopedico Gaetano Pini - U.O.C. Anestesia e Rianimazione, Milano, Italy|Azienda Ospedaliera della Provincia di Pavia - Ospedale Asilo Vittoria di Mortara - U.O. di Pneumotisiologia, Mortara, Italy|Clinica San Carlo - Casa di Cura Polispecialistica S.p.A. - UnitÃ  di Terapia del Dolore, Paderno Dugnano, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Servizi alla Persona, ASP, ""II.AA.RR."" - Istituto di Riabilitazione ""Santa Margherita"" - Struttura Complessa di Riabilitazione, Pavia, Italy|Fondazione Salvatore Maugeri - sede di Via Boezio - UO Cure Palliative e Terapia del Dolore, Pavia, Italy|IRCCS Istituto Clinico ""Humanitas"" - Anestesia, Day Hospital chirurgico - Chronic Pain Service, Rozzano, Italy|Dipartimento Integrato di Lungassistenza Anziani - ASL TO1, Torino, Italy|Ospedale di circolo Fondazione Macchi - SSD Anestesia Day Surgery, Varese, Italy|Azienda Ospedaliera della Provincia di Pavia - Ospedale Civile di Vigevano - Servizio di Anestesia e Rianimazione, Vigevano, Italy|Azienda Ospedaliera della Provincia di Pavia - Ospedale Civile di Voghera- U.O. di Medicina Interna - U.O. di Riabilitazione specialistica, Voghera, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Recruiting,NCT02464813,SCOLIOSIS|SPONDYLOLISTHESIS,All,"10 Years to 21 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Turku University Hospital, Turku, Finland",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Completed,NCT00784810,OSTEOARTHRITIS|BACK PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Coventry, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Terminated,NCT01902186,HIV INFECTION|OSTEOPENIA,Female,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Milano, Milano, Italy|University of Torino, Torino, Italy",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Recruiting,NCT03426761,BONE INFECTION|OSTEOMYELITIS|SEPTIC ARTHRITIS|JOINT INFECTION|PROSTHETIC JOINT INFECTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Infectious Diseases Physicians, Inc., Annandale, Virginia, United States",A61K9/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Terminated,NCT01734694,HEALTH CARE ASSOCIATED PNEUMONIA|OSTEOMYELITIS/SEPTIC ARTHRITIS|ENDOCARDITIS|BACTEREMIA|ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Henry Ford Hospital, Detroit, Michigan, United States",A61K9/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O,1,DB00512,__VANCOMYCIN,10188697,Recruiting,NCT04042233,PROSTHETIC JOINT INFECTION|VANCOMYCIN|JOINT DISEASES,All,"19 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Houston Methodist Hospital, Houston, Texas, United States",A61K9/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,38.768763218957204,1648.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.11,1449.254,530.49,24.0,19.0,10.0,138.7,346.61,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1
NCCCCCC(=O)O,1,DB00513,__AMINOCAPROIC_ACID,3937752,Completed,NCT00958581,SCOLIOSIS,All,"10 Years to 80 Years Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","New York University School of Medicine - Department of Orthopaedic Surgery - Spine, New York, New York, United States",C09J177/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,38.1445204213638,1263.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,131.1729,63.32,3.0,2.0,0.0,14.71,34.66,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,1,DB00533,__ROFECOXIB,5474995,Terminated,NCT00140920,PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D275/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,23.0312737427873,348.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.32,314.356,60.44,3.0,0.0,3.0,31.74,84.08,3.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0
CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,1,DB00533,__ROFECOXIB,5474995,Terminated,NCT00140894,ADENOMATOUS POLYPOSIS COLI,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07D275/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,23.0312737427873,348.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.32,314.356,60.44,3.0,0.0,3.0,31.74,84.08,3.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0
CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,1,DB00533,__ROFECOXIB,5474995,Completed,NCT00157872,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D275/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,23.0312737427873,348.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.32,314.356,60.44,3.0,0.0,3.0,31.74,84.08,3.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,NCT03533231,DENTAL PULP NECROSIS|PERIAPICAL ABSCESS|ROOT CANAL INFECTION,All,"8 Years to 18 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,1,DB00539,__TOREMIFENE,4696949,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07C43/225,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,19.975769522988106,1776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.65,405.96,12.47,2.0,0.0,3.0,46.49,133.41,9.0,0.0,1.0,0.0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNCCC=C1c2ccccc2CCc2ccccc21,1,DB00540,__NORTRIPTYLINE,4175119,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,198.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.65,263.3767,12.03,1.0,1.0,3.0,31.87,96.21,3.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CNCCC=C1c2ccccc2CCc2ccccc21,1,DB00540,__NORTRIPTYLINE,4175119,Recruiting,,TINNITUS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,198.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.65,263.3767,12.03,1.0,1.0,3.0,31.87,96.21,3.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,1,DB00542,__BENAZEPRIL,6162802,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,681.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.14,424.4895,95.94,5.0,2.0,3.0,44.98,115.23,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0
O=c1[nH]cc(F)c(=O)[nH]1,1,DB00544,__FLUOROURACIL,6670335,Unknown status,NCT01295099,KELOID,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barts and the London NHS Trust, London, UK, United Kingdom",A61K8/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
O=c1[nH]cc(F)c(=O)[nH]1,1,DB00544,__FLUOROURACIL,6670335,Completed,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)C(=O)Oc1ccc[n+](C)c1,1,DB00545,__PYRIDOSTIGMINE,3931205,Recruiting,NCT03510546,MYASTHENIA GRAVIS,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Department of Neurology Aarhus University Hospital, Aarhus, Midtjylland, Denmark",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,29.635105443643603,905.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.1,181.2117,33.42,1.0,0.0,1.0,19.38,49.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB00547,__DESOXIMETASONE,5990100,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,14.8504076059056,768.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.13,376.4617,74.6,4.0,2.0,4.0,40.09,101.17,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,1,DB00555,__LAMOTRIGINE,5698226,Completed,NCT04523935,CEREBRAL PALSY|CRYING,All,up to 15 Years Â  (Child),Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,18.333025318795,193.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,256.091,90.71,5.0,2.0,2.0,23.1,66.62,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0
FC(F)(F)C(F)(F)C(F)(F)F,1,DB00556,__PERFLUTREN,6723303,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/223,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,,"SCLERODERMA, SYSTEMIC",,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02275299,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Peking Union Medical College Hospital, Beijing, Beijing, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Not yet recruiting,NCT04077957,ANKYLOSING SPONDYLITIS|SPONDYLOARTHRITIS,All,18 Years to 50 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China",A61M5/2425,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT03254589,"RHEUMATOID ARTHRITIS|STIFFNESS, AORTIC|ENDOTHELIAL DYSFUNCTION|CARDIOVASCULAR RISK FACTOR",All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT03739853,PSORIATIC ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00443430,JUVENILE CHRONIC POLYARTHRITIS|JUVENILE IDIOPATHIC ARTHRITIS|JUVENILE RHEUMATOID ARTHRITIS,All,2 Years to 17 Years Â  (Child),Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Stanford University Medical Center, Palo Alto, California, United States|Rady Children's Hospital, San Diego, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Children's Hospital of Boston, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Children's Hospital of Columbus, Columbus, Ohio, United States|Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States|Texas Scottish Rite Hospital, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital and Regional Medical Center, Seattle, Washington, United States",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT01895764,ANKYLOSING SPONDYLITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rhumatologie, CH de BLOIS, Blois, France|Rhumatologie, CHRU de BREST, Brest, France|Rhumatologie, CHD LA ROCHE SUR YON, La Roche Sur Yon, France|Rhumatologie, CHR du MANS, Le Mans, France|Rhumatologie, CHRU de NANTES, Nantes, France|Rhumatologie / IPROS, CHR d'ORLEANS, Orleans, France|Rhumatologie, CHRU de POITIERS, Poitiers, France|Rhumatologie, CHRU de RENNES, Rennes, France|Rhumatologie, CH de SAINT BRIEUC, Saint Brieuc, France|MÃ©decine polyvalente, CH de SAINT NAZAIRE, Saint Nazaire, France|Rhumatologie, CHRU de TOURS, Tours, France",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Withdrawn,NCT00298012,"SPONDYLARTHROPATHIES|SPONDYLITIS, ANKYLOSING",All,18 Years to 50 Years Â  (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Rheumatism Foundation Hospital, Heinola, Finland|Helsinki University Central Hospital, Helsinki, Finland|Central Finland Central Hospital, JyvÃ¤skylÃ¤, Finland|Kuopio University Hospital, Kuopio, Finland|Tampere University Hospital, Tampere, Finland",A61M5/2425,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT03492658,RHEUMATOID ARTHRITIS|RHEUMATIC DISEASES,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Leiden University Medical Center, Leiden, Netherlands",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02714634,RHEUMATOID ARTHRITIS|INSUFFICIENT RESPONSE TO METHOTREXATE.,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Terminated,NCT01927757,MODERATE TO SEVERE RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Tuscaloosa, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Covina, California, United States|Research Site, Hemet, California, United States|Research Site, Murrieta, California, United States|Research Site, San Diego, California, United States|Research Site, Victorville, California, United States|Research Site, Denver, Colorado, United States|Research Site, Brandon, Florida, United States|Research Site, Dunedin, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Bowling Green, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Battle Creek, Michigan, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Smithtown, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Hixson, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Clarksburg, West Virginia, United States|Research Site, Victoria, British Columbia, Canada|Research Site, Quispamsis, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Caguas, Puerto Rico",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Not yet recruiting,NCT04311567,RHEUMATOID ARTHRITIS|INTERSTITIAL LUNG DISEASE DUE TO SYSTEMIC DISEASE (DISORDER)|RA|ILD,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"SkÃ¥ne University Hospital, Department of Rheumatology, Lund, SkÃ¥ne, Sweden|Clinical Rheumatology Research Center, The Sahlgrenska University Hospital, GÃ¶teborg, VÃ¤stra GÃ¶taland, Sweden|Karolinska University Hospital, Department of Rheumatology, Stockholm, Sweden",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT00291915,RHEUMATOID ARTHRITIS|ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hopital Cochin, Paris, France",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT04326894,PAIN REDUCTION|PHYSICAL FUNCTION IMPROVEMENT,All,"60 Years to 100 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Faculty of Medicine, Alexandria, Egypt",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00161655,"PSORIASIS|ARTHRITIS, PSORIATIC",All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fredriksberg Alle, Copenhagen, Denmark|Gentofte Amtsygehus, Hellerup, Denmark|Helsinki, Finland|Tampere, Finland|Rikshospitalet, Olso, Norway|Hudlegekontoret Akutten, Tromso, Norway|Lakarhuset Fasta Centrum, Farsta, Sweden|Lakarhuset, Vallingby, Sweden",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CC(C)NCC(O)COc1cccc2ccccc12,1,DB00571,__PROPRANOLOL,6500454,Completed,NCT02032758,OCCUPATIONAL; CRAMP(S),All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00572,__ATROPINE,3935303,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, HajdÃº-Bihar, Hungary",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,38.834472987124904,459.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.19,289.3694,49.77,3.0,1.0,3.0,31.28,80.82,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
Clc1cccc(Cl)c1NC1=NCCN1,1,DB00575,__CLONIDINE,5869100,Completed,NCT02365961,HIP DYSPLASIA|FEMOROACETABULAR IMPINGEMENT|ACETABULAR LABRUM TEAR,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Steadman Hawkins Clinic of the Carolinas - Greenville Health System, Greenville, South Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.5486560298979,3720.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.55,230.09400000000002,36.42,3.0,2.0,2.0,21.7,59.09,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
Clc1cccc(Cl)c1NC1=NCCN1,1,DB00575,__CLONIDINE,5869100,Completed,NCT00858845,HEART FAILURE,All,"21 Years to 65 Years Â  (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","University of California, Los Angeles Medical Center, Los Angeles, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,19.5486560298979,3720.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.55,230.09400000000002,36.42,3.0,2.0,2.0,21.7,59.09,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
Clc1cccc(Cl)c1NC1=NCCN1,1,DB00575,__CLONIDINE,5869100,Completed,NCT04026074,"KNEE ARTHROPATHY|HIP ARTHRITIS|FRACTURES, CLOSED",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical University Hospital LKH Graz, Graz, Austria",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.5486560298979,3720.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.55,230.09400000000002,36.42,3.0,2.0,2.0,21.7,59.09,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
Clc1cccc(Cl)c1NC1=NCCN1,1,DB00575,__CLONIDINE,5869100,Withdrawn,NCT02365727,KNEE OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Steadman Hawkins Clinic of the Carolinas - Greenville Health System, Greenville, South Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.5486560298979,3720.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.55,230.09400000000002,36.42,3.0,2.0,2.0,21.7,59.09,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
Clc1cccc(Cl)c1NC1=NCCN1,1,DB00575,__CLONIDINE,5869100,Completed,NCT02530151,"FEMORACETABULAR IMPINGEMENT|PAIN, POSTOPERATIVE",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Joshua Barett, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.5486560298979,3720.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.55,230.09400000000002,36.42,3.0,2.0,2.0,21.7,59.09,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
Clc1cccc(Cl)c1NC1=NCCN1,1,DB00575,__CLONIDINE,5869100,Terminated,NCT03119038,OSTEOARTHRITIS|DEGENERATIVE JOINT DISEASE,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.5486560298979,3720.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.55,230.09400000000002,36.42,3.0,2.0,2.0,21.7,59.09,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
Clc1cccc(Cl)c1NC1=NCCN1,1,DB00575,__CLONIDINE,5869100,Enrolling by invitation,NCT02570503,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Virginia Commonwealth University, Richmond, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.5486560298979,3720.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.55,230.09400000000002,36.42,3.0,2.0,2.0,21.7,59.09,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,1,DB00580,__VALDECOXIB,5633272,Completed,NCT00650455,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Glendale, Arizona, United States|Pfizer Investigational Site, Glendale, Arizona, United States|Pfizer Investigational Site, Mesa, Arizona, United States|Pfizer Investigational Site, Paradise Valley, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Fullerton, California, United States|Pfizer Investigational Site, Rancho Mirage, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Jupiter, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Palm Harbor, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Zephyrhills, Florida, United States|Pfizer Investigational Site, Idaho Falls, Idaho, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Frederick, Maryland, United States|Pfizer Investigational Site, Greenbelt, Maryland, United States|Pfizer Investigational Site, Lansing, Michigan, United States|Pfizer Investigational Site, Jackson, Mississippi, United States|Pfizer Investigational Site, Marlton, New Jersey, United States|Pfizer Investigational Site, Passaic, New Jersey, United States|Pfizer Investigational Site, Teaneck, New Jersey, United States|Pfizer Investigational Site, Brooklyn, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Duncansville, Pennsylvania, United States|Pfizer Investigational Site, Erie, Pennsylvania, United States|Pfizer Investigational Site, Johnstown, Pennsylvania, United States|Pfizer Investigational Site, Mechanicsburg, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadephia, Pennsylvania, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, El Paso, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Plano, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Arlington, Virginia, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada",C07D261/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,23.6555165403807,182.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.32,314.3590000000001,86.19,3.0,1.0,3.0,31.76,84.71,3.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB00581,__LACTULOSE,4057655,Completed,NCT00160264,OSTEOPENIA,Female,"55 Years to 65 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Site 1, Barcelona, Spain|Site 2, Barcelona, Spain|Site 3, Barcelona, Spain",C13K13/005,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,16.0988932010924,393.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.3,342.2965,189.53,11.0,8.0,2.0,31.49,68.77,5.0,1.0,0.0,0.0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT01860833,KNEE OSTEOARTHRITIS,All,"50 Years to 85 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Orthopedic and Trauma Surgery, Catanzaro, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, HajdÃº-Bihar, Hungary",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT00140972,OSTEOARTHRITIS,All,"40 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT02087748,PAIN|DELAYED ONSET MUSCLE SORENESS,All,18 Years to 35 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Lotus Clinical Research, LLC, Pasadena, California, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Withdrawn,NCT01190722,HALLUX VALGUS|POSTOPERATIVE PAIN,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Unknown status,NCT01067430,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northumbria Healthcare NHS Foundation Trust, North Shields, Tyne and Wear, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT00792376,ACHILLES TENDINOPATHY,Male,18 Years to 50 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Argentine Tennis Association, Buenos Aires, Argentina",4,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Terminated,NCT03473665,ANKYLOSING SPONDYLITIS|AXIAL SPONDYLOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Columbia University Irving Medical Center, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT02528201,ANKYLOSING SPONDYLITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Bekkestua legesenter, Bekkestua, Norway|Dr. Johannessen Kontor, Bergen, Norway|Dr.Wiigs kontor, Bergen, Norway|Nordland Medisinske Senter, BodÃ¸, Norway|Martina Hansens hospital, BÃ¦rum Postterminal, Norway|Sykehuset Buskerud HF, Drammen, Norway|LÃ¦gene pÃ¥ Kongens torv, Gamle Fredrikstad, Norway|Centre For Clinical Trials, Hamar, Norway|Harstad sykehus, Harstad, Norway|Haugesund sanitetsforenings revmatismesykehus, Haugesund, Norway|Horten legesenter, Horten, Norway|Solli Klinikk AS, Jessheim, Norway|Kongsvinger sykehus HF, Kongsvinger, Norway|Vest-Agder sentralsykehus, Kristiansand, Norway|Dr. Svensens kontor, Kristiansand, Norway|Lensbygda Legekontor, Lena, Norway|Helse Nord-TrÃ¸ndelag HF, Sykehuset Levanger, Levanger, Norway|LSF Reumatismesykehus, Lillehammer, Norway|Helgelandssykehuset HF, Mo I Rana, Norway|Rikshospitalet, Oslo, Norway|Ãkernlegene, Oslo, Norway|Diakonhjemmet Hospital, Oslo, Norway|Betanien Hospital, Skien, Norway|Rosten legesenter, Tiller, Norway|Universitetssykehuset Nord-Norge HF, TromsÃ¸, Norway|St.Olavs Hospital, Trondheim, Norway|Ãlesund sykehus, Ãlesund, Norway",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Terminated,NCT00766402,"SPONDYLITIS, ANKYLOSING|PAIN",All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT00447759,OSTEOARTHRITIS|RHEUMATOID ARTHRITIS,All,"60 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Southern Denmark, Odense, Denmark|Julius Clinical Research, Zeist, Netherlands|University of Aberdeen, Aberdeen, United Kingdom|University of Birmingham, Birmingham, United Kingdom|University of Dundee, Dundee, United Kingdom|University of Edinburgh, Edinburgh, United Kingdom|University of Glasgow, Glasgow, United Kingdom|NHS Highlands, Inverness, United Kingdom|University of Nottingham, Nottingham, United Kingdom|University of Oxford, Oxford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT00141102,"OSTEOARTHRITIS|ARTHRITIS, RHEUMATOID",All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, LiÃ¨ge, Belgium|Pfizer Investigational Site, GoiÃ¢nia, GO, Brazil|Pfizer Investigational Site, GoiÃ¢nia, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, SÃ£o Paulo, SP, Brazil|Pfizer Investigational Site, SÃ£o Paulo, SP, Brazil|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste Foy, Quebec, Canada|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Chengdu, Sichuan, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Floridablanca, Santander, Colombia|Pfizer Investigational Site, Cartago, Costa Rica|Pfizer Investigational Site, Heredia, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Opatija, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Plzen, Bory, Czech Republic|Pfizer Investigational Site, Ostrava, Trebovice, Czech Republic|Pfizer Investigational Site, Ceske Budejovice, Czech Republic|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Prague 1, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 4, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Cuenca, Azuay, Ecuador|Pfizer Investigational Site, Guayaquil, Guayas, Ecuador|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Amiens, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Deggingen, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hoyerswerda, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Ciudad de Guatemala, Guatemala|Pfizer Investigational Site, Guatemala 01010, Guatemala|Pfizer Investigational Site, Lai Chi Kok, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Alytus, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Klaipeda, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vlaardingen, ZH, Netherlands|Pfizer Investigational Site, Alkmaar, Netherlands|Pfizer Investigational Site, Leidschendam, Netherlands|Pfizer Investigational Site, Ciudad de Panama, Panama|Pfizer Investigational Site, Surco, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisbon, Portugal|Pfizer Investigational Site, Ponta Delgada, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ekaterinburg, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Petrozavodsk, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Niska Banja, Serbia|Pfizer Investigational Site, Novi Sad, Serbia|Pfizer Investigational Site, Sinapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bloemfontein, Free State, South Africa|Pfizer Investigational Site, Johannesburg, Gauteng Province, South Africa|Pfizer Investigational Site, Durban, KZN, South Africa|Pfizer Investigational Site, Parow, Western Cape, South Africa|Pfizer Investigational Site, Bellville, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Kempton Park, South Africa|Pfizer Investigational Site, Observatory Cape Town, South Africa|Pfizer Investigational Site, Partida de Bacarot, Alicante, Spain|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Barakaldo, Vizcaya, Spain|Pfizer Investigational Site, Avila, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Lulea, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Tao-Yuan, Taiwan|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Ivano-Frankivsk, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kiev, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lutsk, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Simferopol, Ukraine|Pfizer Investigational Site, Zaporizhzhia, Ukraine|Pfizer Investigational Site, Helensburgh, Argyle & Clyde, United Kingdom|Pfizer Investigational Site, Maidenhead, Berks, United Kingdom|Pfizer Investigational Site, Aston Clinton, Buckinghamshire, United Kingdom|Pfizer Investigational Site, St Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Aldershot, Hampshire, United Kingdom|Pfizer Investigational Site, Basingstoke, Hampshire, United Kingdom|Pfizer Investigational Site, Odiham, Hampshire, United Kingdom|Pfizer Investigational Site, Ashford, Middlesex, United Kingdom|Pfizer Investigational Site, Harrow, Middlesex, United Kingdom|Pfizer Investigational Site, Camberley, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Leatherhead, Surrey, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Bradford-on-Avon, Wiltshire, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, United Kingdom|Pfizer Investigational Site, Upton, Wirral, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, United Kingdom|Pfizer Investigational Site, Canterbury, United Kingdom|Pfizer Investigational Site, Chesterfield, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, St Leonards on Sea, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom|Pfizer Investigational Site, Vale of Glamorgan, United Kingdom|Pfizer Investigational Site, Wansford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Recruiting,NCT03781544,OSTEOARTHRITIS OF MULTIPLE JOINTS OF ANKLE OR FOOT|HEALTHY,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Heart Center Zurich, Zurich, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT00174317,"OSTEOARTHRITIS, HIP",All,"45 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Pfizer Investigational Site, Aston Clinton, Bucks, United Kingdom|Pfizer Investigational Site, Ely, Cambs, United Kingdom|Pfizer Investigational Site, St. Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Lancaster, England, United Kingdom|Pfizer Investigational Site, Sheffield, England, United Kingdom|Pfizer Investigational Site, Newport, Gwent, United Kingdom|Pfizer Investigational Site, Chingford, London, United Kingdom|Pfizer Investigational Site, Harrow, Middlesex, United Kingdom|Pfizer Investigational Site, Greenisland, Carrickfergus, Northern Ireland, United Kingdom|Pfizer Investigational Site, Oxford, Oxon, United Kingdom|Pfizer Investigational Site, Greenock, Renfrewshire, United Kingdom|Pfizer Investigational Site, Barry, South Glamorgan, United Kingdom|Pfizer Investigational Site, Barnsley, South Yorkshire, United Kingdom|Pfizer Investigational Site, Ashford, Surrey, United Kingdom|Pfizer Investigational Site, Newcastle-Upon-Tyne, Tyne & Wear, United Kingdom|Pfizer Investigational Site, Trowbridge, Wiltshire, United Kingdom|Pfizer Investigational Site, Aberdeen, United Kingdom|Pfizer Investigational Site, Amersham, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Bath, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Bradford, United Kingdom|Pfizer Investigational Site, Cardiff, United Kingdom|Pfizer Investigational Site, Carshalton, United Kingdom|Pfizer Investigational Site, Chertsey, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Lancaster, United Kingdom|Pfizer Investigational Site, Leystonstone, London, United Kingdom|Pfizer Investigational Site, Liverpool, United Kingdom|Pfizer Investigational Site, Liverpool, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Northampton, United Kingdom|Pfizer Investigational Site, Norwich, United Kingdom|Pfizer Investigational Site, Nuneaton, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, Sheffield, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom|Pfizer Investigational Site, Truro, United Kingdom|Pfizer Investigational Site, Wansford, United Kingdom|Pfizer Investigational Site, Watford, United Kingdom|Pfizer Investigational Site, Westbury, United Kingdom|Pfizer Investigational Site, Wigan, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT01666197,ANKLE SPRAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigator, BrÃ¼hl, Germany|Investigator, Essen, Germany|Investigator, Gilching, Germany|Investigator, KÃ¶ln, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Terminated,NCT00140920,PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00118716,BRONCHOSPASM|ACTIVITY/EXERCISE INDUCED BRONCHOSPASM,All,4 Years to 17 Years Â  (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palmdale, California, United States|GSK Investigational Site, Paramount, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Centennial, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Lilburn, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Hoffman Estates, Illinois, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Glen Burnie, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Summit, New Jersey, United States|GSK Investigational Site, Commack, New York, United States|GSK Investigational Site, Utica, New York, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Gresham, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Hershey, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Mount Pleasant, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Dyersburg, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Murray, Utah, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00355342,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Berkeley, California, United States|GSK Investigational Site, Fullerton, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Fort Collins, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Hartford, Connecticut, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Tamarac, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, North Chicago, Illinois, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Cadillac, Michigan, United States|GSK Investigational Site, Saint Charles, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Bronxville, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Greer, South Carolina, United States|GSK Investigational Site, Simpsonville, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Milan, Tennessee, United States|GSK Investigational Site, Corsicana, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Bellingham, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Spokane, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,1,DB00601,__LINEZOLID,5688792,Terminated,NCT01734694,HEALTH CARE ASSOCIATED PNEUMONIA|OSTEOMYELITIS/SEPTIC ARTHRITIS|ENDOCARDITIS|BACTEREMIA|ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Henry Ford Hospital, Detroit, Michigan, United States",C07D413/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.468592784246,159.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,337.3461,71.11,5.0,1.0,3.0,34.06,84.47,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/60,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Completed,NCT00805519,OSTEO ARTHRITIS OF THE KNEES,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"ArdabiUMS Clinic of Rheumatology, Ardabil, Iran, Islamic Republic of",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Completed,NCT03449758,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 250007, Argenteuil, France|Investigational Site Number 250006, Besancon, France|Investigational Site Number 250027, Bobigny, France|Investigational Site Number 250016, Bordeaux, France|Investigational Site Number 250014, Caen, France|Investigational Site Number 250032, CAHORS Cedex 9, France|Investigational Site Number 250019, Cannes, France|Investigational Site Number 250013, Cholet, France|Investigational Site Number 250002, Clermont Ferrand, France|Investigational Site Number 250009, Echirolles, France|Investigational Site Number 250005, La Roche Sur Yon, France|Investigational Site Number 250024, Le Mans Cedex 9, France|Investigational Site Number 250004, Lille Cedex, France|Investigational Site Number 250012, Limoges Cedex, France|Investigational Site Number 250021, Lyon, France|Investigational Site Number 250018, Montivilliers, France|Investigational Site Number 250029, MONTPELLIER Cedex 5, France|Investigational Site Number 250025, NANTES Cedex 1, France|Investigational Site Number 250026, Nice cedex 1, France|Investigational Site Number 250020, Paris Cedex 10, France|Investigational Site Number 250011, PARIS Cedex 13, France|Investigational Site Number 250010, Paris, France|Investigational Site Number 250015, Paris, France|Investigational Site Number 250028, Paris, France|Investigational Site Number 250033, Paris, France|Investigational Site Number 250031, Poitiers, France|Investigational Site Number 250023, Pontoise, France|Investigational Site Number 250017, RENNES Cedex, France|Investigational Site Number 250008, Rouen, France|Investigational Site Number 250001, St Etienne, France|Investigational Site Number 250034, Strasbourg Cedex 2, France|Investigational Site Number 250022, Toulouse, France|Investigational Site Number 250003, Tours, France",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,1,DB00611,__BUTORPHANOL,4315936,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,26.021068194418696,660.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.65,327.4605,43.7,3.0,2.0,5.0,37.94,95.92,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,1,DB00611,__BUTORPHANOL,4315936,Recruiting,,ANALGESIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,26.021068194418696,660.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.65,327.4605,43.7,3.0,2.0,5.0,37.94,95.92,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0
O=C1OCCN1N=Cc1ccc([N+](=O)[O-])o1,1,DB00614,__FURAZOLIDONE,3980434,Completed,,GASTRIC ULCER,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,13.5362122425511,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.15,225.1583,98.18,5.0,0.0,2.0,19.78,50.08,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12,1,DB00618,__DEMECLOCYCLINE,3966922,Completed,NCT02576652,OSTEOPOROSIS,All,"50 Years to 100 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helen Hayes Hospital, West Haverstraw, New York, United States|Research Site, West Haverstraw, New York, United States",A23K20/174,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,59.237356003203296,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,464.853,181.62,9.0,6.0,4.0,43.8,114.35,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Unknown status,NCT02437461,ARTHRITIS OF THE KNEE,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Section of Rheumatology, GÃ¤vle hospital, Gavle, Sweden",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT03086759,KNEE OSTEOARTHRITIS,All,"40 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT02451748,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Outpatient Care Center, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Recruiting,NCT03797872,PSORIATIC ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Unknown status,NCT01295099,KELOID,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barts and the London NHS Trust, London, UK, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01652495,TENDINOPATHY|ADRENAL INSUFFICIENCY,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Rizzoli Orthopaedic Institute, Bologna, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Enrolling by invitation,NCT03166761,SACRO-ILIAC SPONDYLOSIS,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Byron Schneider, Nashville, Tennessee, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Not yet recruiting,NCT04278833,OSTEOARTHRITIS|TENDINOPATHY|IMPINGEMENT SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Stanford University, Redwood City, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Recruiting,NCT04002037,TRIGGER FINGER DISORDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Missouri Health Care, Columbia, Missouri, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01230424,OSTEOARTHRITIS (OA) OF THE KNEE,All,"45 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Tufts Medical Center / Division of Rheumatology, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Unknown status,NCT03046108,MORTON NEUROMA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario Granada, Granada, SPA, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Terminated,NCT02120261,MYOFASCIAL PAIN SYNDROME,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Lyndon Baines Johnson General Hospital, Houston, Texas, United States|Memorial Hermann Hospital Texas Medical Center, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Terminated,NCT01045694,ARTHRITIS MULTIPLE JOINT,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Missouri, Columbia, Missouri, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Unknown status,NCT02022722,DYSPAREUNIA,Female,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Division of Urogynecology, University of Cincinnati Medical Center, Cincinnati, Ohio, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Recruiting,NCT03636373,GOUT ATTACK,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rutgers, Robert Wood Johnson Medical School, Clinical Research Center, New Brunswick, New Jersey, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Withdrawn,NCT03319784,ROTATOR CUFF TEAR|ROTATOR CUFF INJURY|ROTATOR CUFF TENDINITIS|DIABETES MELLITUS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Penn State College of Medicine, Hershey, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Unknown status,NCT02618603,STROKE|PAIN,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hang Zhou, Zhejiang, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Terminated,NCT00554476,LATERAL EPICONDYLITIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Azad University of Medical Sciences, Boo-Ali Hospital, Tehran, Iran, Islamic Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT03120923,IMPINGEMENT SHOULDER,All,"20 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT04361513,PAIN|JOINT FUNCTION DISORDER|INFLAMMATION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Minia university, Minya, Egypt",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,"Active, not recruiting",NCT03586687,GLENOHUMERAL OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Unknown status,NCT03090698,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital dos Servidores do Estado do Rio de Janeiro, Rio de Janeiro, Brazil",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Unknown status,NCT02949466,PHYSICAL ACTIVITY|FUNCTIONAL PERFORMANCE,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01335321,OSTEOARTHRITIS,All,"45 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Instituto de Ortopedia e Traumatologia do Hospital das ClÃ­nicas da Universidade de SÃ£o Paulo, SÃ£o Paulo, Brazil",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT00826462,"TENNIS ELBOW|EPICONDYLITIS, LATERAL HUMERAL",All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GrÃ¥lum legesenter, Sarpsborg, Norway",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Recruiting,NCT03982862,SCAR KELOID|HYPERTROPHIC SCAR,All,18 Years to 60 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Kaohsiung Medical University Hospital, Kaohsiung, Taiwan",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Active Not Recruiting,,"RADICULOPATHY, CERVICAL",,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,1,DB00622,__NICARDIPINE,5164405,Completed,NCT02271191,SPINAL STENOSIS,All,"20 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,24.871147251483606,1273.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.34,479.525,113.69,6.0,1.0,3.0,49.95,134.8,11.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1
COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1,1,DB00622,__NICARDIPINE,5164405,Completed,,MANDIBULAR PROGNATHISM,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,24.871147251483606,1273.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.34,479.525,113.69,6.0,1.0,3.0,49.95,134.8,11.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,1,DB00623,__FLUPHENAZINE,3993072,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61M31/002,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,13.240518285796401,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.4,437.522,29.95,4.0,1.0,4.0,44.92,117.27,7.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Terminated,NCT00240981,SARCOPENIA|HYPOGONADISM|MUSCULAR DISEASES,Male,65 Years and older Â  (Older Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Boston University Medical Center, Boston, Massachusetts, United States|VA Boston Healthcare System (Jamaica Plain Campus), Boston, Massachusetts, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00182871,AGING|FRAILTY|OSTEOPOROSIS,Male,"60 Years and older Â  (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"Center on Aging, University of Connecticut Health Center, Farmington, Connecticut, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00018356,MUSCLE WEAKNESS|MUSCULAR ATROPHY,Male,65 Years and older Â  (Older Adult),U.S. Fed,,"Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock, No. Little Rock, Arkansas, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,MUSCLE WEAKNESS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,,CENTRAL NERVOUS SYSTEM DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",C07D411/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,DB00626,__BACITRACIN,,Terminated,NCT01350102,"DIABETES, TYPE 1|DIABETES, TYPE 2|FOOT ULCER, DIABETIC",All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1422.693,530.87,20.0,17.0,4.0,149.32,363.14,31.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,DB00626,__BACITRACIN,,Completed,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1422.693,530.87,20.0,17.0,4.0,149.32,363.14,31.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0
O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,1,DB00628,__CLORAZEPIC_ACID,WO-1998022114-A1,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.68,314.723,78.76,4.0,2.0,3.0,30.63,82.68,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,OSTEOPENIA,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,"BONE DISEASES, METABOLIC",,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,BONE RESORPTION,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,OSTEOGENESIS IMPERFECTA,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT04307290,ARTHROPATHY OF KNEE|SPINAL ANESTHESIA|TOURNIQUET|ISCHEMIA-REPERFUSION INJURY,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","WonwangUH, Iksan, Jeonbuk, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Recruiting,NCT04111328,"ANALGESIA, PATIENT-CONTROLLED",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"The First Affiliated Hosipital of China Medical University, Shenyang, Liaoning, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT02469961,SHOULDER PAIN,All,"21 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Maimonides Medical Center, Brooklyn, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT02784626,"ARTHRITIS, DEGENERATIVE",All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT03270033,"PAIN, POSTOPERATIVE|SHOULDER JOINT DISORDER|AMBULATORY SURGICAL PROCEDURES|BRACHIAL PLEXUS BLOCK",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pan Am Surgical Centre, Winnipeg, Manitoba, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Recruiting,NCT04391855,"ANALGESIA|PAIN, POSTOPERATIVE|SPINAL STENOSIS|SPINAL DISEASE",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AHEPA University Hospital, Thessaloniki, Greece",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT01748630,FAILED MODERATE SEDATION DURING PROCEDURE,All,"12 Years to 18 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inonu University Turgut Ozal Medical Center, Malatya, Turkey",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Withdrawn,NCT02915042,CLEFT PALATE,All,6 Months to 12 Years Â  (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Recruiting,NCT03069638,JUVENILE IDIOPATHIC ARTHRITIS|JOINT INFLAMMATION,All,"1 Year to 18 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oulu university hospital, Oulu, Finland",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Unknown status,NCT02535273,SPINAL DISEASES|LOCAL ANESTHESIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Completed,NCT00808665,SPINAL FUSION ACQUIRED|SPINAL STENOSIS|LESIONS OF LUMBOSACRAL INTERVERTEBRAL DISC|SPINAL DISEASES,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT02370550,SJOGREN'S SYNDROME,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking University People's Hospital, Beijing, Beijing, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT02451748,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Outpatient Care Center, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00987116,MYASTHENIA GRAVIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hopital Raymond PoincarÃ©, Garches, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT02190994,PITUITARY NEOPLASMS|CRANIOPHARYNGIOMAS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"West China Hospital, Sichuan University, Chengdu, Sichuan, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT04169100,LONG QT SYNDROME|CONNECTIVE TISSUE DISEASES|RHEUMATOID ARTHRITIS,All,"18 Years to 89 Years Â  (Adult, Older Adult)",Other|U.S. Fed,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"VA New York Harbor Healthcare System, NY and Brooklyn Campuses, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT01400464,GIANT CELL ARTERITIS,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU de CAEN, Caen, Etat, France|HÃ´pital Cochin-APHP, Paris, Etat, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, Etat, France|CH de Valenciennes, Valenciennes, Etat, France|CHU Avicennes, Bobigny, France|CHU Jean Verdier (AP-HP), Bondy, France|HÃ´pital Gabriel Montpied, Clermont-Ferrand, France|CHU de Lille, Lille, France|Centre Hospitalier Universitaire de Limoges, Limoges, France|CHU de Nantes, Nantes, France|HÃ´pital PitiÃ©-SalpÃªtriÃ¨re-APHP, Paris, France|CHU de Rouen, Rouen, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT01169597,POLYMYALGIA RHEUMATICA,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinica Reumatologica, Dipartimento di medicina Interna, UniversitÃ  di Genova, Genova, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT04177173,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Hospital, Lahore, Punjab, Pakistan",C07D205/08Â ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,"Active, not recruiting",NCT03653663,STATIN ADVERSE REACTION|SKELETAL MYOPATHY,All,"40 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Hartford Hospital, Hartford, Connecticut, United States|University of Connecticut, Storrs, Connecticut, United States",C07D205/08Â ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Recruiting,NCT04507373,"MUSCLE CRAMP|ACHE|WEAKNESS, MUSCLE|STATIN ADVERSE REACTION",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","UT Southwestern Medical Center, Dallas, Texas, United States",C07D205/08Â ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT00738296,CARDIOVASCULAR DISEASE,All,"30 Years to 75 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07D205/08Â ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
O=S(=O)([O-])[O-].[Mg+2],1,DB00653,__MAGNESIUM_SULFATE,6946149,Not yet recruiting,NCT04514731,ARTHROPATHY OF KNEE|MAGNESIUM SULFATE|CORTISOL|DEHYDROEPIANDROSTERONE,Female,"30 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of",7,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,40.7072013799051,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.84,120.368,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Mg+2],1,DB00653,__MAGNESIUM_SULFATE,6946149,Completed,NCT04161729,"ANALGESIA|PAIN, POSTOPERATIVE|SPINE DISEASE",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AHEPA University Hospital, Thessaloniki, Greece",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,40.7072013799051,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.84,120.368,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Mg+2],1,DB00653,__MAGNESIUM_SULFATE,6946149,Terminated,NCT03253224,ARTHRITIS KNEE|MAGNESIUM SULFATE|DEXMEDETOMIDINE,All,"50 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,40.7072013799051,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.84,120.368,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,1,DB00656,__TRAZODONE,6607748,Completed,NCT00791739,FIBROMYALGIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto de Neurociencias, Granada, Spain",A61K9/2059,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,43.0,37.651697160105904,222.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.68,371.86400000000003,42.39,4.0,0.0,4.0,40.12,105.88,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
C=CCN.ClCC1CO1,1,DB00658,__SEVELAMER,5496545,Completed,NCT03451019,CHRONIC KIDNEY DISEASE,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Nephrology, Hypertension and Kidney Transplantation, ÅÃ³dÅº, Poland",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,22.012772336187602,6.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.68,149.619,12.53,1.0,0.0,1.0,8.38,20.06,2.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,1,DB00661,__VERAPAMIL,5785994,Completed,NCT01295047,MARFAN SYNDROME,All,"16 Years to 60 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wales Heart Research Institute, Cardiff University, Cardiff, United Kingdom",A61K9/0004,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,75.8619273496375,982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.23,454.6016,63.95,6.0,0.0,2.0,51.7,132.65,13.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0
COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,1,DB00661,__VERAPAMIL,5785994,Terminated,NCT01720056,KELOID SCARS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Royal Perth Hospital, Perth, Western Australia, Australia",A61K9/0004,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,75.8619273496375,982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.23,454.6016,63.95,6.0,0.0,2.0,51.7,132.65,13.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Withdrawn,NCT02426164,"PAIN, POSTOPERATIVE|ARTHROPLASTY, REPLACEMENT, KNEE|OSTEOARTHRITIS",All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Miller Orthopedic Specialists, Council Bluffs, Iowa, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT02464176,"OSTEOARTHRITIS, HIP",All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT02462148,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT02365961,HIP DYSPLASIA|FEMOROACETABULAR IMPINGEMENT|ACETABULAR LABRUM TEAR,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Steadman Hawkins Clinic of the Carolinas - Greenville Health System, Greenville, South Carolina, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Withdrawn,NCT02365727,KNEE OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Steadman Hawkins Clinic of the Carolinas - Greenville Health System, Greenville, South Carolina, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Terminated,NCT03119038,OSTEOARTHRITIS|DEGENERATIVE JOINT DISEASE,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT02658149,OSTEOARTHRITIS|ARTHROPLASTY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Beaumont Hospital, Royal Oak, Michigan, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT04023695,TRIGGER FINGER DISORDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Withdrawn,NCT02765815,"OSTEOARTHRITIS, KNEE|ARTHROPLASTY, REPLACEMENT, KNEE",All,"18 Years to 88 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Holy Cross Hospital Orthopedic Research Institute, Fort Lauderdale, Florida, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Completed,,"OBESITY, MORBID",,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Active Not Recruiting,,ANTIPHOSPHOLIPID SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT02292082,OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, HajdÃº-Bihar, Hungary",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Recruiting,NCT03933007,GOUT FLARE,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HÃ´pital LariboisiÃ¨re-Service de Rhumatolologie, Paris, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT01748630,FAILED MODERATE SEDATION DURING PROCEDURE,All,"12 Years to 18 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inonu University Turgut Ozal Medical Center, Malatya, Turkey",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,,"OBESITY, MORBID",,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,1,DB00700,__EPLERENONE,6410524,Suspended,NCT03418649,DEGENERATIVE INTERVERTEBRAL DISCS|SCIATIC RADICULOPATHY|LOW BACK PAIN,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UC Health Pain Medicine Center in Midtown, Cincinnati, Ohio, United States|UC Health Pain Medicine Center in West Chester, West Chester, Ohio, United States|UC Health Pain Medicine Center West Chester, West Chester, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,105.0,31.639253372759104,243.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.67,414.4914,82.2,4.0,0.0,6.0,43.79,106.68,2.0,0.0,1.0,0.0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,1,DB00704,__NALTREXONE,5792477,Unknown status,NCT02806440,FIBROMYALGIA,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Multidisciplinary Pain Centre, Give, Denmark",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,15.310375983079698,233.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,341.4009,70.0,5.0,2.0,6.0,35.97,91.5,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,1,DB00706,__TAMSULOSIN,4703063,Recruiting,NCT03808155,URINARY RETENTION POSTOPERATIVE|ARTHROPATHY OF KNEE|ARTHROPATHY OF HIP,Male,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Kantonsspital GraubÃ¼nden, Chur, GraubÃ¼nden, Switzerland",C07D203/10,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,27.3024086736894,325.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.05,408.51199999999994,99.88,6.0,2.0,2.0,43.95,108.86,11.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,1,DB00708,__SUFENTANIL,8202535,Recruiting,NCT04111328,"ANALGESIA, PATIENT-CONTROLLED",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"The First Affiliated Hosipital of China Medical University, Shenyang, Liaoning, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,65.4469290950532,1368.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.4,386.551,32.78,3.0,0.0,3.0,43.85,111.42,8.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Recruiting,NCT02156999,OSTEOPOROSIS,All,"20 Years to 100 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Showa Inan General Hospital, Komagane, Nagano, Japan",C07F9/405,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Completed,NCT00303485,POST MENOPAUSAL OSTEOPOROSIS,Female,65 Years and older Â  (Older Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Beverly Hills, California, United States|La Jolla, California, United States|Augusta, Georgia, United States|Woodbury, Minnesota, United States|Bronx, New York, United States|Hopwood, Pennsylvania, United States|Madison, Wisconsin, United States|Ponce, Puerto Rico|San Juan, Puerto Rico|San Juan, Puerto Rico",C07F9/405,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Completed,NCT00271713,"OSTEOPOROSIS, POSTMENOPAUSAL",Female,"60 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre for Muscle and Bone Research, CharitÃ© - Campus Benjamin Franklin, Berlin, Germany",C07F9/405,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Withdrawn,NCT00662077,HIV INFECTION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Germans Trias i Pujol Hospital - Lluita Sida Foundation, Badalona, Barcelona, Spain",C07F9/405,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Completed,NCT02553707,PAIN; BONE NEOPLASMS; NEOPLASM METASTASIS,Female,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Gyor, Hungary|Gyula, Hungary|Kecskemet, Hungary|NyÃ­regyhÃ¡za, Hungary|Szeged, Hungary|Szekesfehervar, Hungary|Szombathely, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary",C07F9/405,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Completed,NCT01287533,RHEUMATOID ARTHRITIS|OSTEOPOROSIS|OSTEOPENIA,Female,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Seoul National University Hospital, Seoul, Korea, Republic of",C07F9/405,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Completed,NCT00668330,SYSTEMIC LUPUS ERYTHEMATOSUS,Female,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","School of Pharmacy CUHK, Hong Kong, China",C07F9/405,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Completed,NCT02604836,POSTMENOPAUSAL OSTEOPOROSIS,Female,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|Columbiana, Alabama, United States|Huntsville, Alabama, United States|Mobile, Alabama, United States|Montgomery, Alabama, United States|Chandler, Arizona, United States|Gilbert, Arizona, United States|Paradise Valley, Arizona, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tempe, Arizona, United States|Tucson, Arizona, United States|Carlisle, Arkansas, United States|Jonesboro, Arkansas, United States|Little Rock, Arkansas, United States|Pine Bluff, Arkansas, United States|Rogers, Arkansas, United States|Searcy, Arkansas, United States|Sherwood, Arkansas, United States|Anaheim, California, United States|Beverly Hills, California, United States|Laguna Hills, California, United States|Mission Viejo, California, United States|Palm Desert, California, United States|Palo Alto, California, United States|Sacramento, California, United States|San Diego, California, United States|Tacoma, California, United States|Vista, California, United States|Westlake Village, California, United States|Colorado Springs, Colorado, United States|Lakewood, Colorado, United States|Avon, Connecticut, United States|Cromwell, Connecticut, United States|Hamden, Connecticut, United States|New London, Connecticut, United States|Waterbury, Connecticut, United States|Wilmington, Delaware, United States|Aventura, Florida, United States|Clearwater, Florida, United States|Deland, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Gainesville, Florida, United States|Longwood, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Palm Bay, Florida, United States|Palm Harbor, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Decatur, Georgia, United States|Rome, Georgia, United States|Boise, Idaho, United States|Coeur D'alene, Idaho, United States|Champaign, Illinois, United States|Creve Coeur, Illinois, United States|Peoria, Illinois, United States|Evansville, Indiana, United States|Arkansas City, Kansas, United States|Newton, Kansas, United States|Wichita, Kansas, United States|Natchitoches, Louisiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Chelsea, Michigan, United States|Detroit, Michigan, United States|St Joseph, Michigan, United States|Chaska, Minnesota, United States|Jefferson City, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|St Louis, Missouri, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Clifton, New Jersey, United States|Middletown, New Jersey, United States|New Brunswick, New Jersey, United States|Princeton, New Jersey, United States|Brooklyn, New York, United States|East Syracuse, New York, United States|New York, New York, United States|Olean, New York, United States|Rochester, New York, United States|Stony Brook, New York, United States|Durham, North Carolina, United States|Durham, North Carolina, United States|Fayetteville, North Carolina, United States|Morehead City, North Carolina, United States|Morganton, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Wilmington, North Carolina, United States|Winston-salem, North Carolina, United States|Fargo, North Dakota, United States|Grand Forks, North Dakota, United States|Beachwood, Ohio, United States|Canfield, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Portland, Oregon, United States|Bala Cynwyd, Pennsylvania, United States|Langhorne, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Charleston, South Carolina, United States|Mount Pleasant, South Carolina, United States|Spartanburg, South Carolina, United States|Bristol, Tennessee, United States|Memphis, Tennessee, United States|Murfreesboro, Tennessee, United States|Nashville, Tennessee, United States|Sevierville, Tennessee, United States|Carrollton, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Denton, Texas, United States|San Antonio, Texas, United States|Wichita Falls, Texas, United States|Norfolk, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Renton, Washington, United States|Seattle, Washington, United States|Seattle, Washington, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States",C07F9/405,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Completed,NCT00129623,POST-MENOPAUSAL OSTEOPENIA,Female,45 Years to 60 Years Â  (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Lakewood, Colorado, United States|Stuart, Florida, United States|Bethesda, Maryland, United States|Detroit, Michigan, United States|St Louis, Missouri, United States|Omaha, Nebraska, United States|Albuquerque, New Mexico, United States|Cincinnati, Ohio, United States|Portland, Oregon, United States|Amarillo, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States",C07F9/405,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Completed,NCT00551174,POST-MENOPAUSAL OSTEOPOROSIS,Female,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Gainesville, Georgia, United States|St Louis, Missouri, United States|Omaha, Nebraska, United States|Bismarck, North Dakota, United States|Fargo, North Dakota, United States|Madison, Wisconsin, United States|St. Leonards, Australia|Sydney, Australia|Bruxelles, Belgium|Liege, Belgium|Plzen, Czech Republic|Praha, Czech Republic|Aalborg, Denmark|Ballerup, Denmark|KÃ¸benhavn, Denmark|Vejle, Denmark|Ãrhus, Denmark|Lyon, France|Orleans, France|Berlin, Germany|Essen, Germany|Hamburg, Germany|Budapest, Hungary|Arenzano, Italy|Siena, Italy|Valeggio Sul Mincio, Italy|Mexico City, Mexico|Monterrey, Mexico|Haugesund, Norway|Oslo, Norway|Stavanger, Norway|Grudziadz, Poland|Krakow, Poland|Krakow, Poland|Cape Town, South Africa|Pretoria, South Africa|Sommerset West, South Africa|Madrid, Spain|Aberdeen, United Kingdom",C07F9/405,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1,1,DB00715,__PAROXETINE,5811436,Completed,NCT00610610,FIBROMYALGIA SYNDROME,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Duke University Medical Center, Durham, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,25.692519353580106,485.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.1,329.3654,39.72,4.0,1.0,4.0,34.48,88.02,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,1,DB00722,__LISINOPRIL,9463183,Terminated,NCT01837069,OSTEOARTHRITIS|CARDIOVASCULAR DISEASE,All,"21 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NYU Hospital for Joint Diseases, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,11.1706605885131,274.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,405.4879,132.96,7.0,4.0,2.0,43.5,107.37,12.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
CC(C)Cn1cnc2c(N)nc3ccccc3c21,1,DB00724,__IMIQUIMOD,4689338,Terminated,NCT01059110,PLANTAR WARTS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical center, Athis Mons, France",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,21.289964886342602,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.83,240.3036,56.73,3.0,1.0,3.0,26.67,72.54,2.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],1,DB00727,__NITROGLYCERIN,5186938,Completed,NCT02832115,RADIAL ARTERY SPASM|ANGINA|CORONARY ARTERY DISEASE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Aultman Hospital, Canton, Ohio, United States",A61K9/7061,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,18.3658802028789,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.25,227.0865,157.11,9.0,0.0,0.0,15.68,37.59,8.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,1,DB00728,__ROCURONIUM,5962536,Completed,NCT02724111,NEUROMUSCULAR BLOCKADE|SURGERY|ANESTHESIA|SPINAL DISEASES,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","Korea University Guro Hospital, Seoul, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,1,DB00728,__ROCURONIUM,5962536,Completed,NCT03540030,OPIOID USE|SHOULDER OSTEOARTHRITIS|AVASCULAR NECROSIS|ROTATOR CUFF TEAR|ARTHRITIS;INFLAMMATORY,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OrthoCarolina Research Institute, Charlotte, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,1,DB00728,__ROCURONIUM,5962536,Recruiting,NCT02778945,NEUROMUSCULAR BLOCK|ORTHOPEDIC DISORDER OF SPINE|MUSCLE WEAKNESS,All,"19 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","Yeouido St. Mary's Hospital, Seoul, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,1,DB00728,__ROCURONIUM,5962536,Terminated,NCT01579864,ANESTHESIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Hopital Foch, Suresnes, Ile de France, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,1,DB00734,__RISPERIDONE,5792477,Recruiting,NCT00768820,VELOCARDIOFACIAL SYNDROME|WILLIAMS SYNDROME|FRAGILE X SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Schneider Children's Mediac Center of Israel, Petach-Tikva, Israel",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT00719160,OSTEOPOROSIS,All,18 Years to 45 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Yale New Haven Hospital Hospital Research Unit, New Haven, Connecticut, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Completed,NCT00754247,"KELOID|HYPERTROPHIC SCAR|CICATRIX, HYPERTROPHIC",All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"University of Miami Skin Research Group Office, Miami, Florida, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Recruiting,NCT04082533,"PAIN|ARTHROFIBROSIS|OSTEOARTHRITIS, KNEE",All,"18 Years to 83 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Unknown status,NCT02190994,PITUITARY NEOPLASMS|CRANIOPHARYNGIOMAS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"West China Hospital, Sichuan University, Chengdu, Sichuan, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,1,DB00745,__MODAFINIL,RE37516,Completed,NCT02155257,OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",A61K9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,33.5119817655393,214.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.71,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,NCT02372786,TATTOO|ACNE KELOIDALIS NUCHAE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Erasmus MC, Rotterdam, Zuid-Holland, Netherlands",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,NCT02384915,KNEE ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Istituto Ortopedico G. Pini, Milan, Milano, Italy",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,,ARTHRITIS OF THE HIP,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,,ARTHRITIS OF THE KNEE JOINT,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NC1CC1c1ccccc1,1,DB00752,__TRANYLCYPROMINE,3961073,Completed,,OSTEO ARTHRITIS OF THE KNEES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.039241052177598,31.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.5,133.194,26.02,1.0,1.0,2.0,15.51,41.7,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
NC1CC1c1ccccc1,1,DB00752,__TRANYLCYPROMINE,3961073,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.039241052177598,31.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.5,133.194,26.02,1.0,1.0,2.0,15.51,41.7,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00759,__TETRACYCLINE,6350468,Completed,NCT02576652,OSTEOPOROSIS,All,"50 Years to 100 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helen Hayes Hospital, West Haverstraw, New York, United States|Research Site, West Haverstraw, New York, United States",A61K9/4808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,37.0,20.3700281319945,4978.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.56,444.4346,181.62,9.0,6.0,4.0,43.03,114.19,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00759,__TETRACYCLINE,6350468,Completed,,GASTRIC ULCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/4808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,20.3700281319945,4978.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.56,444.4346,181.62,9.0,6.0,4.0,43.03,114.19,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0065,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0065,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Unknown Status,,COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Unknown Status,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,1,DB00775,__TIROFIBAN,5658929,Completed,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07C311/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,24.969711903735103,371.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,440.597,104.73,6.0,3.0,2.0,49.27,117.48,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00778,__ROXITHROMYCIN,,Completed,NCT00439062,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Nazilli State Hospital, Nazilli, Aydin, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,837.0465,216.89,16.0,5.0,3.0,91.84,211.24,13.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT00860964,OSTEOPOROSIS,Female,40 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT00294463,POSTMENOPAUSE|OSTEOPOROSIS,Female,"Child, Adult, Older Adult",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus MC, Rotterdam, Netherlands",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Unknown status,NCT01698164,MENOPAUSAL SYNDROME|CARDIOVASCULAR DISEASE|OSTEOPOROSIS|BREAST CANCER,Female,40 Years to 60 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PUMCH, Peking, Beijing, China",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Withdrawn,NCT03724955,CYSTIC FIBROSIS RELATED BONE DISEASE,Female,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Emory University Hospital, Atlanta, Georgia, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT02451748,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Outpatient Care Center, Chicago, Illinois, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT03448536,DYSMENORRHEA,Female,"15 Years to 35 Years Â  (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Radiant Research, Inc., Chandler, Arizona, United States|Radiant Research, Inc., Scottsdale, Arizona, United States|Radiant Research, Inc., Pinellas Park, Florida, United States|Radiant Research, Inc., Chicago, Illinois, United States|Radiant Research, Inc., Akron, Ohio, United States|Radiant Research, Inc., Cincinnati, Ohio, United States|Radiant Research, Inc., Dallas, Texas, United States|Synexus US, LP- Plano, Plano, Texas, United States",1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT02500641,GOUT,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Klinik und Poliklinik III/Rheumatologie UniversitÃ¤tsklinikum ""Carl Gustav Carus"" Der Technischen UniversitÃ¤t, Dresden, Germany|Presidio Ospedaliero San Filippo e Nicola UniversitÃ  degli Studi dell'Aquila U.O.C Geriatria e Lungodegenza Geriatrica, Avezzano, L'Aquila, Italy|Ospedale San Salvatore U.O.C. Medicina Interna e Nefrologia Dipartimento MeSVA UniversitÃ  degli Studi dell'Aquila, Coppito, L'Aquila, Italy|Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Policlinico SS. Annunziata UniversitÃ  degli Studi ""G. d'Annunzio"". Dipartimento di Medicina e Scienze dell'Invecchiamento., Chieti, Italy|Reade Clinic, Amsterdam, Netherlands|GdaÅskie Centrum Zdrowia Sp.z o.o., GdaÅsk, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, GrudziÄdz, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Centrum Medyczne Plejady, KrakÃ³w, Poland|Krakowski Szpital Specjalistyczny im. Jana PawÅa II w Krakowie, KrakÃ³w, Poland|Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, KrakÃ³w, Poland|Pratia S,A, Warsaw, Poland|Reumatika- Centrum Reumatologii, Warsaw, Poland|OddziaÅ Kardiologiczny, WSS im. W. BiegaÅskiego w Åodzi, ÅÃ³dÅº, Poland|Polimedica, ÅÃ³dÅº, Poland|Clinica MedicalÄ Data Plus SRL, Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|S.C. Centrul Medical Sana S.R.L., Bucharest, Romania|S.C. Cardiomed S.R.L., Craiova, Romania|Institutul de Boli Cardiovasculare Clinica de Cardiologie si Recuperare Cardiovasculara, Timisoara, Romania|Cabinet Medical Medicina Interna, TimiÅoara, Romania|Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia|Institut za reumatologiju, Belgrade, Serbia|KliniÄko-bolniÄki centar ""BeÅ¾anijska kosa"" Klinika za imunologiju i alergologiju, Belgrade, Serbia|Vojnomedicinska akademija Klinika za reumatologiju, Belgrade, Serbia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Unknown status,NCT03699293,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Inova Heart and Vascular Institute, Falls Church, Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT04066426,TEMPOROMANDIBULAR DISORDER,All,18 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Van Yuzuncu Yil University, Faculty of Dentistry, Van, TuÅba, Turkey",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT02501564,OSTEOARTHRITIS,All,"40 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT00826462,"TENNIS ELBOW|EPICONDYLITIS, LATERAL HUMERAL",All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GrÃ¥lum legesenter, Sarpsborg, Norway",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT00807846,"ARTHRITIS, JUVENILE RHEUMATOID",All,2 Years to 17 Years Â  (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Catalina Pointe Clinical Research, Inc., Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Children's Hospital-San Diego, San Diego, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Children's National Medical Center / Division of Rheumatology, Washington, District of Columbia, United States|Arthritis Associates of South Florida, Delray Beach, Florida, United States|Delray Research Associates, Delray Beach, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Administrative Site-Hawaii Pacific Health Research Institute, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Kosair Charities Pediatric Clinical Research Unit - University of Louisville, Louisville, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|University Pediatric Rheumatology of Kentucky, Louisville, Kentucky, United States|Children's Hospital and Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center Pediatric Research Office, Omaha, Nebraska, United States|Akron Children's Hospital, Akron, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital Roberto del Rio, Santiago, RM, Chile|Hospital Regional de Concepcion Guillermo Grant Benavente, Concepcion, VIII Region, Chile|Instituto de Atencion Pediatrica, San Jose, Costa Rica|Clinica San Borja/Centro de Investigacion de Reumatologia, San Borja, Lima, Peru|Clinica Ricardo Palma/Sitio de Investigacion de Reumatologia, San Isidro, Lima, Peru|Philippine General Hospital, Manila, Philippines|University of Santo Tomas Hospital, Manila, Philippines|State Healthcare Institution of Moscow ""Izmailovskaya City Children's Hospital"", Moscow, Russian Federation|First Moscow State Medical University I.M. Sechenov of the Minzdravsocrazvitiya of Russia, Moscow, Russian Federation|Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|SEIHPE ""Smolensk State Medical Academy""of the Minzdravsocrazvitiya of Russia, Smolensk, Russian Federation|Institute of Rheumatology, Belgrade, Serbia|Children's Clinic of Internal Medicine, Nis, Serbia|Clinical Research Unit, Pretoria, Gauteng Province, South Africa|CHUV - Unit of Immuno-Allergology and Rhumatology, CH-1011 Lausanne, Switzerland|Universitaets-Kinderspital, CH-8032 Zuerich, Switzerland|Department of Cardioreumatology, Kharkiv, Ukraine|Institute of Pediatrics, Obstetrics and Gynecology, Kiev, Ukraine|Kyiv City Children Clinical Hospital #1, Kyiv, Ukraine|Crimean State Medical University, Chair of Pediatrics with a course of Children Infectious Diseases, Simferopol, Ukraine|Zaporizhzhya Regional Clinical Pediatric Hospital, Zaporizhzhya, Ukraine",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT00643799,OSTEO ARTHRITIS OF THE KNEES,All,"40 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Montgomery, Alabama, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Tempe, Arizona, United States|Pfizer Investigational Site, Buena Park, California, United States|Pfizer Investigational Site, Paramount, California, United States|Pfizer Investigational Site, Rancho Mirage, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Deland, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Pembroke Pines, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Zephyrhills, Florida, United States|Pfizer Investigational Site, Rockford, Illinois, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Covington, Louisiana, United States|Pfizer Investigational Site, Metairie, Louisiana, United States|Pfizer Investigational Site, Clinton, Maryland, United States|Pfizer Investigational Site, Greenbelt, Maryland, United States|Pfizer Investigational Site, Hagerstown, Maryland, United States|Pfizer Investigational Site, Wheaton, Maryland, United States|Pfizer Investigational Site, Milford, Massachusetts, United States|Pfizer Investigational Site, Lansing, Michigan, United States|Pfizer Investigational Site, Flowood, Mississippi, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Beachwood, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Bethlehem, Pennsylvania, United States|Pfizer Investigational Site, Duncansville, Pennsylvania, United States|Pfizer Investigational Site, Media, Pennsylvania, United States|Pfizer Investigational Site, Warwick, Rhode Island, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, San Angelo, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT01525043,EPICONDYLITIS OF THE ELBOW,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"International Clinical Research Institute, Overland Park, Kansas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC,1,DB00790,__PERINDOPRIL,5162362,Completed,NCT01295047,MARFAN SYNDROME,All,"16 Years to 60 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wales Heart Research Institute, Cardiff University, Cardiff, United Kingdom",C07K5/0222,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,106.482679315797,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.56,368.4678,95.94,5.0,2.0,2.0,39.99,95.69,9.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,1,DB00795,__SULFASALAZINE,4849416,Not yet recruiting,NCT04077957,ANKYLOSING SPONDYLITIS|SPONDYLOARTHRITIS,All,18 Years to 50 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,11.7620485020226,1339.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,398.39300000000003,141.31,8.0,3.0,3.0,39.69,104.6,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,1,DB00795,__SULFASALAZINE,4849416,Unknown status,NCT02638896,ANKYLOSING SPONDYLITIS,All,18 Years to 45 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,11.7620485020226,1339.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,398.39300000000003,141.31,8.0,3.0,3.0,39.69,104.6,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,1,DB00795,__SULFASALAZINE,4849416,Completed,NCT00259610,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,11.7620485020226,1339.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,398.39300000000003,141.31,8.0,3.0,3.0,39.69,104.6,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,1,DB00795,__SULFASALAZINE,4849416,Recruiting,NCT03254589,"RHEUMATOID ARTHRITIS|STIFFNESS, AORTIC|ENDOTHELIAL DYSFUNCTION|CARDIOVASCULAR RISK FACTOR",All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,11.7620485020226,1339.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,398.39300000000003,141.31,8.0,3.0,3.0,39.69,104.6,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,1,DB00795,__SULFASALAZINE,4849416,Terminated,NCT00637780,"ARTHRITIS, JUVENILE RHEUMATOID",All,6 Years to 17 Years Â  (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospitals Case Medical Center, Cleveland, Ohio, United States|Private Office, Guadalajara, Jalisco, Mexico",6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,11.7620485020226,1339.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,398.39300000000003,141.31,8.0,3.0,3.0,39.69,104.6,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,1,DB00795,__SULFASALAZINE,4849416,Recruiting,NCT03739853,PSORIATIC ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,11.7620485020226,1339.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,398.39300000000003,141.31,8.0,3.0,3.0,39.69,104.6,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00806,__PENTOXIFYLLINE,4189469,Completed,NCT02368457,OSTEORADIONECROSIS,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vall d'HebrÃ³n Hospital, Barcelona, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00948220,"HEPATITIS C, CHRONIC|LIVER DISEASES|VIRUS DISEASES",Male,"18 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University Hospital Ulm, Ulm, Germany",7,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, HajdÃº-Bihar, Hungary",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT04026074,"KNEE ARTHROPATHY|HIP ARTHRITIS|FRACTURES, CLOSED",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical University Hospital LKH Graz, Graz, Austria",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01127100,NEUROPATHIC PAIN|SPINAL STENOSIS,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Seoul National University, College of Medicine, Department of Orthopedic Surgery, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01748630,FAILED MODERATE SEDATION DURING PROCEDURE,All,"12 Years to 18 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inonu University Turgut Ozal Medical Center, Malatya, Turkey",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01795898,OSTEOARTHRITIS|LOW BACK PAIN,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Quezon City, Philippines",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT02721017,PECTUS EXCAVATUM|FUNNEL CHEST,All,"13 Years and older Â  (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF-Benioff Children's Hospital, San Francisco, California, United States",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT00524160,ARTHRITIS|OSTEOARTHRITIS|RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT00236366,OSTEOARTHRITIS|ARTHRITIS,All,"41 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT00562627,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asker and Baerum Hospital, Rud, Norway",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT01666379,POSTOPERATIVE PAIN,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Management of Turku University Hospital, Turku, Finland",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Terminated,NCT00270322,"PAIN, POSTOPERATIVE|OSTEOARTHRITIS",All,"55 Years to 85 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Rambam Health Care Campus, Haifa, Israel",A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,1,DB00814,__MELOXICAM,6184220,Completed,NCT00635349,OSTEOARTHRITIS,All,"40 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,22.47274071336161,1458.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.28,351.401,99.6,5.0,2.0,3.0,34.25,88.62,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1
Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1,1,DB00814,__MELOXICAM,6184220,Terminated,NCT03473665,ANKYLOSING SPONDYLITIS|AXIAL SPONDYLOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Columbia University Irving Medical Center, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,22.47274071336161,1458.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.28,351.401,99.6,5.0,2.0,3.0,34.25,88.62,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02292082,OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01932424,SPINE DEFORMITIES|IDIOPATHIC SCOLIOSIS|NEUROMUSCULAR DYSTROPHY,All,"5 Years to 18 Years Â  (Child, Adult)",Other,"Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)","Great Ormond Street Hospital for Children NHS trust, London, United Kingdom",0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Unknown status,NCT02944292,INTRA-ABDOMINAL HYPERTENSION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tartu University Hospital, Tartu, Tartumaa, Estonia",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01270620,OBESITY|ARTHRITIS,All,65 Years and older Â  (Older Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Recruiting,NCT03625076,SHOULDER DISLOCATION,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kendall Regional Medical Center, Miami, Florida, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02469961,SHOULDER PAIN,All,"21 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Maimonides Medical Center, Brooklyn, New York, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Recruiting,NCT03783494,JOINT DISLOCATION|LIMB FRACTURE,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Emergency Department, Nice, France",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT01947114,PEDIATRIC RIGID BRONCHOSCOPY,All,1 Month to 12 Years Â  (Child),Other,Allocation: Randomized|Masking: Single (Participant)|Primary Purpose: Treatment,"Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT03540030,OPIOID USE|SHOULDER OSTEOARTHRITIS|AVASCULAR NECROSIS|ROTATOR CUFF TEAR|ARTHRITIS;INFLAMMATORY,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OrthoCarolina Research Institute, Charlotte, North Carolina, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02784626,"ARTHRITIS, DEGENERATIVE",All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Unknown status,NCT03215446,VASCULAR SURGERY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"CHU dijon Bourgogne, Dijon, France",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Completed,NCT00644956,ERECTILE DYSFUNCTION,Male,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Leeds, United Kingdom",C07D471/14,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Completed,NCT01070511,BECKER MUSCULAR DYSTROPHY,Male,18 Years to 55 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Cedars-Sinai Medical Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States",C07D471/14,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
C[C@@H]1O[C@@H]1P(=O)(O)O,1,DB00828,__FOSFOMYCIN,,Recruiting,NCT03260010,PROSTHETIC JOINT INFECTION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CharitÃ© - UniveristÃ¤tsmedizin, Berlin, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.86,138.059,70.06,4.0,2.0,1.0,10.8,25.87,1.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21,1,DB00829,__DIAZEPAM,5462740,Completed,NCT04523935,CEREBRAL PALSY|CRYING,All,up to 15 Years Â  (Child),Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",,A61M5/24,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,25.4296802809092,2386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.63,284.74,32.67,2.0,0.0,3.0,29.39,79.81,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB00838,__CLOCORTOLONE,4376767,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",C07J71/0031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,129.0,26.3496170352573,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.73,410.907,74.6,4.0,2.0,4.0,41.8,105.74,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,1,DB00841,__DOBUTAMINE,4425336,Suspended,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,19.5815109139818,420.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.97,301.3801,72.72,4.0,4.0,2.0,34.44,88.39,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Terminated,NCT01633593,ELDERLY|DELIRIUM OF UNKNOWN (AXIS III) ETIOLOGY|INTENSIVE CARE (ICU) MYOPATHY,All,"60 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","FAMEMA, Marilia, Sao Paulo, Brazil",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, HajdÃº-Bihar, Hungary",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,1,DB00850,__PERPHENAZINE,4175119,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.15,403.969,29.95,4.0,1.0,4.0,44.77,116.1,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00805519,OSTEO ARTHRITIS OF THE KNEES,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"ArdabiUMS Clinic of Rheumatology, Ardabil, Iran, Islamic Republic of",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00443430,JUVENILE CHRONIC POLYARTHRITIS|JUVENILE IDIOPATHIC ARTHRITIS|JUVENILE RHEUMATOID ARTHRITIS,All,2 Years to 17 Years Â  (Child),Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Stanford University Medical Center, Palo Alto, California, United States|Rady Children's Hospital, San Diego, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Children's Hospital of Boston, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Children's Hospital of Columbus, Columbus, Ohio, United States|Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States|Texas Scottish Rite Hospital, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital and Regional Medical Center, Seattle, Washington, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Unknown status,NCT00609752,CROHN'S DISEASE,All,7 Years to 17 Years Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Royal Liverpool Children's Hospital, Liverpool, Merseyside, United Kingdom|Oxford Children's Hospital, Oxford, Oxfordshire, United Kingdom|Sheffield Children's Hospital, Sheffield, South Yorkshire, United Kingdom|Birmingham Children's Hospital, Birmingham, West Midlands, United Kingdom|Bristol Royal Hospital for Sick Children, Bristol, United Kingdom|St George's University Hospital, London, United Kingdom",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT02644499,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, Pondicherry UT, India",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Not yet recruiting,NCT03633565,MYOPATHY,Male,5 Years to 15 Years Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0056,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT01619163,PAIN,All,65 Years and older Â  (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Faculty of Medicine, University of Alexandria, Alexandria, Egypt",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT01850979,SJOGREN SYNDROME|DRY EYE SYNDROME,All,40 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Sao Paulo General Hospital, Sao Paulo, SP, Brazil",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT03737708,RHEUMATOID ARTHRITIS,All,"19 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site KR82003, Daegu, Korea, Republic of|Site KR82007, Daegu, Korea, Republic of|Site KR82006, Daejeon, Korea, Republic of|Site KR82002, Incheon, Korea, Republic of|Site KR82009, Seongnam, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site KR82005, Seoul, Korea, Republic of|Site KR82010, Seoul, Korea, Republic of|Site KR82012, Seoul, Korea, Republic of|Site KR82013, Suwon, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,1,DB00878,__CHLORHEXIDINE,5538353,Completed,NCT02097615,SOFT TISSUE INFECTIONS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Leon, Leon, Guanajuato, Mexico",A45D34/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,1,DB00878,__CHLORHEXIDINE,5538353,Not yet recruiting,NCT04512638,MEDICATION RELATED OSTEONECROSIS OF THE JAW,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ZNA Middelheim, Antwerp, Belgium|Antwerp University Hospital, Edegem, Belgium|UZ Leuven, Leuven, Belgium|AZ Nikolaas, Sint Niklaas, Belgium",A45D34/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,1,DB00889,__GRANISETRON,5952340,Completed,NCT02230371,MYOFASCIAL PAIN|TEMPOROMANDIBULAR DISORDERS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Karolinska Institutet, Department of Dental Medicine, Huddinge, Sweden",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,39.7215548573892,477.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.64,312.4170000000001,50.16,3.0,1.0,4.0,35.57,101.83,2.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT02208778,OSTEOARTHRITIS|CHRONIC PAIN,All,"35 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Nottingham - School of Medicine - Radiological Sciences, Nottingham, Nottinghamshire, United Kingdom",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT01947114,PEDIATRIC RIGID BRONCHOSCOPY,All,1 Month to 12 Years Â  (Child),Other,Allocation: Randomized|Masking: Single (Participant)|Primary Purpose: Treatment,"Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey",C07D211/58,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT04026074,"KNEE ARTHROPATHY|HIP ARTHRITIS|FRACTURES, CLOSED",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical University Hospital LKH Graz, Graz, Austria",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1,1,DB00899,__REMIFENTANIL,5019583,Completed,NCT01052324,CERVICAL DISC HERNIATION|CERVICAL SPINAL STENOSIS|CERVICAL SPINE DAMAGE,All,"20 Years to 65 Years Â  (Adult, Older Adult)",Other,Primary Purpose: Prevention,"Severance Hospital, Seoul, Korea, Republic of",C07D211/58,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,17.511653216698402,216.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,376.4467,76.15,4.0,0.0,2.0,40.82,100.56,9.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1
NS(=O)(=O)Cc1noc2ccccc12,1,DB00909,__ZONISAMIDE,4172896,Withdrawn,NCT00259636,FIBROMYALGIA|MIGRAINE,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",C07D261/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,16.8217006509373,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.67,212.226,86.19,3.0,1.0,2.0,19.48,50.3,2.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Terminated,NCT01725113,KIDNEY FAILURE|SECONDARY HYPERPARATHYROIDISM|HYPERPHOSPHATEMIA|HYPERCALCEMIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Winthrop University Hospital, Mineola, New York, United States",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
Cc1ncc([N+](=O)[O-])n1CCO,1,DB00916,__METRONIDAZOLE,5536743,Completed,NCT03533231,DENTAL PULP NECROSIS|PERIAPICAL ABSCESS|ROOT CANAL INFECTION,All,"8 Years to 18 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,22.7355797860325,1267.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.15,171.15400000000002,83.87,4.0,1.0,1.0,15.82,41.22,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1
Cc1ncc([N+](=O)[O-])n1CCO,1,DB00916,__METRONIDAZOLE,5536743,Active Not Recruiting,,PERI-IMPLANTITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,60.0,22.7355797860325,1267.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.15,171.15400000000002,83.87,4.0,1.0,1.0,15.82,41.22,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,1,DB00920,__KETOTIFEN,4232002,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0078,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,23.1626932791227,287.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.49,309.425,20.31,2.0,0.0,4.0,34.61,101.73,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT00324038,OSTEOARTHRITIS,All,65 Years and older Â  (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Napp Pharmaceuticals Ltd, Cambridge, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Terminated,NCT00552578,OPIATE ADDICTION|REFRACTORY PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erie County Medical Center, Buffalo, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT02416804,"SPINAL STENOSIS|PAIN, POSTOPERATIVE",All,"20 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT02519387,OSTEOARTHRITIS|RHEUMATOID ARTHRITIS|LOWER BACK PAIN|JOINT PAIN|MUSCLE PAIN,All,"40 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital University Sains Malaysia, Kota Bahru, Kelantan, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia|University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT01818700,SPINAL DISORDERS,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Samsung Medical Center, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT02575664,PAIN|OSTEOARTHRITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kuopio University Hospital, Kuopio, Northern Savo, Finland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT01276431,OSTEOARTHRITIS PAIN OF THE HIP AND OR KNEE,All,"50 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Professor Jon Karlsson, Molndal, Sweden|Dr Bengt Olav Tengmark, Stockholm, Sweden",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT00426647,OSTEOARTHRITIS|PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Dr. Olavi Airaksinen, Oma LÃ¤Ã¤kÃ¤ri Oy, Vuorikatu 20, Kuopio, Finland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,1,DB00922,__LEVOSIMENDAN,6340764,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",G01N30/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,11.039241052177598,104.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,280.2847,113.43,6.0,2.0,2.0,28.67,77.63,3.0,0.0,1.0,0.0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Unknown status,NCT01041495,FIBROMYALGIA|PAIN|SLEEP|FATIGUE,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SUNY Upstate Medical University, Syracuse, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Completed,NCT00246389,PAIN|SPASM,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Unknown Status,,FATIGUE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,1,DB00927,__FAMOTIDINE,5075114,Completed,NCT01563185,JUVENILE IDIOPATHIC ARTHRITIS,All,10 Years to 16 Years Â  (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital, New Orleans, Louisiana, United States|Floating Hospital for Children @ Tufts Medical Center, Boston, Massachusetts, United States|UMASS Memorial Children's Medical Center, Worcester, Massachusetts, United States|Altoona Center for Clinical Research Altoona Arthritis, Duncansville, Pennsylvania, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States",A61K9/5047,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,19.05583276864,1184.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.2,337.445,175.83,8.0,4.0,1.0,31.66,80.46,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,1,DB00927,__FAMOTIDINE,5075114,Completed,,PEPTIC ULCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/5047,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,19.05583276864,1184.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.2,337.445,175.83,8.0,4.0,1.0,31.66,80.46,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT00355342,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Berkeley, California, United States|GSK Investigational Site, Fullerton, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Fort Collins, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Hartford, Connecticut, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Tamarac, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, North Chicago, Illinois, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Cadillac, Michigan, United States|GSK Investigational Site, Saint Charles, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Bronxville, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Greer, South Carolina, United States|GSK Investigational Site, Simpsonville, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Milan, Tennessee, United States|GSK Investigational Site, Corsicana, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Bellingham, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Spokane, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Unknown status,NCT03699293,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Inova Heart and Vascular Institute, Falls Church, Virginia, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Recruiting,NCT03933007,GOUT FLARE,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HÃ´pital LariboisiÃ¨re-Service de Rhumatolologie, Paris, France",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Unknown status,NCT02477852,"TUBERCULOSIS, SPINAL",All,"15 Years to 75 Years Â  (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing chest hospital, Beijing, Beijing, China",C08G73/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT03082092,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Queen Elizabeth Hospital, Hong Kong, Hong Kong",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT03479502,ADHESIVE CAPSULITIS|ADHESIVE CAPSULITIS OF UNSPECIFIED SHOULDER|FROZEN SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt Medical Center, Nashville, Tennessee, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT03797872,PSORIATIC ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT02292082,OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT01652495,TENDINOPATHY|ADRENAL INSUFFICIENCY,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Rizzoli Orthopaedic Institute, Bologna, Italy",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT01382940,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Uni Of Alabama,Birmingham; Medicine - Rheumatology, Birmingham, Alabama, United States|Clnical & Translational Reseach Center for Alabama, PC, Tuscaloosa, Alabama, United States|ArthroCare, Arthritis Care; and Research P.C., Gilbert, Arizona, United States|Valley Arthritis Care, Phoenix, Arizona, United States|Catalina Pointe Rheumatology, Tucson, Arizona, United States|Medvin Clinical Research, Covina, California, United States|Triwest Research Associates, La Mesa, California, United States|Medvin Clinical Research, Los Angeles, California, United States|Brigid Freyne-Private Practice; Internal Medicine, Rheum, Murrieta, California, United States|Desert Medical Advances; Rheumatology, Palm Desert, California, United States|San Diego Arthritis Med Clnc, San Diego, California, United States|Pacific Arthritis Ctr Med Grp, Santa Maria, California, United States|Inland Rheumatology; Clinical Trials, Inc., Upland, California, United States|Medvin Clinical Research, Whittier, California, United States|Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs, Colorado Springs, Colorado, United States|Denver Arthritis Clinic, Denver, Colorado, United States|Rheum & Internal Med Assoc-Bri, Bridgeport, Connecticut, United States|Arthritis & Osteoporosis Center Pc, Hamden, Connecticut, United States|Rheumatolgy Consultants of Deleware, Lewes, Delaware, United States|Javed Rheumatology Associates, Inc., Newark, Delaware, United States|Arthritis & Rheumatism; Disease Specialities, Aventura, Florida, United States|Florida Arthritis Center, PI, Lake Mary, Florida, United States|Omega ResearchConsultants LLC, Orlando, Florida, United States|Millenium Research, Ormond Beach, Florida, United States|Arthritis Center Palm Harbor, Palm Harbor, Florida, United States|Arthritis Rsrch of Florida, Inc., Palm Harbor, Florida, United States|Center For Arthritis; Research Dept, South Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Florida Medical Clinic; Clinical Research, Zephyrhills, Florida, United States|Parris & Associates, Lawrenceville, Georgia, United States|St. Luke's Intermountain Research Center, Boise, Idaho, United States|Institute of Arthritis Research, Idaho Falls, Idaho, United States|Quad City Rheumatology, Sc, Moline, Illinois, United States|Physician'S Clinic of Iowa, Cedar Rapids, Iowa, United States|Bluegrass Comm Research, Inc., Lexington, Kentucky, United States|Klein & Associates, M.D. P.A., Cumberland, Maryland, United States|Klein & Associates, M.D., P.A., Hagerstown, Maryland, United States|St. Luke's Hospital Association of Duluth, Duluth, Minnesota, United States|Arthritis and Osteoporosis; Treatment and Research Center, Flowood, Mississippi, United States|Jackson Arthritis Clinic, Flowood, Mississippi, United States|North Mississippi Med Clinics, Inc., Tupelo, Mississippi, United States|David S Rosenberg, Florissant, Missouri, United States|Arthritis Center of Reno, Reno, Nevada, United States|Rheumatology Research Group, Lebanon, New Hampshire, United States|Rheumatology Associates Of New Jersey, Teaneck, New Jersey, United States|The Center for Rheumatology, Albany, New York, United States|Arthritis & Osteoporosis Center, Brooklyn, New York, United States|NYU Center for Musculoskeletal Care, New York, New York, United States|Buffalo Rheumatology Associates, Orchard Park, New York, United States|Office of Premier Chatpar Md, Plainview, New York, United States|Aair Research Center, Rochester, New York, United States|Rheumatology Associates of Long Island, Smithtown, New York, United States|Arthritis Health Associates; Clinical Research, Syracuse, New York, United States|Arth&OsteoConsof theCarolinas-Charlotte, Charlotte, North Carolina, United States|Box Arthritis & Rheumatology, Charlotte, North Carolina, United States|Carolina Bone & Joint P.A., Charlotte, North Carolina, United States|Physicians East Pa, Greenville, North Carolina, United States|Shanahan Rheumatology & Immunology, PLLC, Raleigh, North Carolina, United States|Crystal Arthritis Center, Inc., Akron, Ohio, United States|CarePoint East, Columbus, Ohio, United States|Stat Research, Inc, Dayton, Ohio, United States|Paramount Medical Research, Middleburg Heights, Ohio, United States|LION Research, Norman, Oklahoma, United States|Arthritis and Rheumatology; Center of Oklahoma PLLC, Oklahoma City, Oklahoma, United States|East Penn Rheumatology Associates, Pc, Bethlehem, Pennsylvania, United States|Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States|Pivotal Clinical Research, Llc, Perkasie, Pennsylvania, United States|Arthritis Group, Philadelphia, Pennsylvania, United States|Rheumatic Disease Associates; Clinical Research Unit, Willow Grove, Pennsylvania, United States|Clinical Research Center of Reading, Wyomissing, Pennsylvania, United States|Pennsylvania Regional Center for Arthritis and Osteoporosis Research, Wyomissing, Pennsylvania, United States|Low Country Rheumatology, PA, Charleston, South Carolina, United States|Rheumatology Associates, Charleston, South Carolina, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Ramesh Gupta - PP, Memphis, Tennessee, United States|Amarillo Center For Clinical Research, Amarillo, Texas, United States|Lovelace Scientific Resources Inc., Austin, Texas, United States|Adriana Pop-Moody MD Clinic PA, Corpus Christi, Texas, United States|Arthritis Centers of Texas, Dallas, Texas, United States|Southwest Rheumatology, Mesquite, Texas, United States|Arthritis Clinic of Northern Virginia, Arlington, Virginia, United States|Apex Clinical Research, Kennewick, Washington, United States|Seattle Arthritis Clinic, Seattle, Washington, United States|Arthritis Northwest, Spokane, Spokane, Washington, United States|Cedar Medical Center, Tacoma, Washington, United States|Rheumatic Disease Center, Glendale, Wisconsin, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT02283996,ADHESIVE CAPSULITIS|FROZEN SHOULDER|SHOULDER FROZEN,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MGH, Massachusetts General Hospital, Boston, Massachusetts, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT02403856,CALCIFYING TENDINITIS OF SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","La Roche sur Yon Hospital, La Roche sur Yon, France|Nantes University Hospital, Nantes, France|Rennes University hospital, Rennes, France",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT01995019,ARTHRALGIA|TMJ,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Orofacial pain unit, Malar Hospital Eskilstuna, Eskilstuna, SÃ¶dermanland, Sweden|Dental specialist clinic Kaniken, Uppsala, Uppland, Sweden|Specialist clinic Stomatognathic physiology, Goteborg, VastraGotaland, Sweden|Specialist center, Uddevalla, VastraGotaland, Sweden|Orofacial pain unit, VÃ¤stmanland Hospital VÃ¤sterÃ¥s, VÃ¤sterÃ¥s, VÃ¤stmanland, Sweden|Orofacial pain unit Eastman Institute, Stockholm, Sweden|Orofacial pain unit, Dental Specialist Education Center, Ãrebro, Sweden",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Withdrawn,NCT02426164,"PAIN, POSTOPERATIVE|ARTHROPLASTY, REPLACEMENT, KNEE|OSTEOARTHRITIS",All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Miller Orthopedic Specialists, Council Bluffs, Iowa, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
Cc1cccc(C)c1NC(=O)C1CCCCN1C,1,DB00961,__MEPIVACAINE,4001413,Completed,NCT02384915,KNEE ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Istituto Ortopedico G. Pini, Milan, Milano, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,13.9633257356413,1031.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.16,246.34799999999998,32.34,2.0,1.0,2.0,28.61,76.32,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
Cc1cccc(C)c1NC(=O)C1CCCCN1C,1,DB00961,__MEPIVACAINE,4001413,Unknown status,NCT03046108,MORTON NEUROMA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Complejo Hospitalario Universitario Granada, Granada, SPA, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,13.9633257356413,1031.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.16,246.34799999999998,32.34,2.0,1.0,2.0,28.61,76.32,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
Cc1cccc(C)c1NC(=O)C1CCCCN1C,1,DB00961,__MEPIVACAINE,4001413,Not yet recruiting,NCT04257682,KNEE OSTEOARTHRITIS|HIP OSTEOARTHRITIS,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,13.9633257356413,1031.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.16,246.34799999999998,32.34,2.0,1.0,2.0,28.61,76.32,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
Cc1cccc(C)c1NC(=O)C1CCCCN1C,1,DB00961,__MEPIVACAINE,4001413,Completed,NCT03948386,"OSTEOARTHRITIS, HIP",All,"18 Years to 84 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Rothman Orthopedic Specialty Hospital, Bensalem, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,13.9633257356413,1031.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.16,246.34799999999998,32.34,2.0,1.0,2.0,28.61,76.32,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Completed,NCT00738296,CARDIOVASCULAR DISEASE,All,"30 Years to 75 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07D205/08Â ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
NCCc1ccc(O)c(O)c1,1,DB00988,__DOPAMINE,3947590,Completed,NCT00595140,ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Klinik - Innenstadt of the University of Munich, Munich, Germany",C07D207/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.0618903878929,5659.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,153.1784,66.48,3.0,3.0,1.0,16.21,43.25,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Recruiting,,EARLY BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Recruiting,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT03449758,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 250007, Argenteuil, France|Investigational Site Number 250006, Besancon, France|Investigational Site Number 250027, Bobigny, France|Investigational Site Number 250016, Bordeaux, France|Investigational Site Number 250014, Caen, France|Investigational Site Number 250032, CAHORS Cedex 9, France|Investigational Site Number 250019, Cannes, France|Investigational Site Number 250013, Cholet, France|Investigational Site Number 250002, Clermont Ferrand, France|Investigational Site Number 250009, Echirolles, France|Investigational Site Number 250005, La Roche Sur Yon, France|Investigational Site Number 250024, Le Mans Cedex 9, France|Investigational Site Number 250004, Lille Cedex, France|Investigational Site Number 250012, Limoges Cedex, France|Investigational Site Number 250021, Lyon, France|Investigational Site Number 250018, Montivilliers, France|Investigational Site Number 250029, MONTPELLIER Cedex 5, France|Investigational Site Number 250025, NANTES Cedex 1, France|Investigational Site Number 250026, Nice cedex 1, France|Investigational Site Number 250020, Paris Cedex 10, France|Investigational Site Number 250011, PARIS Cedex 13, France|Investigational Site Number 250010, Paris, France|Investigational Site Number 250015, Paris, France|Investigational Site Number 250028, Paris, France|Investigational Site Number 250033, Paris, France|Investigational Site Number 250031, Poitiers, France|Investigational Site Number 250023, Pontoise, France|Investigational Site Number 250017, RENNES Cedex, France|Investigational Site Number 250008, Rouen, France|Investigational Site Number 250001, St Etienne, France|Investigational Site Number 250034, Strasbourg Cedex 2, France|Investigational Site Number 250022, Toulouse, France|Investigational Site Number 250003, Tours, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Withdrawn,NCT02281799,PANCREATITIS|INFLAMMATORY BOWEL DISEASES,All,"5 Years to 60 Years Â  (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shaare Zedek, Jerusalem, Israel",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT00987116,MYASTHENIA GRAVIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hopital Raymond PoincarÃ©, Garches, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT04523935,CEREBRAL PALSY|CRYING,All,up to 15 Years Â  (Child),Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",,C07C229/28,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT03540030,OPIOID USE|SHOULDER OSTEOARTHRITIS|AVASCULAR NECROSIS|ROTATOR CUFF TEAR|ARTHRITIS;INFLAMMATORY,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OrthoCarolina Research Institute, Charlotte, North Carolina, United States",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT02155257,OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT03334903,KNEE OSTEOARTHRITIS|KNEE PAIN CHRONIC|OPIOID USE|OPIOID DEPENDENCE,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brigham and Women's Faulkner Hospital, Boston, Massachusetts, United States",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT03005483,"PAIN, POSTOPERATIVE|ORTHOPEDIC DISORDER",All,3 Months to 16 Years Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hospital Infantil Albert Sabin, Fortaleza, Ceara, Brazil",C07C229/28,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Unknown status,NCT02339662,MYOFACIAL PAIN,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hadassah MO, Jerusalem, Israel",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT03241875,"PAIN, POSTOPERATIVE|CHOLECYSTECTOMY, LAPAROSCOPIC",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Sahloul Teaching Hospital, Sousse, Tunisia",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT01127100,NEUROPATHIC PAIN|SPINAL STENOSIS,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Seoul National University, College of Medicine, Department of Orthopedic Surgery, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/5537,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT02182713,ASTHMA,All,7 Years to 12 Years Â  (Child),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Recruiting,NCT03586544,"ASTHMA IN CHILDREN|OBESITY, CHILDHOOD|EXERCISE INDUCED BRONCHOSPASM",All,8 Years to 12 Years Â  (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Childrens Lung Specialists, Las Vegas, Nevada, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00273689,EXERCISE INDUCED BRONCHOSPASM,All,7 Years to 17 Years Â  (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of New Mexico, Albuquerque, New Mexico, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,"Active, not recruiting",NCT02508311,SPINAL CORD INJURY|RESPIRATORY MUSCLE WEAKNESS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Active Not Recruiting,,RESPIRATORY MUSCLE WEAKNESS,,,,,"FISABIO, Elche, Alicante, Spain",B65D83/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Recruiting,NCT03607227,"HEAD AND NECK CANCER|PAIN, MUSCULOSKELETAL",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Skane University Hospital Lund, Divison of Anaestesia and Intensive Care, Lund, Skane, Sweden",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,NCT02293330,HALLUX VALGUS|SURGERY,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)","University Hospital Antwerp, Antwerp, Belgium",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Not yet recruiting,NCT04397484,MUSCULOSKELETAL DISEASES OR CONDITIONS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,NCT01106001,OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cappagh National Orthopaedic Hospital, Dublin, Finglas, Ireland|Orthopaedic Research and Innovation Foundation, Dublin, Santry, Ireland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Unknown status,NCT00926666,FEMORAL NECK FRACTURES,All,"35 Years to 95 Years Â  (Adult, Older Adult)",Other,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)","Western Infirmary, Glasgow, Lanarkshire, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Unknown status,NCT02893228,PHRENIC NERVE PALSY,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","Adelaide and Meath Hospital, Incorporating National Children Hospital, Tallagh, Dublin 24, Ireland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Completed,NCT00688909,BREAST CANCER,Female,"50 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Clearview Cancer Center, Huntsville, Alabama, United States|Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States|Grass Valley Hematology Oncology, Grass Valley, California, United States|Aptium Oncology - Comprehensive Cancer Care of the Desert, Palm Springs, California, United States|Bay Area Cancer Research Group, Pleaseant Hill, California, United States|Front Range Specialist, Fort Collins, Colorado, United States|Lynn Cancer Center, Boca Raton, Florida, United States|Florida Cancer Specialists, Fort Meyers, Florida, United States|Memorial Cancer Center, Hollywood, Florida, United States|Palm Beach Cancer Specialists, West Palm Beach, Florida, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Augusta Oncology, Augusta, Georgia, United States|Oncology Specialist of North Georgia, Gainesville, Georgia, United States|The Cancer Instiute at Alexian Brothers, Elk Grove Village, Illinois, United States|Evanston Northwestern Hospital, Evanston, Illinois, United States|Edward H. Kaplan MD & Associates - North Shore Cancer Research Associates, Skokie, Illinois, United States|Cancer Care of Kansas, Wichita, Kansas, United States|Kentuckiana Cancer Institute, Louisville, Kentucky, United States|Mercy Hospital, Portland, Maine, United States|Mercey Hospital, Baltimore, Maryland, United States|Maryland Hematology Oncology Associates, PA, Baltimore, Maryland, United States|Suburban Hospital Cancer Program, Bethesda, Maryland, United States|Hematology Oncology Asssociates of Ohio & Michigan, Lambertville, Michigan, United States|Center for Cancer Care and Research, St Louis, Missouri, United States|Ballas Cancer Center, LLC DBA - St Louis, St. Louis, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, Lincoln, Nebraska, United States|Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey, United States|Hematology-Oncology Assoc of Northern New Jersey, Morristown, New Jersey, United States|Somerset Hematology & Oncology, Somerville, New Jersey, United States|Cooper University Hospital, Vorhees, New Jersey, United States|Broom Oncology, Binghamton, New York, United States|Cancer Care of W. NC, Ashville, North Carolina, United States|Marion L. Shepard Cancer Center, Washington, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Mukesh Bhatt, MD, INC., Medina, Ohio, United States|Berks Hematology Oncology, West Reading, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|The West Clinic, Memphis, Tennessee, United States|Tenessee Oncology, Nashville, Tennessee, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|Center for Oncology Research and Treatment, Dallas, Texas, United States|Central Utah Clinic, American Fork, Utah, United States|Northern Utah Associates, Ogden, Utah, United States|Medical Oncology & Hematology Associates of Northern Virginia, Fairfax, Virginia, United States|Rockingham Memorial Hospital Regional Cancer Center, Harrisonburg, Virginia, United States|Peninsula Cancer Center, Newport News, Virginia, United States|Green Bay Oncologist, St Vincent Hospital, Green Bay, Wisconsin, United States|Oncology Alliance, Wauwatosa, Wisconsin, United States",C07D213/57,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Unknown status,NCT02137538,SHORT STATURE,Male,10 Years to 17 Years Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lucile Packard Children's Hospital, Palo Alto, California, United States",C07D213/57,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,NCT02638831,GONARTHROSIS|LOW BACK PAIN,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C51/09,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,ANKLE SPRAINS,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,"Active, not recruiting",NCT03994172,MALE OSTEOPOROSIS,Male,"60 Years to 85 Years Â  (Adult, Older Adult)",U.S. Fed|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States",3,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT03123406,"HYPERPARATHYROIDISM; SECONDARY, RENAL",All,"18 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nanjing Jinling Hospital, Nanjing, Jiangsu, China",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,NCT02417389,"HYPERPARATHYROIDISM, PRIMARY|OSTEOPOROSIS",All,"50 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Istituto Auxologico Italiano IRCCS, Milano, Italy",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB01013,__CLOBETASOL_PROPIONATE,6106848,Not yet recruiting,NCT03926377,OSTEOPOROSIS|BULLOUS PEMPHIGOID,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K8/062,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,34.9904515493131,799.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.49,466.97,80.67,4.0,1.0,4.0,48.28,119.32,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB01013,__CLOBETASOL_PROPIONATE,6106848,Completed,,HYPERTROPHIC SCARS,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/062,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.9904515493131,799.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.49,466.97,80.67,4.0,1.0,4.0,48.28,119.32,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB01013,__CLOBETASOL_PROPIONATE,6106848,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/062,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.9904515493131,799.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.49,466.97,80.67,4.0,1.0,4.0,48.28,119.32,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
O=[N+]([O-])O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@H]12,1,DB01020,__ISOSORBIDE_MONONITRATE,4065488,Recruiting,NCT04310995,CORONARY ARTERY BYPASS GRAFT|RADIAL ARTERY GRAFTS|ANTISPASTIC THERAPY|PILOT STUDY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China",C07D493/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.053594529661801,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.74,191.1388,93.74,6.0,1.0,2.0,15.85,38.08,2.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Recruiting,NCT03122431,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)|JUVENILE SLE|CUTANEOUS LUPUS,All,"5 Years to 64 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital das Clinicas da Faculdade de Medicina da USP, SÃ£o Paulo, Brazil",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC12CC3CC(C)(C1)CC(N)(C3)C2,1,DB01043,__MEMANTINE,5061703,Completed,NCT00638027,MULTIPLE SCLEROSIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Rochester, Rochester, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,18.5958643914659,484.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,179.3018,26.02,1.0,1.0,3.0,21.82,54.49,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0
CC12CC3CC(C)(C1)CC(N)(C3)C2,1,DB01043,__MEMANTINE,5061703,Completed,NCT00280774,PHYSIOLOGICAL EFFECTS OF DRUGS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"Parkland Health and Hospital System (Asthma, Allergy, & Arthritis Clinics), Dallas, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,18.5958643914659,484.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,179.3018,26.02,1.0,1.0,3.0,21.82,54.49,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Unknown status,NCT02477852,"TUBERCULOSIS, SPINAL",All,"15 Years to 75 Years Â  (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing chest hospital, Beijing, Beijing, China",C07D498/18,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Recruiting,NCT03012529,OSTEOMYELITIS|DIABETES|AMPUTATION,All,"18 Years to 89 Years Â  (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona, United States|VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States|VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States|VA Northern California Health Care System, Mather, CA, Sacramento, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States|Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado, United States|Washington DC VA Medical Center, Washington, DC, Washington, District of Columbia, United States|Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida, United States|North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|St. Louis VA Medical Center John Cochran Division, St. Louis, MO, Saint Louis, Missouri, United States|James J. Peters VA Medical Center, Bronx, NY, Bronx, New York, United States|Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio, United States|Dayton VA Medical Center, Dayton, OH, Dayton, Ohio, United States|Oklahoma City VA Medical Center, Oklahoma City, OK, Oklahoma City, Oklahoma, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States|William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Terminated,NCT01200069,"DEPRESSION, MYALGIA",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University Hospital, Newark, New Jersey, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT00565500,ISCHEMIC HEART DISEASE|OSTEOARTHRITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Ce.S.I., Center of Excellence on Aging, G. d'Annunzio University, Chieti, CH, Italy",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT00145730,"OSTEOARTHRITIS, HIP|ARTHROPLASTY, REPLACEMENT, HIP|ARTHRITIS, RHEUMATOID",All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT01563185,JUVENILE IDIOPATHIC ARTHRITIS,All,10 Years to 16 Years Â  (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital, New Orleans, Louisiana, United States|Floating Hospital for Children @ Tufts Medical Center, Boston, Massachusetts, United States|UMASS Memorial Children's Medical Center, Worcester, Massachusetts, United States|Altoona Center for Clinical Research Altoona Arthritis, Duncansville, Pennsylvania, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT00346216,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Carol M. Johnson MD, LLC, Alabaster, Alabama, United States|Orthopaedics West, Bessemer, Alabama, United States|Central Alabama Research, Birmingham, Alabama, United States|Simon Williamson Clinic/Clinical Research Advantage, Inc., Birmingham, Alabama, United States|Achieve Clinical Research, LLC, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Cahaba Research Inc., Birmingham, Alabama, United States|Winston Technology Inc., Haleyville, Alabama, United States|Clinical Research Consultants, Inc, Hoover, Alabama, United States|Medical Affiliated Research Center, Incorporated, Huntsville, Alabama, United States|Rheumatology Associates of North Alabama, PC, Huntsville, Alabama, United States|Montgomery Rheumatology Associates, Montgomery, Alabama, United States|James P. Beretta, PC, Pelham, Alabama, United States|Alabama Clinical Research Associates, Pell City, Alabama, United States|Pell City Internal and Family Medicine, Pell City, Alabama, United States|Scottsboro Quick Care Clinic, Scottsboro, Alabama, United States|Clinic for Rheumatic Diseases, Tuscaloosa, Alabama, United States|Terence T. Hart , MD, Tuscumbia, Alabama, United States|Clinical Research Advantage Inc./ Warner Family Practice, PC, Chandler, Arizona, United States|ArthroCare, Arthritis Care & Research P.C., Gilbert, Arizona, United States|Clinical Research Advantage Inc., /Thunderbird Internal Medicine, Glendale, Arizona, United States|Arizona Center for Clinical Research, Glendale, Arizona, United States|Clinical Research Advantage, Inc./ Lenzmeier Family Medicine, Glendale, Arizona, United States|Clinical Research Advantage, Inc./Central Arizona Medical Associates, PC, Mesa, Arizona, United States|Novara Clinical Research, Mesa, Arizona, United States|Clinical Research Advantage, Inc., Mesa, Arizona, United States|Sun Valley Arthritis Center, Limited, Peoria, Arizona, United States|Lovelace Scientific Resources, Inc., Phoenix, Arizona, United States|Clinical Research Advantage, Inc./ Family Practice Specialists, LTD, Phoenix, Arizona, United States|NPHC Research, Phoenix, Arizona, United States|Phoenix Clinical, Phoenix, Arizona, United States|Arizona Research Center, Inc., Phoenix, Arizona, United States|Precision Trials AZ. LLC; AZ, Phoenix, Arizona, United States|43rd Medical Associates, P.C., Phoenix, Arizona, United States|Southwest Health Ltd., Scottsdale, Arizona, United States|Advanced Arthritis Care and Research, Scottsdale, Arizona, United States|Arizona Pain Specialist, PLLC, Scottsdale, Arizona, United States|Sonora Quest Laboratories, Scottsdale, Arizona, United States|Cochise Clinical Research, Sierra Vista, Arizona, United States|Clinical Research Advantage, Inc./Skyline Medical Center PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Urban Family Practice Associates, PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Warner Family Practice, PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc/Manning Family Care, Tempe, Arizona, United States|Clinical Research Advantage, Incl Colorado Springs Health Partners, East, Tempe, Arizona, United States|Family Medicine Associates/Clinical Research Advantage, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Fiel Family and Sports Medicine, PC, Tempe, Arizona, United States|ARA-Arizona Research Associates, Tucson, Arizona, United States|Canyon Clinical Research LLC, Tucson, Arizona, United States|Tucson Clinical Researh, Tucson, Arizona, United States|ACRC/Arizona Clinical Research Center, Incorporated, Tucson, Arizona, United States|Clinical Research Advantage, Inc./ Orange Grove Family Practice, Tucson, Arizona, United States|Genova Clinical Research, Tucson, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Fayetteville Diagnostic Clinic Limited, Fayetteville, Arkansas, United States|Hearne Family Practice Clinic, Little Rock, Arkansas, United States|Larry S. Watkins, M.D., Little Rock, Arkansas, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Rx Medical Research of AR, Little Rock, Arkansas, United States|Anaheim Family Medical Center, Anaheim, California, United States|Advanced Research Center, Anaheim, California, United States|Advanced Arthritis & Rheumatology Center, Artesia, California, United States|Bina Akamdar MD, Azusa, California, United States|Rx for Life, Inc, Bell, California, United States|Clinical Research Advantage Inc., /Cassidy Medical Group-Carlsbad, Carlsbad, California, United States|Capitol Interventional Cardiology, Carmichael, California, United States|Northern California Research, Carmichael, California, United States|CORE Orthopaedic Medical Center, Encinitas, California, United States|Arthritis Medical Clinic of North County, Inc., Escondido, California, United States|Med Investigations, Inc., Fair Oaks, California, United States|Valley Research, Fresno, California, United States|Creekside Clinical Research, Greenbrae, California, United States|C. V. Mehta, MD Medical Corporation, Hemet, California, United States|Talbert Medical Group, Huntington Beach, California, United States|Alia Clinical Research, Inc, Huntington Park, California, United States|Time Clinical Research Inc., Huntington Park, California, United States|Lindora Research Center, Irvine, California, United States|Office of Dr. Robert L. Freed, MD, Irvine, California, United States|Office of Dr. Alan Schenk, Laguna Hills, California, United States|Prime Care Clinical Research, Laguna Hills, California, United States|Jeremy Anuntiyo, Lakewood, California, United States|Premiere Clinical Research, LLC, Lakewood, California, United States|Stuart J. Finkelstein, Lakewood, California, United States|Clinical Trials Research, Lincoln, California, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|Narbonne Multi-Specialty Medical Group Inc., Lomita, California, United States|Office of Dr. Arvind J. Mehta, Long Beach, California, United States|Pacific Internal Medicine Group, Inc, Long Beach, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|National Institute of Clinical Research, Long Beach, California, United States|Alliance Research, LLC, Long Beach, California, United States|Valerius Medical Group and Research Center, Los Alamitos, California, United States|IMD Medical Group, Los Angeles, California, United States|Pacific Arthritis Care Center, Los Angeles, California, United States|Wagdy W. Kades, MD, Inc., Los Angeles, California, United States|Samaritan Center for Medical Research Medical Group, Los Gatos, California, United States|Office of Lewis Gamarra, MD M.P.H., Los Osos, California, United States|Adegbenga A. Adetola, M.D., Lynwood, California, United States|Facey Medical Group, Mission Hills, California, United States|Providence Clinical Research, North Hollywood, California, United States|Desert Medical Group, Palm Springs, California, United States|The Office of Dr. Marcos Yang, Palos Verdes Estates, California, United States|Bayview Research Group, LLC, Paramount, California, United States|Sierra Rheumatology, Roseville, California, United States|Center for Clinical Trials of Sacramento, Inc., Sacramento, California, United States|Sacramento Heart and Vascular Research Center, Sacramento, California, United States|California Research Foundation, San Diego, California, United States|San Diego Arthritis Medical Clinic, San Diego, California, United States|Wetlin Research Associates, Inc, San Diego, California, United States|Medical Associates Research Group, San Diego, California, United States|San Jose Valley Research, Inc., San Jose, California, United States|Comprehensive Adult Risk Evaluation, San Leandro, California, United States|East Bay Rheumatology Medical Group Inc, San Leandro, California, United States|Central Coast Pathology Consultants, San Luis Obispo, California, United States|Coastal Medical Research Group, Inc., San Luis Obispo, California, United States|Family Medical Center, San Luis Obispo, California, United States|Office of Ajay G. Meka, MD, Santa Ana, California, United States|Pacific Arthritis Center Medical Group, Santa Maria, California, United States|Orrin M. Troum & Medical Associates, Santa Monica, California, United States|Northern California Medical Associates, Santa Rosa, California, United States|Robert Simon, MD, Sherman Oaks, California, United States|St. Joseph Medical Associates, Stockton, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Paradigm Clinical Research Institute, Inc., Torrance, California, United States|Orange County Research Center, Tustin, California, United States|Inland Rheumatology and Osteoporosis Medical Group, Upland, California, United States|Inland Rheumatology Clinical Trials, Inc., Upland, California, United States|Bayview Research Group, Valley Village, California, United States|Medvin Clinical Research, Van Nuys, California, United States|Center for Clinical Trials of San Gabriel, West Covina, California, United States|Agilence Arthritis and Osteoporosis Medical Center, Inc., Whittier, California, United States|Avalon Family Medical Group, Wilmington, California, United States|Darrell E. Gorman, MD, Arvada, Colorado, United States|Aurora Denver Cardiology Associates, Aurora, Colorado, United States|Azmi Emil Farag, MD, Colorado Springs, Colorado, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Colorado Springs Health Partners- East/Clinical Research Advantage, Colorado Springs, Colorado, United States|Mountain View Clinical Research, Inc., Denver, Colorado, United States|Saint Luke's Medical Clinic, Fort Collins, Colorado, United States|New West Physicians, Golden, Colorado, United States|Ranch View Family Medicine, Highlands Ranch, Colorado, United States|Colorado Center for Bone Research PC, Lakewood, Colorado, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Lynn Institute of Pueblo, Pueblo, Colorado, United States|Connecticut Clinical Research, LLC, Bridgeport, Connecticut, United States|Connecticut Gastroenterology Institute, Bristol, Connecticut, United States|Arthritis and Osteoporosis Center, PC, Hamden, Connecticut, United States|Robert Lang, MD, P.C., Hamden, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Office of Edward J. McDermott, Jr., MD, New London, Connecticut, United States|Orthopaedics Foundation for Active Lifestyles, Stamford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|New England Research Associates, LLC, Trumbull, Connecticut, United States|Arthritis Center of Connecticut, Waterbury, Connecticut, United States|Rheumatology Consultants of Delaware, Lewes, Delaware, United States|Office of Cynthia Morgan, MD, Washington, D.C., District of Columbia, United States|The Center for Rheumatology and Bone Research, Washington, D.C., District of Columbia, United States|Medical Specialist of the Palm Beaches, Atlantis, Florida, United States|South Florida Medical Research, Aventura, Florida, United States|RASF - Clinical Research Center, Boca Raton, Florida, United States|Orthopedic Research Institute, Boynton Beach, Florida, United States|Clinical Research of Brandon, LLC, Brandon, Florida, United States|Family Healthcare of Chipley, Chipley, Florida, United States|Health First Clinical Research Group, Inc., Chipley, Florida, United States|Southern Family Healthcare and Health First Research Group Inc., Chipley, Florida, United States|Florida Research & Testing, LLC, Clearwater, Florida, United States|Alba Clinical Research, Clearwater, Florida, United States|Appletree Medical, Clearwater, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Rameshwar N. Mathur, MD, PA, Cocoa, Florida, United States|Nature Coast Clinical Research, LLC, Crystal River, Florida, United States|Atlantic Institute of Clinical Research, Daytona Beach, Florida, United States|International Medical Research, Daytona Beach, Florida, United States|Omega Research Consultants, LLC, DeBary, Florida, United States|Physicians Research Alliance, LLC, DeBary, Florida, United States|Deerfield Beach Cardiology Associates, Deerfield Beach, Florida, United States|Doctors Medical Center of Walton County, DeFuniak Springs, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Florida Research Associates, LLC/Florida Orthopaedic Associates, P.A., DeLand, Florida, United States|Cohen Medical Associates, PA, Delray Beach, Florida, United States|Clark Family Medicine & Emerald Coast Research Group, Destin, Florida, United States|SJS Clinical Research, Inc, Destin, Florida, United States|Robert W. Levin MD, Dunedin, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Invesclinic, Fort Lauderdale, Florida, United States|M&O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Maxine Hamilton, MD PA, Fort Lauderdale, Florida, United States|Holy Cross Medical Group Northridge Internal Medicine, Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|Emerald Coast Mood & Memory, Fort Walton Beach, Florida, United States|White-Wilson Medical Center, PA, Fort Walton Beach, Florida, United States|Cardiology West, Gainesville, Florida, United States|Florida Research Network, LLC, Gainesville, Florida, United States|Southeastern Integrated Medical, PL, Gainesville, Florida, United States|Shands at the University of Florida, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Genetic Medical Research Corporation, Hialeah, Florida, United States|Direct Helpers Medical Center, Inc., Hialeah, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Reliable Clinical Research, LLC, Hialeah, Florida, United States|Orthopaedic Associates of South Broward, P.A., Hollywood, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Pasco Cardiology Center, Hudson, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Jacksonville Center for Clincal Research, Jacksonville, Florida, United States|St. Vincent's Cardiology, Jacksonville, Florida, United States|Dr. Ricardo A. Bedoya, M.D., Jupiter, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Christopher Chappel, Kissimmee, Florida, United States|Florida Arthritis Center, LLC, Lake Mary, Florida, United States|Pedro Ylisastigui, MD, Lehigh Acres, Florida, United States|Adult Medicine Specialists, Longwood, Florida, United States|Genesis Research International, Longwood, Florida, United States|Doctors Inn, Madeira Beach, Florida, United States|Everest Medical Care and Palm Court Research Group, Marianna, Florida, United States|Panhandle Family Care Associates & Emerald Coast Research Group, Marianna, Florida, United States|The Doctor's Office, Marianna, Florida, United States|Health First Medical Group, Melbourne, Florida, United States|Holmes Regional Medical Center, Melbourne, Florida, United States|Pharmaceutical Research Associates, Merritt Island, Florida, United States|Orthopaedic Specialist of Miami Beach, Miami Beach, Florida, United States|AMPM Research Clinic, Miami Gardens, Florida, United States|Crystal Biomedical Research, LLC, Miami Lakes, Florida, United States|Pembroke Clinical Trials, Miami Lakes, Florida, United States|Homestead Associates in Research, Inc, Miami, Florida, United States|Pharmax Research Clinic, Miami, Florida, United States|Life Spring Research Foundation, Miami, Florida, United States|Miami International Cardiology Consultants, Miami, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|The Center for Arthritis and Rheumatic Diseases, Miami, Florida, United States|Well Pharma Medical Research Corporation, Miami, Florida, United States|DC Health Clinical Trials, Miami, Florida, United States|School of Clinical Research USA, LLC, Miami, Florida, United States|Advance Medical Research Services, Corp, Miami, Florida, United States|Future Care Solution, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Miami Cardiology Group, Miami, Florida, United States|M & M Medical Center, Miami, Florida, United States|Office of Dr. Juvenal E. Martinez, MD, PA, Miami, Florida, United States|Anchor Research Center, Naples, Florida, United States|Jeffrey Alper M.D. Research, Naples, Florida, United States|Anchor Health Centers, Naples, Florida, United States|Medical Surgical Specialists, Physicians Regional Medical Center, Naples, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Magnolia Research Group, Inc., Ocala, Florida, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|Paddock Park Clinical Research, Ocala, Florida, United States|Southeastern Rehabilitation Medicine, Ocala, Florida, United States|Tequesta Research Group, Ocala, Florida, United States|CEC Research, INC., Ocoee, Florida, United States|Florida Heart Group, PA, Orlando, Florida, United States|Florida Hospital, Orlando, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|DCT FMC, LLC dba Discovery Clinical Trials, Orlando, Florida, United States|DCT-FMC, LLC dba Discovery Clinical Trials, Orlando, Florida, United States|Arthur L. Hall MD PA, Orlando, Florida, United States|Block and Nation, PA, Oviedo, Florida, United States|Arthritis Research of Florida, Inc., Palm Harbor, Florida, United States|Florida Med Center of Countryside, Palm Harbor, Florida, United States|Rene CaSanova Medical Office Inc, Pembroke Pines, Florida, United States|Boulevard Professional Centre, Pembroke Pines, Florida, United States|Research Physician Network Alliance, Pembroke Pines, Florida, United States|South Broward Research LLC, Pembroke Pines, Florida, United States|South Florida Research Solutions, LLC, Pembroke Pines, Florida, United States|DMI Research, Inc., Pinellas Park, Florida, United States|Sunbelt Research, LLC, Plantation, Florida, United States|Boca Raton Clinical Research, Plantation, Florida, United States|St. Johns Center for Clinical Research, Ponte Vedra, Florida, United States|Accord Clinical Research, LLC, Port Orange, Florida, United States|Administrative Address: Florida Arthritis & Osteoporosis Center, Port Richey, Florida, United States|Heart & Vascular Center Research, Sarasota, Florida, United States|Edgar R. Blecker, MD, Sebastian, Florida, United States|Phoenix Clinical Research, LLC., Tamarac, Florida, United States|Clinical Research of West Florida, Tampa, Florida, United States|Soutwest Florida Clinical Research Center, Tampa, Florida, United States|Clinyx/Floria Cardiovascular, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|West Wind'r Research, Tampa, Florida, United States|Health Point Medical Group, Inc, Tampa, Florida, United States|Causeway Medical Clinic, Tampa, Florida, United States|Office of Alastair C. Kennedy, MD, Vero Beach, Florida, United States|Metabolic Research Institute, Incorporated, West Palm Beach, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Central Florida Primary Care, Winter Park, Florida, United States|Florida Medical Clinic, PA, Zephyrhills, Florida, United States|The Kaufmann Clinic, Atlanta, Georgia, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States|Atlanta Center for Clinical Research, Corp., Atlanta, Georgia, United States|Atlanta Vascular Research Foundation, Atlanta, Georgia, United States|Executive Health and Research Associates, Atlanta, Georgia, United States|Southern Clinical Research and Management, Inc. (SCRAM), Augusta, Georgia, United States|Masters of Clinical Research, Inc., Augusta, Georgia, United States|Amelia Medical Plaza, Bainbridge, Georgia, United States|Bainbridge Medical Associates, Bainbridge, Georgia, United States|Abdul Bari MD Inc, Cairo, Georgia, United States|Southern Clinical Research Management and Consulting, Cairo, Georgia, United States|North Georgia Rheumatology Group, PC, Duluth, Georgia, United States|United Osteoporosis Centers, Gainesville, Georgia, United States|North Georgia Rheumatology Group, PC, Lawrenceville, Georgia, United States|GCH Research Dr. G Craig Heigerick DO, Lilburn, Georgia, United States|Mercer University Mercer Medicine, Macon, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Clinical Research Advantage, Inc./Urban Family Practice Associates, PC, Marietta, Georgia, United States|In-Quest Medical Research, LLC, Norcross, Georgia, United States|Harbin Clinic, Rome, Georgia, United States|Atlanta Center for Clinical Research, Roswell, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Archibold Primary Care, Thomasville, Georgia, United States|Clinical Trial Providers, Inc., Tucker, Georgia, United States|VSC, Valdosta, Georgia, United States|Kaufmann Clinic, INC, Woodstock, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|North Georgia Internal Medicine, Woodstock, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Orthopedic Health Care Clinic, Boise, Idaho, United States|Sonora Clinical Research, LLC, Boise, Idaho, United States|Eagle's View Family Medicine, Boise, Idaho, United States|Coeur D'Alene Arthritis Clinic, Coeur d'Alene, Idaho, United States|CTL Research, Eagle, Idaho, United States|Women's Healthcare Associates P.A. dba Rosemark WomenCare Specialists, Idaho Falls, Idaho, United States|Idaho Arthritis and Osteoporosis Center, Meridian, Idaho, United States|Advanced Clinical Research, Meridian, Idaho, United States|AMR Sakeena Research, Aurora, Illinois, United States|Arthur I Davida, MD PC, Bloomingdale, Illinois, United States|Cardiac Wellness Consultants, Chicago, Illinois, United States|Chicago Peripheral Nerve Center, Chicago, Illinois, United States|ICCT Research International Incorporated, Chicago, Illinois, United States|Claude Mandel Medical Center, Chicago, Illinois, United States|Windy City Orthopedics and Sports Medicine, Evanston, Illinois, United States|South Suburban Health Professional Group, Hazel Crest, Illinois, United States|Prairie Rheumatology Associates, SC, Joliet, Illinois, United States|Lake Zurich Family Treatment Center, Lake Zurich, Illinois, United States|Southern Illiniois Clinical Research Centre, O'Fallon, Illinois, United States|Speciality phhysicians of Illinois, LLC, Olympia Fields, Illinois, United States|Redhead Research Inc., DBA Research Associates of Central Illinois, Peoria, Illinois, United States|Trinity Medical Center, Rock Island, Illinois, United States|Rockford Health Physicians, Rockford, Illinois, United States|Prairie Cardiovascular Consultants, Springfield, Illinois, United States|Prairie Education & Research, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Deerbrook Medical Associates, Vernon Hills, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|American Health Network of Indiana, LLC, Avon, Indiana, United States|Robert D. Barnes, MD, LLC, Evansville, Indiana, United States|Clinical Research Advantage, Inc., Evansville, Indiana, United States|Destiny Clinical Research, LLC, Evansville, Indiana, United States|Clinical Research Advantage/Family Medicine Associates, Evansville, Indiana, United States|American Health Network of Indiana, LLC, Franklin, Indiana, United States|Internal Medicine Center of Northwest Indiana, P.C., Gary, Indiana, United States|Beacon Medical Group Rheumatology, Granger, Indiana, United States|American Health Network of IN, LLC, Greenfield, Indiana, United States|Diagnostic Rheumatology And Research, PC, Indianapolis, Indiana, United States|Investigators research Group, Indianapolis, Indiana, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|Dawes Fretzin Dermatology Group, LLC, Indianapolis, Indiana, United States|Arthritis Associates of Southern Indiana, Jeffersonville, Indiana, United States|Research Institute of Middle America/River Cities Cardiology, Jeffersonville, Indiana, United States|Beacon Medical Group LaPorte, LaPorte, Indiana, United States|Cardiovascular Clinics, PC, Merrillville, Indiana, United States|Community Clinical Research Center, Muncie, Indiana, United States|Medical Specialists Clinical Research Center, Munster, Indiana, United States|Medical Specialists, Munster, Indiana, United States|Arthritis Associates of Southern Indiana, New Albany, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Physician's Clinic of Iowa, PC, Cedar Rapids, Iowa, United States|Ridge Family Practice, PC/Clinical Research Advantage, Inc., Council Bluffs, Iowa, United States|Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States|Office of Jerrold V Flatt, Des Moines, Iowa, United States|Medical Associates Clinic, PC, Dubuque, Iowa, United States|Family Health Center of Waterloo, PC, Waterloo, Iowa, United States|Northeast IA Medical Education Foundation/Family Practice Center, Waterloo, Iowa, United States|Heartland Research Associates LLC, Arkansas City, Kansas, United States|Community House of Wellness, Kansas City, Kansas, United States|Associates Reseach Inc., Lansing, Kansas, United States|Radiant Research, Inc., Overland Park, Kansas, United States|International Clinical Research Institute, Inc, Overland Park, Kansas, United States|Arthritis Specialists of Greater KC, Overland Park, Kansas, United States|Pinnacle Medical Research, Overland Park, Kansas, United States|Quivira Internal Medicine, Overland Park, Kansas, United States|Health Science Research Center, Pratt, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Via Christi Clinic, Wichita, Kansas, United States|Howard L. Feinberg, D.O., Ashland, Kentucky, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Internal Medicine Research Association, Campbellsville, Kentucky, United States|Center for Arthritis and Osteoporosis, Elizabethtown, Kentucky, United States|Arthritis Center of Lexington, Lexington, Kentucky, United States|Kentuckiana Center for Better Bone and Joint Health, Louisville, Kentucky, United States|KY Research PLLC., Louisville, Kentucky, United States|University Medical Associates, Louisville, Kentucky, United States|Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, United States|Office of Gaurang B. Shah,MD, PSC, Richmond, Kentucky, United States|Richmond Regional Research, Richmond, Kentucky, United States|Chandler Family Practice, Bossier City, Louisiana, United States|McFarland Family Clinic, Shreveport, Louisiana, United States|TFD Research, LLC, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Southern Maine Health Care, Biddeford, Maine, United States|Central Maine Heart & Vascular Institute, Lewiston, Maine, United States|Chesapeake CardioVascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, PA, Baltimore, Maryland, United States|Health Trends Research, LLC, Baltimore, Maryland, United States|One Heart, LLC, Baltimore, Maryland, United States|Chesapeake CardioVascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, Pa, Baltimore, Maryland, United States|Saint Agnes HealthCare Incorporated, Baltimore, Maryland, United States|Stephen R Smith, MD FACP, Baltimore, Maryland, United States|MidAtlantic Cardiovascular Associates, PA, Baltimore, Maryland, United States|Peter A. Holt, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates PA, Bel Air, Maryland, United States|Shah Associates MD, LLC, Charlotte Hall, Maryland, United States|Cardiovascular Specialists, LLC, Columbia, Maryland, United States|Johns Hopkins University, Columbia, Maryland, United States|The Osteoporosis & Clinical Trials Center, Cumberland, Maryland, United States|Arthritis Treatment Center, Frederick, Maryland, United States|The Spine & Joint Center, Greenbelt, Maryland, United States|Klein & Associates, MD, PA, Hagerstown, Maryland, United States|Community Health Research, North East, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Shah Associates, Prince Frederick, Maryland, United States|Cardiac Associates, Shady Grove Adventist Hospital, Rockville, Maryland, United States|The Center for Rheumatology and Bone Research, Rockville, Maryland, United States|Rockville Internal Medicine Group, Rockville, Maryland, United States|IRC Clinics, Towson, Maryland, United States|Midatlantic Cardiovascular Associates, P.A., Westminster, Maryland, United States|The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States|Primary Care Cardiology Research, Ayer, Massachusetts, United States|Genesis Clinical Research & Consulting, Fall River, Massachusetts, United States|NECCR Internal Medicine and Cardiology Associates, LLC, Fall River, Massachusetts, United States|Phase III Clinical Research, Fall River, Massachusetts, United States|Pentucket Medical Associates, Incorporated, Haverhill, Massachusetts, United States|Clinical Research Center of Cape Cod, Inc., Hyannis, Massachusetts, United States|Charles River Medical Associates, Pchi, Natick, Massachusetts, United States|Novex Clinical Research, LLC, New Bedford, Massachusetts, United States|Northampton Internal Medicine Associates, PC, Northampton, Massachusetts, United States|FutureCare Studies, Springfield, Massachusetts, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Great Lakes Research Group, Incorporated, Bay City, Michigan, United States|Professional Clinical Research-Benzonia, Benzonia, Michigan, United States|Cadillac Clinical Research, Cadillac, Michigan, United States|Livernois Family Medical Services, Detroit, Michigan, United States|Office of Dr. Susan Courtnage, Eaton Rapids, Michigan, United States|McLaren Regional Medical Center-Research Dept., Flint, Michigan, United States|Grand Valley Medical Specialist, PLC, Grand Rapids, Michigan, United States|Spectrum Health Medical Group-Rheumatology, Grand Rapids, Michigan, United States|Michigan Medical Cardiovascular PC, Grand Rapids, Michigan, United States|Professional Clinical Research, Interlochen, Michigan, United States|Justus J Fiechtner, MD, Lansing, Michigan, United States|Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Synergy Medical Education Alliance, Saginaw, Michigan, United States|Shores Rheumatology, Saint Clair Shores, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|Troy Internal Medicine Research, Troy, Michigan, United States|St. Luke's Hospital Association of Duluth, DBA St Luke's Rheumatology Assoc., Duluth, Minnesota, United States|St. Luke's Hospital Association of Duluth, Inc., Duluth, Minnesota, United States|St. Luke's Hospital Association of Duluth, Duluth, Minnesota, United States|Central Minnesota Heart Center at St. Cloud Hospital, Saint Cloud, Minnesota, United States|St. Paul Heart Clinic, Saint Paul, Minnesota, United States|The Center for Clinical Trials, Biloxi, Mississippi, United States|Planters Clinic, Port Gibson, Mississippi, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|Cape Girardeau Physicians Associates, Cape Girardeau, Missouri, United States|Patterson Medical Clinic / d.b.a. Prime Care Research Associates, Florissant, Missouri, United States|Allergy Asthma Immunology Services, LLC, Jefferson City, Missouri, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|University of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States|Truman Medical Center, Inc., Kansas City, Missouri, United States|Clinical Research Advantage, Inc./Manning Family Care, LLC, Kansas City, Missouri, United States|St. Louis Center for Clinical Research, Saint Louis, Missouri, United States|Physician Groups, LC, DBA Rheumatology and Internal Medicine Associates, Saint Louis, Missouri, United States|Southampton Healthcare, Inc., Saint Louis, Missouri, United States|Barbara A. Caciolo, MD, Saint Louis, Missouri, United States|A & A Pain Institute, Saint Louis, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Patients First Health Care, LLC, Washington, Missouri, United States|Glacier View Research Institute, Cardiology, Kalispell, Montana, United States|Alliance Medical Center, Alliance, Nebraska, United States|Cody Medical Associates, Alliance, Nebraska, United States|Bellevue Family Practice/Clinical Research Advantage, Inc., Bellevue, Nebraska, United States|Clinical Research Advantage, Inc./ Skyline Medical Center, PC, Elkhorn, Nebraska, United States|Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC, Fremont, Nebraska, United States|Internal Medicine Associates, PC, Grand Island, Nebraska, United States|Physician, Research Collaboration, Southwest Family Health, Lincoln, Nebraska, United States|Lincoln Internal Medicine Associates, Lincoln, Nebraska, United States|Platte River Nephrology, North Platte, Nebraska, United States|Quality Clinical Research LLC, Omaha, Nebraska, United States|Westroads Medical Group, Omaha, Nebraska, United States|Heartland Clinical Research, Inc., Omaha, Nebraska, United States|Clinical Research Advantage, Inc./Primary Care Physicians, LLP, Omaha, Nebraska, United States|Clinical Research Advantage, Inc., Henderson, Nevada, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Henderson, Nevada, United States|Sierra Internal Medicine Associates, Incline Village, Nevada, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Clinical Research Advantage/Peter Philander, MD, Las Vegas, Nevada, United States|Rancho Internal Medicine, Las Vegas, Nevada, United States|Steven D. Folkerth, MD, Las Vegas, Nevada, United States|Ladner Family Practice, Las Vegas, Nevada, United States|VA Southern Nevada Healthcare System, North Las Vegas, Nevada, United States|Arthritis Center of Reno, Reno, Nevada, United States|New Jersey Physicians, LLC, Clifton, New Jersey, United States|Clifton-Wallington Medical Group, Clifton, New Jersey, United States|Anderson and Collins, Clinical Research Inc., Edison, New Jersey, United States|Drs. Collins and Uthappa, Edison, New Jersey, United States|Central Jersey Health Care, Elizabeth, New Jersey, United States|Andron Medical Associates, Englewood, New Jersey, United States|Advocare Heights Primary Care, Haddon Heights, New Jersey, United States|Hazlet Health Care, Hazlet, New Jersey, United States|Family Care Physicians, Lawrenceville, New Jersey, United States|Penn Cardiac Care at Mercer Bucks, Lawrenceville, New Jersey, United States|Family Medicine of Lindenwold, Lindenwold, New Jersey, United States|Rheumatology and Arthritis Associates PC, Medford, New Jersey, United States|Adult & Pediatric Rheumatology, Midland Park, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Maynard Holgado LLC, Sicklerville, New Jersey, United States|Shore Health Group, Toms River, New Jersey, United States|Hopewell Valley Medical Group, P.A., Trenton, New Jersey, United States|Arthritis, Rheumatic and Back Disease Associates, PA, Voorhees, New Jersey, United States|Lourdes Medical Associates, Willingboro, New Jersey, United States|Kenneth F. Solinsky, MD, Babylon, New York, United States|LifeLine Research Institute, Brooklyn, New York, United States|Lee Medical Associates, Dunkirk, New York, United States|AMS Research, Elmira, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Drug Trials America, Inc., Hartsdale, New York, United States|United Health Service Hospitals, Office of Clinical Trials, Johnson City, New York, United States|IMA Medical Research PC, Kew Gardens, New York, United States|NYU Langone Medical Center, Laura and Issac Perlmutter Cancer Center, Infusion Center, Lake Success, New York, United States|NYU Langone Medical Center, Laura and Issac Perlmutter Cancer Center, Investigational Pharmacy, Lake Success, New York, United States|NYU Langone Rheumatology Associates Long Island, Lake Success, New York, United States|Office of Dr. Allen Chodock, Mamaroneck, New York, United States|Winthrop University Hospital / Clinical Trials Center, Mineola, New York, United States|New York University Pain Management Center, New York, New York, United States|NYU Pain Research, New York, New York, United States|Office of Dr. Richard Stern, New York, New York, United States|DiGiovanna Family Care Center, North Massapequa, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|AAIR Research Center, Rochester, New York, United States|Institute for Clinical Studies, Rosedale, New York, United States|Rheumatology Associates of Long Island, Smithtown, New York, United States|Office of Dr. Chadia Morcos, Syosset, New York, United States|Arthritis Health Associates, Syracuse, New York, United States|Crouse Medical Practice, PLLC d/b/a Internist Associates of Central New York, Syracuse, New York, United States|East Meadow Family Practice Associates, PC, Wantagh, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|Buffalo Cardiology and Pulmonary Associates, PC, Williamsville, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Asheville Arthritis & Osteoporosis, PA, Asheville, North Carolina, United States|Kernodle Clinic Inc., Burlington, North Carolina, United States|Calabash Medical Center, Calabash, North Carolina, United States|PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States|Chapel Hill Family Medicine, Chapel Hill, North Carolina, United States|Thurston Arthritis Reaserch Ctr, Chapel Hill, North Carolina, United States|Mid Carolina Cardiology Research, Charlotte, North Carolina, United States|Presbyterian Novant Heart and Wellness, Charlotte, North Carolina, United States|Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, United States|PMG Research of Charlotte, Charlotte, North Carolina, United States|Barat Research Group, Inc., Charlotte, North Carolina, United States|Sensenbrenner Primary Care, Charlotte, North Carolina, United States|Duke Health Center at Pickett Road, Durham, North Carolina, United States|Bland Clinic, PA, Greensboro, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Physicians East P. A., Greenville, North Carolina, United States|Physicians East, PA, Greenville, North Carolina, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|PMG Research Of Hickory, LLC, Hickory, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Research Institute of the Carolinas, PLLC, Mooresville, North Carolina, United States|Crystal Coast Family Practice, Morehead City, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|Pinehurst Medical Clinic. Inc., Pinehurst, North Carolina, United States|Blue Ridge Family Physicians, PPLC, Raleigh, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|Wake Internal Medicine Consultants, Inc., Raleigh, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Boice-Willis Clinic, Rocky Mount, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Tabor City Family Medicine, Tabor City, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|PMG Research Wilmington Research Associates, Wilmington, North Carolina, United States|Natalie A. Doyle, MD PA, Wilson, North Carolina, United States|Ardmore Family Practice, Winston-Salem, North Carolina, United States|Clinical Trials of America, Inc., Winston-Salem, North Carolina, United States|Clinical Trials of America, inc, Winston-Salem, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Winston-Salem Health Care, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, Fargo, North Dakota, United States|Daystar Clinical Research, Akron, Ohio, United States|CFP Research, Inc., Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Feldman Family Practice, Columbus, Ohio, United States|MidWest Cardiology Research Foundation, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Remington-Davis Incorporated, Columbus, Ohio, United States|Midtowne Family Practice Centre, Columbus, Ohio, United States|PriMed Clinical Research, Dayton, Ohio, United States|HWC Women's Research Center, Englewood, Ohio, United States|Cleveland Clinic Fairview Cardiovascular Medicine, Fairview Park, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|TriPhase Research, Ltd., Franklin, Ohio, United States|Holzer Clinic, Inc, Gallipolis, Ohio, United States|Office of Dr. Saleem Khan, MD, Inc, London, Ohio, United States|North Central Research, Mansfield, Ohio, United States|OhioHealth Research Institute, Mansfield, Ohio, United States|R&R Research-Smith Clinic, Marion, Ohio, United States|David R. Mandel, MD, Inc, Mayfield, Ohio, United States|Paramount Medical Research and Consulting, LLC, Middleburg Heights, Ohio, United States|Newark Physician Associates, Newark, Ohio, United States|Family Medicine and Occupational Health Center, Inc., Shaker Heights, Ohio, United States|Abner Cordero, M.D., Tiffin, Ohio, United States|Arthritis Associates of Northwest Ohio, Inc., Toledo, Ohio, United States|Mercy St Vincent Medical Center, Toledo, Ohio, United States|Toledo Cardiology Consultants c/o Cardiac Research, Toledo, Ohio, United States|South Toledo Internists, Toledo, Ohio, United States|University of Toledo Health Science Campus, Toledo, Ohio, United States|UT Medical Center Medicine Clinic, Toledo, Ohio, United States|Trenton Family Medicine, Trenton, Ohio, United States|Lake Medical Research, LLC, Willoughby Hills, Ohio, United States|Pharmacotherapy Research Associates Incorporated, Zanesville, Ohio, United States|LION Research, Norman, Oklahoma, United States|Integris Physicians Services, Oklahoma City, Oklahoma, United States|Integris Cardiovascular Physicians LLC, Oklahoma City, Oklahoma, United States|Integris Family Care Central, Oklahoma City, Oklahoma, United States|Integris Physician Services, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Healthcare Research Consultants, Tulsa, Oklahoma, United States|Integrated Medical Research, PC, Ashland, Oregon, United States|Lane Medical Research Group, Eugene, Oregon, United States|Oregon Medical Group Adult Medicine Clinic, Eugene, Oregon, United States|Oregon Medical Group Clinical Research, Eugene, Oregon, United States|Institute of Diabetes and Endocrinology, Medford, Oregon, United States|Rogue Valley Physicians-Clinical Research Group, Medford, Oregon, United States|Fanno Creek Clinic, Portland, Oregon, United States|Affinity Research, Portland, Oregon, United States|Portland Rheumatology Clinic, LLC, Portland, Oregon, United States|Internal Medicine Research, Portland, Oregon, United States|University Orthopedics Center, Altoona, Pennsylvania, United States|Tri-State Medical Group, Beaver, Pennsylvania, United States|East Penn Rheumatology Associates, PC, Bethlehem, Pennsylvania, United States|Buckingham Family Medicine, Buckingham, Pennsylvania, United States|Camp Hill Clinical Research Center, Camp Hill, Pennsylvania, United States|Butler Medical Associates, Chicora, Pennsylvania, United States|Perkiomen Valley Family Practice, PC, Collegeville, Pennsylvania, United States|Rheumatology Associates, Ltd, Colmar, Pennsylvania, United States|Office of J. Miller Oppy, MD, Youghiogheny Primary Care Practice, Connellsville, Pennsylvania, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Saint Vincent Consultant in Cardiovascular Diseases, LLC, Erie, Pennsylvania, United States|Arthritis Associates, Erie, Pennsylvania, United States|Center for Assessment and Research of Erie, Erie, Pennsylvania, United States|Stan F. Slabic, M.D., Erie, Pennsylvania, United States|AMH Feasterville Family HealthCare Center, Feasterville, Pennsylvania, United States|Westmoreland Neurology Associates, Incorporated, Greensburg, Pennsylvania, United States|Harleysville Medical Assoc, Harleysville, Pennsylvania, United States|Lederach Family Medicine, Harleysville, Pennsylvania, United States|Dr. Bruce Morrison, Family Practice, Huntingdon Valley, Pennsylvania, United States|Detweiler Family Medicine and Associates, PC, Lansdale, Pennsylvania, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Lansdale Medical Group Family Practice, Lansdale, Pennsylvania, United States|Bucks County Clinical Research, Morrisville, Pennsylvania, United States|Pearl Clinical Research, Inc., Norristown, Pennsylvania, United States|Lehigh Wellness Center Outpatient Services, Philadelphia, Pennsylvania, United States|Founders Research Corporation, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Dairyland Medical Center, Red Lion, Pennsylvania, United States|Sfm Clinical Trials, PC, Scotland, Pennsylvania, United States|Elite Medical Research, Inc., Sellersville, Pennsylvania, United States|Prime Health Network, Springfield, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|The Office of Dr. Joseph T. Morelli, DO, Stoneboro, Pennsylvania, United States|Tipton Medical and Diagnostic Center, Tipton, Pennsylvania, United States|Pish Medical Associates, Uniontown, Pennsylvania, United States|PEAK Research, LLC, Upper Saint Clair, Pennsylvania, United States|Allegheny Rheumatology - WPAHS - ASRI, Wexford, Pennsylvania, United States|Clinical Research Center of Reading, LLC, Wyomissing, Pennsylvania, United States|Cardiology Consultants of Philadelphia, Yardley, Pennsylvania, United States|Jeffry A. Lindenbaum DO, PC, Yardley, Pennsylvania, United States|New England Center for Clinical Research, Cranston, Rhode Island, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Hugo M. Yamada, MD, Lincoln, Rhode Island, United States|Rheumatology Associates, Pawtucket, Rhode Island, United States|Medical Office Center, Providence, Rhode Island, United States|Anderson Heart, Anderson, South Carolina, United States|AnMed Health, Anderson, South Carolina, United States|Low Country Rheumatology, PA/Low Country Research Center, Charleston, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|St. Andrews Medical, Charleston, South Carolina, United States|Neem Research Group Inc., Columbia, South Carolina, United States|Columbia Arthritis Center Pa, Columbia, South Carolina, United States|MedTrial, Columbia, South Carolina, United States|Clinical Research Associates, LLC, Florence, South Carolina, United States|Palmetto Clinical Trial Services, LLC, Greenville, South Carolina, United States|Paris View Family Practice, Greenville, South Carolina, United States|John Milas, Greer, South Carolina, United States|Radiant Research, Inc, Greer, South Carolina, United States|DeGarmo Institute of Medical Research, Greer, South Carolina, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Palmetto Clinical Trial Services, LLC at the Family Healthcare Center, Laurens, South Carolina, United States|Berkeley Medical Center, Moncks Corner, South Carolina, United States|PMG Research of Charleston, Mount Pleasant, South Carolina, United States|North Myrtle Beach Family Practice, North Myrtle Beach, South Carolina, United States|Coulter Clinic, Orangeburg, South Carolina, United States|Orangeburg Medical Associates, PA, Orangeburg, South Carolina, United States|The Carolina Center for Rheumatology & Arthritis Care, PA, Rock Hill, South Carolina, United States|Hillcrest Clinical Research, LLC, Simpsonville, South Carolina, United States|Hillcrest Family Practice, Simpsonville, South Carolina, United States|Palmetto Research, Spartanburg, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Southeastern Research Associates, Inc., Taylors, South Carolina, United States|Odyssey Research/Sanford Clinic - Aberdeen, Aberdeen, South Dakota, United States|Sanford Clinic - Aberdeen, Aberdeen, South Dakota, United States|Regional Health Clinic Research, Rapid City, South Dakota, United States|Regional Medical Clinic-Rheumatology, Rapid City, South Dakota, United States|Health Concepts, Rapid City, South Dakota, United States|Brown Clinic PLLP, Watertown, South Dakota, United States|Odyssey Research, Watertown, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|Internal Medicine & Pediatric Associates of Bristol, Bristol, Tennessee, United States|PMG Research of Bristol, Bristol, Tennessee, United States|Parkway Medical Group, Fayetteville, Tennessee, United States|Stern Cardiovascular Foundation, inc., Germantown, Tennessee, United States|Arthritis Clinic, Jackson, Tennessee, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|State of Franklin Healthcare Associates Clinical Research, Johnson City, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Holston Valley Surgery Center, Kingsport, Tennessee, United States|Gupta, Ramesh C MD, Memphis, Tennessee, United States|Access Clinical Trials, Inc., Nashville, Tennessee, United States|Premier Orthopaedics, Nashville, Tennessee, United States|The Cholesterol Center of Nashville, Nashville, Tennessee, United States|Nashville Medical Research Institute, Nashville, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Amarillo Medical Specialists, LLP, Amarillo, Texas, United States|Pharma Tex Research, LLC, Amarillo, Texas, United States|Family Health Care Association, Arlington, Texas, United States|South Arlington Primary Care Associates PA, Arlington, Texas, United States|DCT - Anchor, LLC dba Discovery Clinical Trials, Arlington, Texas, United States|DCT-AACT, LLC dba Discovery Clinical Trials, Austin, Texas, United States|Southeast Texas Cardiology Associates, Beaumont, Texas, United States|Southeast Texas Clinical Research Center, Beaumont, Texas, United States|Kaner Medical Group PA, Bedford, Texas, United States|Nexxus Research Group, LLC, Bedford, Texas, United States|Texas Orthopedic Specialists, PLLC, Bedford, Texas, United States|MedicalEdge Healthcare Group, PA, dba Leading Edge Research, PA, Carrollton, Texas, United States|Prentiss Family Medicine, Colleyville, Texas, United States|Carlos B. Everett, MD, Corpus Christi, Texas, United States|Discovery Clinical Research, Corpus Christi, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Soltero Cardiovascular Research Center/Baylor University Medical Center, Dallas, Texas, United States|Arthritis Care and Diagnostic Center, P.A., Dallas, Texas, United States|Medical Specialists Associated, Dallas, Texas, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|SouthWest Rheumatology, P.A., Dallas, Texas, United States|DCT - Genesis Neighborhood Research, LLC dba Discovery Clinical Trials, Dallas, Texas, United States|Rajendra K. Marwah, MD, El Paso, Texas, United States|Kaner Medical Group, PA, Euless, Texas, United States|The Medical Group of Texas, Fort Worth, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|T & R Clinic, P. A., Fort Worth, Texas, United States|Rheumatology-UTMB, Galveston, Texas, United States|Towngate Plaza Medical Center, Garland, Texas, United States|ProCare Clinical Trials, Grand Prairie, Texas, United States|The Office of Amer Zaheer MD, PA, Houston, Texas, United States|Salim Gopalani, MD, PA, Houston, Texas, United States|Office of Cyril Wolf, MD, Houston, Texas, United States|Village Family Practice, Houston, Texas, United States|Kelsey Seybold Clinic, Houston, Texas, United States|Oxford Clinical Research, LLC, Houston, Texas, United States|MCA Research, Houston, Texas, United States|Texas Health Physicians Group, Irving, Texas, United States|One World Medical Associates, P.A., Lewisville, Texas, United States|Pri-Med Care, Lewisville, Texas, United States|South Texas Institute of Health, McAllen, Texas, United States|DCT - Genesis Seidmeyer Research, LLC dba Discovery Clinical Trials, McKinney, Texas, United States|Southwest Rheumatology, PA, Mesquite, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Basin Orthopedics Surgical Specialists, Odessa, Texas, United States|Center for Hypertension and Internal Medicine, Odessa, Texas, United States|Odessa Heart Institute, Odessa, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Office of David K. McDonald, M.D.. P.A., Pasadena, Texas, United States|Centex Studies, Inc., Pharr, Texas, United States|Clinical Investigations of Texas, LLC, Plano, Texas, United States|DCT-Genesis naini, LLC dba Discovery Clinical Trials, Plano, Texas, United States|North Texas Medical Research, Plano, Texas, United States|MedicalEdge Healthcare Group, PA, Richardson, Texas, United States|Texas Health Physicians Group, Richardson, Texas, United States|Ivan N. Mefford, MD, PhD, PA, Richmond, Texas, United States|Paragon Research Center, LLC, San Antonio, Texas, United States|Quality Assurance Research Center, San Antonio, Texas, United States|Quality Research Inc., San Antonio, Texas, United States|Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute, San Antonio, Texas, United States|GSA Research, San Antonio, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Radiant Research San Antonio Northeast, San Antonio, Texas, United States|Briggs Clinical Research, LLC, San Antonio, Texas, United States|DCT - Barlite, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|S.A.M. Clinical Research Center, San Antonio, Texas, United States|WellMed Clinical Research, San Antonio, Texas, United States|DCT-Westover Hills, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|DCT - Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|The Office of Shahbaz Yazdani, MD, PA, San Antonio, Texas, United States|Southlake Clinical Trials, Southlake, Texas, United States|Sugar Land Med-Ped Clinic, PA, Sugar Land, Texas, United States|Crossroads Clinical Research, LLC, Victoria, Texas, United States|Crossroads Clinical Research, Victoria, Texas, United States|Office of Pamela Dugano-Daphnis, Webster, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Burke Internal Medicine, Burke, Virginia, United States|Center for Arthritis and Rheumatic Diseases, Chesapeake, Virginia, United States|Bayview Physicians oa Cardiovascular Associates, Ltd, Chesapeake, Virginia, United States|David Ramstad, MD, MPH and Associates, Chesapeake, Virginia, United States|Danville Internal Medicine, Inc., Danville, Virginia, United States|Danville Orthopedic Clinic, Danville, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|Hampton Family Practice, Hampton, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Bruton Avenue Family Practice, Newport News, Virginia, United States|Internal Medicine Kidney and Hypertension Center, Norfolk, Virginia, United States|National Clinical Research - Norfolk Inc., Norfolk, Virginia, United States|Sentara Medical Group, Norfolk, Virginia, United States|Ettrick Health Center, Petersburg, Virginia, United States|Arthritis and Rheumatic Research, Portsmouth, Virginia, United States|Roanoke Heart Institute, Roanoke, Virginia, United States|Harbourview Professional Center, Suffolk, Virginia, United States|Chase Research Group, LLC, Virginia Beach, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Highline Medical Center Laboratory, Burien, Washington, United States|Puget Sound Osteoporosis Center, Seattle, Washington, United States|Arthritis Northwest, Seattle, Washington, United States|Arthritis Northwest Rheumatology, Spokane, Washington, United States|Lawrence S. Eastburn, MD, PS, Spokane, Washington, United States|Pulmonary and Research Associates, Spokane, Washington, United States|The Office of William Gray, Md, Family Practice, Spokane, Washington, United States|John F. Long, D.O., Spokane, Washington, United States|George H. Krick, MD, Tacoma, Washington, United States|Northwest Family and Spinal Clinic, Tacoma, Washington, United States|Rheumatology Infusion Services, Tacoma, Washington, United States|Tacoma Center for Arthritis Research, PS, Tacoma, Washington, United States|Wenatchee Valley Medical Center, Research Department, Wenatchee, Washington, United States|Clinical Trials Northwest, Yakima, Washington, United States|Rheumatology and Pulmonary Clinic, Beckley, West Virginia, United States|Mountain State Clinical Research, Clarksburg, West Virginia, United States|University Cardiovascular Services. Robert C. Byrd Clinical Center, Huntington, West Virginia, United States|WVVA Healthcare Alliance, Lewisburg, West Virginia, United States|Parkersburg Cardiology Associates, Parkersburg, West Virginia, United States|Meriter Medical Group, Madison, Wisconsin, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|UW Health Physicians, Madison, Wisconsin, United States|St. Lukes Pain Management Center, Milwaukee, Wisconsin, United States|Zablocki VA Medical Center, Milwaukee, Wisconsin, United States|Aspirus Cardiovascular Associates - Rhinelander, Rhinelander, Wisconsin, United States|Aspirus Cardiovascular Associates, Wausau, Wisconsin, United States|Aspirus Heart & Vascular lnstitute--Research & Education), Wausau, Wisconsin, United States|Aspirus Wausau Hospital, Wausau, Wisconsin, United States|Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States|Hunter Clinical Research, Broadmeadow, New South Wales, Australia|Wesley Medical Centre, Auchenflower, Queensland, Australia|Australian Clinical Research Organisation, Caboolture, Queensland, Australia|Rheumatology Department, Cairns, Queensland, Australia|AusTrials Pty Ltd, Kippa Ring, Queensland, Australia|Core Research Group, Milton, Queensland, Australia|AusTrials Pty Ltd, Sherwood, Queensland, Australia|Monash Medical Centre, Department of Rheumatology, Clayton, Victoria, Australia|Rheumatology Department, Heidelberg West, Victoria, Australia|Emeritus Research, Malvern East, Victoria, Australia|The Goatcher Clinical Research Unit, Shenton Park, Western Australia, Australia|The Colin Bayliss Research and Teaching Unit, Victoria Park, Western Australia, Australia|CLINCOR - Clinica de Exames Cardiologicos e Ecografia S/C Ltda, Maceio, AL, Brazil|Hospital do Coracao de Alagoas, Maceio, AL, Brazil|CIP - Centro Internacional de Pesquisas, Goiania, GO, Brazil|Via Medica - Centro Clinico, Goiania, GO, Brazil|CMIP - Centro Mineiro de Pesquisa, Juiz de Fora, MG, Brazil|Hopsital das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Hospital e Maternidade Angelina Caron, Sala Pesquisa Clinica, Campina Grande do Sul, PR, Brazil|CEPEME-CERHFAC Centro de Estudos e Pesquisas Medicas, Curitiba, PR, Brazil|Centro de Estudos do Hospital de ClÃ­nicas da UFPR, Curitiba, PR, Brazil|Hospital UniversitÃ¡rio Clementino Fraga Filho - UFRJ, Rio de Janeiro, RJ, Brazil|CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda, Rio de Janeiro, RJ, Brazil|Hospital Ipanema Plus, Rio de Janeiro, RJ, Brazil|Clinica de Reumatologia do Centro MÃ©dico BarraShopping, Rio de Janeiro, RJ, Brazil|Centro de Pesquisa Clinica, Porto Alegre, RS, Brazil|AssociaÃ§Ã£o Hospitalar Moinhos de Vento (AHMV) / CMIC, Porto Alegre, RS, Brazil|Hospital SÃ£o Lucas - Pontificia, Porto Alegre, RS, Brazil|Hospital e Maternidade Celso Pierro - Puc Campinas, Campinas, Sao Paulo, Brazil|Centro de Ensino e Pesquisa Hospital Sao Lucas, Aracaju, SE, Brazil|PUC Campinas, Campinas, SP, Brazil|Hospital das Clinicas da UNICAMP, Campinas, SP, Brazil|Hospital das Clinicas da Faculdade de Medicina de Marilia, Marilia, SP, Brazil|Hospital de Base - Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Setor de Lip., Arterosc. e BioVasc. - Disc. de Cardiologia, Sao Paulo, SP, Brazil|CEPIC - Centro Paulista de Investigacao ClÃ­nica, Sao Paulo, SP, Brazil|IMA Brasil - Instituto de Medicina Avancada, Sao Paulo, SP, Brazil|CPCLIN - Centro de Pesquisas ClÃ­nicas, SÃ£o Paulo, SP, Brazil|Hospital Sao Salvador - Medicos Reunidos Ltda., Goiania-GO, Brazil|Ambulatorio de Especialidades Mario Covas, Marilia/SP, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital das Clinicas da UFPE, Recife - Pernambuco, Brazil|Hospital Dos Servidores Do Estado do Rio de Janeiro, Rio de Janeiro, Brazil|Faculdade de Medicina DO ABC, Santo Andre, Brazil|South Calgary Medical Clinic - Sunpark Professional Center, Calgary, Alberta, Canada|Allin Clinic, Edmonton, Alberta, Canada|Dr. MPJ Senaratne Professional Corporation, Edmonton, Alberta, Canada|Medical Arts Health Research Group, Kelowna, British Columbia, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|Ocean West Research Clinic Inc., Surrey, British Columbia, Canada|Prohealth Clinical Research Inc., Vancouver, British Columbia, Canada|Office of Dr. Milton F. Baker, Victoria, British Columbia, Canada|The Medical Arts Health Research Group, West Vancouver, British Columbia, Canada|Rivergrove Medical Clinic, Winnipeg, Manitoba, Canada|Manitoba Clinic, Winnipeg, Manitoba, Canada|G.A. Research Associates Ltd/Ltee, Moncton, New Brunswick, Canada|Eric N. Grant Professional Corporation, Quispamis, New Brunswick, Canada|Office of Dr. Brian N. Craig, Saint John, New Brunswick, Canada|Commonwealth Medical Clinic, Mount Pearl, Newfoundland and Labrador, Canada|Paradise Medical Clinic, Paradise, Newfoundland and Labrador, Canada|White Hills Medical Clinic, St. John's, Newfoundland and Labrador, Canada|Nexus Clinic Research, St. John's, Newfoundland and Labrador, Canada|The Clinical Trials Centre, St. John's, Newfoundland and Labrador, Canada|Topsail Road Medical Clinic, St. John's, Newfoundland and Labrador, Canada|MSHJ Research Associates, Inc., Halifax, Nova Scotia, Canada|Colchester Research Group, Truro, Nova Scotia, Canada|Office of Dr. Rohit Nagpal, Brampton, Ontario, Canada|Aggarwal and Associates Ltd., Brampton, Ontario, Canada|Aviva Clinical Trial Group Inc., Burlington, Ontario, Canada|Corunna Medical Research Center, Corunna, Ontario, Canada|C & L Research, Fort Erie, Ontario, Canada|Office of Dr. Jonathan D. Adachi, Hamilton, Ontario, Canada|Office of Dr. John Mutrie, Kitchener, Ontario, Canada|KW Musculoskeletal Research Inc., Kitchener, Ontario, Canada|East London Medical Centre, London, Ontario, Canada|London East Medical Centre, London, Ontario, Canada|Office of Dr. Gordon Schacter, London, Ontario, Canada|Office of Dr. William Blake Bowler, London, Ontario, Canada|Office of Dr. Robert G. Luton, London, Ontario, Canada|Malton Medical Centre, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|SKDS Research Inc., Newmarket, Ontario, Canada|Office of Dr. Azim M. Velji, Niagara Falls, Ontario, Canada|AIM Health Group Trainyards Health and Wellness Centre, Ottawa, Ontario, Canada|London Road Diagnostic Clinic & Medical Center, Sarnia, Ontario, Canada|London Road Diagnostic Clinic & Medical Centre, Sarnia, Ontario, Canada|Office of Dr. Swaran K. Syan, Sudbury, Ontario, Canada|Keele Medical Place, Toronto, Ontario, Canada|Prime Health Clinical Research, Toronto, Ontario, Canada|Office of Dr. Ira Bernstein, Toronto, Ontario, Canada|Office of Dr. Subodh Kanani, Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|North Walkerville Orthopaedic Associates, Windsor, Ontario, Canada|Research Office, Windsor, Ontario, Canada|Clinical Research and Arthritis Centre, Windsor, Ontario, Canada|Centre de sante et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada|ECOGENE-21 / Centre de sante et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada|Clinique de Medicine Familiale de Cowansville, Cowansville, Quebec, Canada|Centre de recherche clinique Adapra Inc., L'Ancienne-Lorette, Quebec, Canada|Centre de Recherche Hochelaga/ Clinique Medicale Hochelaga, Montreal, Quebec, Canada|Recherche Medicale Appliquee Informatics (AMIR) Inc., Montreal, Quebec, Canada|Kells Medical Research Group, Inc., Pointe-Claire, Quebec, Canada|Le Manoir de l'Atrium, Quebec City, Quebec, Canada|Clinique Services Sante Rosemere, Rosemere, Quebec, Canada|Centre Medical des Carrieres, Saint-Marc-des-Carrieres, Quebec, Canada|St-Jerome Medical Research Inc., St-Jerome, Quebec, Canada|Centre de Recherche Musculo-Squelettique, Trois-Rivieres, Quebec, Canada|Cardiology and Research, Westmount, Quebec, Canada|Downtown Medical Specialists, Saskatoon, Saskatchewan, Canada|Recherche Clinique Sigma, Inc., Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de QuÃ©bec, Quebec, Canada|Hospital Pablo Tobon Uribe - Unidad de Investigaciones, Medellin, Antioquia, Colombia|Reumalab S.A.S., Medellin, Antioquia, Colombia|IPS Rodrigo Botero S.A.S., Medellin, Antioquia, Colombia|Fundacion Cardioinfantil, Bogota, Cundinamarca, Colombia|Clinica Colsanitas Sa, Bogota, Cundinamarca, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Santander, Colombia|Fundacion Valle del Lili, Cali, Colombia|ClÃ­nica VÃ­a San Juan, La union de Tres Rios, Cartago, Costa Rica|Clinica San Agustin, Desamparados Centro, San Jose, Costa Rica|Hospital CIMA San Jose, Escazu, San Jose, Costa Rica|Hospital Hotel La Catolica, Goicoechea, San Jose, Costa Rica|Consultorio Privado Dr. Alberto Lainez Ventosilla, Moravia, San JosÃ©, Costa Rica|Centro Medico San Rafael, Alajuela, Costa Rica|Centro de Reumatologia y Osteoporosis, Cartago, Costa Rica|ClÃ­nica Garzona, Cartago, Costa Rica|Clinica de Especialidades Medicas Drs. Saenz Castro, Heredia, Costa Rica|ClÃ­nica Monte SiÃ³n, Heredia, Costa Rica|ClÃ­nica San Antonio, Heredia, Costa Rica|Centro Medico San Jose, San Jose, Costa Rica|Edificio Panda, San Jose, Costa Rica|Hospital Clinica Biblica, San Jose, Costa Rica|Hospital ClÃ­nica Biblica, San Jose, Costa Rica|Oficina Privada, San Jose, Costa Rica|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Centre for Assessment and Treatment of Rheumatic Diseases, Department of Medicine and Geriatrics, New Territories, NT, Hong Kong|Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong|Department of Medicine, North District Hospital, Sheung Shui, NT, Hong Kong|Centro de Investigacion del Noroeste SC, Tijuana, Baja California, Mexico|Comite Mexicano para la Prevencion de la Osteoporosis, A.C., Mexico, D.f., Mexico|Instituto Mexicano de InvestigaciÃ³n ClÃ­nica, S.A. de C.V, Mexico, D.f., Mexico|CIF-BIOTEC, Medica Sur, Mexico, DF, Mexico|Centro Medico Toluca, Metepec, Estado de Mexico, Mexico|Hospital Regional ISSSTE, Leon, Guanajuato, Mexico|Instituto Jalisciense de InvestigaciÃ³n ClÃ­nica SA de CV, Guadalajara, Jalisco, Mexico|Centro de Estudios de Investigacion Basica y Clinica SC., Guadalajara, Jalisco, Mexico|Unidad de Investigacion Dr. Mario Alvizouri MuÃ±oz Ac Del Hospital General Dr. Miguel Silva, Morelia, Michoacan, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"" Unidad Regional de Reumatologia y Osteoporosis, San Luis Potosi, SLP, Mexico|Clinicos Asociados BOCM, S.C., Mexico City, Mexico|Centro de InvestigaciÃ³n Marbella, Panama City, Panama|IPC - Centro de Salud Integral S.A., San Isidro, Lima, Peru|Centro Empresarial - Altavista Polo 4, Santiago de Surco, Lima, Peru|Instituto de Ginecologia y ReproducciÃ³n & Cirugia Minimamente Invasiva, Santiago de Surco, Lima, Peru|Clinica San Felipe, Lima, Peru|Centro de Investigaciones Medical, Lima, Peru|Clinica San Juan Bautista, Lima, Peru|Mary Mediatrix Medical Center, Lipa City, Batangas, Philippines|De La Salle Health Sciences Institute, Dasmarinas, Cavite, Philippines|Chong Hua Hospital, Cebu City, Philippines|Southern Philippines Medical Center, Davao City, Philippines|Jose R. Reyes Memorial Medical Center, Manila, Philippines|Chinese General Hospital and Medical Center, Manila, Philippines|Hospital Research Unit, University of Santo Tomas Hospital, Manila, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Chang Gung Memorial Hospital-Kaohsiung branch, Section of Allergy, Immunology, Nio Sung Township, Kaohsiung County, Taiwan|Tri-Service General Hospital, Neihu District, Taipei City, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Gueishan Township, Taoyuan County, Taiwan|Chi-Mei Medical Center, Tainan, Yung Kang, Taiwan|Buddhist Tzu Chi Dailin General Hospital, Chia-Yi County, Taiwan|Chung-Ho Memorial Hospital, Kaoshiung Medical University Hospital, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tri-service General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|CRI ""Clinical Territorial Medical Association ""University Clinic"",, Simferopol, Crimea, Ukraine|Municipal Medical Institution ""City Clinical Hospital #3"", Department of Rheumatology, Chernivtsi, Ukraine|MI Dnipropetrovsk Regional Clinical Hospital named after I.I Mechnikov, Dnipropetrovsk, Ukraine|State Institution ""Dnipropetrovsk Medical Academy of MOH, Ukraine, Dnipropetrovsk, Ukraine|Rheumatology Department, MMI ""City Clinical Hospital #5"", DNMU n.a. M.Gorkyy,, Donetsk, Ukraine|Donetsk National Med University, Chair of Propaedeutics and Internal Medicine, Donetsk, Ukraine|Municipal Establishment of Health Care, Kharkiv, Ukraine|City Clinical Hospital # 8, Dept of Cardiology and Functional Diagnostics, Kharkiv, Ukraine|City Clinical Hospital #1, Kyiv, Ukraine|National Scientific Center ""The Strazhesko Institute of Cardiology"", Kyiv, Ukraine|State Institution ""Republican clinical hospital of MOH of Ukraine"", Kyiv, Ukraine|Family Medicine Department of NMAPE named after PL Shupyk,, Kyiv, Ukraine|Lutsk City Clinical Hospital, Lutsk, Ukraine|Municipal City Clinical Hospital #5, Lviv, Ukraine|Center of Reconstructive and Regenerative Medicine (University clinic) of, Odesa, Ukraine|Treatment-and-Diagnostic Center LLC ""Desna"" Ltd, Ternopil, Ukraine|Municipal enterprise "" City Hospital # 7"",, Zaporizhzhia, Ukraine|Municipal Institution ""Zaporizhzhya City Multiple Discipline Clinical Hospital #9"", Zaporizhzhya, Ukraine|Zhytomyr Regional Clinical Hospital n.a. O.F. Gerbachevs'kyy/ Rheumatology Center, Zhytomyr, Ukraine",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT01860833,KNEE OSTEOARTHRITIS,All,"50 Years to 85 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Orthopedic and Trauma Surgery, Catanzaro, Italy",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT01066676,OSTEOARTHRITIS OF THE HIP OR KNEE,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Rehabzentrum fÃ¼r Erkrankungen des rheumat. Formenkreises, Bad Hofgastein, Salzburg, Austria|Rheuma Zentrum Favoriten, Vienna, Austria",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT00630929,OSTEO ARTHRITIS OF THE KNEES,All,"40 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Bad Muender, Germany|Pfizer Investigational Site, Beckum, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Ostseebad Damp, Germany|Pfizer Investigational Site, Schwerin, Germany|Pfizer Investigational Site, Stade, Germany|Pfizer Investigational Site, Tostedt, Germany|Pfizer Investigational Site, Weener, Germany|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Cadiz, Spain|Pfizer Investigational Site, Guadalajara, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Oviedo, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Chelmsly Wood, Birmingham, United Kingdom|Pfizer Investigational Site, Truro, Cornwall, United Kingdom|Pfizer Investigational Site, Chorley, Lancs, United Kingdom|Pfizer Investigational Site, Liverpool, Lancs, United Kingdom|Pfizer Investigational Site, Cannock, Mid Staffordshire, United Kingdom|Pfizer Investigational Site, Addlestone, Surrey, United Kingdom|Pfizer Investigational Site, Huddersfield, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Newcastle Upon Tyne, United Kingdom|Pfizer Investigational Site, Wigan, United Kingdom",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Recruiting,NCT04123873,"PAIN, ACUTE|HIP ARTHROPATHY|ANALGESIA|POSTOPERATIVE PAIN",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GildhÃ¸j Privathospital, KÃ¸benhavn, BrÃ¸ndby, Denmark|NÃ¦stved-Slagelse-Ringsted Hospitals, NÃ¦stved, Danmark, Denmark|Aarhus University Hospital, Aarhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Gentofte Hospital, Hellerup, Denmark|KÃ¸ge Hospital, KÃ¸ge, Denmark|Odense University Hospital (OUH), Odense, Denmark",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT03228992,MUSCLE SORENESS,All,18 Years to 55 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Jean Brown Research, Salt Lake City, Utah, United States",A61K9/0056,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT01953978,PAIN,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Glostrup University Hospital, Glostrup, Denmark",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1,1,DB01068,__CLONAZEPAM,4316897,Completed,NCT04523935,CEREBRAL PALSY|CRYING,All,up to 15 Years Â  (Child),Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,17.4459434485307,264.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,315.711,87.28,4.0,1.0,3.0,29.59,84.02,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Terminated,NCT01902186,HIV INFECTION|OSTEOPENIA,Female,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Milano, Milano, Italy|University of Torino, Torino, Italy",C07C281/04,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,NCT00638443,LUMBAR SPINAL STENOSIS,All,"50 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2180 South Clinton Avenue, Rochester, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Unknown status,NCT01674686,VARIANT ANGINA,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Hyoen-Cheol Gwon, MD,PhD, Seoul, Korea, Republic of",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Terminated,NCT01837069,OSTEOARTHRITIS|CARDIOVASCULAR DISEASE,All,"21 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NYU Hospital for Joint Diseases, New York, New York, United States",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT02590653,MYOCARDIAL INFARCTION,All,"35 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Valentin Oleynikov, Penza, Russian Federation",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Recruiting,NCT04347434,"MYOCARDIAL INFARCTION, ACUTE|MYOCARDIAL STRAIN|ARTERIAL STIFFNESS|QUALITY OF LIFE",All,"30 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Valentin Oleynikov, Penza, Russian Federation",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00356473,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00199745,MUSCULAR DISEASES,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Lipidklinikken, Rikshospitalet-Radiumhospitalet HF, Oslo, Norway",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Terminated,NCT00127335,MYOPATHIC CONDITIONS,All,"21 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Scripps Mercy Hospital, San Diego, California, United States",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00120055,MYOPATHY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT02342015,OSTEOPOROSIS|HYPERCHOLESTEROLEMIA,Female,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,C07D405/06,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(O)(P(=O)(O)O)P(=O)(O)O,1,DB01077,__ETIDRONIC_ACID,,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,206.0282,135.29,7.0,5.0,0.0,13.97,34.51,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,1,DB01079,__TEGASEROD,5510353,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.4417955194151,53.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,301.394,85.29,5.0,4.0,2.0,34.96,110.25,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
C=CC(N)CCC(=O)O,1,DB01080,__VIGABATRIN,4178463,Withdrawn,NCT01413711,INFANTILE SPASMS,All,1 Month to 6 Months Â  (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),,C07D207/277,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,22.3413211770262,458.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,129.157,63.32,3.0,2.0,0.0,13.64,34.29,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,1,DB01083,__ORLISTAT,4598089,Completed,,FATTY LIVER,,,,,"FISABIO, Elche, Alicante, Spain",C12R1/465,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,24.411178874309503,431.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.61,495.7348,81.7,3.0,1.0,1.0,61.12,139.94,23.0,1.0,0.0,0.0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1
CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,1,DB01085,__PILOCARPINE,3947573,Completed,NCT00438048,PRIMARY SJOGREN|SECONDARY SJOGREN|XEROSTOMIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Unidad Docente Asociada Dermatologia. Escuela de MEdicina Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile",C08L71/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.380233680363,24.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.15,208.2569,44.12,2.0,0.0,2.0,22.34,56.53,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1
CCOC(=O)c1ccc(N)cc1,1,DB01086,__BENZOCAINE,4041174,Completed,,ANALGESIA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,35.7789687673258,1497.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.2,165.1891,52.32,2.0,1.0,1.0,17.46,47.53,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0
CC(C)n1c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,1,DB01095,__FLUVASTATIN,5354772,Completed,NCT00489424,OSTEOPOROSIS,Female,"45 Years to 79 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Refer to the E-portal link for ZOL446HUS136, Http://www.osteoporosisclinicalresearch.com, New Jersey, United States",C07D405/06,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,10.5464177909197,1359.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.69,411.4659,82.69,4.0,3.0,3.0,44.31,114.86,8.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Unknown status,NCT02275299,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Peking Union Medical College Hospital, Beijing, Beijing, China",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Recruiting,NCT03739853,PSORIATIC ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Unknown status,NCT02024334,JUVENILE IDIOPATHIC ARTHRITIS,All,"2 Years to 19 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mashhad, Khorasan Razavi, Iran, Islamic Republic of",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Not yet recruiting,NCT04417114,PSORIASIS|PSORIATIC ARTHRITIS|CARDIOVASCULAR RISK FACTOR,All,"40 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,C07D239/42Â ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/42Â ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)c1ccco1,1,DB01112,__CEFUROXIME,,Completed,NCT00530400,SURGICAL WOUND INFECTION,All,"19 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HÃ´pitaux Universitaire de GenÃ¨ve, Geneva, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.24,424.385,173.76,7.0,3.0,3.0,38.75,97.17,8.0,0.0,1.0,0.0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)c1ccco1,1,DB01112,__CEFUROXIME,,Completed,NCT00901628,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 81 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Joint Reconstruction Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.24,424.385,173.76,7.0,3.0,3.0,38.75,97.17,8.0,0.0,1.0,0.0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1,1,DB01120,__GLICLAZIDE,,Completed,NCT01679899,TYPE 2 DIABETES MELLITUS|MENOPAUSE|OSTEOPOROSIS|OSTEOPENIA,Female,"40 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centro de Diabetes Curitiba, Curitiba, Parana, Brazil",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,323.411,78.51,4.0,2.0,3.0,34.22,83.88,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Unknown status,NCT02429232,OSTEOPOROSIS|DIABETES MELLITUS,All,"40 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Unknown status,NCT00819845,DUCHENNE MUSCULAR DYSTROPHY|BECKER MUSCULAR DYSTROPHY,Male,"2 Years to 45 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Unione Italiana lotta Distrofia Muscolare, Rome, Italy",A61K9/5026,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Unknown status,NCT00606775,DUCHENNE MUSCULAR DYSTROPHY|CARDIOMYOPATHIES,Male,"8 Years to 45 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Suzuka Hospial, Suzuka, Mie, Japan",A61K9/5026,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
CNCCCN1c2ccccc2CCc2ccccc21,1,DB01151,__DESIPRAMINE,3961060,Completed,NCT03726996,INFANTILE NEUROAXONAL DYSTROPHY,All,3 Years to 17 Years Â  (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Health Center, Durham, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,76.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,266.3807,15.27,2.0,1.0,3.0,31.74,85.31,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CNCCCN1c2ccccc2CCc2ccccc21,1,DB01151,__DESIPRAMINE,3961060,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,76.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,266.3807,15.27,2.0,1.0,3.0,31.74,85.31,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CNCCCN1c2ccccc2CCc2ccccc21,1,DB01151,__DESIPRAMINE,3961060,Recruiting,,"PAIN, CHRONIC",,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,76.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,266.3807,15.27,2.0,1.0,3.0,31.74,85.31,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Active Not Recruiting,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,1,DB01161,__CHLOROPROCAINE,8969412,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,101.882995544056,725.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.72,270.755,55.56,3.0,1.0,1.0,28.74,75.1,7.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0
CC1(C)S[C@@H]2[C@H](N=CN3CCCCCC3)C(=O)N2[C@H]1C(=O)O,1,DB01163,__AMDINOCILLIN,4127649,Recruiting,,COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,18.201605782459602,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.41,325.426,73.21,5.0,1.0,3.0,34.18,84.31,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1
CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01165,__OFLOXACIN,5401741,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,23.4912421199613,725.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Completed,,INTERMITTENT CLAUDICATION,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
Cc1cc(C2CCCCC2)n(O)c(=O)c1,1,DB01188,__CICLOPIROX,7018656,Completed,NCT02679911,FOOT DERMATOSES,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"TÃ¼bingen, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,102.34296392123001,694.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.15,207.2689,40.54,2.0,1.0,2.0,23.12,60.91,1.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Completed,NCT01270620,OBESITY|ARTHRITIS,All,65 Years and older Â  (Older Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",F16L37/47,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Completed,NCT03540030,OPIOID USE|SHOULDER OSTEOARTHRITIS|AVASCULAR NECROSIS|ROTATOR CUFF TEAR|ARTHRITIS;INFLAMMATORY,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OrthoCarolina Research Institute, Charlotte, North Carolina, United States",F16L37/47,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
FC(F)OC(F)C(F)(F)F,1,DB01189,__DESFLURANE,5617906,Unknown status,NCT01486953,PECTUS EXCAVATUM,All,"15 Years and older Â  (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Seoul St. Mary's Hospital, Seoul, Korea, Republic of",F16L37/47,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,22.439885829277802,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.19,168.0378,9.23,1.0,0.0,0.0,7.89,18.12,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CC[C@@H](C(N)=O)N1CCCC1=O,1,DB01202,__LEVETIRACETAM,6471992,Completed,NCT00252954,"INJURIES, SPINAL CORD|PAIN",All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Danish Pain Research Center, Aarhus University Hospital, Aarhus, Denmark|Clinic for Spinal Cord Injuries, Rigshospitalet, Hornbaek, Denmark|The Spinal Cord Unit, Dept of Rheumatology, Viborg, Denmark",A61K9/2072,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,56.2475615515718,30.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.64,170.21200000000005,63.4,2.0,1.0,1.0,17.79,44.08,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(=O)[nH]n3C)CS[C@H]12)c1csc(N)n1,1,DB01212,__CEFTRIAXONE,4427678,Recruiting,NCT04141787,STAPHYLOCOCCAL INFECTIONS|OSTEOMYELITIS|CNS INFECTION|SEPTIC ARTHRITIS|DIABETIC FOOT INFECTION|VERTEBRAL OSTEOMYELITIS|ABSCESS|COAGULASE NEGATIVE STAPHYLOCOCCAL INFECTION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.01,554.58,208.98,12.0,4.0,4.0,51.47,128.47,8.0,1.0,0.0,0.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,1,DB01217,__ANASTROZOLE,RE36617,Completed,NCT00082277,BREAST CANCER,Female,"55 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Palm Springs, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, New Orleans, Louisiana, United States|Research Site, New York, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Burnaby, Canada|Research Site, Edmonton, Canada|Research Site, Montreal, Canada|Research Site, Quebec City, Canada|Research Site, Vancouver, Canada|Research Site, Bordeaux, France|Research Site, Caen, France|Research Site, Lyon, France|Research Site, Saint-Cloud, France|Research Site, Saint-Herblain, France|Research Site, Athens, Greece|Research Site, Iraklion, Greece|Research Site, Den Haag, Netherlands|Research Site, Goes, Netherlands|Research Site, Ijssel, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Bloemfontain, South Africa|Research Site, Cape Town, South Africa|Research Site, Tygerberg, South Africa|Research Site, Pamplona, Spain|Research Site, Pontevedra, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Belfast, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Luton, United Kingdom",C07D239/26,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,1,DB01217,__ANASTROZOLE,RE36617,Unknown status,NCT02137538,SHORT STATURE,Male,10 Years to 17 Years Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lucile Packard Children's Hospital, Palo Alto, California, United States",C07D239/26,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,1,DB01217,__ANASTROZOLE,RE36617,Completed,NCT00323479,EARLY BREAST CANCER,Female,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Bordeaux, France|Research Site, Caen, France|Research Site, Lyon, France|Research Site, Paris, France|Research Site, Poitiers, France",C07D239/26,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT01947114,PEDIATRIC RIGID BRONCHOSCOPY,All,1 Month to 12 Years Â  (Child),Other,Allocation: Randomized|Masking: Single (Participant)|Primary Purpose: Treatment,"Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Recruiting,NCT03861988,MAJOR DEPRESSIVE DISORDER|SURGERY|ORTHOPEDIC DISORDER,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Stanford University, Stanford, California, United States",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT03586154,BREAST NEOPLASM,Female,18 Years to 64 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MansouraU, Mansourah, Mansoura, Egypt",C07D307/52,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT01544725,FRACTURE|DISLOCATION,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HÃ´pital St Roch, Nice, France",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Not yet recruiting,NCT03909594,"PAIN, MUSCULOSKELETAL",All,"18 Years to 120 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Maimonides Medical Center, Brooklyn, New York, United States",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT01325493,IDIOPATHIC SCOLIOSIS|SPONDYLOLISTHESIS,All,"10 Years to 18 Years Â  (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Children's National Medical Center, Washington, District of Columbia, United States",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Unknown status,NCT02651324,IDIOPATHIC SCOLIOSIS|POST-OPERATIVE PAIN,All,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Albany Medical Center, Albany, New York, United States",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,"PAIN, ACUTE",,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,"PAIN, CHRONIC",,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,,FAILED MODERATE SEDATION DURING PROCEDURE,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Withdrawn,NCT02357277,OSTEOPOROSIS,Female,"60 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other",,A61K9/008,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/008,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,NCT00675896,MAJOR DEPRESSIVE DISORDER,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Dr. A McIntyre Inc, Penticton, British Columbia, Canada",C07D281/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,NCT01458964,FIBROMYALGIA,All,18 Years to 60 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","East Tennessee State University, Johnson City, Tennessee, United States",C07D281/16,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/6925,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,PREGNANCY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT02292082,OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04123873,"PAIN, ACUTE|HIP ARTHROPATHY|ANALGESIA|POSTOPERATIVE PAIN",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GildhÃ¸j Privathospital, KÃ¸benhavn, BrÃ¸ndby, Denmark|NÃ¦stved-Slagelse-Ringsted Hospitals, NÃ¦stved, Danmark, Denmark|Aarhus University Hospital, Aarhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Gentofte Hospital, Hellerup, Denmark|KÃ¸ge Hospital, KÃ¸ge, Denmark|Odense University Hospital (OUH), Odense, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01953978,PAIN,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Glostrup University Hospital, Glostrup, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT03161938,HIP DYSPLASIA|POSTOPERATIVE COMPLICATIONS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rigshospitalet, Copenhagen, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT04200885,THIRD MOLAR SURGERY,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Tokat Gaziosmanpasa University, Faculty of Dentistry, Tokat, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT02346110,"ARTHROSIS, UNSPECIFIED, ANKLE AND FOOT",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Department of Anesthesiology, Aarhus University Hospital, Aarhus, Midtjylland, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT01275014,ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Medical Centre Groningen, Groningen, Netherlands",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Enrolling by invitation,NCT03166761,SACRO-ILIAC SPONDYLOSIS,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Byron Schneider, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04278833,OSTEOARTHRITIS|TENDINOPATHY|IMPINGEMENT SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Stanford University, Redwood City, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04126278,CALCIFIC TENDINITIS,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01414569,SHOULDER IMPINGEMENT SYNDROME|ARTHRITIS,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Horsens Hospital, Horsens, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04002037,TRIGGER FINGER DISORDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Missouri Health Care, Columbia, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04047446,SHOULDER PAIN,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT02760459,OSTEO ARTHRITIS OF THE KNEES,All,"40 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Orthopedics, Chiang Mai University, ChiangMai, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT02464176,"OSTEOARTHRITIS, HIP",All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT03270033,"PAIN, POSTOPERATIVE|SHOULDER JOINT DISORDER|AMBULATORY SURGICAL PROCEDURES|BRACHIAL PLEXUS BLOCK",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pan Am Surgical Centre, Winnipeg, Manitoba, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03542617,"LOCALIZED PRIMARY OSTEOARTHRITIS OF BOTH HIPS (DIAGNOSIS)|OSTEOARTHRITIS, HIP",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Orthopedics, Chiang Mai University, ChiangMai, Thailand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03763760,POSTOPERATIVE PAIN|POSTOPERATIVE NAUSEA AND VOMITING|HIP OSTEOARTHRITIS|PERIOPERATIVE/POSTOPERATIVE COMPLICATIONS|SURGERY|OPIOID USE|CATASTROPHIZING PAIN|CHRONIC PAIN,All,"40 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hvidovre Hospital, Capital Region of Denmark., Hvidovre, Denmark|Vejle Sygehus, Vejle, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03763734,POSTOPERATIVE PAIN|POSTOPERATIVE NAUSEA AND VOMITING|KNEE OSTEOARTHRITIS|PERIOPERATIVE/POSTOPERATIVE COMPLICATIONS|SURGERY|OPIOID USE|CATASTROPHIZING PAIN|CHRONIC PAIN,All,"40 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hvidovre Hospital, Capital Region of Denmark., Hvidovre, Denmark|Vejle Sygehus, Vejle, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03758170,POSTOPERATIVE PAIN|POSTOPERATIVE NAUSEA AND VOMITING|KNEE OSTEOARTHRITIS|PERIOPERATIVE/POSTOPERATIVE COMPLICATIONS|SURGERY,All,"40 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hvidovre Hospital, Capital Region of Denmark., Hvidovre, Denmark|Vejle Sygehus, Vejle, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Suspended,NCT02219581,POSTOPERATIVE PAIN|INFLAMMATION|OSTEOARTHRITIS,All,"18 Years to 100 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Emory Orthopedic and Spine Hospital, Tucker, Georgia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04544683,"CERVICAL RADICULOPATHY|CERVICAL SPONDYLOSIS|DISK, HERNIATED",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Utah, Salt Lake City, Utah, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04432259,ARTHRITIS KNEE|POSTOPERATIVE NAUSEA|POSTOPERATIVE PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01586806,"ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION|REGIONAL ANESTHESIA, SAPHENOUS NERVE BLOCK",All,"16 Years to 65 Years Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Withdrawn,NCT02624856,"OSTEOARTHRITIS|PAIN, POSTOPERATIVE",All,"40 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Albany Medical Center, Albany, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04507412,"ARTHROPLASTY, REPLACEMENT, SHOULDER",All,"58 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Christian Candrian, Lugano, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04432012,TOTAL KNEE REPLACEMENT,All,"50 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Ospedale Regionale di Lugano Civico e Italiano, Lugano, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT03239964,KELOID,Female,20 Years to 45 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"KasralainiH, Cairo, Egypt",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01450007,SHOULDER INJURY,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Mayo Clinic in Arizona, Phoenix, Arizona, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Active Not Recruiting,,"RADICULOPATHY, CERVICAL",,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,1,DB01235,__LEVODOPA,6858199,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,49.0,56.4775457401589,1144.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.3,197.1879,103.78,5.0,4.0,1.0,18.91,49.08,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT03540030,OPIOID USE|SHOULDER OSTEOARTHRITIS|AVASCULAR NECROSIS|ROTATOR CUFF TEAR|ARTHRITIS;INFLAMMATORY,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OrthoCarolina Research Institute, Charlotte, North Carolina, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Unknown status,NCT03215446,VASCULAR SURGERY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"CHU dijon Bourgogne, Dijon, France",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Unknown status,NCT01486953,PECTUS EXCAVATUM,All,"15 Years and older Â  (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Seoul St. Mary's Hospital, Seoul, Korea, Republic of",0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Active Not Recruiting,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21,1,DB01240,__EPOPROSTENOL,8318802,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,69.8166286782069,658.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.83,352.4651,86.99,5.0,3.0,2.0,41.09,99.01,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0
CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,1,DB01242,__CLOMIPRAMINE,5008262,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,35.8775334195774,561.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,314.8520000000001,6.48,2.0,0.0,3.0,35.73,95.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0
C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,1,DB01255,__LISDEXAMFETAMINE,7223735,Completed,NCT01071044,CHRONIC FATIGUE SYNDROME|COGNITIVE IMPAIRMENTS,All,18 Years to 60 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,35.8775334195774,7.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.01,263.3785,81.14,3.0,3.0,1.0,31.28,78.31,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT02060383,CUSHING'S DISEASE|ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States|LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States|Coastal Metabolic Research Centre SC, Ventura, California, United States|East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States|Washington University SC - SOM230B2411, Saint Louis, Missouri, United States|Great Falls Clinic, Great Falls, Montana, United States|Robert Wood Johnson Medical School - Rutgers SC, New Brunswick, New Jersey, United States|The Mount Sinai Hospital SC, New York, New York, United States|Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC, New York, New York, United States|Allegheny Endocrinology Associates SC, Pittsburgh, Pennsylvania, United States|Vanderbilt Clinical Trials Center SOM230B2219, Nashville, Tennessee, United States|Baylor College of Medicine Ben Taub General Hosp., Houston, Texas, United States|Virginia Endocrinology Research SC-2, Chesapeake, Virginia, United States|Swedish Medical Center Dept.ofSeattle Neuroscience(2), Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, SÃ£o Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Terminated,NCT02015910,TYPE 2 DIABETES,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medstar Georgetown University Hospital, Washington, District of Columbia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,1,DB01283,__LUMIRACOXIB,6291523,Completed,NCT00170781,ACUTE GOUTY ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Novartis, Nuernberg, Germany|For Site Information, contact Novartis Pharma AG, Basel, CH, Switzerland",C07C229/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,36.7974701739255,390.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.56,293.721,49.33,3.0,2.0,2.0,28.53,75.91,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,1,DB01283,__LUMIRACOXIB,6291523,Completed,NCT00419796,OSTEOARTHRITIS WITH CONTROLLED HYPERTENSION,All,"50 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Novartis, East Hanover, New Jersey, United States",C07C229/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,36.7974701739255,390.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.56,293.721,49.33,3.0,2.0,2.0,28.53,75.91,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,1,DB01283,__LUMIRACOXIB,6291523,Completed,NCT00267176,OSTEOARTHRITIS|CONTROLLED HYPERTENSION,All,"50 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Southern Illinois Clinical Research, O'Fallon, Illinois, United States|Novartis, Nuernberg, Germany",C07C229/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,36.7974701739255,390.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.56,293.721,49.33,3.0,2.0,2.0,28.53,75.91,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,1,DB01283,__LUMIRACOXIB,6291523,Completed,NCT00170898,MUSCULOSKELETAL PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"For site information contact, Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom",C07C229/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,36.7974701739255,390.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.56,293.721,49.33,3.0,2.0,2.0,28.53,75.91,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01296,__GLUCOSAMINE,4120954,Completed,NCT01906801,OSTEOARTHRITIS|GLUCOSAMINE|DIACEREIN,All,"50 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Mahidol University, Bangkok, Thailand",C07H13/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,18.431589971046602,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,179.1711,116.17,6.0,5.0,1.0,16.87,37.58,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01296,__GLUCOSAMINE,4120954,Completed,NCT03743896,OSTEO ARTHRITIS OF THE KNEES,All,"21 Years to 80 Years Â  (Adult, Older Adult)",Industry|Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"T&T Family Heath Clinic and Surgery, Singapore, Singapore",C07H13/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,21.0,18.431589971046602,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,179.1711,116.17,6.0,5.0,1.0,16.87,37.58,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01296,__GLUCOSAMINE,4120954,Completed,NCT00251069,OSTEOARTHRITIS,All,"40 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Slidgigtinstituttet, IshÃ¸j, Denmark",C07H13/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,18.431589971046602,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,179.1711,116.17,6.0,5.0,1.0,16.87,37.58,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,1,DB01327,__CEFAZOLIN,3937655,Not yet recruiting,NCT04538053,BONE INFECTION|SEPTIC ARTHRITIS|BONE AND JOINT INFECTION|OSTEOMYELITIS,All,"1 Year to 18 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Royal Children's Hospital, Melbourne, Victoria, Australia",C12Q1/18,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,21.8484979157682,879.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,454.50699999999995,156.09,9.0,2.0,4.0,41.44,119.86,7.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,1,DB01327,__CEFAZOLIN,3937655,Recruiting,NCT04141787,STAPHYLOCOCCAL INFECTIONS|OSTEOMYELITIS|CNS INFECTION|SEPTIC ARTHRITIS|DIABETIC FOOT INFECTION|VERTEBRAL OSTEOMYELITIS|ABSCESS|COAGULASE NEGATIVE STAPHYLOCOCCAL INFECTION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada",C12Q1/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,21.8484979157682,879.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,454.50699999999995,156.09,9.0,2.0,4.0,41.44,119.86,7.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,1,DB01327,__CEFAZOLIN,3937655,"Active, not recruiting",NCT03190668,IDIOPATHIC SCOLIOSIS,All,"12 Years to 20 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Florida, Gainesville, Florida, United States",C12Q1/18,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,21.8484979157682,879.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,454.50699999999995,156.09,9.0,2.0,4.0,41.44,119.86,7.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,1,DB01327,__CEFAZOLIN,3937655,Recruiting,NCT03283878,ARTHROPATHY OF KNEE|ANTIBIOTIC PROPHYLAXIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hoag Orthopedics, Irvine, California, United States|University of California, San Francisco, San Francisco, California, United States|Florida Orthopaedic Institute (FORE), Temple Terrace, Florida, United States|Emory University, Atlanta, Georgia, United States|Illinois Bone and Joint, Morton Grove, Illinois, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|University of Maryland St. Joseph Medical Center & Orthopedic Associates, Towson, Maryland, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Mississippi Bone and Joint Clinic, Starkville, Mississippi, United States|University Orthopaedic Associates, LLC, Somerset, New Jersey, United States|NYU School of Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Rothman Institute, Philadelphia, Pennsylvania, United States|University of South Carolina, Columbia, South Carolina, United States|University of Virginia, Charlottesville, Virginia, United States|Augusta Health, Fishersville, Virginia, United States",C12Q1/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,21.8484979157682,879.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,454.50699999999995,156.09,9.0,2.0,4.0,41.44,119.86,7.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1,1,DB01327,__CEFAZOLIN,3937655,Completed,NCT02292082,OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",C12Q1/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,21.8484979157682,879.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,454.50699999999995,156.09,9.0,2.0,4.0,41.44,119.86,7.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,1,DB01339,__VECURONIUM,,Completed,NCT03540030,OPIOID USE|SHOULDER OSTEOARTHRITIS|AVASCULAR NECROSIS|ROTATOR CUFF TEAR|ARTHRITIS;INFLAMMATORY,All,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OrthoCarolina Research Institute, Charlotte, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.07,557.8274,55.84,3.0,0.0,6.0,66.85,169.31,6.0,0.0,1.0,0.0,0,0,1,0,1,1,0,1,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,0,1
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,1,DB01339,__VECURONIUM,,Completed,NCT03219294,ARTHROPATHY OF HIP,All,"50 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Other","Maine Medical Center, Portland, Maine, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.07,557.8274,55.84,3.0,0.0,6.0,66.85,169.31,6.0,0.0,1.0,0.0,0,0,1,0,1,1,0,1,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,0,1
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01362,__IOHEXOL,4278654,Not Yet Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/0452,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
C#CCN[C@@H]1CCc2ccccc21,1,DB01367,__RASAGILINE,5387612,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,20.698576972833106,136.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.26,171.2383,12.03,1.0,1.0,2.0,20.25,54.47,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,1,DB01394,__COLCHICINE,7619004,Completed,NCT02500641,GOUT,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Klinik und Poliklinik III/Rheumatologie UniversitÃ¤tsklinikum ""Carl Gustav Carus"" Der Technischen UniversitÃ¤t, Dresden, Germany|Presidio Ospedaliero San Filippo e Nicola UniversitÃ  degli Studi dell'Aquila U.O.C Geriatria e Lungodegenza Geriatrica, Avezzano, L'Aquila, Italy|Ospedale San Salvatore U.O.C. Medicina Interna e Nefrologia Dipartimento MeSVA UniversitÃ  degli Studi dell'Aquila, Coppito, L'Aquila, Italy|Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Policlinico SS. Annunziata UniversitÃ  degli Studi ""G. d'Annunzio"". Dipartimento di Medicina e Scienze dell'Invecchiamento., Chieti, Italy|Reade Clinic, Amsterdam, Netherlands|GdaÅskie Centrum Zdrowia Sp.z o.o., GdaÅsk, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, GrudziÄdz, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Centrum Medyczne Plejady, KrakÃ³w, Poland|Krakowski Szpital Specjalistyczny im. Jana PawÅa II w Krakowie, KrakÃ³w, Poland|Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, KrakÃ³w, Poland|Pratia S,A, Warsaw, Poland|Reumatika- Centrum Reumatologii, Warsaw, Poland|OddziaÅ Kardiologiczny, WSS im. W. BiegaÅskiego w Åodzi, ÅÃ³dÅº, Poland|Polimedica, ÅÃ³dÅº, Poland|Clinica MedicalÄ Data Plus SRL, Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|S.C. Centrul Medical Sana S.R.L., Bucharest, Romania|S.C. Cardiomed S.R.L., Craiova, Romania|Institutul de Boli Cardiovasculare Clinica de Cardiologie si Recuperare Cardiovasculara, Timisoara, Romania|Cabinet Medical Medicina Interna, TimiÅoara, Romania|Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia|Institut za reumatologiju, Belgrade, Serbia|KliniÄko-bolniÄki centar ""BeÅ¾anijska kosa"" Klinika za imunologiju i alergologiju, Belgrade, Serbia|Vojnomedicinska akademija Klinika za reumatologiju, Belgrade, Serbia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,1,DB01394,__COLCHICINE,7619004,Completed,NCT02060552,PRIMARY GOUT,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yikai YU, Wuhan, Hubei, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,1,DB01394,__COLCHICINE,7619004,Recruiting,NCT03933007,GOUT FLARE,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HÃ´pital LariboisiÃ¨re-Service de Rhumatolologie, Paris, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,1,DB01394,__COLCHICINE,7619004,Completed,NCT01451645,INTERCRITICAL GOUT,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Alabaster, Alabama, United States|Mesa, Arizona, United States|Upland, California, United States|Trumbull, Connecticut, United States|Debary, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Canton, Georgia, United States|Boise, Idaho, United States|Lexington, Kentucky, United States|Bethesda, Maryland, United States|Reisterstown, Maryland, United States|Bingham Farms, Michigan, United States|Brooklyn Center, Minnesota, United States|Kansas City, Missouri, United States|Billings, Montana, United States|Elizabeth, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Morganton, North Carolina, United States|Winston-Salem, North Carolina, United States|Duncansville, Pennsylvania, United States|Reading, Pennsylvania, United States|West Reading, Pennsylvania, United States|Greer, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Johnson City, Tennessee, United States|Dallas, Texas, United States|Katy, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Wauwatosa, Wisconsin, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,1,DB01394,__COLCHICINE,7619004,Withdrawn,NCT02995512,MYOCARDIAL INFARCTION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,1,DB01394,__COLCHICINE,7619004,Recruiting,NCT03913442,OSTEOARTHRITIS|OSTEO ARTHRITIS KNEE,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","NYU Langone Health, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,1,DB01399,__SALSALATE,3954533,Completed,NCT03222206,NON ALCOHOLIC FATTY LIVER|OSTEO ARTHRITIS,All,"19 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Korea University Guro Hospital, Seoul, Korea, Republic of",C06B23/007,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,78.1617692355079,627.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,258.2262,83.83,4.0,2.0,2.0,24.92,67.1,4.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,1,DB01400,__NEOSTIGMINE,4439427,"Active, not recruiting",NCT03210376,MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS|MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF MALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF URINARY TRACT,All,65 Years and older Â  (Older Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,1,DB01400,__NEOSTIGMINE,4439427,Completed,NCT02390817,SPINAL CURVATURES,All,"10 Years to 25 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,"Ebru Biricik, Adana, SarÄ±Ã§am, Turkey|Ãukurova University, Adana, Ãukurova, Turkey",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,1,DB01400,__NEOSTIGMINE,4439427,Recruiting,NCT03111121,MICROLARYNGOSCOPY|RIGID BRONCHOSCOPY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"WVU Healthcare Ruby Memorial Hospital, Morgantown, West Virginia, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,1,DB01400,__NEOSTIGMINE,4439427,Completed,NCT02543658,ACUTE PANCREATITIS|INTRA-ABDOMINAL HYPERTENSION,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,17.281669028111402,79.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,223.2915,29.54,1.0,0.0,1.0,25.08,75.28,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Unknown status,NCT01765010,OSTEOPOROSIS,Male,20 Years to 40 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seoul National University Medical School, Seoul, Korea, Republic of",A23K20/174,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Completed,NCT00168909,"OSTEOPOROSIS, POSTMENOPAUSAL|OSTEOPENIA|FALLS",Female,65 Years and older Â  (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Centre for Muscle and Bone Research, CharitÃ© - Campus Benjamin Franklin, Berlin, Germany|Centre for Muscle and Bone Research, Aerpah-Kliniken Esslingen, Stuttgart, Germany",A23K20/174,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
O=C(O)CCCO,1,DB01440,__GAMMA-HYDROXYBUTYRIC_ACID,6780889,Terminated,NCT00498485,CHRONIC FATIGUE SYNDROME,All,"21 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UMDNJ - Pain & Fatigue Study Center, ADMC 1618, Newark, New Jersey, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,25.4625351649931,3.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.63,104.1045,57.53,3.0,2.0,0.0,10.17,23.8,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB01590,__EVEROLIMUS,5665772,Completed,NCT00414440,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,All,18 Years to 50 Years Â  (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Nantes Cedex, France|Novartis Investigative Site, Paris cedex 15, France|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt am Main, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, LÃ¼beck, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, WÃ¼rzburg, Germany",C07D498/18,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O,1,DB01597,__CILASTATIN,8487093,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,358.45300000000015,129.72,6.0,4.0,1.0,38.28,92.85,11.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,1,DB01599,__PROBUCOL,4719237,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,23.4583872358775,847.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.92,516.842,40.46,2.0,2.0,2.0,62.35,159.26,8.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](N=CN3CCCCCC3)[C@H]2SC1(C)C,1,DB01605,__PIVMECILLINAM,4203972,Recruiting,,COMPLICATIONS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,25.9225035421671,142.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.23,439.569,88.51,5.0,0.0,3.0,47.7,113.03,7.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,NCT00673608,HEMOGLOBINOPATHIES|MYELODYSPLASTIC SYNDROMES|OTHER INHERITED OR ACQUIRED ANAEMIA|MPD SYNDROME|DIAMOND-BLACKFAN ANEMIA|OTHER RARE ANAEMIAS|TRANSFUSIONAL IRON OVERLOAD,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novarts Investigative Site, Adelaide, Australia|Novarts Investigative Site, Brisbane, Australia|Novarts Investigative Site, Melbourne, Australia|Novarts Investigative Site, Sydney, Australia",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Not yet recruiting,NCT04077957,ANKYLOSING SPONDYLITIS|SPONDYLOARTHRITIS,All,18 Years to 50 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China",2,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Completed,NCT00259610,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Unknown status,NCT02714634,RHEUMATOID ARTHRITIS|INSUFFICIENT RESPONSE TO METHOTREXATE.,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Recruiting,NCT03122431,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)|JUVENILE SLE|CUTANEOUS LUPUS,All,"5 Years to 64 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital das Clinicas da Faculdade de Medicina da USP, SÃ£o Paulo, Brazil",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Completed,,ANKYLOSING SPONDYLITIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,1,DB01618,__MOLINDONE,4065453,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,13.831906199305902,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,276.374,45.33,3.0,1.0,3.0,32.0,81.06,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT00140972,OSTEOARTHRITIS,All,"40 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D213/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT00142558,ACUTE GOUT,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D213/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT00733421,POSTOPERATIVE PAIN,Female,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Foot & Ancle Surgical Center, Stockholm, Sweden",C07D213/65,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Withdrawn,NCT01190722,HALLUX VALGUS|POSTOPERATIVE PAIN,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07D213/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT04144101,RHEUMATOID ARTHRITIS,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,C07D213/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT00927004,OSTEOARTHRITIS|PAIN,All,"50 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Perth Hospital, Perth, Western Australia, Australia",C07D213/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT00792376,ACHILLES TENDINOPATHY,Male,18 Years to 50 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Argentine Tennis Association, Buenos Aires, Argentina",C07D213/65,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Unknown status,NCT00755521,FIBROMYALGIA,Female,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Medicine 'D', Meir Medical Center, Kfar-Saba, Israel",C07D213/65,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT03582332,AXIAL SPONDYLOARTHRITIS,All,18 Years to 45 Years Â  (Adult),Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D213/65,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT00757627,PAIN,All,"20 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D213/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1,1,DB01751,__TETRAIODOTHYROACETIC_ACID,4490221,Completed,NCT02372786,TATTOO|ACNE KELOIDALIS NUCHAE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Erasmus MC, Rotterdam, Zuid-Holland, Netherlands",C07C51/377,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,19.9429146389042,24.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,747.8288,66.76,3.0,2.0,2.0,45.76,119.04,4.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1,1,DB01751,__TETRAIODOTHYROACETIC_ACID,4490221,Completed,NCT02576652,OSTEOPOROSIS,All,"50 Years to 100 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helen Hayes Hospital, West Haverstraw, New York, United States|Research Site, West Haverstraw, New York, United States",C07C51/377,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,19.9429146389042,24.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,747.8288,66.76,3.0,2.0,2.0,45.76,119.04,4.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(O)CO,1,DB01839,__PROPYLENE_GLYCOL,,Completed,,MYOPIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,76.0944,40.46,2.0,2.0,0.0,8.01,18.97,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Not Yet Recruiting,,LATERAL EPICONDYLITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02379,__BETA-D-GLUCOSE,3964974,Unknown status,NCT03238183,PHYSICAL ACTIVITY|FUNCTIONAL DISTURBANCE,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",C12Q1/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02379,__BETA-D-GLUCOSE,3964974,Recruiting,NCT04082533,"PAIN|ARTHROFIBROSIS|OSTEOARTHRITIS, KNEE",All,"18 Years to 83 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",C12Q1/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02379,__BETA-D-GLUCOSE,3964974,"Active, not recruiting",NCT01934868,SCIATICA|SPINAL STENOSIS OF LUMBAR REGION|DEGENERATION OF LUMBAR OR LUMBOSACRAL INTERVERTEBRAL DISC,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pain Unit, Hadassah Medical Center, Jerusalem, Israel",C12Q1/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02772,__SUCROSE,,Unknown status,NCT02544828,OSTEOARTHRITIS,All,"19 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C,1,DB03247,__FLAVIN_MONONUCLEOTIDE,3960840,Completed,,KERATOCONUS,,,,,"FISABIO, Elche, Alicante, Spain",C07H21/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,41.0686051048276,247.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.78,456.3438,201.58,11.0,6.0,3.0,42.19,107.14,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0
O=C(O)C[C@H](NC(=O)CP(=O)(O)O)C(=O)O,1,DB03459,__SPARFOSIC_ACID,4154759,Terminated,NCT00208403,OSTEOARTHRITIS|POST-TRAUMATIC ARTHRITIS|AVASCULAR NECROSIS,All,"60 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital of Trondheim, Trondheim, Sor-Trondelag, Norway",C07F9/3808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,9.13365777531366,84.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,255.1193,161.23,8.0,5.0,0.0,19.82,46.97,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0
NC(CO)(CO)CO,1,DB03754,__TROMETHAMINE,,Terminated,NCT03694821,OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UConn Health, Farmington, Connecticut, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,121.135,86.71,4.0,4.0,0.0,12.02,28.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
NC(CO)(CO)CO,1,DB03754,__TROMETHAMINE,,Completed,NCT02658149,OSTEOARTHRITIS|ARTHROPLASTY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Beaumont Hospital, Royal Oak, Michigan, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,121.135,86.71,4.0,4.0,0.0,12.02,28.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
NC(CO)(CO)CO,1,DB03754,__TROMETHAMINE,,Completed,NCT02638831,GONARTHROSIS|LOW BACK PAIN,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,121.135,86.71,4.0,4.0,0.0,12.02,28.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
NC(N)=O,1,DB03904,__UREA,,Completed,NCT02705664,FOOT DERMATOSES,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Principal Investigator, Reykjavik, Iceland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,60.0553,69.11,1.0,2.0,0.0,5.1,13.14,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)CC(O)(CC(=O)O)C(=O)O,1,DB04272,__CITRIC_ACID,8481083,Completed,NCT03578900,XEROSTOMIA|HYPOSALIVATION|QUALITY OF LIFE|SJOGREN'S SYNDROME,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,56.937514117333,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.3,192.1235,132.13,7.0,4.0,0.0,15.54,35.62,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,NCT01014338,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Royal Brompton Hospital, London, United Kingdom",C13K5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C13K5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1,1,DB04794,__BIFONAZOLE,4457938,Completed,NCT02705664,FOOT DERMATOSES,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Principal Investigator, Reykjavik, Iceland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,28.8794431097147,534.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.92,310.3917,17.82,1.0,0.0,4.0,35.41,97.94,4.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0
Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C,1,DB04817,__METAMIZOLE,4699776,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, HajdÃº-Bihar, Hungary",A61K9/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,27.4995379781925,194.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.4,311.36,81.16,6.0,1.0,2.0,31.41,80.04,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0
Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1,1,DB04841,__FLUNARIZINE,4505914,Unknown status,NCT02747940,CHRONIC PAIN|CHRONIC MIGRAINE|FIBROMYALGIA,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Headache Center, Teipei Veterans General Hospital, Taipei, Taiwan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,19.680075566233302,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.3,404.4948,6.48,2.0,0.0,4.0,44.2,120.3,6.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1
COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2,1,DB04844,__TETRABENAZINE,4316897,Completed,NCT04523935,CEREBRAL PALSY|CRYING,All,up to 15 Years Â  (Child),Other,"Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care",,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,17.4459434485307,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.23,317.4226,38.77,4.0,0.0,3.0,36.59,91.31,4.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0
CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1,1,DB04846,__CELIPROLOL,4767784,Completed,NCT00190411,"EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT|CHROMOSOME 2Q31.2 DELETION SYNDROME",All,"15 Years to 65 Years Â  (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D215/227,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,21.059980697755602,352.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.29,379.501,90.9,5.0,3.0,1.0,43.18,108.25,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Enrolling by invitation,NCT03336203,GOUT|CKD STAGE 1-4|SUA LEVEL (>8 MG/DL; 480 ÎMOL/L),All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical Practice Prof D.Ivanov, Kiev, Ukraine",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,"Active, not recruiting",NCT02579096,GOUT|CHRONIC KIDNEY DISEASES,All,"18 Years and older Â  (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States|Iowa City VA Health Care System, Iowa City, IA, Iowa City, Iowa, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri, United States|Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|Asheville VA Medical Center, Asheville, NC, Asheville, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,NCT02500641,GOUT,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Klinik und Poliklinik III/Rheumatologie UniversitÃ¤tsklinikum ""Carl Gustav Carus"" Der Technischen UniversitÃ¤t, Dresden, Germany|Presidio Ospedaliero San Filippo e Nicola UniversitÃ  degli Studi dell'Aquila U.O.C Geriatria e Lungodegenza Geriatrica, Avezzano, L'Aquila, Italy|Ospedale San Salvatore U.O.C. Medicina Interna e Nefrologia Dipartimento MeSVA UniversitÃ  degli Studi dell'Aquila, Coppito, L'Aquila, Italy|Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Policlinico SS. Annunziata UniversitÃ  degli Studi ""G. d'Annunzio"". Dipartimento di Medicina e Scienze dell'Invecchiamento., Chieti, Italy|Reade Clinic, Amsterdam, Netherlands|GdaÅskie Centrum Zdrowia Sp.z o.o., GdaÅsk, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, GrudziÄdz, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Centrum Medyczne Plejady, KrakÃ³w, Poland|Krakowski Szpital Specjalistyczny im. Jana PawÅa II w Krakowie, KrakÃ³w, Poland|Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, KrakÃ³w, Poland|Pratia S,A, Warsaw, Poland|Reumatika- Centrum Reumatologii, Warsaw, Poland|OddziaÅ Kardiologiczny, WSS im. W. BiegaÅskiego w Åodzi, ÅÃ³dÅº, Poland|Polimedica, ÅÃ³dÅº, Poland|Clinica MedicalÄ Data Plus SRL, Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|S.C. Centrul Medical Sana S.R.L., Bucharest, Romania|S.C. Cardiomed S.R.L., Craiova, Romania|Institutul de Boli Cardiovasculare Clinica de Cardiologie si Recuperare Cardiovasculara, Timisoara, Romania|Cabinet Medical Medicina Interna, TimiÅoara, Romania|Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia|Institut za reumatologiju, Belgrade, Serbia|KliniÄko-bolniÄki centar ""BeÅ¾anijska kosa"" Klinika za imunologiju i alergologiju, Belgrade, Serbia|Vojnomedicinska akademija Klinika za reumatologiju, Belgrade, Serbia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,NCT02060552,PRIMARY GOUT,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yikai YU, Wuhan, Hubei, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,NCT02600780,HYPERURICEMIA,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dow University of Health Sciences, Karachi, Sindh, Pakistan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,NCT01472692,PREHYPERTENSION|GOUT|PULSE WAVE VELOCITY|HYPERTENSION|24 HOUR BLOOD PRESSURE,All,18 Years to 50 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Univerisity Of California San Diego, San Diego, California, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,NCT02344602,TYPE 1 DIABETES,All,18 Years to 40 Years Â  (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renal Physiology Laboratory, University Health Network, Toronto, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,,GOUTY ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Completed,NCT03930433,CORONARY VASOSPASM,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Korea University Anam Hospital, Seoul, Korea, Republic of",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01679899,TYPE 2 DIABETES MELLITUS|MENOPAUSE|OSTEOPOROSIS|OSTEOPENIA,Female,"40 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centro de Diabetes Curitiba, Curitiba, Parana, Brazil",A61K45/06,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01472432,CHRONIC FOOT ULCERS,All,"40 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Second university of Naples, Naples, Italy",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Completed,NCT01234675,SLEEP DISORDERS|FIBROMYALGIA|SLEEP,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cleveland Sleep Research Center, Middleburg Heights, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Withdrawn,NCT01359826,SYSTEMIC LUPUS ERYTHEMATOSUS|WIDESPREAD PAIN|FIBROMYALGIA,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Loma Linda University Medical Center, Loma Linda, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Completed,NCT01225991,RHEUMATOID ARTHRITIS,All,"50 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA Semel Institute, Los Angeles, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Completed,NCT01777581,RADICULAR PAIN RELATED TO LUMBOSACRAL DISC DISEASE,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Completed,NCT01780389,KNEE PAIN AFTER TOTAL KNEE ARTHROPLASTY|OSTEOARTHRITIS PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Unknown status,NCT01329406,OSTEOARTHRITIS,All,"21 Years to 75 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Analgesic Solutions, Natick, Massachusetts, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Completed,NCT01510457,KNEE OSTEOARTHRITIS|DEGENERATIVE JOINT DISEASE|CHRONIC PAIN,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Completed,NCT01173055,FIBROMYALGIA,Female,"18 Years to 70 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","University of Michigan, Chronic Pain and Fatigue Research Center, Ann Arbor, Michigan, United States",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Completed,NCT01289236,CHRONIC SHOULDER PAIN,All,"25 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Delray Research Associates, Delray Beach, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
Cc1ccc(=O)n(-c2ccccc2)c1,1,DB04951,__PIRFENIDONE,7988994,Unknown status,NCT02821689,DERMATOPOLYMYOSITIS|INTERSTITIAL LUNG DISEASE,All,"16 Years and older Â  (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Rheumatology, Ren Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,58.3174192488552,419.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,185.2218,20.31,1.0,0.0,2.0,20.28,57.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,1,DB05039,__INDACATEROL,6878721,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,58.3174192488552,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,392.4907,81.59,4.0,4.0,4.0,44.96,118.1,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+],1,DB05245,__SILVER_SULFADIAZINE,3983209,Completed,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,765.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.19,357.13699999999994,95.17,6.0,1.0,2.0,24.1,63.4,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0
CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,1,DB05676,__APREMILAST,6020358,Enrolling by invitation,NCT04515732,PSORIASIS|PSORIATIC ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup, Glostrup, Denmark|Dansk Gigthospital, SÃ¸nderborg, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,15.0803917944927,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.86,460.5,119.08,7.0,1.0,3.0,46.71,119.1,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0
CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,1,DB05676,__APREMILAST,6020358,Recruiting,NCT04102449,PSORIATIC ARTHRITIS,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Medical University of Graz, Graz, Styria, Austria",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,15.0803917944927,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.86,460.5,119.08,7.0,1.0,3.0,46.71,119.1,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0
CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC,1,DB05676,__APREMILAST,6020358,Recruiting,NCT03747939,"ARTHRITIS, PSORIATIC",All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Arizona Arthritis and Rheumatology Research, PLLC, Phoenix, Arizona, United States|Covina Arthritis Clinic, Covina, California, United States|East Bay Rheumatology Medical, San Leandro, California, United States|Inland Rheumatology Clinical Trials, Upland, California, United States|Center for Rheumatology, Immunology, & Arthritis, Fort Lauderdale, Florida, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Integral Rheumatology and Immunology Specialists, Plantation, Florida, United States|North Georgia Rheumatology, Lawrenceville, Georgia, United States|Klein and Associates MD, PA - Cumberland, Cumberland, Maryland, United States|Klein and Associates MD, PA - Hagerstown, Hagerstown, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Advanced Rheumatology, Lansing, Michigan, United States|Shores Rheumatology, Saint Clair Shores, Michigan, United States|St. Paul Rheumatology, PA, Eagan, Minnesota, United States|Arthritis, Rheumatic, and Back Disease Associates, Sewell, New Jersey, United States|NYU Langone Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Joint and Muscle Research Institute, Charlotte, North Carolina, United States|Arthritis & Osteoporosis Center of Southwest Ohio, Springboro, Ohio, United States|Health Research of Oklahoma, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Arthritis Group, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|West Texas Clinical Research, Lubbock, Texas, United States|Seattle Rheumatology Associates, Seattle, Washington, United States|KH Hietzing, Vienna, Austria|AKH Wien, Wein, Austria|CHU Brugmann, Brussels, Belgium|Hopital Erasme, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Jan Palfijn Ziekenhuis, Merksem, Belgium|Manitoba Clinic, Winnipeg, Manitoba, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Dr. Sabeen Anwar Medicine Professional Corporation, Windsor, Ontario, Canada|Institut de Rhumatologie de Montreal, Montreal, Quebec, Canada|Ipros-Chr Orleans, Orleans, France|Hopital Lariboisiere, Paris Cedex 10, France|Assistance Publique- Hopitaux de Paris AP-HP, Paris, France|CH Toulouse Hopital Pierre-Paul Riquet, Toulouse, France|Praxis fur Rheumatologie - Amberg, Amberg, Germany|Kerckhoff-Klinik gGmbH, Bad Nauheim, Germany|Charite - Campus Mitte, Berlin, Germany|Universitaetsklinikum Duesseldorf, Dusseldorf, Germany|MVZ Ambulantes Rheumazentrum Erfurt, Erfurt, Germany|Klinikum der Johann Wolfgang Goethe-UniversitÃ¤t Frankfurt/Main, Frankfurt am Main, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Rheumazentrum Ruhrgebiet, Herne, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Rhein-Maas Klinikum, Wurselen, Germany|Policlinico di Bari UOC, Bari, Italy|AO Spedali Civili di Brescia, Brescia, Italy|Universita degli studi Messina, Messina, Italy|Ospedale San Raffaele S.r.l., Milano, Italy|Humanitas Research Hospital - Humanitas Mirasole S.p.A, Milan, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Policlinico San Matteo Universita Di Pavia, Pavia 2, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|Medisch Spectrum Twente, Enschede, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Kazan State Medical University, Kazan, Russian Federation|Kursk Regional Clinical Hospital, Kursk, Russian Federation|Research Institute of Rheumatology named after V.A.Nasonova, Moscow, Russian Federation|Moscow Regional Research Institute n.a. Vladimirsky, Moscow, Russian Federation|Research Institute of Clinical and Experimental Lymphology, Novosibirsk, Russian Federation|Republican Hospital na VA Baranov, Petrozavodsk, Russian Federation|Municipal Budgetary Healthcare Institution City Emergency Hospital, Rostov-on-don, Russian Federation|I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation|Medical Center Sanavita, St. Petersburg, Russian Federation|Tomsk Regional Clinical Hospital, Tomsk, Russian Federation|Hospital Universitario de Cruces, Baracaldo, Spain|Hospital Galdakao-Usansolo, Galdakao, Spain|Hospital Universitario Insular de Gran Canaria, Gran Canaria, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital de Merida, Merida, Spain|Eastbourne District General Hospital, Eastbourne, United Kingdom|Western General Hospital, Edinburgh Scotland, United Kingdom|Kings College Hospital, London, United Kingdom|Luton and Dunstable University Hosptial, Luton, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|Torbay Hospital, Torquay South Devon, United Kingdom|Royal Cornwall Hospitals Trust, Truro, United Kingdom|Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,15.0803917944927,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.86,460.5,119.08,7.0,1.0,3.0,46.71,119.1,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,1,DB05812,__ABIRATERONE,5604213,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J41/0005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O,1,DB06196,__ICATIBANT,5648333,Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,25.2654058604899,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.2,1304.54,516.22,23.0,18.0,7.0,135.1,363.79,30.0,1.0,0.0,0.0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C,1,DB06204,__TAPENTADOL,6071970,Completed,NCT03604354,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","All India Institute of Medical Sciences, Bhubaneswar, Odisha, India",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,185.0,59.9930183371321,171.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.47,221.3385,23.47,2.0,1.0,1.0,26.58,69.56,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,"Active, not recruiting",NCT03210376,MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS|MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF MALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF URINARY TRACT,All,65 Years and older Â  (Older Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Completed,NCT02724111,NEUROMUSCULAR BLOCKADE|SURGERY|ANESTHESIA|SPINAL DISEASES,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","Korea University Guro Hospital, Seoul, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Completed,NCT02390817,SPINAL CURVATURES,All,"10 Years to 25 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,"Ebru Biricik, Adana, SarÄ±Ã§am, Turkey|Ãukurova University, Adana, Ãukurova, Turkey",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Recruiting,NCT03111121,MICROLARYNGOSCOPY|RIGID BRONCHOSCOPY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"WVU Healthcare Ruby Memorial Hospital, Morgantown, West Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Completed,,ELECTROMYOGRAPHY,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Completed,,LAPAROSCOPIC CHOLECYSTECTOMY,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,"Active, not recruiting",NCT03949894,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,All,19 Years to 50 Years Â  (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Inje University Busan Paik Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Hallym University Medical Center, Pyeongchon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Recruiting,NCT03596957,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Aarhus University Hospital - Site 43, Skejby, Aarhus N, Denmark|Odense University Hospital - Site 45, Odense, Odense C, Denmark|Rigshospitalet - Site 42, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Nordsjaellands Hospital - Site 41, HillerÃ¸d, Denmark|SjÃ¦llands University Hospital Roskilde, Roskilde, Denmark",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Active Not Recruiting,,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ï¼ADPKD),,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Recruiting,NCT02893293,OSTEONECROSIS,All,"8 Years to 40 Years Â  (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Lucile Packard Children's Hospital, Stanford, California, United States",B82Y5/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,1,DB06216,__ASENAPINE,5763476,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,19.9100597548204,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.72,401.84,12.47,1.0,0.0,4.0,30.9,81.65,2.0,0.0,1.0,0.0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,Completed,NCT02379663,"OSTEOARTHRITIS, HIP|FEMUR HEAD NECROSIS|FEMORAL NECK FRACTURES",All,"20 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,Unknown status,NCT02453802,OSTEO ARTHRITIS OF THE KNEES,All,"50 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Kaohsiung Chang Gung Memorial Hospital, Koahsiung, Taiwan",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Unknown status,NCT02742233,DIABETIC FOOT ULCER,All,"50 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","The Second Affiliated Hospital, Third Military Medical University, Chongqing, Chongqing, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Completed,NCT02602704,RHEUMATOID ARTHRITIS,Female,"45 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hanyang University, Seoul, Korea, Republic of",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Completed,NCT02090400,"OSTEOPOROSIS, POSTMENOPAUSAL",Female,"55 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Gabinete MÃ©dico VelÃ¡zquez, Madrid, Spain|Instituto Palacios, Madrid, Spain|Instituto de GinecologÃ­a EGR, Madrid, Spain",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Completed,,POSTMENOPAUSAL OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Suspended,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1,1,DB06413,__ARMODAFINIL,4927855,Completed,NCT00678691,"FIBROMYALGIA, PRIMARY",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SUNY Upstate Medical University, Syracuse, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,39.754409741473104,527.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.2,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1,1,DB06590,__CEFTAROLINE_FOSAMIL,6417175,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/65613,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,25.0682765559867,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.79,684.67,223.24,13.0,4.0,5.0,63.9,171.63,11.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,DB06663,__PASIREOTIDE,6225284,Completed,NCT02060383,CUSHING'S DISEASE|ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States|LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States|Coastal Metabolic Research Centre SC, Ventura, California, United States|East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States|Washington University SC - SOM230B2411, Saint Louis, Missouri, United States|Great Falls Clinic, Great Falls, Montana, United States|Robert Wood Johnson Medical School - Rutgers SC, New Brunswick, New Jersey, United States|The Mount Sinai Hospital SC, New York, New York, United States|Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC, New York, New York, United States|Allegheny Endocrinology Associates SC, Pittsburgh, Pennsylvania, United States|Vanderbilt Clinical Trials Center SOM230B2219, Nashville, Tennessee, United States|Baylor College of Medicine Ben Taub General Hosp., Houston, Texas, United States|Virginia Endocrinology Research SC-2, Chesapeake, Virginia, United States|Swedish Medical Center Dept.ofSeattle Neuroscience(2), Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, SÃ£o Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,DB06663,__PASIREOTIDE,6225284,Unknown status,NCT02668172,ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus Medical Center, Rotterdam, South Holland, Netherlands",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,DB06663,__PASIREOTIDE,6225284,"Active, not recruiting",NCT01794793,CUSHING'S DISEASE|ACROMEGALY|NEUROENDOCRINE TUMORS|PITUITARY TUMORS|ECTOPIC ACTH SECRETING (EAS) TUMORS|DUMPING SYNDROME|PROSTATE CANCER|MELANOMA NEGATIVE FOR BRAF|MELANOMA NEGATIVE FOR NRAS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ximed Research SC - SOM230B2412, La Jolla, California, United States|Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States|Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford, California, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center SC, New York, New York, United States|Virginia Endocrinology Research SC, Chesapeake, Virginia, United States|Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, Botucatu, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Toulouse, Cedex 9, France|Novartis Investigative Site, Angers cedex 09, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, TÃ¼bingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Nankoku city, Kochi, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, MÃ©xico, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,1,DB06684,__VILAZODONE,5532241,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,21.0928355818394,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,441.5249,102.29,4.0,2.0,5.0,50.03,129.71,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1
[N-]=[N+]=O,1,DB06690,__NITROUS_OXIDE,,Completed,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.45,44.0128,51.21,2.0,0.0,0.0,2.55,27.67,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Recruiting,,PROSTATIC NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,1,DB06700,__DESVENLAFAXINE,6673838,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,22.801289554200203,131.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.6,263.3752,43.7,3.0,2.0,2.0,30.29,78.54,4.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,1,DB06700,__DESVENLAFAXINE,6673838,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,22.801289554200203,131.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.6,263.3752,43.7,3.0,2.0,2.0,30.29,78.54,4.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0
O=C([O-])C[N+]12CC[N+]3(CC(=O)[O-])CC[N+]4([C@@H](CO)[C@@H](O)CO)CC[N+](CC(=O)[O-])(CC1)[Gd-]234,1,DB06703,__GADOBUTROL,5980864,Completed,,FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D257/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,103.722869052752,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,604.72,181.08,9.0,3.0,4.0,45.39,143.47,10.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0
NC(N)=NCc1cccc(I)c1,1,DB06704,__IOBENGUANE,4584187,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K51/0406,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,60.6829709028932,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.53,275.0896,64.4,3.0,2.0,1.0,21.93,58.32,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Recruiting,NCT02322099,BONE DEMINERALIZATION,All,"30 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Mater Misericordiae University Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland",A61K33/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Recruiting,NCT02370550,SJOGREN'S SYNDROME,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking University People's Hospital, Beijing, Beijing, China",A61K33/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Enrolling by invitation,NCT02237534,"RENAL INSUFFICIENCY, CHRONIC|HYPERPHOSPHATEMIA|BONE DISEASES, METABOLIC",All,"20 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Osaka University Hospital, Suita, Osaka, Japan",A61K33/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Completed,NCT00785473,"MULTIPLE SCLEROSIS, OSTEOPOROSIS",All,18 Years to 50 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University Hospital of North Norway, TromsÃ¸, Norway",A61K33/10,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Completed,NCT00592917,FRACTURES|OSTEOPOROSIS,Female,65 Years and older Â  (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Bone and Cartilage Research Unit, Clinical Research Centre, University of Kuopio, Kuopio, Finland",A61K33/10,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Completed,NCT01578434,NUTRITIONAL RICKETS,All,6 Months to 5 Years Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,,A61K33/10,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Completed,NCT01067898,HYPOVITAMINOSIS D,Female,70 Years and older Â  (Older Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland",A61K33/10,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB06736,__ACECLOFENAC,4548952,Completed,NCT00635349,OSTEOARTHRITIS,All,"40 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,19.252962073143106,222.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.88,354.18,75.63,4.0,2.0,2.0,32.76,86.32,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB06736,__ACECLOFENAC,4548952,Completed,NCT04144101,RHEUMATOID ARTHRITIS,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.252962073143106,222.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.88,354.18,75.63,4.0,2.0,2.0,32.76,86.32,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB06736,__ACECLOFENAC,4548952,Completed,NCT02682524,OSTEO ARTHRITIS OF THE KNEES,All,"35 Years to 80 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Inha university hospital, Chung gu, Incheon, Korea, Republic of",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,19.252962073143106,222.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.88,354.18,75.63,4.0,2.0,2.0,32.76,86.32,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,1,DB06772,__CABAZITAXEL,5438072,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,20.2714634797429,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.69,835.9324,202.45,10.0,3.0,6.0,86.25,213.4,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,1,1,0,1,0,0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,NCT03124407,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years and older Â  (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Center, Clearwater, Florida, United States|Research Center, Tampa, Florida, United States|Research Center, Dallas, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,1,DB06791,__LANREOTIDE,5595760,Completed,NCT00145405,ACROMEGALY,All,"22 Years to 72 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",A61M5/284,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,22.505595597445502,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1096.33,355.08,12.0,13.0,6.0,114.68,292.92,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
O=C([O-])[O-].O=C([O-])[O-].O=C([O-])[O-].[La+3].[La+3],1,DB06792,__LANTHANUM_CARBONATE,5968976,Enrolling by invitation,NCT02237534,"RENAL INSUFFICIENCY, CHRONIC|HYPERPHOSPHATEMIA|BONE DISEASES, METABOLIC",All,"20 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Osaka University Hospital, Suita, Osaka, Japan",C01F17/005,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,21.5199490749296,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.65,457.835,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].O=C([O-])[O-].O=C([O-])[O-].[La+3].[La+3],1,DB06792,__LANTHANUM_CARBONATE,5968976,Completed,NCT03451019,CHRONIC KIDNEY DISEASE,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Nephrology, Hypertension and Kidney Transplantation, ÅÃ³dÅº, Poland",C01F17/005,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,21.5199490749296,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.65,457.835,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].O=C([O-])[O-].O=C([O-])[O-].[La+3].[La+3],1,DB06792,__LANTHANUM_CARBONATE,5968976,Enrolling by Invitation,,"BONE DISEASES, METABOLIC",,,,,"FISABIO, Elche, Alicante, Spain",C01F17/005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,21.5199490749296,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.65,457.835,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCc1ccc(S(N)(=O)=O)cc1,1,DB06795,__MAFENIDE,3983209,Terminated,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.37,186.232,86.18,3.0,2.0,1.0,18.24,46.69,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,1,DB06803,__NICLOSAMIDE,4283400,Recruiting,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",A23K10/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,23.0312737427873,319.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.49,327.12,95.15,4.0,2.0,2.0,28.47,80.51,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Terminated,NCT01902186,HIV INFECTION|OSTEOPENIA,Female,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Milano, Milano, Italy|University of Torino, Torino, Italy",C07D239/557,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT00939874,HIV|OSTEOPENIA|OSTEOPOROSIS|HIV INFECTIONS,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"East Sydney Doctors, Sydney, New South Wales, Australia|Holdsworth Medical Practice, Sydney, New South Wales, Australia|St Vincents Hospital, Sydney, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O,1,DB06825,__TRIPTORELIN,5776885,"Active, not recruiting",NCT00840944,IDIOPATHIC SHORT STATURE,All,7 Years to 15 Years Â  (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antwerp University Hospital, Edegem, Antwerpen, Belgium|Jessah Ziekenhuis, Hasselt, Limburg, Belgium|Kinderziekenhuis UGent, Gent, Oost Vlaanderen, Belgium|Hopital Universitaire Reine Fabiola (HUDERF), Brussels, Belgium|Kinderziekenhuis UZ Brussel, Brussel, Belgium|CHU ND-des BruyÃ¨res, Liege, Belgium",A61K38/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,52.83065360685021,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.07,1311.473,487.92,17.0,18.0,8.0,135.23,352.43,33.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,1,DB08439,__PARECOXIB,6323226,Completed,NCT02198924,PAIN|INFLAMMATION,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking Union Medical College Hospital, Beijing, China",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,13.3719378221318,707.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.42,370.42199999999997,89.27,4.0,1.0,3.0,38.0,98.9,4.0,0.0,1.0,0.0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0
CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,1,DB08439,__PARECOXIB,6323226,Completed,NCT01843010,"POSTOPERATIVE PAIN MANAGEMENT, PAIN THRESHOLD, SHOULDER PAIN, LAPAROSCOPIES",Female,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University., Guangzhou, Guangdong, China",3,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,13.3719378221318,707.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.42,370.42199999999997,89.27,4.0,1.0,3.0,38.0,98.9,4.0,0.0,1.0,0.0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0
COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O,1,DB08689,__UBIQUINONE_Q1,,Terminated,NCT00590408,STATIN-ASSOCIATED MYALGIA,All,"19 Years to 79 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The Cardiac Center of Creighton University Medical Center, Omaha, Nebraska, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.2,250.2903,52.6,4.0,0.0,1.0,26.94,72.38,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,1,DB08815,__LURASIDONE,5532372,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.0705147949649,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.25,492.676,56.75,5.0,0.0,7.0,56.26,139.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Completed,NCT02874092,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New York University School of Medicine, New York, New York, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Completed,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Not yet recruiting,NCT04117893,"OSTEOARTHRITIS, KNEE|CHRONIC PAIN",All,"50 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Beijing Tiantan Hospital, Beijing, Beijing, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Unknown status,NCT03238183,PHYSICAL ACTIVITY|FUNCTIONAL DISTURBANCE,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Completed,NCT04110587,TEMPOROMANDIBULAR JOINT DISC DISPLACEMENT|TEMPOROMANDIBULAR JOINT DISORDERS,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitario de La Princesa, Madrid, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Unknown status,NCT02949466,PHYSICAL ACTIVITY|FUNCTIONAL PERFORMANCE,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Completed,NCT00731289,OSTEOARTHRITIS,All,"35 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Orthopaedics, Movement Analysis Lab, University Hospital MÃ¼nster, Germany, Muenster, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Completed,NCT01524913,TEMPOROMANDIBULAR JOINT DYSFUNCTION|PAIN|ARTHROCENTESIS,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University California Los Angeles, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|University of Cinncinati, Cinncinati, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Completed,NCT00782197,JOINT DISEASE,All,"40 Years to 72 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCA (Unidad de CirugÃ­a Artroscopica Mikel Sanchez.) Clinica USP La Esperanza., Vitoria, Alava, Spain|Hospital Donostia., San Sebastian, Gipuzkoa, Spain|Policlinica Gipuzkoa, San Sebastian, Gipuzkoa, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Not yet recruiting,NCT04521387,ELBOW TENDINOPATHY,All,30 Years to 50 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Not yet recruiting,NCT04165902,KNEE OSTEOARTHRITIS,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Recruiting,NCT03431584,RHIZARTHROSIS,All,"40 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHD VendÃ©e, La Roche-sur-Yon, France|CH Le Mans, Le Mans, France|CHU Nantes, Nantes, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Completed,NCT03245463,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","Hospital for Special Surgery, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Unknown status,NCT02625727,PHYSICAL ACTIVITY,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Completed,NCT01670578,"KNEE CHONDROPATHY|OSTEOARTHRITIS, KNEE",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","III Orthopaedic Clinic and Nano-biotechnology Lab, Rizzoli Orthopaedic Institute, Bologna, Emilia Romagna, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Unknown status,NCT03077009,PLANTARIS FRICTION SYNDROME|NON-INSERTIONAL ACHILLES TENDINOPATHY,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fortius Clinic, London, United Kingdom|Fortius Clinic, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,"Active, not recruiting",NCT02984228,OSTEOARTHRITIS|SHOULDER PAIN,All,"18 Years to 100 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Unknown status,NCT02429232,OSTEOPOROSIS|DIABETES MELLITUS,All,"40 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CCOc1ccc(C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)O)cc1.[Gd+3],1,DB08884,__GADOXETIC_ACID,6039931,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07F15/025,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,65.47978397913711,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.24,681.75,213.94,14.0,2.0,1.0,50.67,159.21,20.0,1.0,0.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,"Active, not recruiting",NCT04464642,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bangabandhu Seikh Mujib Medical University, Dhaka, Bangladesh",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Not yet recruiting,NCT04311567,RHEUMATOID ARTHRITIS|INTERSTITIAL LUNG DISEASE DUE TO SYSTEMIC DISEASE (DISORDER)|RA|ILD,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"SkÃ¥ne University Hospital, Department of Rheumatology, Lund, SkÃ¥ne, Sweden|Clinical Rheumatology Research Center, The Sahlgrenska University Hospital, GÃ¶teborg, VÃ¤stra GÃ¶taland, Sweden|Karolinska University Hospital, Department of Rheumatology, Stockholm, Sweden",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Unknown status,NCT03504072,SPONDYLOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,1,DB08899,__ENZALUTAMIDE,7709517,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D233/70,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Active Not Recruiting,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0043,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,"Active, not recruiting",NCT02462421,DIABETES MELLITUS|GOUT|HYPERURICEMIA,All,"21 Years and older Â  (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
N#C/C(=C1/SC[C@@H](c2ccc(Cl)cc2Cl)S1)n1ccnc1,1,DB08933,__LULICONAZOLE,5900488,Completed,NCT02394340,TINEA PEDIS|TINEA CRURIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"TKL Research, Fair Lawn, New Jersey, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,16.0660383170085,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.27,354.27,41.61,2.0,0.0,3.0,33.65,101.0,2.0,0.0,1.0,0.0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,1,DB09009,__ARTICAINE,5858410,Completed,,PERIODONTITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,18.792993695969106,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.93,284.374,67.43,3.0,2.0,1.0,30.54,76.78,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,1,DB09009,__ARTICAINE,5858410,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,18.792993695969106,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.93,284.374,67.43,3.0,2.0,1.0,30.54,76.78,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1,1,DB09034,__SUVOREXANT,7951797,Terminated,NCT02684136,INSOMNIA|FIBROMYALGIA,Female,"21 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HFHS Sleep Disorders Ctr, Detroit, Michigan, United States",C07D491/052,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,41.988541859175704,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.86,450.93,80.29,5.0,0.0,5.0,46.68,134.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,0,1
C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C,1,DB09070,__TIBOLONE,6096338,Completed,NCT00431431,OSTEOPENIA,Female,"60 Years to 79 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K47/44,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,37.158873898848,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,312.453,37.3,2.0,1.0,4.0,36.77,91.73,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0
C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C,1,DB09070,__TIBOLONE,6096338,Completed,NCT00294463,POSTMENOPAUSE|OSTEOPOROSIS,Female,"Child, Adult, Older Adult",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus MC, Rotterdam, Netherlands",A61K47/44,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,25.0,37.158873898848,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,312.453,37.3,2.0,1.0,4.0,36.77,91.73,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0
O=C([O-])CCCO.[Na+],1,DB09072,__SODIUM_OXYBATE,6780889,Terminated,NCT00498485,CHRONIC FATIGUE SYNDROME,All,"21 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UMDNJ - Pain & Fatigue Study Center, ADMC 1618, Newark, New Jersey, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,25.4625351649931,19.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.34,126.087,60.36,3.0,1.0,0.0,9.74,34.64,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
CCCCNc1ccc(C(=O)OCCN(C)C)cc1,1,DB09085,__TETRACAINE,5658583,Completed,NCT02372786,TATTOO|ACNE KELOIDALIS NUCHAE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Erasmus MC, Rotterdam, Zuid-Holland, Netherlands",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,51.0,24.7397277151481,1441.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.54,264.369,41.57,3.0,1.0,1.0,31.9,80.17,9.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1
O=C(OOC(=O)c1ccccc1)c1ccccc1,1,DB09096,__BENZOYL_PEROXIDE,7820186,Recruiting,NCT04000347,BENZOYL PEROXIDE|FOOT DERMATOSES,Male,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Department of Dermatology Siriraj Hospital, Bangkok, Thailand",2,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,94.096388016181,5475.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.75,242.2268,52.6,2.0,0.0,2.0,24.16,64.77,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,1,DB09099,__SOMATOSTATIN,,Completed,NCT00595140,ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Klinik - Innenstadt of the University of Munich, Munich, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,1637.9,613.23,22.0,22.0,6.0,165.8,420.26,26.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,1,DB09099,__SOMATOSTATIN,,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,1637.9,613.23,22.0,22.0,6.0,165.8,420.26,26.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1,DB09123,__DIENOGEST,6133251,Unknown Status,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,483.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,311.425,61.09,3.0,1.0,4.0,35.4,90.19,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+],1,DB09125,__POTASSIUM_CITRATE,,Completed,NCT00357331,"BONE DISEASES, METABOLIC|OSTEOPOROSIS, POSTMENOPAUSAL",Female,"45 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Weill Cornell Medical College, New York, New York, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.7,306.394,140.62,7.0,1.0,0.0,14.23,68.14,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O.O.O.OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-],1,DB09146,__IRON_SUCROSE,6174442,Unknown status,NCT02544828,OSTEOARTHRITIS,All,"19 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A23L5/273,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.99,866.546,189.53,11.0,8.0,2.0,30.97,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Completed,NCT02403856,CALCIFYING TENDINITIS OF SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","La Roche sur Yon Hospital, La Roche sur Yon, France|Nantes University Hospital, Nantes, France|Rennes University hospital, Rennes, France",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Completed,NCT02346110,"ARTHROSIS, UNSPECIFIED, ANKLE AND FOOT",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Department of Anesthesiology, Aarhus University Hospital, Aarhus, Midtjylland, Denmark",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Terminated,NCT02421419,TRIGGER FINGER DISORDER,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Enrolling by invitation,NCT02570503,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Virginia Commonwealth University, Richmond, Virginia, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Completed,NCT01212653,ANKYLOSING SPONDYLITIS(AS),All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Prince of Wales Hospital, Hong Kong, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Completed,NCT01486576,OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medicinsk forskningsafsnit, Regionshospitalet Holstebro, Holstebro, Denmark",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Completed,NCT01230424,OSTEOARTHRITIS (OA) OF THE KNEE,All,"45 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Tufts Medical Center / Division of Rheumatology, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COc1ccc(Oc2cc(N(C)CCOc3ccc(CC4SC(=O)NC4=O)cc3)ncn2)cc1,1,DB09198,__LOBEGLITAZONE,,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,480.54,102.88,7.0,1.0,4.0,49.64,129.63,10.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CCCC[C@H](C)C[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC/C=C/C(=O)O,1,DB09211,__LIMAPROST,5811547,Completed,NCT01888536,NEUROLOGIC CLAUDICATION IN PATIENTS WITH LUMBAR SPINAL STENOSIS,All,"20 Years to 75 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of|Hanyang University Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of|KyungHee University Medical Center, Seoul, Korea, Republic of|Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",A61K9/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,39.4587157847183,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.03,380.525,94.83,5.0,3.0,1.0,45.22,108.56,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1
CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1,1,DB09212,__LOXOPROFEN,4161538,Completed,NCT03800797,ANKYLOSING SPONDYLITIS,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",C07C279/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,16.2303127374278,565.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.99,246.3016,54.37,3.0,1.0,2.0,27.08,68.8,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CC(C)Cc1ccc([C@H](C)C(=O)O)cc1,1,DB09213,__DEXIBUPROFEN,4154962,Completed,NCT01066676,OSTEOARTHRITIS OF THE HIP OR KNEE,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Rehabzentrum fÃ¼r Erkrankungen des rheumat. Formenkreises, Bad Hofgastein, Salzburg, Austria|Rheuma Zentrum Favoriten, Vienna, Austria",C07C57/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,18.3987350869627,266.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.81,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB09214,__DEXKETOPROFEN,4097522,Completed,NCT04200885,THIRD MOLAR SURGERY,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Tokat Gaziosmanpasa University, Faculty of Dentistry, Tokat, Turkey",C07C51/09,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,126.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.88,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB09214,__DEXKETOPROFEN,4097522,Completed,NCT03428503,MUSCULOSKELETAL PAIN,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pamukkale University, Denizli, Turkey",C07C51/09,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,126.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.88,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB09214,__DEXKETOPROFEN,4097522,Completed,,"PAIN, ACUTE",,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,126.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.88,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(NCCO[N+](=O)[O-])c1cccnc1,1,DB09220,__NICORANDIL,4769381,Recruiting,NCT04310995,CORONARY ARTERY BYPASS GRAFT|RADIAL ARTERY GRAFTS|ANTISPASTIC THERAPY|PILOT STUDY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.7786402184849,316.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,211.17700000000002,94.36,5.0,1.0,1.0,19.34,49.86,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1
N#Cc1c(N(CC(=O)[O-])CC(=O)[O-])sc(C(=O)[O-])c1CC(=O)[O-].[Sr+2].[Sr+2],1,DB09267,__STRONTIUM_RANELATE,,Completed,NCT01222026,PRIMARY HYPERPARATHYROIDISM|OSTEOPENIA|OSTEOPOROSIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Vienna, General Hospital Vienna (AKH Wien), Vienna, Austria",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.91,513.49,187.55,10.0,0.0,1.0,27.91,116.34,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
N#Cc1c(N(CC(=O)[O-])CC(=O)[O-])sc(C(=O)[O-])c1CC(=O)[O-].[Sr+2].[Sr+2],1,DB09267,__STRONTIUM_RANELATE,,Completed,NCT01544894,POSTMENOPAUSAL OSTEOPOROSIS|COMPLIANCE,Female,"50 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Dr Peset, Valencia, Spain",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.91,513.49,187.55,10.0,0.0,1.0,27.91,116.34,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
N#Cc1c(N(CC(=O)[O-])CC(=O)[O-])sc(C(=O)[O-])c1CC(=O)[O-].[Sr+2].[Sr+2],1,DB09267,__STRONTIUM_RANELATE,,Completed,NCT00479037,OSTEOPOROSIS,Female,"50 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nycomed, Roskilde, Denmark",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.91,513.49,187.55,10.0,0.0,1.0,27.91,116.34,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
N#Cc1c(N(CC(=O)[O-])CC(=O)[O-])sc(C(=O)[O-])c1CC(=O)[O-].[Sr+2].[Sr+2],1,DB09267,__STRONTIUM_RANELATE,,Completed,NCT00239629,POSTMENOPAUSAL OSTEOPOROSIS,Female,"45 Years to 90 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Magdeburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vogelsang, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kifissia, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.91,513.49,187.55,10.0,0.0,1.0,27.91,116.34,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
COC1=C(OC)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(C)C1=O,1,DB09270,__UBIDECARENONE,4325942,Completed,,MUSCLE WEAKNESS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,21.158545350007106,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.94,863.3435,52.6,4.0,0.0,1.0,112.38,286.61,31.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21,1,DB09290,__RAMOSETRON,6235745,Completed,NCT01102491,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 86 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Joint Reconstruction Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.220107189059306,160.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.22,279.343,50.68,2.0,1.0,4.0,31.2,82.14,2.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12,1,DB09401,__ISOSORBIDE,4065488,Withdrawn,NCT02011620,ENDOTHELIAL DYSFUNCTION|BONE DISEASE,All,"40 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Tameside General Hospital NHS Foundation Trust, Manchester, United Kingdom",C07D493/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.053594529661801,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,146.1412,58.92,4.0,2.0,2.0,13.54,31.38,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12,1,DB09401,__ISOSORBIDE,4065488,Recruiting,NCT04310995,CORONARY ARTERY BYPASS GRAFT|RADIAL ARTERY GRAFTS|ANTISPASTIC THERAPY|PILOT STUDY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China",C07D493/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.053594529661801,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,146.1412,58.92,4.0,2.0,2.0,13.54,31.38,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OCC(O)CO,1,DB09462,__GLYCERIN,9034300,Recruiting,NCT03355326,GASTROSCHISIS,All,up to 1 Year Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Riley Hospital for Children, Indianapolis, Indiana, United States",A61K49/226,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,55.0976406086367,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,92.0938,60.69,3.0,3.0,0.0,8.93,20.52,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
OCC(O)CO,1,DB09462,__GLYCERIN,9034300,Completed,NCT01271855,PAIN,Female,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Loyola Univeristy Medical Center, Maywood, Illinois, United States|Gottlieb Memorial Hospital, Melrose Park, Illinois, United States",A61K49/226,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,55.0976406086367,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,92.0938,60.69,3.0,3.0,0.0,8.93,20.52,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,1,DB11089,__DOCUSATE,4156715,Terminated,,ANALGESIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/466,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.9716215938725,95.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.48,422.577,106.97,5.0,1.0,0.0,46.82,107.35,18.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Completed,NCT01400516,RHEUMATOID ARTHRITIS,All,"45 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,"Active, not recruiting",NCT03994172,MALE OSTEOPOROSIS,Male,"60 Years to 85 Years Â  (Adult, Older Adult)",U.S. Fed|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Completed,NCT01731340,CARDIOVASCULAR DISEASES|OSTEOPOROSIS,Female,"50 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Department of Internal Medicine; Montreal General Hospital, Montreal, Quebec, Canada",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
OC[C@H](O)[C@@H](O)[C@H](O)CO,1,DB11195,__XYLITOL,,Unknown status,NCT02104596,KNEE OSTEOARTHRITIS,All,"45 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, Israel",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,152.1458,101.15,5.0,5.0,0.0,14.42,32.44,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.[Cr+3],1,DB11255,__CHROMIUM_PICOLINATE,,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,418.3005,53.02,3.0,0.0,3.0,10.94,41.62,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11348,__CALCIUM_PHOSPHATE,,Not Yet Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,310.177,86.25,4.0,0.0,0.0,4.93,11.29,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12,1,DB11560,__LESINURAD,8084483,Terminated,NCT03226899,GOUT|CHRONIC KIDNEY DISEASE (CKD),All,"18 Years to 85 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Central Alabama Research, Birmingham, Alabama, United States|Southern Arizona VA Health Care System, Tucson, Arizona, United States|Medvin Clinical Research, Covina, California, United States|Northern California Research, Sacramento, California, United States|Capital Nephrology Medical Group, Sacramento, California, United States|Inland Rheumatology Clinical Trials, Inc, Upland, California, United States|Medvin Clinical Research - Whittier, Whittier, California, United States|Western Nephrology-Westminster, Westminster, Colorado, United States|New England Research Associates, Llc, Trumbull, Connecticut, United States|Arthritis, Autoimmune, & Allergy LLC, Daytona Beach, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|Florida Medical Research Institute, Gainesville, Florida, United States|Eastern Research, Hialeah, Florida, United States|Savin Medical Group, Miami Lakes, Florida, United States|San Marcus Research Clinic Inc, Miami, Florida, United States|LCC Medical Research Institute, LLC, Miami, Florida, United States|Rheumatology Associates of Central Florida, Orlando, Florida, United States|Omega Research Consultants, LLC, Orlando, Florida, United States|BayCare Medical Group, Inc., Tampa, Florida, United States|Meridien Research - Tampa, Tampa, Florida, United States|The Kaufmann Clinic, Inc, Atlanta, Georgia, United States|Ellipsis Group, Atlanta, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center PA, Idaho Falls, Idaho, United States|Clinical Investigation Specialists, Inc. - Gurnee, Gurnee, Illinois, United States|Nephrology Specialists, Merrillville, Indiana, United States|Kansas Nephrology Research Institute, Wichita, Kansas, United States|Center for Arthritis & Osteoporosis, Elizabethtown, Kentucky, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Clinical Trials Management, LLC - Northshore, Covington, Louisiana, United States|Clinical Trials Management LLC - Southshore, Metairie, Louisiana, United States|Arthritis and Diabetes Clinic, Monroe, Louisiana, United States|Northwest Louisiana Nephrology, Shreveport, Louisiana, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Michigan Kidney Consultants, Pontiac, Michigan, United States|St. Clair Nephrology Research, Roseville, Michigan, United States|CRC of Jackson, LLC, Jackson, Mississippi, United States|VA Medical Center - Kansas City, Kansas City, Missouri, United States|Meridian Clinical Research - Norfolk, NE, Norfolk, Nebraska, United States|New Mexico Clinical Research & Osteoporosis Center Inc., Albuquerque, New Mexico, United States|Ellipsis Research Group, LLC, Brooklyn, New York, United States|Buffalo VA Medical Center, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|DJL Clinical Research PLLC, Charlotte, North Carolina, United States|PhysiqueMed Clinical Trials, Greensboro, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|Sterling Research Group, Ltd. - Auburn, Cincinnati, Ohio, United States|Sterling Research Group, Ltd. - Cincinnati, Cincinnati, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|Columbia Research Group, Inc., Portland, Oregon, United States|Northeast Clinical Research Center, Bethlehem, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, East Providence, Rhode Island, United States|Low Country Rheumatology, Charleston, South Carolina, United States|Piedmont Research Partners, LLC, Fort Mill, South Carolina, United States|Mountain View Clinical Research - Greer, Greer, South Carolina, United States|Knoxville Kidney Center, PLLC, Knoxville, Tennessee, United States|Discovery Alliance International Inc. d/b/a Tennessee Health Research Alliance LLC, Nashville, Tennessee, United States|Nephrology Associates, P.C., Nashville, Tennessee, United States|FMC Science, Lampasas, Texas, United States|P&I Clinical Research, Lufkin, Texas, United States|Clinical Advancement Center, PLLC, San Antonio, Texas, United States|Briggs Clinical Research, Inc., San Antonio, Texas, United States|3rd Coast Research Associates, Victoria, Texas, United States|Spectrum Medical, Inc., Danville, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Clinical Research Partners, LLC, Richmond, Virginia, United States|CCBR Czech Brno, s. r. o, Brno, Czechia|REVMACLINIC s.r.o. - Revmatologicka ambulance, Brno, Czechia|DTTO Faculty Hospital Brno, Brno, Czechia|Revmatologie MUDr. Bilkova s.r.o., Olomouc, Czechia|CCBR Ostrava s.r.o., Ostrava, Czechia|CCBR Clinical Research, Pardubice, Pardubice, Czechia|CCBR Czech Prague s.r.o., Prague, Czechia|MEDICAL PLUS, s.r.o. - Revmatologicka ambulance, Uherske Hradiste, Czechia|Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o.z., Usti nad Labem, Czechia|PV - MEDICAL, s.r.o., ZlÃ­n, Czechia|Nemocnice Znojmo p.o - Interni oddeleni, Znojmo, Czechia|Bajai Szent Rokus Korhaz, Baja, Hungary|DRC Gyogyszervizsgalo Kozpont Kft, BalatonfÃ¼red, Hungary|Clinexpert Kft., Budapest, Hungary|Dr Lakatos Ferenc Belgyogyaszati-Kardiologiai Maganrendelo, BÃ©kÃ©scsaba, Hungary|Vaszary Kolos Korhaz Esztergom - Reumatologiai osztaly, Esztergom, Hungary|BKS Research Kft., Hatvan, Hungary|Kalocsai Szent Kereszt Korhaz, Kalocsa, Hungary|Selye Janos Hospital - Rheumatology Department, KomÃ¡rom, Hungary|CRU Hungary Kft., Miskolc, Hungary|Clinfan Ltd SMO, SzekszÃ¡rd, Hungary|Allergo-Derm Bakos Kft., Szolnok, Hungary|Mentahaz Maganorvosi Kozpont (SMO), SzÃ©kesfehÃ©rvÃ¡r, Hungary|Medical Expert Kft., Veszprem, Hungary|Stacja Dializ Zyrardow, Zyrardow, Zyrardo, Poland|B_Serwis Popenda Sp. J., ChorzÃ³w, Poland|Centrum Kliniczno Badawcze J. Brzezicki B. Gornikiewicz - Brzezicka Lekarze Sp. p., ElblÄg, Poland|MCBK s.c., Grodzisk Mazowiecki, Poland|NZOZ Praktyka Lekarza Rodzinnego Elzbieta Kelm, Katowice, Poland|Centrum Medyczne Pratia Krakow, KrakÃ³w, Poland|Malopolskie Centrum Medyczne, KrakÃ³w, Poland|Centrum Medyczne Chodzki, Lublin, Poland|Alfa Specjalistyczne Gabinety Lekarskie Ewa Moroz, Nowy SÄcz, Poland|Centrum Zdrowia Metabolicznego Pawel Bogdanski, PoznaÅ, Poland|Centrum Badan Klinicznych s.c., PoznaÅ, Poland|Praktyka Lekarska Ewa Krzyzagorska, PoznaÅ, Poland|Prywatny Gabinet Lekarski NZOZ Centrum Medyczne Aeskulap, Radom, Poland|Centrum Medyczne Pratia Warszawa, Warszawa, Poland|Centrum Medyczne K2J2, WoÅomin, Poland|KO - MED Centra Kliniczne Sp. z o.o., Osrodek Badan Klinicznych w Zamosciu, ZamoÅÄ, Poland|Samodzielny Publiczny ZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi, Oddzial Kliniczny Nefrologii, Hipertensjologii i Transplantologii Nerek, ÅÃ³dÅº, Poland|Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo Akcyjna, ÅÃ³dÅº, Poland|AppleTreeClinics Sp. z o.o., ÅÃ³dÅº, Poland|Centrum Medyczne AMED Oddzial w Lodzi, ÅÃ³dÅº, Poland|NZOZ All - Med Centrum Medyczne Specjalistyczne Gabinety Lekarskie Marcin Ogorek, ÅÃ³dÅº, Poland|Centrum Dializa Sp. z o.o. - Zyrardow, Å»yrardÃ³w, Poland",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,36.994599478428704,29.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.42,404.28,68.01,4.0,1.0,4.0,36.59,109.15,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,0,0
COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2c(c1OC)-c1ccc(SC)c(=O)cc1[C@@H](NC(C)=O)CC2,1,DB11582,__THIOCOLCHICOSIDE,WO-1996041635-A1,Completed,NCT00272532,MYOFASCIAL PAIN SYNDROME,All,18 Years to 50 Years Â  (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Sanofi-Aventis, Istanbul, Turkey",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.78,563.62,164.01,10.0,5.0,4.0,57.72,145.06,7.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0
O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,1,DB11656,__REBAMIPIDE,5476858,Completed,NCT03608761,DRY EYE SYNDROMES|SJÃGREN SYNDROME,Female,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hospital Nacional Profesor A. Posadas, El Palomar, Buenos Aires, Argentina",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,23.425532351793603,66.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.32,370.79,95.5,4.0,3.0,3.0,36.82,98.5,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Active Not Recruiting,,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ï¼ADPKD),,,,,"FISABIO, Elche, Alicante, Spain",C09B61/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Completed,,PERIODONTITIS,,,,,"FISABIO, Elche, Alicante, Spain",C09B61/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Not Yet Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C09B61/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,1,DB11675,__MOSAPRIDE,4870074,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D413/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,29.109427298301807,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,421.9,76.82,5.0,2.0,3.0,43.79,112.34,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1
OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB11698,__IPRAGLIFLOZIN,EP-2009010-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.49,404.45,90.15,5.0,4.0,4.0,40.7,102.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,1,DB11699,__TROPISETRON,5032578,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,9.92217499332635,632.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,284.3529,45.33,2.0,1.0,4.0,31.35,81.5,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB11750,__CLOBETASOL,4333927,Not yet recruiting,NCT03926377,OSTEOPOROSIS|BULLOUS PEMPHIGOID,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,14.8504076059056,513.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.72,410.907,74.6,4.0,2.0,4.0,41.97,105.54,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
CNC(=N)NCCC[C@H](N)C(=O)O,1,DB11815,__TILARGININE,EP-0765668-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K36/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,31.080720343333503,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,188.2275,111.23,6.0,5.0,0.0,20.01,58.7,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,1,DB11817,__BARICITINIB,8158616,Recruiting,NCT04086745,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Arthritis & Rheumatology Research, PLLC, Flagstaff, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Gilbert, Arizona, United States|Arizona Arthritis & Rheumatology Research, Glendale, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Mesa, Arizona, United States|Hope Research Institute, Peoria, Arizona, United States|Sun Valley Arthritis Center, LTD, Peoria, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Arizona Arthritis & Rheumatology Research, Phoenix, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Phoenix, Arizona, United States|Prescott Rheumatology, Prescott, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Sun City, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Tucson, Arizona, United States|Arthritis and Rheumatism Associates, Jonesboro, Arkansas, United States|Hope Clinical Research, Canoga Park, California, United States|Medvin Clinical Research - Weidmann, Covina, California, United States|TriWest Research Associates LLC, El Cajon, California, United States|St. Joseph Heritage Medical Group, Fullerton, California, United States|MD Medical Corporation, Hemet, California, United States|Newport Huntington Med Grp, Huntington Beach, California, United States|BioSolutions Clinical Research Center, La Mesa, California, United States|Valerius Medical Group and Research Center of Greater Long Beach, Los Alamitos, California, United States|Soha Dolatabadi, MD, Los Angeles, California, United States|Providence St. Joseph's Medical Center, Mission Hills, California, United States|Desert Medical Advances, Palm Desert, California, United States|ACRC Studies, Poway, California, United States|East Bay Rheumatology Medical Group, Inc, San Leandro, California, United States|Dan La, MD Inc, Tujunga, California, United States|Iraj Sabahi Research Inc., Turlock, California, United States|Office: Dr Robin K Dore, Tustin, California, United States|Inland Rheumatology & Osteoporosis Medical Group, Upland, California, United States|Nazanin Firooz, MD Inc., West Hills, California, United States|Nazanin Firooz, MD Inc., West Hills, California, United States|Medvin Clinical Research - Weidmann, Whittier, California, United States|Danbury Clinical Research, LLC, Danbury, Connecticut, United States|Delaware Arthritis, Lewes, Delaware, United States|Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States|SIMED Health, Gainesville, Florida, United States|GNP Research at Mark Jaffe, MD, Hollywood, Florida, United States|Arthritis and Rheumatology Center of South Florida, Margate, Florida, United States|Miami Clinical Reserach, Miami, Florida, United States|Rheumatology Associates of Central Florida, Orlando, Florida, United States|Heuer MD Research, Orlando, Florida, United States|Arthritis Center, Inc, Palm Harbor, Florida, United States|Lovelace Scientific Resources, Riverview, Florida, United States|West Broward Rheumatology Associates, Inc, Tamarac, Florida, United States|Avita Clinical Research, Tampa, Florida, United States|Florida Medical Clinic LLC, Zephyrhills, Florida, United States|Arthritis Center of North Georgia, Gainesville, Georgia, United States|Rockford Orthopedic Associates, Rockford, Illinois, United States|Greater Chicago Specialty Physicians, LLC, Schaumburg, Illinois, United States|Center of Robert Hozman, Skokie, Illinois, United States|Beacon Medical Group Clinical Research, South Bend, Indiana, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Western KY Rheumatology PLLC, Hopkinsville, Kentucky, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Arthritis Care Specialists of Maryland, Columbia, Maryland, United States|Klein & Associates, M.D., P.A, Hagerstown, Maryland, United States|NECCR PrimaCare Research, Fall River, Massachusetts, United States|University of Michigan, Brighton, Michigan, United States|Pandit Rheumatology PC, Okemos, Michigan, United States|West County Rheumatology, Saint Louis, Missouri, United States|Clinvest Research LLC, Springfield, Missouri, United States|Allied Clinical Research, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Santa Fe Rheumatology, Santa Fe, New Mexico, United States|NYU Langone, New York, New York, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Cape Fear Arthritis Care, Leland, North Carolina, United States|Carolina Arthritis Associates, Wilmington, North Carolina, United States|Cincinnati Arthritis Associates, Cincinnati, Ohio, United States|Craig S Thompson MD LLC, Marion, Ohio, United States|Paramount Medical Research, Middleburg Heights, Ohio, United States|Arthritis & Rheumatology Center of Oklahoma PLLC, Oklahoma City, Oklahoma, United States|The Oklahoma Center For Arthritis Therapy, Tulsa, Oklahoma, United States|Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States|Pennsylvania Regional Center for Arthritis and Osteoporosis Research, Wyomissing, Pennsylvania, United States|Articularis Healthcare d/b/a/ Low Country Rheumatology, PA, Summerville, South Carolina, United States|Monument Health Clinical Research, a department of Monument Health Rapid City Hospital, Inc., Rapid City, South Dakota, United States|Cumberland Rheumatology, Crossville, Tennessee, United States|Nashville Arthritis and Rheumatology, Nashville, Tennessee, United States|Accent Clinical Research Professionals, LLC, Allen, Texas, United States|Amarillo Center for Clinical Research, Amarillo, Texas, United States|Accurate Clinical Management, Baytown, Texas, United States|Arthritis & Osteoporosis Clinic of Brazos Valley, College Station, Texas, United States|Adriana Pop Moody Clinic PA, Corpus Christi, Texas, United States|Pioneer Research Solutions, Cypress, Texas, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|El Paso Integrated Physicians Group, P.A., an Elligo Health Research, Inc. Healthcare Enabled Research Organization, El Paso, Texas, United States|DM Clinical Research/Rheumatology Clinic of Houston, Houston, Texas, United States|Accurate Clinical Management LLC - Katy, Houston, Texas, United States|Accurate Clinical Research, Houston, Texas, United States|Synergy Group US, Katy, Texas, United States|Accurate Clinical Research, League City, Texas, United States|Southwest Rheumatology, P.A., Mesquite, Texas, United States|Synergy Group US, Missouri City, Texas, United States|Accurate Clinical Research, Inc., San Antonio, Texas, United States|South Texas Arthritis Care Center, San Antonio, Texas, United States|Mt. Olympus Medical Research, Sugar Land, Texas, United States|North Houston Rheumatology Associates, The Woodlands, Texas, United States|Center for Arthritis and Rheumatic Diseases, PC, Chesapeake, Virginia, United States|Spectrum Medical Inc., Danville, Virginia, United States|Arthritis & Osteoporosis Center of Northern Virinia, Manassas, Virginia, United States|TPMG Rheumatology/TPMG Clinical Research, Newport News, Virginia, United States|Arthritis Northwest, PLLC, Spokane, Washington, United States|Rheumatology and Pulmonary Clinic, Beckley, West Virginia, United States|Rheumatic Disease Center, Glendale, Wisconsin, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,1,DB11901,__APALUTAMIDE,8445507,Recruiting,,PROSTATIC NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,73.82492453643809,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,477.44,89.33,4.0,1.0,4.0,43.44,113.6,4.0,0.0,1.0,0.0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1
CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB11921,__DEFLAZACORT,5543417,"Active, not recruiting",NCT04365088,IMPACTED THIRD MOLAR TOOTH,All,18 Years to 40 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Van Yuzuncu Yil University, Faculty of Dentistry, Van, TuÅba, Turkey",A61K45/06,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.5199490749296,511.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,441.524,102.26,5.0,1.0,5.0,46.79,117.12,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,1,DB11992,__OMARIGLIPTIN,WO-2013003249-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,32.7488,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.63,398.43,90.45,6.0,1.0,4.0,39.42,95.14,2.0,0.0,1.0,0.0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0
CC(=O)Oc1cccc2c1C(=O)c1c(OC(C)=O)cc(C(=O)O)cc1C2=O,1,DB11994,__DIACEREIN,4244968,Completed,NCT01906801,OSTEOARTHRITIS|GLUCOSAMINE|DIACEREIN,All,"50 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Mahidol University, Bangkok, Thailand",C07C66/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,46.456806094581005,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,368.29699999999997,124.04,6.0,1.0,3.0,35.37,90.67,5.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1cccc2c1C(=O)c1c(OC(C)=O)cc(C(=O)O)cc1C2=O,1,DB11994,__DIACEREIN,4244968,Completed,NCT02060552,PRIMARY GOUT,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yikai YU, Wuhan, Hubei, China",C07C66/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,46.456806094581005,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,368.29699999999997,124.04,6.0,1.0,3.0,35.37,90.67,5.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1cccc2c1C(=O)c1c(OC(C)=O)cc(C(=O)O)cc1C2=O,1,DB11994,__DIACEREIN,4244968,Unknown status,NCT03404479,KNEE OSTEOARTHRITIS,All,"50 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Seoul ST. Mary's Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of",C07C66/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,46.456806094581005,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,368.29699999999997,124.04,6.0,1.0,3.0,35.37,90.67,5.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1cccc2c1C(=O)c1c(OC(C)=O)cc(C(=O)O)cc1C2=O,1,DB11994,__DIACEREIN,4244968,Completed,NCT01120015,"OSTEOARTHRITIS|OSTEOARTHRITIS, KNEE",All,35 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kuljinder Singh, Amritsar, Punjab, India",C07C66/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,46.456806094581005,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,368.29699999999997,124.04,6.0,1.0,3.0,35.37,90.67,5.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1cccc2c1C(=O)c1c(OC(C)=O)cc(C(=O)O)cc1C2=O,1,DB11994,__DIACEREIN,4244968,Completed,NCT00685542,OSTEOARTHRITIS,All,"40 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Seoul National University Hospital, Seoul, Korea, Republic of",C07C66/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,46.456806094581005,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,368.29699999999997,124.04,6.0,1.0,3.0,35.37,90.67,5.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1cccc2c1C(=O)c1c(OC(C)=O)cc(C(=O)O)cc1C2=O,1,DB11994,__DIACEREIN,4244968,Completed,,OSTEO ARTHRITIS OF THE KNEES,,,,,"FISABIO, Elche, Alicante, Spain",C07C66/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,46.456806094581005,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,368.29699999999997,124.04,6.0,1.0,3.0,35.37,90.67,5.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
O=c1c(-c2ccccc2)coc2ccccc12,1,DB12007,__ISOFLAVONE,4234577,Completed,NCT00668447,OSTEOPOROSIS,Female,65 Years and older Â  (Older Adult),U.S. Fed|Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Connecticut Health Center, Farmington, Connecticut, United States",3,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,20.041479291155802,192.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.51,222.243,26.3,2.0,0.0,3.0,23.64,65.74,1.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,NCT00548509,OSTEOPOROSIS,Female,"49 Years to 90 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kumagaya-shi, Saitama Prefecture, Japan|Hachioji-shi, Tokyo, Japan|Setagaya-Ku, Tokyo, Japan|Nishiyatsushiro-Gun, Yamanashi Prefecture, Japan",A23L3/44,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A23L3/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C(=O)O)c1ccc(/C=C2\CCCCC2=O)cc1,1,DB12150,__PELUBIPROFEN,WO-2003024489-A2,Completed,NCT02682524,OSTEO ARTHRITIS OF THE KNEES,All,"35 Years to 80 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Inha university hospital, Chung gu, Incheon, Korea, Republic of",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,32.7488,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,258.317,54.37,3.0,1.0,2.0,28.63,74.28,3.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0
C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,1,DB12153,__CITICOLINE,4203893,Completed,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/531,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,20.6657220887492,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,488.324,213.5,10.0,4.0,2.0,42.54,113.58,10.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0
CC(C)(S)C(=O)N[C@@H](CS)C(=O)O,1,DB12160,__BUCILLAMINE,4241086,Unknown status,NCT00716248,RHEUMATOID ARTHRITIS,All,"20 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,14.6204234173186,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.52,223.31,66.4,3.0,4.0,0.0,22.09,54.7,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0
COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,1,DB12163,__SARPOGRELATE,5652272,Unknown status,NCT01674686,VARIANT ANGINA,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Hyoen-Cheol Gwon, MD,PhD, Seoul, Korea, Republic of",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,28.4851845007084,36.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.57,429.51300000000003,85.3,6.0,1.0,2.0,46.89,117.35,14.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0
COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,1,DB12163,__SARPOGRELATE,5652272,Unknown Status,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,28.4851845007084,36.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.57,429.51300000000003,85.3,6.0,1.0,2.0,46.89,117.35,14.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0
COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,1,DB12163,__SARPOGRELATE,5652272,Unknown Status,,VASOSPASTIC ANGINA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,28.4851845007084,36.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.57,429.51300000000003,85.3,6.0,1.0,2.0,46.89,117.35,14.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0
CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,1,DB12233,__IGURATIMOD,4954518,Recruiting,NCT03855007,RHEUMATOID ARTHRITIS,All,"16 Years to 90 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu Hospital, Jinan, Shandong, China",C07D405/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,22.899854206451806,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,374.37,110.8,5.0,2.0,3.0,36.19,92.79,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0
CC1=NN(c2ccccc2)C(=O)C1,1,DB12243,__EDARAVONE,6933310,Completed,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,57.2989178422554,88.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.53,174.203,32.67,2.0,0.0,2.0,18.61,49.49,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0
CC1=NN(c2ccccc2)C(=O)C1,1,DB12243,__EDARAVONE,6933310,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,57.2989178422554,88.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.53,174.203,32.67,2.0,0.0,2.0,18.61,49.49,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0
CC(C)(C)NCC(O)c1ccccc1Cl,1,DB12248,__TULOBUTEROL,4018818,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07C49/86,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,23.4912421199613,364.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,227.73,32.26,2.0,2.0,1.0,24.53,63.88,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,1,DB12319,__BENZBROMARONE,5260066,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.7827881476005,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.52,424.083,50.44,2.0,1.0,3.0,35.65,92.37,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0
CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,1,DB12319,__BENZBROMARONE,5260066,Recruiting,,HYPERURICEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.7827881476005,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.52,424.083,50.44,2.0,1.0,3.0,35.65,92.37,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0
CO[C@@]1(NC(=O)C(C(=O)O)c2ccsc2)C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]21,1,DB12343,__TEMOCILLIN,5543417,Unknown Status,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,21.5199490749296,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.13,414.45,133.24,7.0,3.0,3.0,38.91,94.22,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CCCN1CC(c2ccc(S(C)(=O)=O)cc2)=C(c2ccc(C)cc2)C1=O,1,DB12354,__IMRECOXIB,7112605,Recruiting,NCT03932006,ANKYLOSING SPONDYLITIS,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rheumatology Department, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",C07D207/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,40.4443623072342,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.42,369.48,54.45,3.0,0.0,3.0,41.29,105.24,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
CCCN1CC(c2ccc(S(C)(=O)=O)cc2)=C(c2ccc(C)cc2)C1=O,1,DB12354,__IMRECOXIB,7112605,Unknown status,NCT01985165,KNEE OSTEOARTHRITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China|Cangzhou Central Hospital, Cangzhou, Hebei, China|Tongji Hospital, Wuhan, Hubei, China|The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong, China|The Second Hospital of Shangdong University, Jinan, Shandong, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Taizhou Hospital, Taizhou, Zhejiang, China|BeijingChao-YangHospital, Beijing, China|China-Japan Friendship Hospital, Beijing, China|Peking University First Hospital, Beijing, China|Beijing Hospital of the Ministry of Health, Beijing, China|Peking Union Medical College Hospita, Beijing, China|Peking University Third Hospital, Beijing, China|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing, China|Tianjin First Center Hospital, Tianjin, China",C07D207/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,40.4443623072342,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.42,369.48,54.45,3.0,0.0,3.0,41.29,105.24,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,1,DB12412,__GEMIGLIPTIN,WO-2006104356-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.02,489.37,92.42,5.0,1.0,3.0,39.04,97.25,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0
O=[O+][O-],1,DB12510,__OZONE,,Completed,NCT02833545,OSTEO ARTHRITIS OF THE KNEES,All,"55 Years to 79 Years Â  (Adult, Older Adult)",Other,"Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.21,47.997,74.27,3.0,0.0,0.0,2.31,4.24,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0
CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F,1,DB12625,__EVOGLIPTIN,US-20100120790-A1,Unknown status,NCT02587975,"DIABETES MELLITUS, TYPE 2|OSTEOPOROSIS",Female,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dongguk University Ilsan Hospital, Goyang, Gyeonggi, Korea, Republic of",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,41.5285734820016,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.29,401.43,84.66,4.0,2.0,2.0,39.21,97.43,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0
FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,1,DB12978,__PEXIDARTINIB,7893075,Not yet recruiting,NCT04526704,TENOSYNOVIAL GIANT CELL TUMOR,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Honor Health, Scottsdale, Arizona, United States|USC Norris Comprehensive Cancer Cente, Los Angeles, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Rizzoli-Istituto Ortopedico Rizzoli, Bologna, Italy|Fondazione IRCC Istituto Nazionale dei Tumori, Milano, Italy|Leiden University Medical Center (LUMC), Leiden, Netherlands|Hospital Sant Pau, Barcelona, Spain|Hospital Virgen del Rocio, Sevilla, Spain|National Taiwan University Hospital, Taipei, Taiwan",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,39.064457175712,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.64,417.82,66.49,4.0,2.0,4.0,39.33,105.89,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C09K3/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,,FATIGUE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,,HYPEREMESIS GRAVIDARUM,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,1,DB13679,__DEXCHLORPHENIRAMINE,4619934,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.6717797080022,310.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.74,274.79,16.13,2.0,0.0,2.0,30.82,80.85,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00118716,BRONCHOSPASM|ACTIVITY/EXERCISE INDUCED BRONCHOSPASM,All,4 Years to 17 Years Â  (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palmdale, California, United States|GSK Investigational Site, Paramount, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Centennial, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Lilburn, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Hoffman Estates, Illinois, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Glen Burnie, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Summit, New Jersey, United States|GSK Investigational Site, Commack, New York, United States|GSK Investigational Site, Utica, New York, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Gresham, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Hershey, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Mount Pleasant, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Dyersburg, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Murray, Utah, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00355342,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"40 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Berkeley, California, United States|GSK Investigational Site, Fullerton, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Fort Collins, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Hartford, Connecticut, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Sarasota, Florida, United States|GSK Investigational Site, Tamarac, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, North Chicago, Illinois, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Cadillac, Michigan, United States|GSK Investigational Site, Saint Charles, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Bronxville, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Greer, South Carolina, United States|GSK Investigational Site, Simpsonville, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Kingsport, Tennessee, United States|GSK Investigational Site, Milan, Tennessee, United States|GSK Investigational Site, Corsicana, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Bellingham, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Spokane, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,1,DB13873,__FENOFIBRIC_ACID,7259186,Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,37.68455204418978,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.97,318.75,63.6,4.0,1.0,2.0,32.42,83.19,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/31593,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13944,__TESTOSTERONE_ENANTHATE,8021335,Completed,,SARCOPENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,49.93942380747029,149.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.11,400.594,43.37,2.0,0.0,4.0,49.18,116.61,7.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Not Yet Recruiting,,BARIATRIC SURGERY CANDIDATE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,NCT00860964,OSTEOPOROSIS,Female,40 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",,5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Terminated,NCT01902186,HIV INFECTION|OSTEOPENIA,Female,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Milano, Milano, Italy|University of Torino, Torino, Italy",C07F9/65616,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,"Active, not recruiting",NCT02815566,OSTEOPOROSIS|HIV|MENOPAUSE,Female,40 Years to 60 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vancouver ID Research and Care Centre, Vancouver, British Columbia, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre, MontrÃ©al, Quebec, Canada|CHU de QuÃ©bec-UniversitÃ© Laval, QuÃ©bec, Quebec, Canada|Ospedale San Raffaele, Milan, Italy|UniversitÃ  degli Studi di Modena e Reggio Emilia, Modena, Italy",C07F9/65616,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Recruiting,NCT02322099,BONE DEMINERALIZATION,All,"30 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Mater Misericordiae University Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
CC(C)=CCCC(C)(O)[C@H]1CC[C@]2(C)C1CC[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@]12C,1,DB14152,__GINSENOSIDES,,Completed,,FATIGUE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.39,444.744,40.46,2.0,2.0,4.0,55.91,135.64,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0
CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,1,DB14185,__ARIPIPRAZOLE_LAUROXIL,8431576,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,34.2019343313004,10.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.91,660.72,62.32,5.0,0.0,4.0,76.95,183.74,20.0,1.0,0.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,0,1,1,1
O=P([O-])([O-])O.[Na+].[Na+],1,DB14502,"__SODIUM_PHOSPHATE,_DIBASIC",7687075,Terminated,NCT02421419,TRIGGER FINGER DISORDER,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=P([O-])([O-])O.[Na+].[Na+],1,DB14502,"__SODIUM_PHOSPHATE,_DIBASIC",7687075,Recruiting,NCT04544683,"CERVICAL RADICULOPATHY|CERVICAL SPONDYLOSIS|DISK, HERNIATED",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Utah, Salt Lake City, Utah, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=P([O-])([O-])O.[Na+].[Na+],1,DB14502,"__SODIUM_PHOSPHATE,_DIBASIC",7687075,Recruiting,NCT04432012,TOTAL KNEE REPLACEMENT,All,"50 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Ospedale Regionale di Lugano Civico e Italiano, Lugano, Switzerland",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT01652495,TENDINOPATHY|ADRENAL INSUFFICIENCY,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Rizzoli Orthopaedic Institute, Bologna, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT02403856,CALCIFYING TENDINITIS OF SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","La Roche sur Yon Hospital, La Roche sur Yon, France|Nantes University Hospital, Nantes, France|Rennes University hospital, Rennes, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Terminated,NCT03694821,OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UConn Health, Farmington, Connecticut, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT01144143,OSTEO ARTHRITIS OF THE KNEES,All,"35 Years to 85 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University Of Kansas Medical Center, Kansas City, Kansas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00376064,ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Tubingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wurzburg, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00294463,POSTMENOPAUSE|OSTEOPOROSIS,Female,"Child, Adult, Older Adult",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus MC, Rotterdam, Netherlands",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",G06M1/163,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
O=C([O-])[O-],1,DB14531,__CARBONATE_ION,,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.53,60.0089,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,1,DB14631,__PREDNISOLONE_PHOSPHATE,6024981,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.92,440.42900000000003,141.36,7.0,4.0,4.0,43.42,109.37,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB14936,__MENAQUINONE_6,6190695,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,24.37832399022561,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.01,580.8821,34.14,2.0,0.0,2.0,74.54,193.11,17.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
O=C(c1ccc(OCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,,_RALOXIFEN,,Completed,NCT01544894,POSTMENOPAUSAL OSTEOPOROSIS|COMPLIANCE,Female,"50 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Dr Peset, Valencia, Spain",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1
O=C(c1ccc(OCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,,_RALOXIFEN,,Completed,NCT00431431,OSTEOPENIA,Female,"60 Years to 79 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1
O=C(c1ccc(OCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,,_RALOXIFEN,,Completed,NCT00431444,OSTEOPOROSIS,Female,"45 Years to 80 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Women's Health Research, Phoenix, Arizona, United States|Associated Pharma Research Center, Buena Park, California, United States|Washington, District of Columbia, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Women's Physicians of Jacksonville, Jacksonville, Florida, United States|Tampa Clinical Research, Tampa, Florida, United States|Springfield Clinic, Springfield, Illinois, United States|Consultants in Women's Health Care, St Louis, Missouri, United States|Alegent Health, Omaha, Nebraska, United States|Specialty Medical and Research Center, Pahrump, Nevada, United States|UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States|Columbia University, New York, New York, United States|Kernodle Clinic, Inc., Burlington, North Carolina, United States|The Portland Clinic, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Texas Institute for Clinical Research, Fort Worth, Texas, United States|Valley Women's Health Clinic, Renton, Washington, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1
O=C(c1ccc(OCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,,_RALOXIFEN,,Recruiting,NCT03006003,DEPRESSIVE SYNDROME,Female,"20 Years and older Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"outpatient clinic of the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1
O=C(c1ccc(OCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,,_RALOXIFEN,,Recruiting,NCT03623633,"OSTEOPOROSIS, POSTMENOPAUSAL|OSTEOPOROSIS",Female,"45 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1
O=C(c1ccc(OCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,,_RALOXIFEN,,Terminated,NCT00790101,"OSTEOPOROSIS, POSTMENOPAUSAL",Female,"up to 65 Years Â  (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Sanofi-Aventis, Bridgewater, New Jersey, United States",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1
O=C(c1ccc(OCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,,_RALOXIFEN,,Completed,NCT00532428,"OSTEOPOROSIS, POST-MENOPAUSAL",Female,"55 Years to 85 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Granada, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1
O=C(c1ccc(OCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,,_RALOXIFEN,,Completed,NCT00079924,POSTMENOPAUSAL OSTEOPOROSIS,Female,"50 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huntsville, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Des Moines, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Haverstraw, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlotte, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT00239629,POSTMENOPAUSAL OSTEOPOROSIS,Female,"45 Years to 90 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Magdeburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vogelsang, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kifissia, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT01400516,RHEUMATOID ARTHRITIS,All,"45 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,"Active, not recruiting",NCT03994172,MALE OSTEOPOROSIS,Male,"60 Years to 85 Years Â  (Adult, Older Adult)",U.S. Fed|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT01753856,OSTEOPOROSIS,Female,"55 Years to 89 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lakewood, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Recruiting,NCT03735537,OSTEOGENESIS IMPERFECTA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"St Vincent's Hospital, Dublin, Ireland|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|Royal Victoria Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal Liverpool Hospital, Liverpool, United Kingdom|Llandough University Hospital, Llandough, United Kingdom|Guy's and St Thomas' Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Nuffield Orthopaedic Centre, Oxford, United Kingdom|Queen Alexandria Hospital, Portsmouth, United Kingdom|Northern General Hospital, Sheffield, United Kingdom|University Hospital Southampton, Southampton, United Kingdom|Royal National Orthopaedic Hospital, Stanmore, United Kingdom|Haywood Community Hospital, Stoke-on-Trent, United Kingdom|Wishaw General Hospital, Wishaw, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT01153425,"OSTEOPOROSIS, OSTEOPENIA",Female,"60 Years and older Â  (Adult, Older Adult)",Other|Industry|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT00927186,"OSTEOPOROSIS, POST-MENOPAUSAL",Female,"55 Years to 89 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lakewood, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gainesville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Haverstraw, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT00191425,"OSTEOPOROSIS, POSTMENOPAUSAL",Female,"55 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Pyrmont, Germany",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Not yet recruiting,NCT04522622,ADYNAMIC BONE DISEASE|CHRONIC KIDNEY DISEASES|CARDIAC DISEASE|CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER,All,"18 Years to 120 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Steno Diabetes Center Copenhagen, Gentofte, Denmark|Herlev and Gentofte Hospital, Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Suspended,NCT01734824,BONE MARROW OEDEMA SYNDROME|HIGH TURNOVER BONE DISEASE|QUALITY OF LIFE,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Medical University Vienna - St. Vincent Hospital, Vienna, Austria",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,"Active, not recruiting",NCT03472846,POSTMENOPAUSAL OSTEOPOROSIS|DIABETES TYPE 2,Female,"60 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Medical University Vienna; St. Vincent Hospital, Vienna, Austria",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT02090244,SPINAL STENOSIS,All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Ortopedkliniken, Kalmar, Sweden|Ryggkliniken, US LinkÃ¶ping, LinkÃ¶ping, Sweden",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT01292252,LUMBAR SPONDYLOSIS|LUMBAR SPONDYLOLISTHESIS|ADULT DEGENERATIVE LUMBAR SCOLIOSIS,All,"60 Years to 90 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCSF Spine Center, San Francisco, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Unknown status,NCT01945788,POSTMENOPAUSAL OSTEOPOROSIS WITH PATHOLOGICAL FRACTURE,Female,"50 Years to 81 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto de Investigaciones Metabolicas, Ciudad Autonoma de Buenos Aires, Argentina",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT01705587,OSTEOPOROSIS|ATYPICAL FEMORAL FRACTURE,Female,"Child, Adult, Older Adult",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pittsburgh, Osteoporosis Prevention & Treatment Center, Pittsburgh, Pennsylvania, United States",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT00826228,OSTEOPOROSIS|BONE LOSS|SPINAL CORD INJURY,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rehabilitation Institute of Chicago, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl,1,,_DEXMEDETOMIDINE_HYDROCHLORIDE,US-20050101621-A1,Completed,NCT04307290,ARTHROPATHY OF KNEE|SPINAL ANESTHESIA|TOURNIQUET|ISCHEMIA-REPERFUSION INJURY,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","WonwangUH, Iksan, Jeonbuk, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,32.7488,6.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Terminated,NCT01902186,HIV INFECTION|OSTEOPENIA,Female,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Milano, Milano, Italy|University of Torino, Torino, Italy",C07F9/65616,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,"Active, not recruiting",NCT02815566,OSTEOPOROSIS|HIV|MENOPAUSE,Female,40 Years to 60 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vancouver ID Research and Care Centre, Vancouver, British Columbia, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre, MontrÃ©al, Quebec, Canada|CHU de QuÃ©bec-UniversitÃ© Laval, QuÃ©bec, Quebec, Canada|Ospedale San Raffaele, Milan, Italy|UniversitÃ  degli Studi di Modena e Reggio Emilia, Modena, Italy",C07F9/65616,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Recruiting,NCT02322099,BONE DEMINERALIZATION,All,"30 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Mater Misericordiae University Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
O=C([O-])CCC(=O)O.[Na+],1,,_SODIUM_SUCCINATE,,Completed,NCT03082092,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Queen Elizabeth Hospital, Hong Kong, Hong Kong",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)[O-])[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12.[Na+],1,,_METHYLPREDNISOLONE_SODIUM_SUCCINATE,4292300,Completed,NCT03082092,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Queen Elizabeth Hospital, Hong Kong, Hong Kong",A61K9/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,50.333682416476705,144.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+],1,,_POTASSIUM_CITRATE,,Completed,NCT00357331,"BONE DISEASES, METABOLIC|OSTEOPOROSIS, POSTMENOPAUSAL",Female,"45 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Weill Cornell Medical College, New York, New York, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT01850979,SJOGREN SYNDROME|DRY EYE SYNDROME,All,40 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Sao Paulo General Hospital, Sao Paulo, SP, Brazil",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT03737708,RHEUMATOID ARTHRITIS,All,"19 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site KR82003, Daegu, Korea, Republic of|Site KR82007, Daegu, Korea, Republic of|Site KR82006, Daejeon, Korea, Republic of|Site KR82002, Incheon, Korea, Republic of|Site KR82009, Seongnam, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site KR82005, Seoul, Korea, Republic of|Site KR82010, Seoul, Korea, Republic of|Site KR82012, Seoul, Korea, Republic of|Site KR82013, Suwon, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,,_SUGAMMADEX,,"Active, not recruiting",NCT03210376,MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS|MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF MALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF URINARY TRACT,All,65 Years and older Â  (Older Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,,_SUGAMMADEX,,Completed,NCT02724111,NEUROMUSCULAR BLOCKADE|SURGERY|ANESTHESIA|SPINAL DISEASES,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care","Korea University Guro Hospital, Seoul, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,,_SUGAMMADEX,,Completed,NCT02390817,SPINAL CURVATURES,All,"10 Years to 25 Years Â  (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening,"Ebru Biricik, Adana, SarÄ±Ã§am, Turkey|Ãukurova University, Adana, Ãukurova, Turkey",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,,_SUGAMMADEX,,Recruiting,NCT03111121,MICROLARYNGOSCOPY|RIGID BRONCHOSCOPY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"WVU Healthcare Ruby Memorial Hospital, Morgantown, West Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-],1,,_GLYCOPYRROLATE,4824676,Recruiting,NCT03111121,MICROLARYNGOSCOPY|RIGID BRONCHOSCOPY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"WVU Healthcare Ruby Memorial Hospital, Morgantown, West Virginia, United States",A61K9/7023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,26.3496170352573,464.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O=P(O)(O)O,1,,_CODEINE_PHOSPHATE,,Completed,NCT03784105,ESOPHAGEAL MOTILITY DISORDERS,All,18 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","Jan Tack, Leuven, Belgium|UZ Leuven, Leuven, Belgium",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O=P(O)(O)O,1,,_CODEINE_PHOSPHATE,,Completed,NCT00386269,CLEFT PALATE REPAIR,All,4 Months to 8 Months Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Great Ormond Street Hospital, Anaesthetics, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
O.O.O.O.O.O.O.O=S(=O)([O-])[O-].[Mg+2],1,,_MAGNESIUM_SULFATE,,Not yet recruiting,NCT04514731,ARTHROPATHY OF KNEE|MAGNESIUM SULFATE|CORTISOL|DEHYDROEPIANDROSTERONE,Female,"30 Years to 70 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O.O.O.O.O.O.O.O=S(=O)([O-])[O-].[Mg+2],1,,_MAGNESIUM_SULFATE,,Completed,NCT04161729,"ANALGESIA|PAIN, POSTOPERATIVE|SPINE DISEASE",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AHEPA University Hospital, Thessaloniki, Greece",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O.O.O.O.O.O.O.O=S(=O)([O-])[O-].[Mg+2],1,,_MAGNESIUM_SULFATE,,Terminated,NCT03253224,ARTHRITIS KNEE|MAGNESIUM SULFATE|DEXMEDETOMIDINE,All,"50 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.O=S(=O)(O)O,1,,_GLUCOSAMINE_SULFATE,,Completed,NCT01906801,OSTEOARTHRITIS|GLUCOSAMINE|DIACEREIN,All,"50 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Mahidol University, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0
N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,1,,_GLUCOSAMINE,5856143,Completed,NCT01906801,OSTEOARTHRITIS|GLUCOSAMINE|DIACEREIN,All,"50 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Mahidol University, Bangkok, Thailand",C12P19/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,42.9741883816916,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,1,,_GLUCOSAMINE,5856143,Completed,NCT03743896,OSTEO ARTHRITIS OF THE KNEES,All,"21 Years to 80 Years Â  (Adult, Older Adult)",Industry|Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"T&T Family Heath Clinic and Surgery, Singapore, Singapore",C12P19/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,42.9741883816916,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O,1,,_GLUCOSAMINE,5856143,Completed,NCT00251069,OSTEOARTHRITIS,All,"40 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Slidgigtinstituttet, IshÃ¸j, Denmark",C12P19/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,42.9741883816916,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl,1,,_TRAMADOL_HYDROCHLORIDE,5414129,Completed,NCT00246168,RHEUMATOID ARTHRITIS,All,"18 Years to 79 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,19.975769522988106,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl,1,,_TRAMADOL_HYDROCHLORIDE,5414129,Completed,NCT01063842,OSTEOARTHRITIS,All,"35 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,19.975769522988106,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl,1,,_TRAMADOL_HYDROCHLORIDE,5414129,Completed,NCT00766675,PAIN|FIBROMYALGIA,All,"20 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,19.975769522988106,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT00246168,RHEUMATOID ARTHRITIS,All,"18 Years to 79 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT01063842,OSTEOARTHRITIS,All,"35 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT00766675,PAIN|FIBROMYALGIA,All,"20 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, HajdÃº-Bihar, Hungary",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT00733421,POSTOPERATIVE PAIN,Female,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Foot & Ancle Surgical Center, Stockholm, Sweden",C07C213/10,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Terminated,NCT00766402,"SPONDYLITIS, ANKYLOSING|PAIN",All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Recruiting,NCT03781544,OSTEOARTHRITIS OF MULTIPLE JOINTS OF ANKLE OR FOOT|HEALTHY,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Heart Center Zurich, Zurich, Switzerland",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Recruiting,NCT04391855,"ANALGESIA|PAIN, POSTOPERATIVE|SPINAL STENOSIS|SPINAL DISEASE",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AHEPA University Hospital, Thessaloniki, Greece",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT02416804,"SPINAL STENOSIS|PAIN, POSTOPERATIVE",All,"20 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT00426647,OSTEOARTHRITIS|PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Dr. Olavi Airaksinen, Oma LÃ¤Ã¤kÃ¤ri Oy, Vuorikatu 20, Kuopio, Finland",C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT01843660,LOW BACK PAIN|SHOULDER PAIN|NECK PAIN,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,1,,_TRIAMCINOLONE_HEXACETONIDE,4279900,Unknown status,NCT02437461,ARTHRITIS OF THE KNEE,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Section of Rheumatology, GÃ¤vle hospital, Gavle, Sweden",C07J71/0031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,67.0,23.8197909608,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1
CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,1,,_TRIAMCINOLONE_HEXACETONIDE,4279900,Completed,NCT03086759,KNEE OSTEOARTHRITIS,All,"40 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil",C07J71/0031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,67.0,23.8197909608,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1
CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN,1,,_LISDEXAMFETAMINE_DIMESYLATE,,Completed,NCT01071044,CHRONIC FATIGUE SYNDROME|COGNITIVE IMPAIRMENTS,All,18 Years to 60 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Rochester Center for Behavioral Medicine, Rochester Hills, Michigan, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,,_PASIREOTIDE,,Completed,NCT02060383,CUSHING'S DISEASE|ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States|LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States|Coastal Metabolic Research Centre SC, Ventura, California, United States|East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States|Washington University SC - SOM230B2411, Saint Louis, Missouri, United States|Great Falls Clinic, Great Falls, Montana, United States|Robert Wood Johnson Medical School - Rutgers SC, New Brunswick, New Jersey, United States|The Mount Sinai Hospital SC, New York, New York, United States|Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC, New York, New York, United States|Allegheny Endocrinology Associates SC, Pittsburgh, Pennsylvania, United States|Vanderbilt Clinical Trials Center SOM230B2219, Nashville, Tennessee, United States|Baylor College of Medicine Ben Taub General Hosp., Houston, Texas, United States|Virginia Endocrinology Research SC-2, Chesapeake, Virginia, United States|Swedish Medical Center Dept.ofSeattle Neuroscience(2), Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, SÃ£o Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,,_PASIREOTIDE,,Unknown status,NCT02668172,ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus Medical Center, Rotterdam, South Holland, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,,_PASIREOTIDE,,"Active, not recruiting",NCT01794793,CUSHING'S DISEASE|ACROMEGALY|NEUROENDOCRINE TUMORS|PITUITARY TUMORS|ECTOPIC ACTH SECRETING (EAS) TUMORS|DUMPING SYNDROME|PROSTATE CANCER|MELANOMA NEGATIVE FOR BRAF|MELANOMA NEGATIVE FOR NRAS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ximed Research SC - SOM230B2412, La Jolla, California, United States|Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States|Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford, California, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center SC, New York, New York, United States|Virginia Endocrinology Research SC, Chesapeake, Virginia, United States|Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, Botucatu, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Toulouse, Cedex 9, France|Novartis Investigative Site, Angers cedex 09, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, TÃ¼bingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Nankoku city, Kochi, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, MÃ©xico, Distrito Federal, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Tyumen, Russian Federation|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Unknown status,NCT02742233,DIABETIC FOOT ULCER,All,"50 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","The Second Affiliated Hospital, Third Military Medical University, Chongqing, Chongqing, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT01318356,"Q FEVER|FATIGUE SYNDROME, CHRONIC|COXIELLA INFECTION",All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Radboud university medical center, Nijmegen, Gelderland, Netherlands",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Recruiting,NCT03479502,ADHESIVE CAPSULITIS|ADHESIVE CAPSULITIS OF UNSPECIFIED SHOULDER|FROZEN SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt Medical Center, Nashville, Tennessee, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Not yet recruiting,NCT04274244,CHRONIC PERIODONTITIS|PERIODONTAL BONE LOSS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Completed,NCT04557943,KNEE OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Hasanuddin University, Faculty of Medicine, Makassar, South Sulawesi, Indonesia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Unknown status,NCT02323451,OSTEO ARTHRITIS OF THE KNEES,All,"40 Years to 75 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Shanghai Sixth People's Hospital. Orthopedics., Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Completed,NCT00830830,OSTEOARTHRITIS,All,"40 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Sanofi-Aventis Inc, Bridgewater, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONATE,,Unknown status,NCT02640144,CARTILAGE DAMAGE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0
O=C(O)/C=C/C(=O)O.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,,_QUETIAPINE_FUMARATE,WO-2000072827-A2,Completed,NCT00675896,MAJOR DEPRESSIVE DISORDER,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Dr. A McIntyre Inc, Penticton, British Columbia, Canada",A61K9/16Â ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1
Cn1c(=O)c2nc[nH]c2n(C)c1=O,1,,_THEOPHYLLINE,3935196,Not yet recruiting,NCT03718403,PHP IA|PHP IB|PHP1C,All,"5 Years to 21 Years Â  (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
CN[C@H]1C(=O)N[C@@H]2Cc3ccc(cc3)Oc3cc4cc(c3O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)Oc3ccc(cc3Cl)[C@@H](O)[C@@H]3NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@@H](NC2=O)c2cc(cc(O)c2Cl)Oc2cc1ccc2O)c1ccc(O)c(c1)-c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc(O)cc1[C@@H](C(=O)NCCCN(C)C)NC3=O,1,,_DALBAVANCIN,,Recruiting,NCT03426761,BONE INFECTION|OSTEOMYELITIS|SEPTIC ARTHRITIS|JOINT INFECTION|PROSTHETIC JOINT INFECTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Infectious Diseases Physicians, Inc., Annandale, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,1,0,1
CC(=O)N[C@@H]1[C@@H](COC[C@@H]2O[C@H](C(=O)O)[C@@H](CO)[C@H](O)[C@H]2O)[C@@H](CS(=O)(=O)O)[C@@H](CO)O[C@H]1CO,1,,_CHONDROITIN_SULFATE,,Completed,NCT00805519,OSTEO ARTHRITIS OF THE KNEES,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"ArdabiUMS Clinic of Rheumatology, Ardabil, Iran, Islamic Republic of",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
CC(=O)N[C@@H]1[C@@H](COC[C@@H]2O[C@H](C(=O)O)[C@@H](CO)[C@H](O)[C@H]2O)[C@@H](CS(=O)(=O)O)[C@@H](CO)O[C@H]1CO,1,,_CHONDROITIN_SULFATE,,Unknown status,NCT01233739,RHIZARTHROSIS,All,"45 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital ClÃ­nic i Provincial de Barcelona, Barcelona, Catalunya, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,1,,_CALCITONIN,,Withdrawn,NCT00754884,FIBROMYALGIA,Female,18 Years to 50 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital General Regional No. 45, IMSS, Guadalajara, Jalisco, Mexico",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl,1,,_DULOXETINE_HYDROCHLORIDE,EP-1273301-A2,Completed,NCT00673452,FIBROMYALGIA,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pasadena, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cromwell, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Danbury, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bradenton, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Deland, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., South Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oak Brook, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lafayette, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prairie Village, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rockville, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belmont, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fall River, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newton, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ann Arbor, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edison, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Piscataway, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greensboro, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eugene, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Myrtle Beach, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lake Jackson, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waco, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Jordan, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bellevue, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Middleton, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hato Rey, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,58.7116778578615,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Not yet recruiting,NCT04117893,"OSTEOARTHRITIS, KNEE|CHRONIC PAIN",All,"50 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Beijing Tiantan Hospital, Beijing, Beijing, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Unknown status,NCT03238183,PHYSICAL ACTIVITY|FUNCTIONAL DISTURBANCE,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Completed,NCT04110587,TEMPOROMANDIBULAR JOINT DISC DISPLACEMENT|TEMPOROMANDIBULAR JOINT DISORDERS,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitario de La Princesa, Madrid, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Unknown status,NCT02949466,PHYSICAL ACTIVITY|FUNCTIONAL PERFORMANCE,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Completed,NCT00731289,OSTEOARTHRITIS,All,"35 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Orthopaedics, Movement Analysis Lab, University Hospital MÃ¼nster, Germany, Muenster, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Completed,NCT01524913,TEMPOROMANDIBULAR JOINT DYSFUNCTION|PAIN|ARTHROCENTESIS,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University California Los Angeles, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|University of Cinncinati, Cinncinati, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Completed,NCT00782197,JOINT DISEASE,All,"40 Years to 72 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UCA (Unidad de CirugÃ­a Artroscopica Mikel Sanchez.) Clinica USP La Esperanza., Vitoria, Alava, Spain|Hospital Donostia., San Sebastian, Gipuzkoa, Spain|Policlinica Gipuzkoa, San Sebastian, Gipuzkoa, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Not yet recruiting,NCT04521387,ELBOW TENDINOPATHY,All,30 Years to 50 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Not yet recruiting,NCT04165902,KNEE OSTEOARTHRITIS,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Recruiting,NCT03431584,RHIZARTHROSIS,All,"40 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHD VendÃ©e, La Roche-sur-Yon, France|CH Le Mans, Le Mans, France|CHU Nantes, Nantes, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Completed,NCT03245463,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","Hospital for Special Surgery, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Unknown status,NCT02625727,PHYSICAL ACTIVITY,All,"40 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Completed,NCT01670578,"KNEE CHONDROPATHY|OSTEOARTHRITIS, KNEE",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","III Orthopaedic Clinic and Nano-biotechnology Lab, Rizzoli Orthopaedic Institute, Bologna, Emilia Romagna, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Unknown status,NCT03077009,PLANTARIS FRICTION SYNDROME|NON-INSERTIONAL ACHILLES TENDINOPATHY,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fortius Clinic, London, United Kingdom|Fortius Clinic, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,"Active, not recruiting",NCT02984228,OSTEOARTHRITIS|SHOULDER PAIN,All,"18 Years to 100 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital for Special Surgery, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,1,,_CEFTRIAXONE,4427678,Recruiting,NCT04141787,STAPHYLOCOCCAL INFECTIONS|OSTEOMYELITIS|CNS INFECTION|SEPTIC ARTHRITIS|DIABETIC FOOT INFECTION|VERTEBRAL OSTEOMYELITIS|ABSCESS|COAGULASE NEGATIVE STAPHYLOCOCCAL INFECTION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.3515267253947,381.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,1,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,,_DAPTOMYCIN,4874843,Recruiting,NCT04141787,STAPHYLOCOCCAL INFECTIONS|OSTEOMYELITIS|CNS INFECTION|SEPTIC ARTHRITIS|DIABETIC FOOT INFECTION|VERTEBRAL OSTEOMYELITIS|ABSCESS|COAGULASE NEGATIVE STAPHYLOCOCCAL INFECTION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,22.47274071336161,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]1C(=O)NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@@H]([C@H](C)CC(=O)O)C(=O)N[C@@H](CC(=O)c2ccccc2N)C(=O)O[C@@H]1C,1,,_DAPTOMYCIN,4874843,Terminated,NCT01734694,HEALTH CARE ASSOCIATED PNEUMONIA|OSTEOMYELITIS/SEPTIC ARTHRITIS|ENDOCARDITIS|BACTEREMIA|ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Henry Ford Hospital, Detroit, Michigan, United States",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,22.47274071336161,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,1,1,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,1,0,1
NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1,1,,_FAMOTIDINE,,Completed,NCT01563185,JUVENILE IDIOPATHIC ARTHRITIS,All,10 Years to 16 Years Â  (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital, New Orleans, Louisiana, United States|Floating Hospital for Children @ Tufts Medical Center, Boston, Massachusetts, United States|UMASS Memorial Children's Medical Center, Worcester, Massachusetts, United States|Altoona Center for Clinical Research Altoona Arthritis, Duncansville, Pennsylvania, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
CNC(=S)S,1,,_METAM,,Completed,NCT02445599,PAIN|INADEQUATE OR IMPAIRED RESPIRATORY FUNCTION,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIVERSITY OF DEBRECEN FACULTY OF MEDICINE Department of Anesthesiology and Intensive Care, Debrecen, HajdÃº-Bihar, Hungary",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Completed,NCT01265342,BRONCHIAL SPASM|RESPIRATORY SOUNDS|RESPIRATORY TRACT INFECTIONS,All,12 Months to 71 Months Â  (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ASL NA/3 Sud, Castellammare di Stabia, Italy|AUSL Chieti, Chieti, Italy|ASL Monza Brianza, Monza, Italy|ASL Torino 3, Pinerolo, Italy|ASP di Reggio Calabria, Reggio Calabria, Italy|Ausl Roma E, Roma, Italy|AUSL Taranto, Taranto, Italy|Azienda ULSS 20 Verona, Verona, Italy|ASL 12, Viareggio, Italy",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
CC(=O)O.C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,,_METHYLPREDNISOLONE_ACETATE,4012508,Completed,NCT01652495,TENDINOPATHY|ADRENAL INSUFFICIENCY,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Rizzoli Orthopaedic Institute, Bologna, Italy",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,25.331115628657603,217.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0
CC(=O)O.C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,,_METHYLPREDNISOLONE_ACETATE,4012508,Completed,NCT02403856,CALCIFYING TENDINITIS OF SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","La Roche sur Yon Hospital, La Roche sur Yon, France|Nantes University Hospital, Nantes, France|Rennes University hospital, Rennes, France",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,25.331115628657603,217.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0
CC(=O)O.C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,,_METHYLPREDNISOLONE_ACETATE,4012508,Terminated,NCT03694821,OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UConn Health, Farmington, Connecticut, United States",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,25.331115628657603,217.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0
CC(=O)O.C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,,_METHYLPREDNISOLONE_ACETATE,4012508,Completed,NCT01144143,OSTEO ARTHRITIS OF THE KNEES,All,"35 Years to 85 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University Of Kansas Medical Center, Kansas City, Kansas, United States",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,25.331115628657603,217.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT01652495,TENDINOPATHY|ADRENAL INSUFFICIENCY,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Rizzoli Orthopaedic Institute, Bologna, Italy",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Enrolling by invitation,NCT03166761,SACRO-ILIAC SPONDYLOSIS,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Byron Schneider, Nashville, Tennessee, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Recruiting,NCT04002037,TRIGGER FINGER DISORDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Missouri Health Care, Columbia, Missouri, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT01230424,OSTEOARTHRITIS (OA) OF THE KNEE,All,"45 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Tufts Medical Center / Division of Rheumatology, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Terminated,NCT02120261,MYOFASCIAL PAIN SYNDROME,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Lyndon Baines Johnson General Hospital, Houston, Texas, United States|Memorial Hermann Hospital Texas Medical Center, Houston, Texas, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Terminated,NCT01045694,ARTHRITIS MULTIPLE JOINT,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Missouri, Columbia, Missouri, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Unknown status,NCT02022722,DYSPAREUNIA,Female,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Division of Urogynecology, University of Cincinnati Medical Center, Cincinnati, Ohio, United States",A61L2/0023,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Recruiting,NCT03636373,GOUT ATTACK,All,"18 Years to 85 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rutgers, Robert Wood Johnson Medical School, Clinical Research Center, New Brunswick, New Jersey, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Withdrawn,NCT03319784,ROTATOR CUFF TEAR|ROTATOR CUFF INJURY|ROTATOR CUFF TENDINITIS|DIABETES MELLITUS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Penn State College of Medicine, Hershey, Pennsylvania, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Unknown status,NCT02618603,STROKE|PAIN,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hang Zhou, Zhejiang, China",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Terminated,NCT00554476,LATERAL EPICONDYLITIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Azad University of Medical Sciences, Boo-Ali Hospital, Tehran, Iran, Islamic Republic of",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT03120923,IMPINGEMENT SHOULDER,All,"20 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,,_KETOROLAC_TROMETHAMINE,5091182,Terminated,NCT03694821,OSTEOARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UConn Health, Farmington, Connecticut, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.1215425368077,386.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0
NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,,_KETOROLAC_TROMETHAMINE,5091182,Completed,NCT02658149,OSTEOARTHRITIS|ARTHROPLASTY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Beaumont Hospital, Royal Oak, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.1215425368077,386.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0
NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,,_KETOROLAC_TROMETHAMINE,5091182,Completed,NCT02638831,GONARTHROSIS|LOW BACK PAIN,All,"20 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,19.1215425368077,386.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Completed,NCT01691079,"BRONCHOSPASM, EXERCISE-INDUCED",All,"13 Years and older Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Francisco, San Francisco, California, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)n1c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,1,,_FLUVASTATIN,5135935,Completed,NCT00489424,OSTEOPOROSIS,Female,"45 Years to 79 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Refer to the E-portal link for ZOL446HUS136, Http://www.osteoporosisclinicalresearch.com, New Jersey, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,14.6204234173186,1316.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],1,,_NAPROXEN_SODIUM,4571333,Completed,NCT03448536,DYSMENORRHEA,Female,"15 Years to 35 Years Â  (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Radiant Research, Inc., Chandler, Arizona, United States|Radiant Research, Inc., Scottsdale, Arizona, United States|Radiant Research, Inc., Pinellas Park, Florida, United States|Radiant Research, Inc., Chicago, Illinois, United States|Radiant Research, Inc., Akron, Ohio, United States|Radiant Research, Inc., Cincinnati, Ohio, United States|Radiant Research, Inc., Dallas, Texas, United States|Synexus US, LP- Plano, Plano, Texas, United States",1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,32.1977864021848,421.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],1,,_NAPROXEN_SODIUM,4571333,Unknown status,NCT03699293,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Inova Heart and Vascular Institute, Falls Church, Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.1977864021848,421.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],1,,_NAPROXEN_SODIUM,4571333,Completed,NCT04066426,TEMPOROMANDIBULAR DISORDER,All,18 Years to 60 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Van Yuzuncu Yil University, Faculty of Dentistry, Van, TuÅba, Turkey",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.1977864021848,421.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],1,,_NAPROXEN_SODIUM,4571333,Completed,NCT02501564,OSTEOARTHRITIS,All,"40 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.1977864021848,421.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21.Cl,1,,_CYCLOBENZAPRINE_HYDROCHLORIDE,4851228,Completed,NCT00246389,PAIN|SPASM,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0004,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,24.345469106141802,28.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.Cl,1,,_DILTIAZEM_HYDROCHLORIDE,4292068,Recruiting,NCT04310995,CORONARY ARTERY BYPASS GRAFT|RADIAL ARTERY GRAFTS|ANTISPASTIC THERAPY|PILOT STUDY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China",A01N43/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.8484979157682,429.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,,_CHLORHEXIDINE_GLUCONATE,4199567,Completed,NCT02097615,SOFT TISSUE INFECTIONS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Leon, Leon, Guanajuato, Mexico",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1,1,,_TOLVAPTAN,5753677,"Active, not recruiting",NCT03949894,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,All,19 Years to 50 Years Â  (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Inje University Busan Paik Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Hallym University Medical Center, Pyeongchon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,78.0,35.3847101583194,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1,1,,_TOLVAPTAN,5753677,Recruiting,NCT03596957,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Aarhus University Hospital - Site 43, Skejby, Aarhus N, Denmark|Odense University Hospital - Site 45, Odense, Odense C, Denmark|Rigshospitalet - Site 42, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Nordsjaellands Hospital - Site 41, HillerÃ¸d, Denmark|SjÃ¦llands University Hospital Roskilde, Roskilde, Denmark",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])O.[Na+],1,,_DEXAMETHASONE_SODIUM_PHOSPHATE,,Terminated,NCT02421419,TRIGGER FINGER DISORDER,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])O.[Na+],1,,_DEXAMETHASONE_SODIUM_PHOSPHATE,,Recruiting,NCT04544683,"CERVICAL RADICULOPATHY|CERVICAL SPONDYLOSIS|DISK, HERNIATED",All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Utah, Salt Lake City, Utah, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])O.[Na+],1,,_DEXAMETHASONE_SODIUM_PHOSPHATE,,Recruiting,NCT04432012,TOTAL KNEE REPLACEMENT,All,"50 Years to 85 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Ospedale Regionale di Lugano Civico e Italiano, Lugano, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1
CC(=O)O.C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,,_OCTREOTIDE_ACETATE,,Completed,NCT00376064,ACROMEGALY,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Marburg, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Tubingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wurzburg, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Enrolling by invitation,NCT03336203,GOUT|CKD STAGE 1-4|SUA LEVEL (>8 MG/DL; 480 ÎMOL/L),All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical Practice Prof D.Ivanov, Kiev, Ukraine",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,"Active, not recruiting",NCT02579096,GOUT|CHRONIC KIDNEY DISEASES,All,"18 Years and older Â  (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VA Loma Linda Healthcare System, Loma Linda, CA, Loma Linda, California, United States|VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States|Miami VA Healthcare System, Miami, FL, Miami, Florida, United States|Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States|Iowa City VA Health Care System, Iowa City, IA, Iowa City, Iowa, United States|VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States|Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States|Kansas City VA Medical Center, Kansas City, MO, Kansas City, Missouri, United States|Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska, United States|Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York, New York, United States|Asheville VA Medical Center, Asheville, NC, Asheville, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, OH, Cincinnati, Ohio, United States|VA Portland Health Care System, Portland, OR, Portland, Oregon, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States|VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas, United States|VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah, United States|White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont, United States|Salem VA Medical Center, Salem, VA, Salem, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Completed,NCT02500641,GOUT,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Klinik und Poliklinik III/Rheumatologie UniversitÃ¤tsklinikum ""Carl Gustav Carus"" Der Technischen UniversitÃ¤t, Dresden, Germany|Presidio Ospedaliero San Filippo e Nicola UniversitÃ  degli Studi dell'Aquila U.O.C Geriatria e Lungodegenza Geriatrica, Avezzano, L'Aquila, Italy|Ospedale San Salvatore U.O.C. Medicina Interna e Nefrologia Dipartimento MeSVA UniversitÃ  degli Studi dell'Aquila, Coppito, L'Aquila, Italy|Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Policlinico SS. Annunziata UniversitÃ  degli Studi ""G. d'Annunzio"". Dipartimento di Medicina e Scienze dell'Invecchiamento., Chieti, Italy|Reade Clinic, Amsterdam, Netherlands|GdaÅskie Centrum Zdrowia Sp.z o.o., GdaÅsk, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, GrudziÄdz, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Centrum Medyczne Plejady, KrakÃ³w, Poland|Krakowski Szpital Specjalistyczny im. Jana PawÅa II w Krakowie, KrakÃ³w, Poland|Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, KrakÃ³w, Poland|Pratia S,A, Warsaw, Poland|Reumatika- Centrum Reumatologii, Warsaw, Poland|OddziaÅ Kardiologiczny, WSS im. W. BiegaÅskiego w Åodzi, ÅÃ³dÅº, Poland|Polimedica, ÅÃ³dÅº, Poland|Clinica MedicalÄ Data Plus SRL, Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|S.C. Centrul Medical Sana S.R.L., Bucharest, Romania|S.C. Cardiomed S.R.L., Craiova, Romania|Institutul de Boli Cardiovasculare Clinica de Cardiologie si Recuperare Cardiovasculara, Timisoara, Romania|Cabinet Medical Medicina Interna, TimiÅoara, Romania|Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia|Institut za reumatologiju, Belgrade, Serbia|KliniÄko-bolniÄki centar ""BeÅ¾anijska kosa"" Klinika za imunologiju i alergologiju, Belgrade, Serbia|Vojnomedicinska akademija Klinika za reumatologiju, Belgrade, Serbia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Completed,NCT02600780,HYPERURICEMIA,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dow University of Health Sciences, Karachi, Sindh, Pakistan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Completed,NCT01451645,INTERCRITICAL GOUT,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Alabaster, Alabama, United States|Mesa, Arizona, United States|Upland, California, United States|Trumbull, Connecticut, United States|Debary, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Canton, Georgia, United States|Boise, Idaho, United States|Lexington, Kentucky, United States|Bethesda, Maryland, United States|Reisterstown, Maryland, United States|Bingham Farms, Michigan, United States|Brooklyn Center, Minnesota, United States|Kansas City, Missouri, United States|Billings, Montana, United States|Elizabeth, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Morganton, North Carolina, United States|Winston-Salem, North Carolina, United States|Duncansville, Pennsylvania, United States|Reading, Pennsylvania, United States|West Reading, Pennsylvania, United States|Greer, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Johnson City, Tennessee, United States|Dallas, Texas, United States|Katy, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Wauwatosa, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Completed,NCT01310673,GOUT|GOUT ACUTE,Male,"18 Years and older Â  (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","White River Junction VA Medical Center, White River Junction, Vermont, United States",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Completed,NCT02477488,GOUT|RENAL INSUFFICIENCY,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Completed,NCT02956278,CHRONIC GOUT|HYPERURICEMIA,All,18 Years to 40 Years Â  (Adult),Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Open Medicine Institute, Mountain View, California, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,1,,_COLCHICINE,4008719,Completed,NCT02500641,GOUT,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Klinik und Poliklinik III/Rheumatologie UniversitÃ¤tsklinikum ""Carl Gustav Carus"" Der Technischen UniversitÃ¤t, Dresden, Germany|Presidio Ospedaliero San Filippo e Nicola UniversitÃ  degli Studi dell'Aquila U.O.C Geriatria e Lungodegenza Geriatrica, Avezzano, L'Aquila, Italy|Ospedale San Salvatore U.O.C. Medicina Interna e Nefrologia Dipartimento MeSVA UniversitÃ  degli Studi dell'Aquila, Coppito, L'Aquila, Italy|Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Policlinico SS. Annunziata UniversitÃ  degli Studi ""G. d'Annunzio"". Dipartimento di Medicina e Scienze dell'Invecchiamento., Chieti, Italy|Reade Clinic, Amsterdam, Netherlands|GdaÅskie Centrum Zdrowia Sp.z o.o., GdaÅsk, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, GrudziÄdz, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Centrum Medyczne Plejady, KrakÃ³w, Poland|Krakowski Szpital Specjalistyczny im. Jana PawÅa II w Krakowie, KrakÃ³w, Poland|Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, KrakÃ³w, Poland|Pratia S,A, Warsaw, Poland|Reumatika- Centrum Reumatologii, Warsaw, Poland|OddziaÅ Kardiologiczny, WSS im. W. BiegaÅskiego w Åodzi, ÅÃ³dÅº, Poland|Polimedica, ÅÃ³dÅº, Poland|Clinica MedicalÄ Data Plus SRL, Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|S.C. Centrul Medical Sana S.R.L., Bucharest, Romania|S.C. Cardiomed S.R.L., Craiova, Romania|Institutul de Boli Cardiovasculare Clinica de Cardiologie si Recuperare Cardiovasculara, Timisoara, Romania|Cabinet Medical Medicina Interna, TimiÅoara, Romania|Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia|Institut za reumatologiju, Belgrade, Serbia|KliniÄko-bolniÄki centar ""BeÅ¾anijska kosa"" Klinika za imunologiju i alergologiju, Belgrade, Serbia|Vojnomedicinska akademija Klinika za reumatologiju, Belgrade, Serbia",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,63.0,12.6819852563707,1803.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,1,,_COLCHICINE,4008719,Completed,NCT02060552,PRIMARY GOUT,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yikai YU, Wuhan, Hubei, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,63.0,12.6819852563707,1803.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,1,,_COLCHICINE,4008719,Recruiting,NCT03933007,GOUT FLARE,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HÃ´pital LariboisiÃ¨re-Service de Rhumatolologie, Paris, France",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,63.0,12.6819852563707,1803.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,1,,_COLCHICINE,4008719,Completed,NCT01451645,INTERCRITICAL GOUT,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Alabaster, Alabama, United States|Mesa, Arizona, United States|Upland, California, United States|Trumbull, Connecticut, United States|Debary, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Canton, Georgia, United States|Boise, Idaho, United States|Lexington, Kentucky, United States|Bethesda, Maryland, United States|Reisterstown, Maryland, United States|Bingham Farms, Michigan, United States|Brooklyn Center, Minnesota, United States|Kansas City, Missouri, United States|Billings, Montana, United States|Elizabeth, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Morganton, North Carolina, United States|Winston-Salem, North Carolina, United States|Duncansville, Pennsylvania, United States|Reading, Pennsylvania, United States|West Reading, Pennsylvania, United States|Greer, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Johnson City, Tennessee, United States|Dallas, Texas, United States|Katy, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Wauwatosa, Wisconsin, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,63.0,12.6819852563707,1803.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,1,,_COLCHICINE,4008719,Withdrawn,NCT02995512,MYOCARDIAL INFARCTION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,63.0,12.6819852563707,1803.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,1,,_COLCHICINE,4008719,Recruiting,NCT03913442,OSTEOARTHRITIS|OSTEO ARTHRITIS KNEE,All,"18 Years to 99 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","NYU Langone Health, New York, New York, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,63.0,12.6819852563707,1803.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT02500641,GOUT,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Medizinische Klinik und Poliklinik III/Rheumatologie UniversitÃ¤tsklinikum ""Carl Gustav Carus"" Der Technischen UniversitÃ¤t, Dresden, Germany|Presidio Ospedaliero San Filippo e Nicola UniversitÃ  degli Studi dell'Aquila U.O.C Geriatria e Lungodegenza Geriatrica, Avezzano, L'Aquila, Italy|Ospedale San Salvatore U.O.C. Medicina Interna e Nefrologia Dipartimento MeSVA UniversitÃ  degli Studi dell'Aquila, Coppito, L'Aquila, Italy|Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi, Bologna, Italy|Ospedale Policlinico SS. Annunziata UniversitÃ  degli Studi ""G. d'Annunzio"". Dipartimento di Medicina e Scienze dell'Invecchiamento., Chieti, Italy|Reade Clinic, Amsterdam, Netherlands|GdaÅskie Centrum Zdrowia Sp.z o.o., GdaÅsk, Poland|Specjalistyczna Praktyka Lekarska Piotr Kubalski, GrudziÄdz, Poland|Centrum Medyczne Pratia Katowice, Katowice, Poland|Centrum Medyczne Plejady, KrakÃ³w, Poland|Krakowski Szpital Specjalistyczny im. Jana PawÅa II w Krakowie, KrakÃ³w, Poland|Specjalistyczny Gabinet Dermatologiczno-Kosmetyczny, KrakÃ³w, Poland|Pratia S,A, Warsaw, Poland|Reumatika- Centrum Reumatologii, Warsaw, Poland|OddziaÅ Kardiologiczny, WSS im. W. BiegaÅskiego w Åodzi, ÅÃ³dÅº, Poland|Polimedica, ÅÃ³dÅº, Poland|Clinica MedicalÄ Data Plus SRL, Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|S.C. Centrul Medical Sana S.R.L., Bucharest, Romania|S.C. Cardiomed S.R.L., Craiova, Romania|Institutul de Boli Cardiovasculare Clinica de Cardiologie si Recuperare Cardiovasculara, Timisoara, Romania|Cabinet Medical Medicina Interna, TimiÅoara, Romania|Institut za kardiovaskularne bolesti Dedinje, Belgrade, Serbia|Institut za reumatologiju, Belgrade, Serbia|KliniÄko-bolniÄki centar ""BeÅ¾anijska kosa"" Klinika za imunologiju i alergologiju, Belgrade, Serbia|Vojnomedicinska akademija Klinika za reumatologiju, Belgrade, Serbia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT00141102,"OSTEOARTHRITIS|ARTHRITIS, RHEUMATOID",All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, LiÃ¨ge, Belgium|Pfizer Investigational Site, GoiÃ¢nia, GO, Brazil|Pfizer Investigational Site, GoiÃ¢nia, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, SÃ£o Paulo, SP, Brazil|Pfizer Investigational Site, SÃ£o Paulo, SP, Brazil|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste Foy, Quebec, Canada|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Chengdu, Sichuan, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Floridablanca, Santander, Colombia|Pfizer Investigational Site, Cartago, Costa Rica|Pfizer Investigational Site, Heredia, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Opatija, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Plzen, Bory, Czech Republic|Pfizer Investigational Site, Ostrava, Trebovice, Czech Republic|Pfizer Investigational Site, Ceske Budejovice, Czech Republic|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Prague 1, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 4, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Cuenca, Azuay, Ecuador|Pfizer Investigational Site, Guayaquil, Guayas, Ecuador|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Amiens, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Deggingen, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hoyerswerda, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Ciudad de Guatemala, Guatemala|Pfizer Investigational Site, Guatemala 01010, Guatemala|Pfizer Investigational Site, Lai Chi Kok, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Alytus, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Klaipeda, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vlaardingen, ZH, Netherlands|Pfizer Investigational Site, Alkmaar, Netherlands|Pfizer Investigational Site, Leidschendam, Netherlands|Pfizer Investigational Site, Ciudad de Panama, Panama|Pfizer Investigational Site, Surco, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisbon, Portugal|Pfizer Investigational Site, Ponta Delgada, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ekaterinburg, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Petrozavodsk, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Niska Banja, Serbia|Pfizer Investigational Site, Novi Sad, Serbia|Pfizer Investigational Site, Sinapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bloemfontein, Free State, South Africa|Pfizer Investigational Site, Johannesburg, Gauteng Province, South Africa|Pfizer Investigational Site, Durban, KZN, South Africa|Pfizer Investigational Site, Parow, Western Cape, South Africa|Pfizer Investigational Site, Bellville, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Kempton Park, South Africa|Pfizer Investigational Site, Observatory Cape Town, South Africa|Pfizer Investigational Site, Partida de Bacarot, Alicante, Spain|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Barakaldo, Vizcaya, Spain|Pfizer Investigational Site, Avila, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Lulea, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Tao-Yuan, Taiwan|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Ivano-Frankivsk, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kiev, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lutsk, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Simferopol, Ukraine|Pfizer Investigational Site, Zaporizhzhia, Ukraine|Pfizer Investigational Site, Helensburgh, Argyle & Clyde, United Kingdom|Pfizer Investigational Site, Maidenhead, Berks, United Kingdom|Pfizer Investigational Site, Aston Clinton, Buckinghamshire, United Kingdom|Pfizer Investigational Site, St Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Aldershot, Hampshire, United Kingdom|Pfizer Investigational Site, Basingstoke, Hampshire, United Kingdom|Pfizer Investigational Site, Odiham, Hampshire, United Kingdom|Pfizer Investigational Site, Ashford, Middlesex, United Kingdom|Pfizer Investigational Site, Harrow, Middlesex, United Kingdom|Pfizer Investigational Site, Camberley, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Leatherhead, Surrey, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Bradford-on-Avon, Wiltshire, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, United Kingdom|Pfizer Investigational Site, Upton, Wirral, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, United Kingdom|Pfizer Investigational Site, Canterbury, United Kingdom|Pfizer Investigational Site, Chesterfield, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, St Leonards on Sea, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom|Pfizer Investigational Site, Vale of Glamorgan, United Kingdom|Pfizer Investigational Site, Wansford, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT02394340,TINEA PEDIS|TINEA CRURIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"TKL Research, Fair Lawn, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT00582972,OSTEOPOROSIS|ACHLORHYDRIA|GERD|HIP FRACTURE,Female,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,1,,_MODAFINIL,,Completed,NCT02155257,OSTEOARTHRITIS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C)=CCN1Cc2cc(Cl)cc3nc(S)n(c23)CC1C,1,,_TIBO,,Completed,NCT00431431,OSTEOPENIA,Female,"60 Years to 79 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC(C)=CCN1Cc2cc(Cl)cc3nc(S)n(c23)CC1C,1,,_TIBO,,Completed,NCT00294463,POSTMENOPAUSE|OSTEOPOROSIS,Female,"Child, Adult, Older Adult",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erasmus MC, Rotterdam, Netherlands",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT00719160,OSTEOPOROSIS,All,18 Years to 45 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Yale New Haven Hospital Hospital Research Unit, New Haven, Connecticut, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O,1,,_LANREOTIDE,,Completed,NCT00145405,ACROMEGALY,All,"22 Years to 72 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,1,,_LISINOPRIL,6462022,Terminated,NCT01837069,OSTEOARTHRITIS|CARDIOVASCULAR DISEASE,All,"21 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"NYU Hospital for Joint Diseases, New York, New York, United States",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,12.4520010677837,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+],1,,_DICLOFENAC_SODIUM,4234601,Completed,NCT00140972,OSTEOARTHRITIS,All,"40 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,23.0312737427873,504.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+],1,,_DICLOFENAC_SODIUM,4234601,Completed,NCT02087748,PAIN|DELAYED ONSET MUSCLE SORENESS,All,18 Years to 35 Years Â  (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Lotus Clinical Research, LLC, Pasadena, California, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,23.0312737427873,504.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NCCCC(O)(P(=O)([O-])O)P(=O)(O)O.[Na+],1,,_ALENDRONATE_SODIUM,,Completed,NCT00729651,OSTEOPOROSIS POSTMENOPAUSAL,Female,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
NCCCC(O)(P(=O)([O-])O)P(=O)(O)O.[Na+],1,,_ALENDRONATE_SODIUM,,Completed,NCT00504166,OSTEOPENIA|OSTEOPOROSIS,Female,"45 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","University of California Department of Radiology, San Francisco, California, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT02572960,OSTEOPOROSIS|VITAMIN D DEFICIENCY|CARDIOVASCULAR DISEASE,Female,"60 Years to 80 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Endocrinology and Internal Medicine, Aarhus, Denmark",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)(S)C(=O)N[C@H](CS)C(=O)O,1,,_BUCILLAMINE,EP-1584615-A1,Unknown status,NCT00716248,RHEUMATOID ARTHRITIS,All,"20 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan",A61G17/08Â ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,37.8816813486929,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0
Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc21,1,,_RAMOSETRON,6235745,Completed,NCT01102491,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 86 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Joint Reconstruction Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,19.220107189059306,160.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,1
O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O.[Na+],1,,_RISEDRONATE_SODIUM,WO-2001032101-A1,Completed,NCT00082277,BREAST CANCER,Female,"55 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Palm Springs, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, New Orleans, Louisiana, United States|Research Site, New York, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Burnaby, Canada|Research Site, Edmonton, Canada|Research Site, Montreal, Canada|Research Site, Quebec City, Canada|Research Site, Vancouver, Canada|Research Site, Bordeaux, France|Research Site, Caen, France|Research Site, Lyon, France|Research Site, Saint-Cloud, France|Research Site, Saint-Herblain, France|Research Site, Athens, Greece|Research Site, Iraklion, Greece|Research Site, Den Haag, Netherlands|Research Site, Goes, Netherlands|Research Site, Ijssel, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Bloemfontain, South Africa|Research Site, Cape Town, South Africa|Research Site, Tygerberg, South Africa|Research Site, Pamplona, Spain|Research Site, Pontevedra, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Belfast, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Luton, United Kingdom",A61L24/04Â ,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,32.7488,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,1
O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O.[Na+],1,,_RISEDRONATE_SODIUM,WO-2001032101-A1,Completed,NCT00632216,"OSTEOPOROSIS, POSTMENOPAUSAL",Female,"55 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61L24/04Â ,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,32.7488,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,1
O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O.[Na+],1,,_RISEDRONATE_SODIUM,WO-2001032101-A1,Completed,NCT00460733,COLLES' FRACTURE,Female,"Child, Adult, Older Adult",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-Aventis Administrative Office, Sao Paulo, Brazil",A61L24/04Â ,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,32.7488,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,1
CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2,1,,_GRANISETRON,4845092,Completed,NCT02230371,MYOFASCIAL PAIN|TEMPOROMANDIBULAR DISORDERS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Karolinska Institutet, Department of Dental Medicine, Huddinge, Sweden",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,17.478798332614602,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](C)C(N)=O,1,,_ANTIDE,,Completed,NCT00118430,PAIN|DEPRESSION,All,"18 Years and older Â  (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Indiana University Medical Center, Indianapolis, Indiana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+],1,,_DICLOFENAC_POTASSIUM,5674854,Completed,NCT01666197,ANKLE SPRAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Investigator, BrÃ¼hl, Germany|Investigator, Essen, Germany|Investigator, Gilching, Germany|Investigator, KÃ¶ln, Germany",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,36.0089529559128,236.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1.COS(=O)(=O)[O-],1,,_NEOSTIGMINE_METHYLSULFATE,4098899,Completed,NCT02543658,ACUTE PANCREATITIS|INTRA-ABDOMINAL HYPERTENSION,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,10.710692211339001,41.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,1,,_RISPERIDON,,Recruiting,NCT00768820,VELOCARDIOFACIAL SYNDROME|WILLIAMS SYNDROME|FRAGILE X SYNDROME,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Schneider Children's Mediac Center of Israel, Petach-Tikva, Israel",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O=S(=O)(O)O,1,,_MORPHINE_SULFATE,4083982,Completed,NCT00901628,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years to 81 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Joint Reconstruction Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,12.3205815314482,167.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl,1,,_LIDOCAINE_HYDROCHLORIDE,4091090,Terminated,NCT02120261,MYOFASCIAL PAIN SYNDROME,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Lyndon Baines Johnson General Hospital, Houston, Texas, United States|Memorial Hermann Hospital Texas Medical Center, Houston, Texas, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,17.380233680363,1165.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl,1,,_LIDOCAINE_HYDROCHLORIDE,4091090,Recruiting,NCT04123652,CHRONIC NEUROPATHIC PAIN AND FIBROMYALGIA,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Allevio Pain Management Clinic, Toronto, Ontario, Canada",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,17.380233680363,1165.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,1,,_BUPIVACAINE_HYDROCHLORIDE,5322689,Unknown status,NCT02022722,DYSPAREUNIA,Female,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Division of Urogynecology, University of Cincinnati Medical Center, Cincinnati, Ohio, United States",A61K9/0014,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,115.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,1,,_BUPIVACAINE_HYDROCHLORIDE,5322689,Completed,NCT04361513,PAIN|JOINT FUNCTION DISORDER|INFLAMMATION,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Minia university, Minya, Egypt",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,115.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,1,,_BUPIVACAINE_HYDROCHLORIDE,5322689,"Active, not recruiting",NCT03663283,ARTHROPATHY SHOULDER,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Mayo Clinic in Arizona, Phoenix, Arizona, United States",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,115.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,1,,_BUPIVACAINE_HYDROCHLORIDE,5322689,Completed,NCT02630160,MUSCULOSKELETAL PAIN|HIP INJURIES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital del Mar, Barcelona, Spain",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,115.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,1,,_BUPIVACAINE_HYDROCHLORIDE,5322689,Unknown status,NCT03638960,SHOULDER PAIN|POSTOPERATIVE PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Southern California, Los Angeles, California, United States",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,115.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT00324038,OSTEOARTHRITIS,All,65 Years and older Â  (Older Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Napp Pharmaceuticals Ltd, Cambridge, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Terminated,NCT00552578,OPIATE ADDICTION|REFRACTORY PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Erie County Medical Center, Buffalo, New York, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT02416804,"SPINAL STENOSIS|PAIN, POSTOPERATIVE",All,"20 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT02519387,OSTEOARTHRITIS|RHEUMATOID ARTHRITIS|LOWER BACK PAIN|JOINT PAIN|MUSCLE PAIN,All,"40 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital University Sains Malaysia, Kota Bahru, Kelantan, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia|University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT01818700,SPINAL DISORDERS,All,"20 Years to 80 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Samsung Medical Center, Seoul, Korea, Republic of",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT02575664,PAIN|OSTEOARTHRITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kuopio University Hospital, Kuopio, Northern Savo, Finland",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT01276431,OSTEOARTHRITIS PAIN OF THE HIP AND OR KNEE,All,"50 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Professor Jon Karlsson, Molndal, Sweden|Dr Bengt Olav Tengmark, Stockholm, Sweden",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT00426647,OSTEOARTHRITIS|PAIN,All,"18 Years and older Â  (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Dr. Olavi Airaksinen, Oma LÃ¤Ã¤kÃ¤ri Oy, Vuorikatu 20, Kuopio, Finland",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
C[N+](C)(C)CC(O)CC(=O)[O-],1,,_CARNITINE,4221869,Unknown status,NCT01904396,CARNITINE DEFICIENCY,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"University Health Network, Toronto, Ontario, Canada",C12N9/0006,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.7910840058317,4067.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,,_ROXITHROMYCIN,4054737,Completed,NCT00439062,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Nazilli State Hospital, Nazilli, Aydin, Turkey",C07D309/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,13.9304708515575,576.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
O.OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,,_LACTULOSE,WO-2005016898-A2,Completed,NCT00160264,OSTEOPENIA,Female,"55 Years to 65 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double,"Site 1, Barcelona, Spain|Site 2, Barcelona, Spain|Site 3, Barcelona, Spain",A61P25/00Â ,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2c(c1OC)-c1ccc(SC)c(=O)cc1C(NC(C)=O)CC2,1,,_THIOCOLCHICOSIDE,,Completed,NCT00272532,MYOFASCIAL PAIN SYNDROME,All,18 Years to 50 Years Â  (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Sanofi-Aventis, Istanbul, Turkey",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,"Active, not recruiting",NCT02462421,DIABETES MELLITUS|GOUT|HYPERURICEMIA,All,"21 Years and older Â  (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,,_BACITRACIN,,Terminated,NCT01350102,"DIABETES, TYPE 1|DIABETES, TYPE 2|FOOT ULCER, DIABETIC",All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1
O=C(/C=C/c1ccc(O)c(O)c1)O[C@H](Cc1ccc(O)c(O)c1)C(=O)O,1,,_ROSMARINIC_ACID,US-20110159017-A1,Completed,NCT01380015,OSTEO ARTHRITIS OF THE KNEES,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","University of Guelph, Guelph, Ontario, Canada|Human Nutraceutical Research Unit, University of Guelph, Guelph, Ontario, Canada",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,96.0,32.7488,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
C=C1[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H](O)[C@H]1CO,1,,_ENTECAVIR,,"Active, not recruiting",NCT01907230,RHEUMATOID ARTHRITIS|HEPATITIS B REACTIVATION|EXPOSURE TO HEPATITIS B VIRUS,All,"20 Years to 90 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Division of Gastroenterology & Division of Allergy Immunology and Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0
N=S(=O)(O)Cc1noc2ccccc12,1,,_ZONISAMIDE,4172896,Withdrawn,NCT00259636,FIBROMYALGIA|MIGRAINE,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Pittsburgh, Pittsburgh, Pennsylvania, United States",C07D261/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,16.8217006509373,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0
CC(C(=O)[O-])c1ccc(CC2CCCC2=O)cc1.[Na+],1,,_LOXOPROFEN_SODIUM,4599360,Completed,NCT03800797,ANKYLOSING SPONDYLITIS,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,22.9327090905357,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CCCCCCCCCCCCCCCC(=O)OCC(O)COP(=O)([O-])O.[Na+],1,,_PALMITOYL,,Recruiting,NCT04488926,FIBROMYALGIA,All,"18 Years and older Â  (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Anestesia e Rianimazione B - Azienda Ospedaliera Universitaria Integrata di Verona, Verona, VR, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0
NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1,1,,_ARMODAFINIL,,Completed,NCT00678691,"FIBROMYALGIA, PRIMARY",All,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SUNY Upstate Medical University, Syracuse, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Terminated,NCT00217724,"PAIN|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 120 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","OHSU Knight Cancer Institute, Portland, Oregon, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
N[C@@H](Cc1ccc(O)cc1)C(=O)O,0,DB00135,__TYROSINE,,Terminated,NCT01219049,FIBROMYALGIA,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mount Sinai School of Medicine, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,0,DB00162,__VITAMIN_A,3932634,Terminated,NCT02758990,"OBESITY|RHINITIS|RHINITIS, ALLERGIC|RESPIRATORY SOUNDS|DYSPNEA|HEADACHE|MIGRAINE DISORDERS|ARTHRITIS|ARTHRALGIA|ANXIETY|SLEEP INITIATION AND MAINTENANCE DISORDERS|SLEEP DEPRIVATION",All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Verifomics, LLC, Dallas, Texas, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,13.1090987494609,3344.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.38,286.4516,20.23,1.0,1.0,1.0,36.54,97.92,5.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O,0,DB00171,__ATP,3933594,Terminated,NCT01307475,ARTHROGRYPOSIS|CRANIOFACIAL ABNORMALITIES|POSTTRAUMATIC STRESS DISORDER|DEPRESSIVE DISORDER,All,"Child, Adult, Older Adult",Other,Observational Model: Case-Only|Time Perspective: Cross-Sectional,"Freeman-Sheldon Research Group, Inc. Headquarters, Buckhannon, West Virginia, United States|San Juan de Dios General Hospital, Guatemala City, Guatemala",G01N33/525,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,17.150249491775998,2074.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,507.181,279.13,14.0,7.0,3.0,38.92,95.81,8.0,1.0,0.0,0.0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0
C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,0,DB00179,__MASOPROCOL,3995632,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",B01J4/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,26.2510523830058,271.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,302.3649,80.92,4.0,4.0,2.0,33.63,86.62,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,0,DB00188,__BORTEZOMIB,6083903,Terminated,NCT02102594,MYASTHENIA GRAVIS|SYSTEMIC LUPUS ERYTHEMATOSUS|RHEUMATOID ARTHRITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charite - UniversitÃ¤tsmedizin Berlin, NeuroCure Clinical Research Center, Berlin, Germany|CharitÃ© - UniversitÃ¤tsmedizin Berlin, Internal Medicine / Rheumathology, Berlin, Germany",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00227,__LOVASTATIN,6080428,Terminated,NCT00302952,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",NIH|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Alabama, Birmingham, Alabama, United States|University of California, San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Justus J. Fiechtner, MD, PLLC, Lansing, Michigan, United States|Feinstein Institute for Medical Research NS-LIJ Health System, Manhasset, New York, United States|University of Rochester, Rochester, New York, United States|Carolina Bone and Joint, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baylor Research Institute, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,65.4140742109694,5605.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.11,404.5396,72.83,3.0,1.0,3.0,46.11,113.18,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0
COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1,0,DB00243,__RANOLAZINE,6303607,Terminated,NCT00914316,PERIPHERAL ARTERIAL DISEASE,All,"40 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","William Beaumont Hospital, Royal Oak, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,28.68231380521161,174.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.08,427.5365,74.27,6.0,2.0,3.0,47.22,123.46,9.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1
CCCC(CCC)C(=O)O,0,DB00313,__VALPROIC_ACID,6419953,Terminated,NCT00519181,HTLV-I-ASSOCIATED MYELOPATHY,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,42.9084786135238,1051.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.54,144.2114,37.3,2.0,1.0,0.0,17.0,40.25,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,0,DB00398,__SORAFENIB,7351834,Terminated,NCT01425216,KELOIDS,All,18 Years to 50 Years Â  (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Michael H. Tirgan, MD, New York, New York, United States",C07D209/46,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,DB00441,__GEMCITABINE,4808614,Suspended,NCT03468075,SARCOMA|SOFT TISSUE SARCOMA|UNRESECTABLE SOFT TISSUE SARCOMA|METASTATIC BONE TUMOR|BONE SARCOMA,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",C07D317/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,0,DB00455,__LORATADINE,6132758,Terminated,NCT01390441,RHEUMATOID ARTHRITIS,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC,0,DB00460,__VERTEPORFIN,5214036,Terminated,NCT00049959,BASAL CELL CARCINOMA|NEVOID BASAL CELL CARCINOMA SYNDROME|GORLIN SYNDROME,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,38.57163391445409,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,718.7942,173.56,7.0,3.0,6.0,81.29,199.08,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00278512,VASCULITIS,All,"16 Years to 60 Years Â  (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00424489,MYASTHENIA GRAVIS,All,"15 Years to 65 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00278564,MYOPATHY,All,"16 Years to 65 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00960063,NEOPLASMS|SOLID TUMORS|BONE CANCER|KIDNEY TUMOR|NEUROBLASTOMA,All,"up to 21 Years Â  (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00499733,CANCER,All,"18 Years to 120 Years Â  (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brady Urological Institute at Johns Hopkins Hospital, Baltimore, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,0,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT00282412,RHEUMATOID ARTHRITIS,All,18 Years to 60 Years Â  (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,0,DB00541,__VINCRISTINE,6723338,Terminated,NCT00960063,NEOPLASMS|SOLID TUMORS|BONE CANCER|KIDNEY TUMOR|NEUROBLASTOMA,All,"up to 21 Years Â  (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,0,DB00541,__VINCRISTINE,6723338,Terminated,NCT01313884,BONE CANCER|EWING'S SARCOMA,All,"13 Years and older Â  (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,0,DB00549,__ZAFIRLUKAST,4859692,Terminated,NCT02950480,BREAST CANCER,Female,"18 Years to 89 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States",C07D249/18,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,40.214378118647204,840.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.84,575.675,115.73,6.0,2.0,5.0,62.0,158.58,8.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1
CCOc1ccc2ccccc2c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,0,DB00607,__NAFCILLIN,4217274,Withdrawn,NCT02344511,OSTEOMYELITIS,All,2 Years to 16 Years Â  (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07D499/00,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,19.450091377646306,817.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.21,414.475,95.94,5.0,2.0,4.0,42.22,108.14,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1
C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,0,DB00621,__OXANDROLONE,6090799,Terminated,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,60.8801002073964,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.36,306.4397,46.53,2.0,1.0,4.0,35.29,84.75,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0
O=C(O)c1cccnc1,0,DB00627,__NIACIN,6080428,Terminated,NCT01237041,OBESITY|SHORT STATURE|GROWTH HORMONE DEFICIENCY,All,7 Years to 14 Years Â  (Child),NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
NC(N)=NN=Cc1c(Cl)cccc1Cl,0,DB00629,__GUANABENZ,,Terminated,NCT02443103,BONE CANCER|METASTASIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Sidney & Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Spring Mill Medical Center, Indianapolis, Indiana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.25,231.082,76.76,4.0,2.0,1.0,21.58,58.15,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1
NC(N)=NN=Cc1c(Cl)cccc1Cl,0,DB00629,__GUANABENZ,,Terminated,,BONE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.25,231.082,76.76,4.0,2.0,1.0,21.58,58.15,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00638820,OSTEOPETROSIS,All,"up to 45 Years Â  (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of MInnesota, Fairview, Minneapolis, Minnesota, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,0,DB00640,__ADENOSINE,5731296,Terminated,NCT01307475,ARTHROGRYPOSIS|CRANIOFACIAL ABNORMALITIES|POSTTRAUMATIC STRESS DISORDER|DEPRESSIVE DISORDER,All,"Child, Adult, Older Adult",Other,Observational Model: Case-Only|Time Perspective: Cross-Sectional,"Freeman-Sheldon Research Group, Inc. Headquarters, Buckhannon, West Virginia, United States|San Juan de Dios General Hospital, Guatemala City, Guatemala",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,60.2887122938869,1415.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.2,267.2413,139.54,8.0,4.0,3.0,25.28,63.2,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,0,DB00684,__TOBRAMYCIN,5149694,Withdrawn,NCT01079559,INFECTION|OSTEOARTHRITIS OF THE KNEE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","London Health Sciences Centre, University Hospital, London, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,0,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Terminated,NCT00282412,RHEUMATOID ARTHRITIS,All,18 Years to 60 Years Â  (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",C07D307/88,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12,0,DB00713,__OXACILLIN,4199566,Withdrawn,NCT02344511,OSTEOMYELITIS,All,2 Years to 16 Years Â  (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,22.538450481529303,1121.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.05,401.436,112.74,5.0,2.0,4.0,39.61,101.83,4.0,0.0,1.0,0.0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1
Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl,0,DB00756,__HEXACHLOROPHENE,3932684,Terminated,,ANALGESIA,,,,,"FISABIO, Elche, Alicante, Spain",C11D3/43,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.421384422678003,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.77,406.904,40.46,2.0,2.0,2.0,34.07,88.59,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT00960063,NEOPLASMS|SOLID TUMORS|BONE CANCER|KIDNEY TUMOR|NEUROBLASTOMA,All,"up to 21 Years Â  (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC,0,DB00762,__IRINOTECAN,6403569,Terminated,NCT01313884,BONE CANCER|EWING'S SARCOMA,All,"13 Years and older Â  (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,25.4296802809092,2416.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.94,586.678,112.51,6.0,1.0,7.0,65.27,161.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1
C[C@](N)(Cc1ccc(O)cc1)C(=O)O,0,DB00765,__METYROSINE,4117161,Terminated,NCT01127503,VELO-CARDIO-FACIAL SYNDROME|PSYCHOSIS,All,"16 Years to 65 Years Â  (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VCFS International Center, Syracuse, New York, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,16.3617322737633,105.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.9,195.2151,83.55,4.0,3.0,1.0,19.9,51.81,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,0,DB00773,__ETOPOSIDE,4701327,Terminated,NCT00960063,NEOPLASMS|SOLID TUMORS|BONE CANCER|KIDNEY TUMOR|NEUROBLASTOMA,All,"up to 21 Years Â  (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,0,DB00798,__GENTAMICIN,,Terminated,NCT02036528,DIABETIC FOOT ULCERS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Hospital Center, Washington, District of Columbia, United States|GF Professional Research, Corp., Miami Lakes, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|Advanced Foot and Ankle Institute of Georgia LLC, Smyrna, Georgia, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Detroit Clinical Research Center, PC, Farmington Hills, Michigan, United States|Utah Valley Medical Center, Provo, Utah, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,0,DB00798,__GENTAMICIN,,Terminated,NCT00658957,DIABETIC FOOT ULCER,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Chesapeake Foot and Ankle Center, Pasadena, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00960063,NEOPLASMS|SOLID TUMORS|BONE CANCER|KIDNEY TUMOR|NEUROBLASTOMA,All,"up to 21 Years Â  (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT01313884,BONE CANCER|EWING'S SARCOMA,All,"13 Years and older Â  (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,0,DB00863,__RANITIDINE,5098715,Withdrawn,NCT02700087,LARYNGOMALACIA|ACID REFLUX|STRIDOR,All,up to 4 Months Â  (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States",A61K9/2806,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,15.1132466785765,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.79,314.4,83.58,5.0,2.0,1.0,33.78,94.15,10.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,0,DB00877,__SIROLIMUS,5212155,Terminated,NCT01223755,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mario Negri Institute - Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,0,DB00887,__BUMETANIDE,4110445,Terminated,NCT02582476,HYPOKALEMIC PERIODIC PARALYSIS,All,18 Years to 64 Years Â  (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MRC Centre for Neuromuscular Disorders, London, United Kingdom",C07D233/88,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,16.296022505595502,672.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,364.416,118.72,5.0,3.0,2.0,37.21,95.78,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1
COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,0,DB00956,__HYDROCODONE,6348216,Terminated,NCT03586934,SHOULDER PAIN|OPIOID USE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,34.0,56.346126203823395,1296.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.13,299.3642,38.77,4.0,0.0,5.0,32.05,82.74,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314,0,DB00956,__HYDROCODONE,6348216,Withdrawn,NCT02540512,MUSCULOSKELETAL PAIN|PAIN,All,"18 Years to 89 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,34.0,56.346126203823395,1296.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.13,299.3642,38.77,4.0,0.0,5.0,32.05,82.74,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,0,DB00977,__ETHINYLESTRADIOL,5876746,Withdrawn,NCT00117260,OSTEOPENIA,Female,12 Years to 17 Years Â  (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,0,DB00983,__FORMOTEROL,6123924,Withdrawn,NCT00662779,EXERCISE-INDUCED BRONCHOSPASM,All,12 Years to 17 Years Â  (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of New Mexico, Albuquerque, New Mexico, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,0,DB01008,__BUSULFAN,5430057,Terminated,NCT00638820,OSTEOPETROSIS,All,"up to 45 Years Â  (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of MInnesota, Fairview, Minneapolis, Minnesota, United States",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,0,DB01026,__KETOCONAZOLE,5456851,Terminated,NCT01110330,TINEA PEDIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bydgoszcz, Poland|Lodz, Poland|Lublin, Poland|Torun, Poland|Cardiff, United Kingdom|Chorley, United Kingdom|Glasgow, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Reading, United Kingdom|Sunbury On Thames, United Kingdom",A61K8/49,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,18.103041130208002,2611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,531.431,69.06,6.0,0.0,5.0,54.83,138.07,7.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00112619,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CARCINOMA OF UNKNOWN PRIMARY|LEUKEMIA|LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"3 Years to 21 Years Â  (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States",C07D491/22,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,0,DB01060,__AMOXICILLIN,6878386,Withdrawn,NCT02688634,CLEFT PALATE,All,"1 Month to 60 Years Â  (Child, Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"UF Health at Shands Hospital, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT00278512,VASCULITIS,All,"16 Years to 60 Years Â  (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01073,__FLUDARABINE,7547776,Terminated,NCT00282412,RHEUMATOID ARTHRITIS,All,18 Years to 60 Years Â  (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",C07H19/16,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12,0,DB01091,__BUTENAFINE,5021458,Terminated,NCT01119742,INTERDIGITAL TINEA PEDIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D333/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,29.8650896322306,321.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.85,317.4672,3.24,1.0,0.0,3.0,38.41,104.33,5.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT02915172,ADVANCED CANCER|MALIGNANT NEOPLASM OF BREAST|MALIGNANT NEOPLASMS OF BONE AND ARTICULAR CARTILAGE|MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS|MALIGNANT NEOPLASMS OF EYE BRAIN AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM|MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF ILL-DEFINED SECONDARY AND UNSPECIFIED SITES|MALIGNANT NEOPLASMS OF INDEPENDENT (PRIMARY) MULTIPLE SITES|MALIGNANT NEOPLASMS OF LIP ORAL CAVITY AND PHARYNX|MALIGNANT NEOPLASMS OF MALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF MESOTHELIAL AND SOFT TISSUE|MALIGNANT NEOPLASMS OF RESPIRATORY AND INTRATHORACIC ORGANS|MALIGNANT NEOPLASMS OF THYROID AND OTHER ENDOCRINE GLANDS|MALIGNANT NEOPLASMS OF URINARY TRACT,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],0,DB01115,__NIFEDIPINE,5264446,Withdrawn,NCT01586286,LEVATOR ANI SYNDROME,Female,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",A61K9/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,17.7416374052855,1857.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.49,346.3346,110.45,5.0,1.0,2.0,33.85,92.16,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0
CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,0,DB01128,__BICALUTAMIDE,4636505,Terminated,NCT02582749,PROSTATE CANCER|BONE METASTASES|PROSTATE NEOPLASMS,Male,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arizona Cancer Center at Dignity Health St. Joseph's, Phoenix, Arizona, United States|Illinois CancerCare, P. C., Peoria, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|University of Iowa Hopital and Clinics, Iowa City, Iowa, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Metro Health Cancer Center, Wyoming, Michigan, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Integrated Medical Professionals, PLLC, Lake Success, New York, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States|Clement J. Zablocki VA Medical Center, Milwaukee, Wisconsin, United States",C07D333/62,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,41.988541859175704,633.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.7,430.37300000000016,107.26,5.0,2.0,2.0,36.68,96.59,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0
O=P1(NCCCl)OCCCN1CCCl,0,DB01181,__IFOSFAMIDE,5252341,Terminated,NCT00960063,NEOPLASMS|SOLID TUMORS|BONE CANCER|KIDNEY TUMOR|NEUROBLASTOMA,All,"up to 21 Years Â  (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,0,DB01183,__NALOXONE,6159498,Terminated,NCT00716807,TEMPOROMANDIBULAR JOINT DYSFUNCTION SYNDROME|BURNING MOUTH SYNDROME,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","University of California, San Francisco, San Francisco, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,27.3681184418571,1213.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.47,327.3743,70.0,5.0,2.0,5.0,33.83,88.72,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,0,DB01192,__OXYMORPHONE,5662933,Withdrawn,NCT01206907,CHRONIC PAIN,All,2 Years to 6 Years Â  (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,21.979917452103706,1154.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.26,301.3371,70.0,5.0,2.0,5.0,30.77,79.56,0.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,0,DB01268,__SUNITINIB,6573293,Terminated,NCT00906360,METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY SQUAMOUS CELL CARCINOMA|RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE III SALIVARY GLAND CANCER|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE III VERRUCOUS CARCINOMA OF THE LARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY|TONGUE CANCER|UNTREATED METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY,All,"18 Years and older Â  (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Evanston CCOP-NorthShore University HealthSystem, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc - State Boulevard, Fort Wayne, Indiana, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,0,DB01274,__ARFORMOTEROL,5795564,Withdrawn,NCT00662779,EXERCISE-INDUCED BRONCHOSPASM,All,12 Years to 17 Years Â  (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of New Mexico, Albuquerque, New Mexico, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,29.3722663709727,1132.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01249443,"HIV INFECTION|RECURRENT ANAL CANCER|RECURRENT BREAST CANCER|RECURRENT ESOPHAGEAL CANCER|RECURRENT GASTRIC CANCER|RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE IV ANAL CANCER|STAGE IV BREAST CANCER|STAGE IV ESOPHAGEAL CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older Â  (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
NC(=O)c1cccnc1,0,DB02701,__NICOTINAMIDE,3931207,Terminated,NCT02758990,"OBESITY|RHINITIS|RHINITIS, ALLERGIC|RESPIRATORY SOUNDS|DYSPNEA|HEADACHE|MIGRAINE DISORDERS|ARTHRITIS|ARTHRALGIA|ANXIETY|SLEEP INITIATION AND MAINTENANCE DISORDERS|SLEEP DEPRIVATION",All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Verifomics, LLC, Dallas, Texas, United States",C07D207/44,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,0,DB02901,__STANOLONE,4071623,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,20.5014476683299,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,290.4403,37.3,2.0,1.0,4.0,34.69,83.6,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0
O=P(O)(O)OP(=O)(O)OP(=O)(O)O,0,DB03896,__TRIPHOSPHORIC_ACID,,Terminated,NCT01307475,ARTHROGRYPOSIS|CRANIOFACIAL ABNORMALITIES|POSTTRAUMATIC STRESS DISORDER|DEPRESSIVE DISORDER,All,"Child, Adult, Older Adult",Other,Observational Model: Case-Only|Time Perspective: Cross-Sectional,"Freeman-Sheldon Research Group, Inc. Headquarters, Buckhannon, West Virginia, United States|San Juan de Dios General Hospital, Guatemala City, Guatemala",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,257.955,170.82,8.0,5.0,0.0,14.67,36.4,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(O)c1ccc(O)cc1,0,DB04242,__4-HYDROXYBENZOIC_ACID,3939145,Withdrawn,NCT03445611,OSTEO ARTHRITIS OF THE KNEES,All,"19 Years to 89 Years Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Loma Linda University Health, Department of Orthopaedic Surgery, Loma Linda, California, United States",C07H15/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,35.5818394628226,4821.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,138.122,57.53,3.0,2.0,1.0,12.94,35.3,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,0,DB04540,__CHOLESTEROL,,Terminated,NCT01356420,SMITH-LEMLI-OPITZ SYNDROME,All,"up to 85 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pdgen, Nichd, Nih, Dhhs, Bethesda, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children'S Hospital of Pittsburgh of Upmc, Pittsburgh, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,7.02,386.6535,20.23,1.0,1.0,4.0,50.64,120.62,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,0,DB04835,__MARAVIROC,6586430,Terminated,NCT00427934,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Huntington Beach, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Hamden, Connecticut, United States|Pfizer Investigational Site, Meriden, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Daytona Beach, Florida, United States|Pfizer Investigational Site, Port Orange, Florida, United States|Pfizer Investigational Site, Savannah, Georgia, United States|Pfizer Investigational Site, Savannah, Georgia, United States|Pfizer Investigational Site, Moline, Illinois, United States|Pfizer Investigational Site, Madisonville, Kentucky, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Hickory, North Carolina, United States|Pfizer Investigational Site, Hickory, North Carolina, United States|Pfizer Investigational Site, Minot, North Dakota, United States|Pfizer Investigational Site, Duncansville, Pennsylvania, United States|Pfizer Investigational Site, Maroochydore, Queensland, Australia|Pfizer Investigational Site, Woodville, South Australia, Australia|Pfizer Investigational Site, Hobart, Tasmania, Australia|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Pavia, Italy|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Coimbra, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisbon, Portugal|Pfizer Investigational Site, Santiago de Compostela, A CoruÃ±a, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Simferopol, Ukraine",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
C[C@H]1CNCCc2ccc(Cl)cc21,0,DB04871,__LORCASERIN,6953787,Terminated,NCT02523690,MUSCLE WEAKNESS|SEPSIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Johns Hopkins University, Baltimore, Maryland, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,77.0,30.0622189367338,52.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,195.69,12.03,1.0,1.0,2.0,21.51,56.65,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,0,DB04977,__PLITIDEPSIN,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,1110.357,284.74,13.0,4.0,4.0,117.17,288.14,15.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1
CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3,0,DB04982,__TALAMPANEL,6288057,Terminated,,AMYOTROPHIC LATERAL SCLEROSIS (ALS),,,,,"FISABIO, Elche, Alicante, Spain",C07D491/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,77.50467155383059,20.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.97,337.3725,77.15,5.0,1.0,4.0,36.34,94.65,1.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0
CC(=O)[O-].CC(=O)[O-].N.NC1CCCCC1.[Cl-].[Cl-].[Pt+4],0,DB04996,__SATRAPLATIN,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,500.283,26.02,1.0,1.0,1.0,12.44,30.93,0.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
[O-][n+]1cccc(C(Cl)=NOC[C@H](O)CN2CCCCC2)c1,0,DB05025,__ARIMOCLOMOL,,Withdrawn,,AMYOTROPHIC LATERAL SCLEROSIS (ALS),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.45,313.78,70.52,5.0,1.0,2.0,32.93,83.13,6.0,0.0,1.0,0.0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1
CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C,0,DB05087,__GANAXOLONE,5232917,Terminated,NCT00442104,INFANTILE SPASMS,All,4 Months to 24 Months Â  (Child),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital at UCLA, Los Angeles, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Miami Children's Hospital, The Brain Institute, Miami, Florida, United States|Child Neurology Center of Nrothwest Florida, P.A., Pensacola, Florida, United States|University of Chicago Comer Children's Hospital, Chicago, Illinois, United States|Minnesota Epilepsy Group, P.A., Saint Paul, Minnesota, United States|Montefiore Medical Center- Albert Einstein College of Medicine, Bronx, New York, United States|Le Bonheur Children's Medical Center, Memphis, Tennessee, United States|Dallas Pediatric Neurology Associates, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Virginia Commonwealth University Health Systems, Richmond, Virginia, United States|Children's Hospital and Regional Medical Center, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,119.0,23.688371424464503,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.37,332.528,37.3,2.0,1.0,4.0,40.68,97.54,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0
COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,0,DB05253,__TELAPRISTONE_ACETATE,US-20090149434-A1,Terminated,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.63,505.655,72.91,5.0,0.0,5.0,56.9,144.89,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CC(C)(CC1Cc2ccccc2C1)NC[C@@H](O)COc1cc(CCC(=O)O)cc(F)c1F,0,DB05255,__RONACALERET,7514473,Terminated,NCT00471237,OSTEOPOROSIS,Female,"18 Years to 79 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GSK Investigational Site, Oakland, California, United States|GSK Investigational Site, Palm Desert, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Akron, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Duncansville, Pennsylvania, United States|GSK Investigational Site, Ciudad AutÃ³noma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Ciudad AutÃ³noma de Buenos Aires, Argentina|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Footscray, Victoria, Australia|GSK Investigational Site, Geelong, Victoria, Australia|GSK Investigational Site, Heidelberg, Victoria, Australia|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Liege, Belgium|GSK Investigational Site, Tienen, Belgium|GSK Investigational Site, Ballerup, Denmark|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Suwon, Korea, Republic of|GSK Investigational Site, Mexico, D.F., Mexico|GSK Investigational Site, Bergen, Norway|GSK Investigational Site, Hamar, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Grudziadz, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Panorama, South Africa|GSK Investigational Site, Rosebank, South Africa|GSK Investigational Site, Somerset West, South Africa|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Santiago de Compostela, Spain",C07C217/54,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,64.3955728043697,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.37,447.523,78.79,5.0,3.0,3.0,47.78,118.36,11.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,0,DB05575,__MOTESANIB,US-20030125339-A1,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,48.9209224008706,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.59,373.4509,78.94,5.0,3.0,4.0,40.66,114.77,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1,0,DB06178,__TALOTREXIN,EP-1180369-A1,Withdrawn,NCT00458744,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LEUKEMIA|LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"1 Year to 21 Years Â  (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,A61K39/395,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,58.7116778578615,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,573.56,248.43,13.0,7.0,4.0,58.38,154.27,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1,0,DB06178,__TALOTREXIN,EP-1180369-A1,Withdrawn,,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",A61K39/395,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,58.7116778578615,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,573.56,248.43,13.0,7.0,4.0,58.38,154.27,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,0,DB06195,__SELICICLIB,US-20020049218-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61P17/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.11,354.4493,87.89,6.0,3.0,3.0,40.43,106.14,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1
CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1,0,DB06199,__ATRASENTAN,5767144,Terminated,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",C07D403/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,36.5674859853385,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.09,510.6218,88.54,7.0,1.0,4.0,55.33,140.14,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,0,DB06201,__RUFINAMIDE,6740669,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,68.5352881989363,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.95,238.1935,73.8,3.0,1.0,2.0,20.42,67.07,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0
COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1,0,DB06218,__LACOSAMIDE,5654301,Terminated,NCT00485472,OSTEOARTHRITIS,All,"40 Years to 75 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kladno, Czechia|Prague, Czechia|Bad Hersfeld, Germany|Berlin, Germany|Hamburg, Germany|Leipzig, Germany|MÃ¼nchen, Germany|Debrecen, Hungary|Esztegom, Hungary|Gyor, Hungary|Gyula, Hungary|Verseghy, Hungary|Veszprem, Hungary|Bialystok, Poland|Krakow, Poland|Torun, Poland|Warszawa, Poland|Braila, Romania|Lasi, Romania|Targoviste, Romania|Timisoara, Romania|Stockholm, Sweden|Morriston, United Kingdom|Newcastle, United Kingdom|Oxford, United Kingdom|Stanmore, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,47.0,54.7362368837142,182.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.18,250.2936,67.43,3.0,2.0,1.0,26.68,67.57,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1
COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1,0,DB06218,__LACOSAMIDE,5654301,Withdrawn,NCT02342977,OSTEOARTHRITIS|RHEUMATOID ARTHRITIS|AVASCULAR NECROSIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,47.0,54.7362368837142,182.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.18,250.2936,67.43,3.0,2.0,1.0,26.68,67.57,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1
N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1,0,DB06262,__DROXIDOPA,WO-2005085178-A1,Terminated,NCT00977171,CHRONIC FATIGUE SYNDROME|ORTHOSTATIC HYPOTENSION|NEURALLY MEDIATED HYPOTENSION|NEUROGENIC ORTHOSTATIC HYPOTENSION,All,"18 Years to 65 Years Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"7421 Carmel Executive Park Drive, Ste. 320, Charlotte, North Carolina, United States",C07C229/36,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,213.18900000000002,124.01,6.0,5.0,1.0,19.85,50.29,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCNCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O,0,DB06333,__TRODUSQUEMINE,,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,685.07,145.94,8.0,6.0,4.0,84.8,192.01,20.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0
CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,0,DB06346,__FIBOFLAPON,US-20070105866-A1,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,56.4775457401589,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.63,637.84,86.47,6.0,1.0,5.0,73.86,186.32,13.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1
CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,0,DB06350,__ELINOGREL,WO-2012072824-A1,Terminated,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,38.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,523.94,136.71,6.0,4.0,4.0,49.7,125.95,4.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1
NS(=O)(=O)c1ccc(S(=O)(=O)Nc2cccc3c(Cl)c[nH]c23)cc1,0,DB06370,__INDISULAM,6060498,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.4357379001622,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.21,385.846,122.12,4.0,3.0,3.0,35.23,90.94,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0
Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1,0,DB06436,__SEMAXANIB,5792783,Terminated,NCT00006247,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS,All,"up to 21 Years Â  (Child, Adult)",Other|NIH,Primary Purpose: Treatment,"UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States",C07D409/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,26.185342614838,51.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.64,238.2845,44.89,1.0,2.0,3.0,26.98,74.56,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1
COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,0,DB06510,__MURAGLITAZAR,EP-1607103-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.04,516.55,111.33,6.0,1.0,4.0,54.85,149.03,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0
CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,0,DB06536,__TESAGLITAZAR,6258850,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C309/65,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,23.688371424464503,77.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.18,408.465,99.13,6.0,1.0,2.0,42.56,103.52,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,0,DB06573,__REBIMASTAT,WO-2003048119-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,499.67,127.92,5.0,4.0,1.0,54.52,131.54,11.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,0,DB06605,__APIXABAN,6413980,Withdrawn,NCT04198844,ATRIAL FIBRILLATION,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Observational Model: Cohort|Time Perspective: Retrospective,"Pfizer Investigational Site, Seoul, Korea, Republic of",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1,0,DB06670,__ODANACATIB,WO-2003075836-A2,Terminated,NCT00529373,POSTMENOPAUSAL OSTEOPOROSIS,Female,65 Years and older Â  (Older Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,1,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.04,525.56,99.06,5.0,2.0,3.0,50.35,126.95,10.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1,0,DB06670,__ODANACATIB,WO-2003075836-A2,Terminated,NCT01630616,OSTEOPOROSIS,All,"12 Years to 25 Years Â  (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.04,525.56,99.06,5.0,2.0,3.0,50.35,126.95,10.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0
CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1,0,DB06670,__ODANACATIB,WO-2003075836-A2,Withdrawn,NCT01552122,OSTEOPOROSIS|POSTMENOPAUSAL OSTEOPOROSIS,Female,"60 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.04,525.56,99.06,5.0,2.0,3.0,50.35,126.95,10.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0
COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC,0,DB07615,__TRANILAST,4070484,Withdrawn,NCT00717808,RHEUMATOID ARTHRITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,13.1090987494609,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.89,327.3313,84.86,5.0,2.0,2.0,34.2,91.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0
Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1,0,DB07933,__ERTEBEREL,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,282.3337,49.69,3.0,2.0,4.0,30.27,80.5,1.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1
CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,0,DB07941,__PH-797804,US-20040058964-A1,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,70.0,40.3786525390665,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,477.29900000000004,58.64,3.0,1.0,3.0,43.79,116.85,4.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0
COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,0,DB08079,__AMG-208,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.66,383.4027,74.43,6.0,0.0,5.0,40.72,119.54,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1,0,DB08387,__MARDEPODECT,WO-2005120514-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.01,392.4525,52.83,4.0,0.0,5.0,43.9,127.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
NCCc1c[nH]c2ccccc12,0,DB08653,__TRYPTAMINE,3930948,Terminated,,QUALITY OF LIFE,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,17.281669028111402,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.21,160.2157,41.81,1.0,2.0,2.0,18.34,50.37,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,0,DB08828,__VISMODEGIB,7888364,Withdrawn,NCT03767439,BASAL CELL NEVUS SYNDROME,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D417/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,65.4469290950532,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,421.29699999999997,76.13,4.0,1.0,3.0,39.49,107.81,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,0,DB09061,__CANNABIDIOL,10195159,Terminated,NCT02551731,"SPASMS, INFANTILE",All,6 Months to 36 Months Â  (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mattel Children's Hospital at UCLA, Los Angeles, California, United States|University of California - San Francisco, San Francisco, California, United States|Miami Children's Hospital, Miami, Florida, United States|Beaumont Health System, Royal Oak, Michigan, United States",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,46.2268219059939,452.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.1,314.469,40.46,2.0,2.0,2.0,38.35,98.53,6.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,0,DB09078,__LENVATINIB,7253286,Withdrawn,NCT02915172,ADVANCED CANCER|MALIGNANT NEOPLASM OF BREAST|MALIGNANT NEOPLASMS OF BONE AND ARTICULAR CARTILAGE|MALIGNANT NEOPLASMS OF DIGESTIVE ORGANS|MALIGNANT NEOPLASMS OF EYE BRAIN AND OTHER PARTS OF CENTRAL NERVOUS SYSTEM|MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF ILL-DEFINED SECONDARY AND UNSPECIFIED SITES|MALIGNANT NEOPLASMS OF INDEPENDENT (PRIMARY) MULTIPLE SITES|MALIGNANT NEOPLASMS OF LIP ORAL CAVITY AND PHARYNX|MALIGNANT NEOPLASMS OF MALE GENITAL ORGANS|MALIGNANT NEOPLASMS OF MESOTHELIAL AND SOFT TISSUE|MALIGNANT NEOPLASMS OF RESPIRATORY AND INTRATHORACIC ORGANS|MALIGNANT NEOPLASMS OF THYROID AND OTHER ENDOCRINE GLANDS|MALIGNANT NEOPLASMS OF URINARY TRACT,All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0
O=S(=O)(O)CCS,0,DB09110,__COENZYME_M,,Terminated,NCT00278512,VASCULITIS,All,"16 Years to 60 Years Â  (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=S(=O)(O)CCS,0,DB09110,__COENZYME_M,,Terminated,NCT00424489,MYASTHENIA GRAVIS,All,"15 Years to 65 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=S(=O)(O)CCS,0,DB09110,__COENZYME_M,,Terminated,NCT00758667,IMPLANT CAPSULAR CONTRACTURE,Female,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=S(=O)(O)CCS,0,DB09110,__COENZYME_M,,Terminated,NCT00278564,MYOPATHY,All,"16 Years to 65 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
Cc1c(C(=O)Nc2ccc(N3C[C@H](C)O[C@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1,0,DB09143,__SONIDEGIB,8178563,Terminated,NCT02303041,"CARCINOMA, BASAL CELL|RECURRENT SKIN CANCER|SKIN NEOPLASMS|BASAL CELL NEVUS SYNDROME",All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",C07D413/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,60.3872769461385,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.64,485.50699999999995,63.69,5.0,1.0,4.0,49.91,125.34,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+],0,DB09154,__SODIUM_CITRATE,,Withdrawn,NCT01421160,ARTHRITIS,All,"21 Years to 80 Years Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Anesthesiology; Texas Tech University Health Sciences Center; Paul L. Foster School of Medicine, El Paso, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.55,258.068,140.62,7.0,1.0,0.0,14.23,68.14,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
NC(=O)CN1CCCC1=O,0,DB09210,__PIRACETAM,4115579,Withdrawn,NCT01549847,POSTPOLIOMYELITIS SYNDROME,All,18 Years to 60 Years Â  (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UNIFESP, SÃ£o Paulo, SP, Brazil",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,11.006386168093801,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.6,142.1558,63.4,2.0,1.0,1.0,13.96,35.06,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
[F-].[Na+],0,DB09325,__SODIUM_FLUORIDE,8323683,Terminated,NCT01541358,BONE CANCER,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Stanford University, Stanford, California, United States",A61K9/0058,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,90.58091541920773,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.15,41.9882,0.0,0.0,0.0,0.0,0.44,0.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[K+].[O-][Cl+3]([O-])([O-])[O-],0,DB09418,__POTASSIUM_PERCHLORATE,,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.97,138.549,74.27,4.0,0.0,0.0,5.23,11.91,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[Se]CC[C@H](N)C(=O)O,0,DB11142,__SELENOMETHIONINE,,Terminated,NCT01682031,CHEMOTHERAPEUTIC AGENT TOXICITY|MUCOSITIS|RADIATION TOXICITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|XEROSTOMIA,All,"18 Years and older Â  (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Supportive Care,"Roswell Park Cancer Institute, Buffalo, New York, United States|Waikato Hospital, Hamilton, New Zealand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,196.11,63.32,3.0,2.0,0.0,14.64,42.91,4.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cu+2],0,DB11246,__COPPER_GLUCONATE,4112066,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61Q11/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,26.481036571592803,532.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,453.841,141.28,7.0,5.0,0.0,16.62,49.11,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,0,DB11526,__MASITINIB,EP-1525200-B1,Terminated,NCT01410695,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARTMEDI UPD s.r.o, Hostivice, Czechia",Â A61P1/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,50.333682416476705,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,498.65,73.39,6.0,2.0,5.0,55.33,147.0,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1,0,DB11658,__QAV-680,EP-1761529-B1,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06Â ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,71.9521961436579,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.73,358.41,89.26,5.0,1.0,3.0,36.7,94.91,5.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB11666,__BUPARLISIB,WO-2009076170-A2,Terminated,NCT02303041,"CARCINOMA, BASAL CELL|RECURRENT SKIN CANCER|SKIN NEOPLASMS|BASAL CELL NEVUS SYNDROME",All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,32.7488,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,410.3935,89.63,8.0,1.0,4.0,39.25,103.58,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB11666,__BUPARLISIB,WO-2009076170-A2,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,32.7488,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,410.3935,89.63,8.0,1.0,4.0,39.25,103.58,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1,0,DB11704,__ADOMEGLIVANT,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.28,555.638,75.63,4.0,2.0,3.0,59.13,150.1,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0
CCC[C@@H](Nc1c(Cc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,0,DB11711,__NAVARIXIN,,Withdrawn,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.43,410.47,99.85,5.0,2.0,3.0,43.63,114.86,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,0,DB11723,__DUTOGLIPTIN,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,241.1,84.83,5.0,4.0,2.0,25.94,58.91,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)C(C)C)C(N)=O,0,DB11724,__BOMBESIN,,Suspended,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.3,1619.87,686.13,22.0,23.0,4.0,166.6,418.43,51.0,1.0,0.0,0.0,1,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,1,1,1,1,0,1,1,0
CCCOc1ccc(S(=O)(=O)N2CCN(CCO)CC2)cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1,0,DB11792,__MIRODENAFIL,US-20030171361-A1,Terminated,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,56.7403848128298,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.85,531.67,116.47,7.0,2.0,4.0,57.75,146.61,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1
O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1,0,DB11798,__TANZISERTIB,US-20120100213-A1,Terminated,,FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2866,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,25.692519353580106,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.77,448.4415,97.12,7.0,3.0,5.0,44.11,111.52,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,1,0,1
CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1,0,DB11811,__ARHALOFENATE,US-20120232302-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,69.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.98,415.79,64.63,3.0,1.0,2.0,38.21,95.9,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0
C/C=C(/C)C(=O)O[C@H]1C(C)=C2[C@@H]3OC(=O)[C@@](C)(O)[C@@]3(O)[C@@H](OC(=O)CCCCCCCCCCCNC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)C[C@](C)(OC(C)=O)[C@H]2[C@@H]1OC(=O)CCCCCCC,0,DB11813,__MIPSAGARGIN,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.5,1409.5410000000006,529.98,23.0,13.0,3.0,148.12,339.89,50.0,1.0,0.0,0.0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,1
COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,0,DB11816,__OMECAMTIV_MECARBIL,US-20060014761-A1,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,61.0,45.2411753834781,10.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.05,401.44199999999995,86.8,4.0,2.0,3.0,40.95,109.19,5.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Withdrawn,NCT02367690,DIABETIC FOOT ULCERS,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"South Pacific Clinical Trials, Auckland, New Zealand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,0,DB11968,__MK-7145,US-20100286123-A1,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,46.686790283168,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.33,466.534,99.54,6.0,2.0,5.0,49.95,128.43,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1
Nc1cc(N2CCN(CCP(=O)(O)O)CC2)nc(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)n1,0,DB11970,__BURIXAFOR,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.41,566.732,151.9,11.0,6.0,4.0,65.83,161.18,14.0,1.0,0.0,0.0,1,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1
COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,0,DB11973,__TESEVATINIB,US-20080166359-A1,Terminated,,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE ï¼ADPKD),,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,65.0,44.058399556459,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.51,491.39,59.51,6.0,1.0,5.0,51.0,127.76,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0
COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,0,DB11973,__TESEVATINIB,US-20080166359-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,65.0,44.058399556459,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.51,491.39,59.51,6.0,1.0,5.0,51.0,127.76,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0
CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,0,DB11975,__TAK-448,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,1225.376,475.71,17.0,18.0,5.0,126.85,326.01,31.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0
COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,0,DB11979,__ELAGOLIX,6872728,Terminated,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,86.0,25.692519353580106,8.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.68,631.6,99.18,6.0,2.0,4.0,59.44,156.06,12.0,1.0,0.0,0.0,1,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0
Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,0,DB11981,__ELAMIPRETIDE,,Terminated,NCT02976038,PRIMARY MITOCHONDRIAL DISEASE,All,"16 Years and older Â  (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Diego, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Akron Children's Hospital, Akron, Ohio, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.12,639.802,264.56,10.0,10.0,2.0,69.74,186.25,19.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,1,1,0
Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,0,DB11981,__ELAMIPRETIDE,,Terminated,NCT03323749,PRIMARY MITOCHONDRIAL MYOPATHY,All,"16 Years to 80 Years Â  (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California San Diego, La Jolla, California, United States|Stanford University, Palo Alto, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rare Disease Research, LLC, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Columbia University Medical Center, New York, New York, United States|Akron Children's Hospital, Akron, Ohio, United States|Cleveland Clinical Neurological Institute, Cleveland, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Adult Metabolic Diseases Clinic, Vancouver, British Colombia, Canada|McMaster University Medical Center, Hamilton, Ontario, Canada|Copenhagen Neuromuscular Center, Copenhagen, Denmark|University Hospital of Bonn, Bonn, Germany|Klinikum der UniversitÃ¤t MÃ¼nchen, Friedrich-Baur Institute, Munich, Germany|Institute of Genomic Medicine and Rare Disorders, Budapest, Hungary|IRCCS Institute of Neorological Sciences of Bologna, Bellaria Hospital, Bologna, Italy|Azienda Ospedaliero Universitaria Policlinico G. Martino, Messina, Italy|Istituto Nazionale Neurologico Carlo Besta, Milan, Italy|Dipartimento Ambientale di Neuroscienze, Pisa, Italy|Ospedale Pediatrico Bambin GesÃ¹, Rome, Italy|Istituto di Neurologia, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy|MRC Centre for Neuromuscular Diseases, London, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.12,639.802,264.56,10.0,10.0,2.0,69.74,186.25,19.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,1,1,0
FC(F)(F)c1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1,0,DB11985,__DAPACONAZOLE,US-20120196908-A1,Withdrawn,NCT02606383,TINEA PEDIS,All,"16 Years to 60 Years Â  (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ClÃ­nica Gobbato de Dermatologia, Rio Claro, SÃ£o Paulo, Brazil",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,90.0,54.407688042875606,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.91,415.24,27.05,2.0,0.0,3.0,38.05,99.43,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1
CN1C[C@H]2[C@@H](C1)[C@@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1,0,DB11993,__PF-03463275,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.08,376.86,41.37,3.0,0.0,4.0,38.83,100.25,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,0,DB12010,__FOSTAMATINIB,7449458,Terminated,NCT00805467,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, La Jolla, California, United States|Research Site, Palm Desert, California, United States|Research Site, Palo Alto, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Maria, California, United States|Research Site, Hamden, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Aventura, Florida, United States|Research Site, Boca Raton, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange Park, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Venice, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Coeur D'Alene, Idaho, United States|Research Site, South Bend, Indiana, United States|Research Site, Elizabethtown, Kentucky, United States|Research Site, Cumberland, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Lansing, Michigan, United States|Research Site, Omaha, Nebraska, United States|Research Site, Roslyn, New York, United States|Research Site, Smithtown, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Mayfiled Village, Ohio, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Willow Grove, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Jackson, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Oklahoma City, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Antwerp, Belgium|Research Site, Gent, Belgium|Research Site, Liege, Belgium|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bucaramanga, Colombia|Research Site, MedellÃ­n, Colombia|Research Site, Bordeaux, France|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, WÃ¼rzburg, Germany|Research Site, Siena, Italy|Research Site, Udine, Italy|Research Site, Chihuahua, Mexico|Research Site, Cuernava, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Guadalajara, Mexico|Research Site, Leon, Mexico|Research Site, Mexcio, Mexico|Research Site, Mexico, Mexico|Research Site, Morelia, Mexico|Research Site, San Luis PotosÃ­, Mexico|Research Site, Jesus Maria, Peru|Research Site, Lima, Peru|Research Site, BiaÅystok, Poland|Research Site, Bytom, Poland|Research Site, Elblag, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, ToruÅ, Poland|Research Site, Wroclaw, Poland|Research Site, ZyrardÃ³w, Poland|Research Site, Brailari, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Sf. Gheorghe, Romania|Research Site, Sibiu, Romania",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,33.7419659541263,14.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.78,580.4595,186.72,13.0,4.0,4.0,54.48,137.1,10.0,1.0,0.0,0.0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1,0,DB12066,__ORTERONEL,WO-2012068435-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.36,307.353,67.15,3.0,2.0,4.0,33.21,88.3,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
COC[C@H](O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O,0,DB12113,__CE-224535,6974812,Terminated,NCT00418782,OSTEOARTHRITIS,All,"18 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Pfizer Investigational Site, Anniston, Alabama, United States|Pfizer Investigational Site, Bayou La Batre, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Hot Springs, Arkansas, United States|Pfizer Investigational Site, Northridge, California, United States|Pfizer Investigational Site, Sacramento, California, United States|Pfizer Investigational Site, Tarzana, California, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Westminster, Colorado, United States|Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, DeFuniak Springs, Florida, United States|Pfizer Investigational Site, Destin, Florida, United States|Pfizer Investigational Site, Pensacola, Florida, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Gurnee, Illinois, United States|Pfizer Investigational Site, Avon, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Gretna, Louisiana, United States|Pfizer Investigational Site, Kenner, Louisiana, United States|Pfizer Investigational Site, Metairie, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Frederick, Maryland, United States|Pfizer Investigational Site, Flowood, Mississippi, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Missoula, Montana, United States|Pfizer Investigational Site, Trenton, New Jersey, United States|Pfizer Investigational Site, Beavercreek, Ohio, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Kettering, Ohio, United States|Pfizer Investigational Site, Ashland, Oregon, United States|Pfizer Investigational Site, Eugene, Oregon, United States|Pfizer Investigational Site, Duncansville, Pennsylvania, United States|Pfizer Investigational Site, Summerville, South Carolina, United States|Pfizer Investigational Site, Collierville, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Bryan, Texas, United States|Pfizer Investigational Site, Longview, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Arlington, Virginia, United States|Pfizer Investigational Site, Spokane, Washington, United States",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,23.4583872358775,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.19,480.95,131.77,7.0,3.0,3.0,49.05,121.18,8.0,0.0,1.0,0.0,1,1,1,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,0,DB12138,__PF-03715455,7511057,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,43.66414094745271,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.95,700.273,129.6,6.0,4.0,6.0,72.53,208.94,11.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,1
Cc1cccc([C@H](C)c2c[nH]c(=S)[nH]2)c1C,0,DB12143,__REZATOMIDINE,US-20100029659-A1,Terminated,,FIBROMYALGIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,38.900182755292704,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.74,232.35,24.06,0.0,2.0,2.0,26.53,73.33,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2,0,DB12145,__AZD-0328,US-20030166935-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,11.7620485020226,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.51,216.28400000000002,25.36,3.0,0.0,4.0,23.72,61.85,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0,DB12236,__BEXAGLIFLOZIN,WO-2009026537-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00Â ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.33,464.94,108.61,7.0,4.0,4.0,49.38,118.44,9.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1
CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,0,DB12253,__GDC-0810,WO-2012037411-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.36,446.91,65.98,3.0,2.0,4.0,46.2,135.99,6.0,0.0,1.0,0.0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1
O=C(Nc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1,0,DB12260,__RADIPRODIL,WO-2003010159-A1,Terminated,NCT02829827,INFANTILE SPASMS,All,2 Months to 14 Months Â  (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ep0078 401, Paris, France",A61P11/06,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,32.7488,24.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,397.406,87.74,4.0,2.0,4.0,39.05,106.14,4.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0
CC(C)OP(=O)(OC(C)C)C(Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)P(=O)(OC(C)C)OC(C)C,0,DB12276,__APOMINE,6048995,Terminated,NCT00078026,OSTEOPOROSIS,Female,"45 Years to 75 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Omaha, Nebraska, United States|West Haverstraw, New York, United States",C07F9/404,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,19.7129304503172,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.53,562.665,91.29,3.0,1.0,1.0,61.56,151.23,14.0,1.0,0.0,0.0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0
OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,0,DB12310,__TREHALOSE,4010078,Withdrawn,NCT04226924,OCULOPHARYNGEAL MUSCULAR DYSTROPHY,All,"50 Years to 70 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ecogene-21, Chicoutimi, Quebec, Canada|Montreal Neurological Institute and Hospital, MontrÃ©al, Quebec, Canada|CHU de QuÃ©bec-UniversitÃ© Laval- HÃ´pital Enfant-JÃ©sus, QuÃ©bec, Quebec, Canada",C12M41/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,12.222016879196598,9047.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.2,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21,0,DB12320,__PALOVAROTENE,US-20140303223-A1,Terminated,NCT02521792,FIBRODYSPLASIA OSSIFICANS PROGRESSIVA,All,"6 Years to 65 Years Â  (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, Division of Endocrinology and Metabolism, San Francisco, California, United States|University of Pennsylvania, Center for Research in FOP & Related Disorders, Philadelphia, Pennsylvania, United States|HÃ´pital Necker-Enfants Malades, Department of Genetics, Paris, France|The Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,22.045627220271395,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.94,414.54900000000004,55.12,3.0,1.0,4.0,47.96,137.81,5.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0
CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21,0,DB12320,__PALOVAROTENE,US-20140303223-A1,Terminated,,"EXOSTOSES, MULTIPLE HEREDITARY",,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,22.045627220271395,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.94,414.54900000000004,55.12,3.0,1.0,4.0,47.96,137.81,5.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0
CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21,0,DB12320,__PALOVAROTENE,US-20140303223-A1,Terminated,,FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP),,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,22.045627220271395,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.94,414.54900000000004,55.12,3.0,1.0,4.0,47.96,137.81,5.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0
C[C@]12C(=O)OC(=O)[C@@]1(C)[C@@H]1CC[C@H]2O1,0,DB12328,__CANTHARIDIN,4298752,Terminated,NCT03426995,RHEUMATOID ARTHRITIS,Male,"18 Years to 65 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Cambridge, United Kingdom",C07D493/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,13.4705024743834,63.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.1,196.202,52.6,3.0,0.0,3.0,18.54,45.4,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,0,DB12340,__NAVITOCLAX,7390799,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,25.4296802809092,41.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.77,974.613,128.36,10.0,2.0,7.0,99.45,256.36,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1
Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,0,DB12381,__MERESTINIB,US-20100022529-A1,Terminated,NCT03292536,BONE METASTASES|BREAST CANCER,Female,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntsman Cancer Institute, Salt Lake City, Utah, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,26.6453109920121,7.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.75,552.5309,105.14,4.0,2.0,6.0,55.09,163.62,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,1,0,0,1,0,1,1,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1
CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1,0,DB12395,__ESREBOXETINE,6028070,Withdrawn,NCT00796601,FIBROMYALGIA,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,17.183104375859802,590.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.06,313.3908,39.72,4.0,1.0,3.0,34.17,89.48,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,0,DB12406,__LISOFYLLINE,5281731,Terminated,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07F7/1804,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,14.1604550401445,245.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.78,280.328,78.67,4.0,1.0,2.0,30.03,74.65,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2n1cnc2ccccc21,0,DB12415,__GALETERONE,WO-2008154382-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.95,388.5451,38.05,2.0,1.0,6.0,46.69,118.58,1.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0
Cc1sc[n+](CC(=O)c2ccccc2)c1C,0,DB12497,__ALAGEBRIUM,6007865,Terminated,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,45.0,25.2654058604899,17.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.77,232.32,20.95,1.0,0.0,2.0,24.97,65.98,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1,0,DB12511,__IMIGLITAZAR,6251926,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,19.3515267253947,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.16,470.525,94.15,6.0,1.0,4.0,52.47,141.78,11.0,1.0,0.0,0.0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0
O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNCc1ccc([123I])cc1)C(=O)O)C(=O)O,0,DB12514,__IOFOLASTAT_I-123,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.82,531.337,165.06,8.0,6.0,1.0,46.59,114.95,14.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1
CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,0,DB12518,__RACLOPRIDE,6150353,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,14.4890038809831,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,347.24,61.8,4.0,2.0,2.0,35.02,88.07,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0
Cc1cc(C)c2nc(-c3cnc(NCCCC4CCN(C)CC4)nc3C)[nH]c2c1,0,DB12522,__TOREFORANT,WO-2007117399-A2,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.72,392.551,69.73,5.0,2.0,4.0,48.0,131.1,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,1
CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,0,DB12590,__INDIPLON,US-20030004346-A1,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04Â ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,48.9537772849545,44.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.01,376.43,67.57,4.0,0.0,4.0,39.66,114.23,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,1
O=C(NCC12CC3CC(CC(C3)C1)C2)c1cc(CCCNCCCO)ccc1Cl,0,DB12594,__AZD-9056,WO-2001044170-A1,Withdrawn,NCT00920608,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,A61P1/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.33,419.01,61.36,3.0,3.0,4.0,47.83,118.78,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0
CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(=O)NO)cc3)ccc2c1,0,DB12645,__GIVINOSTAT,EP-2344253-B1,Terminated,NCT01557452,JUVENILE IDIOPATHIC ARTHRITIS,All,"2 Years to 18 Years Â  (Child, Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"1st Faculty of Medicine and General Faculty Hospital, Praha, Czech Republic",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,55.0319308404689,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.18,421.49699999999996,90.9,5.0,3.0,3.0,47.59,122.49,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(=O)NO)cc3)ccc2c1,0,DB12645,__GIVINOSTAT,EP-2344253-B1,Terminated,NCT01261624,POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS,All,2 Years to 17 Years Â  (Child),Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitair Ziekenhuis Gent, Gent, Belgium|1st Faculty of Medicine and General Faculty Hospital, Praha 2, Praha, Czech Republic|Ospedale Meyer, Firenze, FI, Italy|Policlinico G. Martino, Messina, ME, Italy|Istituto Gaetano Pini, Milano, MI, Italy|Azienda Ospedaliera-UniversitÃ  di Padova, Padova, PD, Italy|Institutul pentru Ocrotirea Mamei si Copilului ""Alfred Rusescu"", Bucarest, Romania|Spitalul Clinic de Urgenta pentru Copii ""M.S. Curie"", Bucarest, Romania|Mother and Child Health Institute ""Dr Vukan Cupic"", Novi Beograd, Belgrade, Serbia|Institute of Rheumatology Belgrade, Belgrade, Serbia|University Clinical Center Nis, Nis, Serbia|Children's Hospital - University Medical Centre Ljubljana, Ljubljana, Slovenia|Hospital RamÃ³n y Cajal, Madrid, Spain",2,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,55.0319308404689,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.18,421.49699999999996,90.9,5.0,3.0,3.0,47.59,122.49,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1,0,DB12678,__RELAMORELIN,,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,790.98,199.34,7.0,8.0,7.0,84.58,218.07,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0
O=C(O)CC[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1,0,DB12852,__MK-0752,WO-2004013090-A1,Terminated,NCT00572182,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS,All,"3 Years to 21 Years Â  (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|NCI - Pediatric Oncology Branch, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States",C07C315/04Â ,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,20.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,442.9,71.44,4.0,1.0,3.0,42.38,105.98,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0
CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,0,DB12865,__ETELCALCETIDE,8999932,Terminated,NCT01576146,SECONDARY HYPERPARATHYROIDISM,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07K7/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,56.280416435655695,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.4,1048.26,557.71,23.0,22.0,0.0,108.23,303.63,36.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0
CCS(=O)(=O)c1ccc2oc(-c3ccc4ccccc4c3)nc2c1,0,DB12888,__EZUTROMID,US-20090048314-A1,Terminated,NCT02858362,DUCHENNE MUSCULAR DYSTROPHY,Male,"5 Years and older Â  (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA-David Geffen School of Medicine, Los Angeles, California, United States|Children's Hosptial of Colorado, Aurora, Colorado, United States|Nemours Children's Clinic, Orlando, Florida, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Utah Hospital and Clinics, Salt Lake City, Utah, United States|Heart of England NHS Foundation Trust - Heartlands Hospital, Birmingham, United Kingdom|Bristol Children's Hospital, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom|Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom|Royal Manchester Children's Hospital - Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom|The Freeman Hospital, Newcastle Upon Tyne Hospitals, Newcastle, United Kingdom",A61P21/00,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,40.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.07,337.39,60.17,3.0,0.0,4.0,36.97,102.94,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc([nH]c4nc(n1)-c1ccccc1-4)-c1ccccc1-3)c1ccccc21,0,DB12983,__PHTHALOCYANINE,3931097,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C08F255/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.79,514.552,108.92,6.0,2.0,9.0,57.9,155.73,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
O=C(O)c1ccc(C(F)(F)F)cc1-c1ccc2c(c1)OC[C@H](Cc1ccccc1)[C@H]2O,0,DB13053,__CP-195543,WO-2001034134-A2,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.41,428.407,66.76,4.0,2.0,4.0,41.92,109.38,5.0,0.0,1.0,0.0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,0,DB13994,__AZD-7325,US-20070142328-A1,Suspended,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,104.0,20.961416045504,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.53,354.385,90.13,5.0,2.0,3.0,36.88,99.23,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
CC1=C(C)C(=O)C(CC[C@](C)(O)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C1=O,0,DB14094,__TOCOPHERYLQUINONE,US-20100063161-A1,Terminated,,NEUROMUSCULAR DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,38.40735949403471,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.09,446.7055,54.37,3.0,1.0,1.0,56.76,137.43,15.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0
C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O,0,DB14674,__ESTRAMUSTINE_PHOSPHATE,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.23,520.38,96.3,4.0,2.0,4.0,53.82,127.09,8.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0
C[C@@H]1NC(=O)[C@H](CC(=O)O)NC1=O,0,DB14940,__ASPARTYL-ALANYL-DIKETOPIPERAZINE,,Terminated,,SEVERE OSTEOARTHRITIS OF THE KNEE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,186.167,95.5,4.0,3.0,1.0,16.87,40.63,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0
COc1cc2c(cc1OCCC[18F])CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21,0,DB14945,__FLORBENAZINE_F-18,,Terminated,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,364.49199999999996,41.93,4.0,1.0,3.0,42.07,101.86,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0
CCC[C@H](c1ccc(C(=O)NCCC(=O)O)cc1)[C@H](c1ccc(Cl)cc1)c1c[nH]c2c(F)cc(C)cc12,0,DB14957,__MK-3577,EP-2079688-B1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,57.923160639848795,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.27,521.03,82.19,3.0,3.0,4.0,55.92,144.7,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=C(c1ccc(O)c(F)c1)N(c1ccc(O)cc1)c1ccc(F)cc1,0,DB14969,__GTX-758,US-20070265296-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,181.0,60.0587281052999,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.09,341.314,60.77,3.0,2.0,3.0,32.11,88.88,3.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0
CN(Cc1ccc(/C=C/C(=O)NO)cc1)CC12CC3CC(CC(C3)C1)C2,0,DB14979,__MARTINOSTAT,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,354.494,52.57,3.0,2.0,4.0,40.91,105.37,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
CCCCCCCC/C(=C\CCCCCCCC(=O)O)[N+](=O)[O-],0,DB15026,__CXA-10,WO-2009129495-A1,Withdrawn,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,32.7488,14.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.26,327.465,80.44,4.0,1.0,0.0,39.06,92.77,16.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12,0,DB15039,__ITI-214,US-20120238589-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,27.2695537896055,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,507.57300000000004,78.65,6.0,1.0,7.0,54.23,154.78,5.0,1.0,0.0,0.0,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0
CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,0,DB15048,__LICOGLIFLOZIN,WO-2011048112-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.96,416.47,108.61,7.0,4.0,4.0,44.51,109.51,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1
CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N2,0,DB15195,__MIBENRATIDE,,Withdrawn,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,2097.27,940.67,37.0,32.0,5.0,203.7,528.21,32.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,1,1,1
CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,0,DB15242,__MK-0533,US-20050277685-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,42.2842358159305,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.4,527.496,86.99,6.0,1.0,4.0,51.64,138.96,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,0,DB15291,__BMS-986142,US-20140378475-A1,Terminated,NCT02843659,SJÃGREN'S SYNDROME,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","St Joseph Heritage Healthcare, Fullerton, California, United States|Local Institution, Palo Alto, California, United States|Local Institution, Sarasota, Florida, United States|North Georgia Rheumatology Group, Lawrenceville, Georgia, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Local Institution, Tupelo, Mississippi, United States|Arthritis And Osteoporosis Associates, Pa, Freehold, New Jersey, United States|New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, United States|Local Institution, Mineola, New York, United States|Pmg Research Of Wilmington Llc, Wilmington, North Carolina, United States|Paramount Medical Research & Consulting, Llc, Middleburg Heights, Ohio, United States|Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Wexford, Pennsylvania, United States|Acme Research, Llc, Orangeburg, South Carolina, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Tekton Research Inc, Austin, Texas, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Santiago De Chile, Metropolitana, Chile|Local Institution, Bogota, Cundinamarca, Colombia|Local Institution, Bogota, Colombia|Local Institution, Cali, Colombia|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Local Institution, Mexico City, Distrito Fededral, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Cercado De Lima, Lima, Peru|Local Institution, Lima, Peru|Instituto De Ginecologia Y Reproduccion Inv. Clinical Sac, Lima, Peru|Klinika Reumatologii i Chorob Wewnetrznych, Wroclaw, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, Moscow, Russian Federation|Local Institution, Stellenbosch, Western CAPE, South Africa",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,22.505595597445502,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.71,572.613,119.73,4.0,3.0,6.0,59.43,155.31,2.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,0
C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1,0,DB15399,__BMS-754807,8492328,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C12Q1/6886,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,62.2600053389186,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,461.4948,116.13,7.0,3.0,6.0,48.1,139.75,6.0,0.0,1.0,0.0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1
CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2,0,DB15418,__AZD-9977,,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,399.37800000000004,96.97,5.0,2.0,4.0,38.12,101.36,3.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0
O=C(O)c1ccc(CCCc2c(CCNS(=O)(=O)Cc3ccccc3C(F)(F)F)n(C(c3ccccc3)c3ccccc3)c3ccc(Cl)cc23)cc1,0,DB15426,__GIRIPLADIB,US-20070004719-A1,Terminated,,OSTEOARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,56.0,37.388858087435004,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.35,745.25,88.4,4.0,2.0,6.0,76.7,198.91,14.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCc1ccc(CN[C@H](C(=O)OC2CCCC2)C2CCCCC2)cn1)NO,0,DB15440,__GSK-3117391,,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,403.523,100.55,5.0,3.0,3.0,45.52,108.98,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1
N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1,0,DB15670,__GUSACITINIB,US-20130053346-A1,Suspended,,BASAL CELL CARCINOMA IN BASAL CELL NEVUS SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,20.8628513932524,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.46,460.542,129.77,9.0,3.0,5.0,49.8,131.72,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C,0,,_COSYNTROPIN,4127537,Suspended,NCT03347526,INFANTILE SPASM,All,2 Months to 2 Years Â  (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Los Angeles, Los Angeles, California, United States|UCSF Medical Center, San Francisco, California, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Boston Children's Hospital, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|Atrium Health, Charlotte, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Cook Children's Medical Center, Fort Worth, Texas, United States",C07K14/6755,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,17.4130885644469,189.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,0,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,1,0,1,0,1,1,1,0,1,1,0
CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C,0,,_COSYNTROPIN,4127537,Terminated,NCT03400852,"MUSCULAR DYSTROPHY, DUCHENNE",Male,4 Years to 8 Years Â  (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NW FL Clinical Research Group, LLC, Gulf Breeze, Florida, United States|Rare Disease Research, LLC, Atlanta, Georgia, United States|Monroe Carell Jr Childrens Hospital at Vanderbilt, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|UT Health Science Center, San Antonio, San Antonio, Texas, United States|University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia, Bulgaria|Edith Wolfson Medical Center, HÌ±olon, Israel|Ospedale San Raffaele S.r.l. - PPDS, Milano, Lombardia, Italy|Hospital Civil Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|Neurociencias Estudios Clinicos S.C., CuliacÃ¡n, Sinaloa, Mexico|Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango, Mexico|Clinic of Neurology and Psychiatry for Children and Youth, Belgrade, Serbia|Hospital de La Santa Creu i Sant Pau, Barcelona, Spain|Hospital Sant Joan de Deu - PIN, Esplugues De Llobregat, Spain|Hospital Universitari i Politecnic La Fe Valencia, Valencia, Spain|Mersin Universitesi Tip Fakultesi Hastanesi, Mersin, Turkey",C07K14/6755,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,17.4130885644469,189.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,0,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,1,0,1,0,1,1,1,0,1,1,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O,0,,_CARBIDOPA,WO-1999004765-A2,Suspended,NCT03929068,AMYOTROPHIC LATERAL SCLEROSIS|MOTOR NEURON DISEASE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States",A61K9/0007,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
O=S(=O)([O-])CCS.[Na+],0,,_MESNA,,Terminated,NCT00278512,VASCULITIS,All,"16 Years to 60 Years Â  (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])CCS.[Na+],0,,_MESNA,,Terminated,NCT00424489,MYASTHENIA GRAVIS,All,"15 Years to 65 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])CCS.[Na+],0,,_MESNA,,Terminated,NCT00758667,IMPLANT CAPSULAR CONTRACTURE,Female,"18 Years to 65 Years Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])CCS.[Na+],0,,_MESNA,,Terminated,NCT00278564,MYOPATHY,All,"16 Years to 65 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00278512,VASCULITIS,All,"16 Years to 60 Years Â  (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00424489,MYASTHENIA GRAVIS,All,"15 Years to 65 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00278564,MYOPATHY,All,"16 Years to 65 Years Â  (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00960063,NEOPLASMS|SOLID TUMORS|BONE CANCER|KIDNEY TUMOR|NEUROBLASTOMA,All,"up to 21 Years Â  (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00499733,CANCER,All,"18 Years to 120 Years Â  (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brady Urological Institute at Johns Hopkins Hospital, Baltimore, Maryland, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,0,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT00282412,RHEUMATOID ARTHRITIS,All,18 Years to 60 Years Â  (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
NCCC(O)(P(=O)([O-])O)P(=O)([O-])O.O.O.O.O.O.[Na+].[Na+],0,,_PAMIDRONATE_DISODIUM,,Terminated,NCT02007915,FEMORAL HEAD AVASCULAR NECROSIS,All,"10 Years to 18 Years Â  (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Hospital for Sick Children, Toronto, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O=C(O)C(O)C(O)C(=O)O,0,,_HYDROCODONE_BITARTRATE,,Terminated,NCT03586934,SHOULDER PAIN|OPIOID USE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl,0,,_OXYCODONE_HYDROCHLORIDE,4126684,Terminated,NCT03586934,SHOULDER PAIN|OPIOID USE,All,"18 Years and older Â  (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,23.425532351793603,207.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)([O-])[O-])C(=O)C(C)(C)O4)n2)cc(OC)c1OC.O.O.O.O.O.O.[Na+].[Na+],0,,_FOSTAMATINIB_DISODIUM,,Terminated,NCT00805467,RHEUMATOID ARTHRITIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, La Jolla, California, United States|Research Site, Palm Desert, California, United States|Research Site, Palo Alto, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Maria, California, United States|Research Site, Hamden, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Aventura, Florida, United States|Research Site, Boca Raton, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange Park, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Venice, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Coeur D'Alene, Idaho, United States|Research Site, South Bend, Indiana, United States|Research Site, Elizabethtown, Kentucky, United States|Research Site, Cumberland, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Lansing, Michigan, United States|Research Site, Omaha, Nebraska, United States|Research Site, Roslyn, New York, United States|Research Site, Smithtown, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Mayfiled Village, Ohio, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Willow Grove, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Jackson, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Oklahoma City, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Antwerp, Belgium|Research Site, Gent, Belgium|Research Site, Liege, Belgium|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bucaramanga, Colombia|Research Site, MedellÃ­n, Colombia|Research Site, Bordeaux, France|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, WÃ¼rzburg, Germany|Research Site, Siena, Italy|Research Site, Udine, Italy|Research Site, Chihuahua, Mexico|Research Site, Cuernava, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Guadalajara, Mexico|Research Site, Leon, Mexico|Research Site, Mexcio, Mexico|Research Site, Mexico, Mexico|Research Site, Morelia, Mexico|Research Site, San Luis PotosÃ­, Mexico|Research Site, Jesus Maria, Peru|Research Site, Lima, Peru|Research Site, BiaÅystok, Poland|Research Site, Bytom, Poland|Research Site, Elblag, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, ToruÅ, Poland|Research Site, Wroclaw, Poland|Research Site, ZyrardÃ³w, Poland|Research Site, Brailari, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Sf. Gheorghe, Romania|Research Site, Sibiu, Romania",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1
Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O,0,,_AZD1386,US-20090176851-A1,Terminated,NCT00878501,PAIN,All,"40 Years to 80 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Pleven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, St.Johns, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, St Catharines, Ontario, Canada|Research Site, Charlottetown, Prince Edward Island, Canada|Research Site, Saint Romuald, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Helsinki, Finland|Research Site, Hyvinkaa, Finland|Research Site, Lahti, Finland|Research Site, Riihimaki, Finland|Research Site, Tampere, Finland|Research Site, Vantaa, Finland|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Veszprem, Hungary|Research Site, Japan, Japan|Research Site, Bialystok, Poland|Research Site, Elblag, Poland|Research Site, Gdynia, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, Toru, Poland|Research Site, Warszawa, Poland|Research Site, Brastislava, Slovakia|Research Site, Komarno, Slovakia|Research Site, Liptovsky Hradok, Slovakia|Research Site, Poprad, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Ziar nad Hronom, Slovakia|Research Site, Zilina, Slovakia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,32.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,0,,_GENTAMICIN,,Terminated,NCT02036528,DIABETIC FOOT ULCERS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Georgetown University Hospital Center, Washington, District of Columbia, United States|GF Professional Research, Corp., Miami Lakes, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|Advanced Foot and Ankle Institute of Georgia LLC, Smyrna, Georgia, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Detroit Clinical Research Center, PC, Farmington Hills, Michigan, United States|Utah Valley Medical Center, Provo, Utah, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,0,,_GENTAMICIN,,Terminated,NCT00658957,DIABETIC FOOT ULCER,All,"18 Years to 80 Years Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Chesapeake Foot and Ankle Center, Pasadena, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,0,,_ALBUTEROL_SULFATE,4409237,Terminated,NCT00634829,ASTHMA|BRONCHOSPASM,All,"12 Years to 50 Years Â  (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Colorado Allergy and Asthma Center, Denver, Colorado, United States|Colorado Allergy and Asthma Center, Englewood, Colorado, United States|Colorado Allergy and Asthma Center, Lakewood, Colorado, United States",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,29.6679603277274,338.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
COC(=O)C(c1ccccc1)C1CCCCN1.Cl,0,,_METHYLPHENIDATE_HYDROCHLORIDE,5023088,Terminated,NCT01348607,"CENTRAL NERVOUS SYSTEM TUMOR, PEDIATRIC|FATIGUE|SPECIFIC DISORDERS OF SLEEP",All,"8 Years to 18 Years Â  (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,A61K9/0004,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,14.751842953654,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,0,,_VINCRISTINE,3932417,Terminated,NCT00960063,NEOPLASMS|SOLID TUMORS|BONE CANCER|KIDNEY TUMOR|NEUROBLASTOMA,All,"up to 21 Years Â  (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,0,,_VINCRISTINE,3932417,Terminated,NCT01313884,BONE CANCER|EWING'S SARCOMA,All,"13 Years and older Â  (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT00112619,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CARCINOMA OF UNKNOWN PRIMARY|LEUKEMIA|LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"3 Years to 21 Years Â  (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States",A61K49/0021,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
NCCS.O=C(O)C(O)C(O)C(=O)O,0,,_CYSTEAMINE_BITARTRATE,WO-2013062544-A1,Terminated,NCT02473445,MITOCHONDRIAL DISEASES,All,6 Years to 17 Years Â  (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California at San Diego (UCSD), San Diego, California, United States|Stanford University School of Medicine, Stanford, California, United States|Akron Children's Hospital, Akron, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12.Cl,0,,_BUTENAFINE_HYDROCHLORIDE,6017920,Terminated,NCT01119742,INTERDIGITAL TINEA PEDIS,All,"18 Years and older Â  (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,48.6580833281997,99.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,0,,_LOSARTAN,,Terminated,NCT00763893,MARFAN SYNDROME,All,"10 Years and older Â  (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HÃ´pital Bichat, Paris, France",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC.C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)OC)c(CCC(=O)O)c4C)C1(C)C3=CC=C(C(=O)OC)C1C(=O)OC,0,,_VERTEPORFIN,,Terminated,NCT00049959,BASAL CELL CARCINOMA|NEVOID BASAL CELL CARCINOMA SYNDROME|GORLIN SYNDROME,All,"18 Years to 90 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,0,,_ESTROGEN,,Terminated,NCT00000430,OSTEOPENIA|OSTEOPOROSIS,Female,"60 Years and older Â  (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Creighton University Osteoporosis Research Center, Omaha, Nebraska, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0
CCc1c(C)c2cc3nc(cc4nc(cc5cc(C)c(cc1[nH]2)[nH]5)C(C)=C4CCC(=O)O)C(CCC(=O)O)=C3C,0,,_PHOTOFRIN,,Terminated,NCT01966809,"BRAIN TUMOR, RECURRENT",All,"18 Years and older Â  (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical College of Wisconsin/ Froedtert Hospital, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,0,,_GLUCAGON,,Terminated,NCT01573286,INTESTINAL FAILURE|SHORT BOWEL SYNDROME,All,"up to 18 Years Â  (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alberta Children's Hospital, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|Hospital for Sick Children, Toronto, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,0,,_LEUPROLIDE_ACETATE,4851211,Terminated,NCT01257802,"LUPUS ERYTHEMATOSUS, SYSTEMIC|SYSTEMIC VASCULITIS|ISOLATED ANGIITIS OF CENTRAL NERVOUS SYSTEM|LUNG DISEASE WITH SYSTEMIC SCLEROSIS|LUNG DISEASE INTERSTITIAL DIFFUSE",Female,18 Years to 40 Years Â  (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Michigan, Ann Arbor, Michigan, United States|The Ohio State University, Columbus, Ohio, United States",A61K9/008,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,31.967802213597803,302.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,0,,_SUNITINIB_MALATE,EP-2638896-A1,Terminated,NCT00906360,METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY SQUAMOUS CELL CARCINOMA|RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE III SALIVARY GLAND CANCER|STAGE III SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE III SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE III SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE III VERRUCOUS CARCINOMA OF THE LARYNX|STAGE III VERRUCOUS CARCINOMA OF THE ORAL CAVITY|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY|TONGUE CANCER|UNTREATED METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY,All,"18 Years and older Â  (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Evanston CCOP-NorthShore University HealthSystem, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc - State Boulevard, Fort Wayne, Indiana, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,47.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,0,,_RETINAL,3953524,Terminated,NCT02473029,HORTON DISEASE,All,"18 Years and older Â  (Adult, Older Adult)",Other,Observational Model: Case-Only|Time Perspective: Cross-Sectional,"Fondation Ophtalmologique A. de Rotchschild, Paris, France",C07C33/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.561099817244703,248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CC(C)(CO)C(O)C(=O)NCCCO,0,,_PANTHENOL,4416873,Terminated,NCT01531517,DIABETIC FOOT ULCER,All,"18 Years to 70 Years Â  (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alexandria University Hospitals, Alexandria, Egypt|Cairo University Hospitals, Alexandria, Egypt",A61Q19/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,11.3020801248485,2379.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0
CC(=O)O.N=C(N)N/N=C/c1c(Cl)cccc1Cl,0,,_GUANABENZ_ACETATE,4783456,Terminated,NCT02443103,BONE CANCER|METASTASIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Sidney & Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Spring Mill Medical Center, Indianapolis, Indiana, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.920265303188902,67.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
N=C(N)N/N=C/c1c(Cl)cccc1Cl,0,,_GUANABENZ,4027039,Terminated,NCT02443103,BONE CANCER|METASTASIS,All,"18 Years and older Â  (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Sidney & Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Spring Mill Medical Center, Indianapolis, Indiana, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,23.1626932791227,823.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],0,,_BETAMETHASONE_SODIUM_PHOSPHATE,4265875,Withdrawn,NCT00914836,TENDONITIS|BURSITIS,All,"35 Years and older Â  (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Haemek Medical Center, Afula, Israel",A61K9/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.5301546232982,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1
